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SUMMARY
Within the last ten years intense research has led to a greater understanding o f the signalling 
pathways that control normal cell division and cancerous cell proliferation. Enzymes known 
as protein tyrosine kinases (PTKs) play a key role in such growth-related processes by 
catalysing the phosphorylation of tyrosine residues on intracellular protein substrates. This 
knowledge has led to the search for selective PTK inhibitors in the hope o f generating 
chemotherapeutic agents of potential use in the treatment of cancer. Particular attention has 
focused on the signalling events that occur at a receptor tyrosine kinase (RTK) called the 
epidermal growth factor (EGF) receptor since a number o f studies have implicated its 
involvement in many types of human cancer.
Compounds found to possess anticancer activity by acting as PTK inhibitors with a structural 
resemblance to tyrosine are known as the tyrphostins. In this project, an extensive array of 
3-arylpropenonitriles (approximately 140 compounds) akin to the tyrphostins have been 
synthesised (Diagram) and biologically evaluated in cell assays designed to correlate PTK 
inhibition at the EGF receptor to antiproliferative activity. Efforts were directed at producing 
more stable tyrphostin analogues as well as those that incorporate a heterocyclic moiety.
highly potent antiproliferative agents and gave sub-nanomolar IC50 values against the breast 
adenocarcinoma MCF-7 cell line. Consequently, structurally isomeric tyrphostin sets were 
synthesised. More detailed biological analysis demonstrated that some o f these compounds 
were acting in a non-selective cytotoxic fashion. Presently, the compound ethyl 2-cyano-3-
Diagram: 3-ArvIpropenonitriles (Tyrphostins)
 /  R= CN, CO2R \  CONH2, CSNH,, “ > = <
/ = \  - 7 <
CN (R'= H or alkyl group)
4
X= H, OR', N 0 2, Cl and/or F (n -  1 ,2 , or 3) (Y= O or S)
From initial studies, tyrphostins incorporating a nitrothiophene portion were shown to be
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[5-(2-nitrothienyl)]propenoate (A) has been accepted by the National Cancer Institute to 
undergo an in vivo evaluation and represents an interesting new cytotoxic anticancer agent.
encouraging antiproliferative activities against the MCF-7 cell line (IC50 values < 1 p,M). The 
most potent compounds contained the 2-aminoethene-l,l-dicarbonitrile unit [Diagram: R =  
C(NH2)=C(CN)2 ] and, although they produced an additional cytotoxic action, they were 
found to inhibit selectively the phosphorylation o f an unknown signalling protein that was 
found to be linked to EGF receptor activation. The 2 -substituted quinoline (B) also displayed 
a certain degree of selectivity within a panel of 60 tumour cell lines (held at the US National 
Cancer Institute) and may act as an interesting lead for future studies.
In order to determine the stereochemical requirement preferred for biological activity, 
attempts were made to synthesise geometric isomers of some tyrphostins. In particular, the 
cis- and tran s-forms of the known tyrphostin (C ) were synthesised and characterised by 
detailed NMR spectroscopy and X-ray crystallography. Interestingly, the isomer (C ) was 
about 3.5 times more potent than its geometric partner in an antiproliferative assay against a 
cell line (HN5) that overexpresses the EGF receptor. A lso, synthesised were other 
2,3-diarylpropenonitriles akin to compound (C) and some of these displayed equally effective 
IC50 values against the MCF-7 cell line.
During a search for heterocyclic tyrphostins some quinoline derivatives were found to display
NH2
(B)
(C)
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0 INTRODUCTION 0
“The mission o f pharmacology is to establish the active 
substances within natural drugs, to find chemical properties 
responsible fo r  their action, and to prepare synthetically 
drugs that are more effective R. Buchheim, 1876.
P r e f a c e
O ne m ight define m edicinal chemistry as R udolf Bucheim  had described  
pharmacology at the University o f Giessen in 1876 (above quotation) . 1 Indeed, this 
discovery/design/development description could equally apply to the objective o f this 
research work which, over three years, has endeavoured to synthesise a more effective 
anticancer agent. As one might expect, this type of programme involves many disciplines 
and therefore it is necessary to equip the reader with some relevant background.
As an appropriate start, a brief general account of cancer is given followed by more in-depth 
sections into cell biology and such like. This should be suitable armoury for later sections 
which explain the biochemistry of a growth control pathway which is at the core o f this 
Ph.D. project. As the reader will soon learn, a new era has begun, not only in cancer 
research but in the whole area of medicinal chemistry, namely: de novo design, i.e. the 
rational design o f useful new drugs for a particular disease directly from knowledge o f that 
disease.
CHAPTER «1» Cancer—An Overview
Cancer is a feared disease. Indeed, it is many diseases; that is one o f the problems. Cancer 
arises from cells in the body that were once normal cells and these ‘transformed’ cells differ 
only subtly at the biochemical level. Indeed this feature has bedevilled the search for a 
‘cure’ as there will always be an inherent lack of selectivity. In the words o f Walt Kelly: 
“We have met the enemy and they are us.” However, recent research is starting to decipher 
the intricate control mechanisms o f cells and revealing potential strategies in this disease 
without affecting normal cells. In the clinic, the hope is no more side-effects.
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This burgeoning knowledge has taken time to collate and has had to wait for advances in 
molecular biology and fundamental cell biology. Today these findings are being translated 
into clinically viable treatment strategies (see Section 4.3). Obviously it will take more time 
(years) before these are at a stage to be put to test in the clinic and although human society 
has waited for many centuries for a ‘cancer cure’ one should take heed o f Alexander 
Fleming’s statement on discovering penicillin: “The spores didn’t just stand up on the agar 
and say, ‘I produce an antibiotic, you know.’”
1.1 Cancer— A Brief History
Cancer is an old problem and has been with us throughout the history o f the human race. 
Although, in saying this, it is not a disease which only afflicts humans and traces of tumours 
have been found in dinosaurs from the Cretaceous Age as well as in a Pleistocene cave bear. 
In human society it was well known to the ancient Egyptians and succeeding civilisations. 
Egyptian mummies from the third to fifth dynasties (c irca  3000-2500 BC) displayed 
evidence o f tumours and there are similar indications in Inca remains from about 500 BC. 
Two of the oldest documented accounts of cancer include the Edwin Smith Papyrus (circa 
1660 BC) and the Ebers Papyrus, dating from about 1552 BC.2
The great medical authority, Hippocrates (460-370 BC) described many varieties of cancers 
(skin, breast, stomach, cervix uteri and rectum) and established an initial classification 
system .3 Also his writers introduced a variety of terms- “phyma”, “oidema”, “karkinos” and 
“karkinoma”— to signify different types of chronic ulcerations, growths and swellings.4 At 
least some o f these descriptions appear to have been tumours in today’s sense and the Greek 
term for cancer, “karkinos” meaning “crab”, still aptly describes the crab-like appearance or 
texture of more advanced cases of this disease, e.g. breast cancer.
In 1800 and 1801, Marie Frangois Xavier Bichat, a brilliant young French anatomist laid 
down the principle that all tissues o f the body are fundamentally similar in structure and 
each consists o f “cellular” units capable of reproducing themselves. Later that century 
Mathias Schleiden, Theodor Schwann and Johannes Mueller (1838) developed their cellular 
theory5 and W ilhelm Waldeyer published two papers which outlined the fundamental 
principals on cancer.6 From that time on, cell theory gave a solid conceptual basis for 
twentieth century cancer research.
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1.2 Cancer of Today
Cancer holds a strange place in modem mythology. Although it is a common disease and it 
is true to say that one person in five will die of cancer, it is equally true to say that four out 
of five will die of some other disease. Heart disease, for example, a more common cause of 
death, does not carry with it the gloomy overtones, not always justifiable, of a diagnosis of 
cancer. Maybe the fear of cancer stems from the fact that one’s own body has revolted 
against the whole, leading to destruction within. Indeed, cancer results from the abnormal 
growth o f otherwise healthy cells and is a disease characterised by uncontrolled cell 
proliferation. Unless checked, the cancer cells invade surrounding normal tissues, enter the 
circulation, and spread throughout the body, and eventually interfere with the function of 
normal cells leading to death of an afflicted individual.
Ironically, it has been the triumph of medical science over the last century which has 
resulted in a shift from diseases which were prevalent in the past towards cancer and other 
disease types (Table 1). To put this in context, it is estimated that an adult of today will live 
to over 70 years o f age whereas the average age of the onset o f cancer is about 67 years.7 
This means that in say, the United States, one person dies from cancer every 62 seconds and 
30 % of the living population will eventually be afflicted with the disease. On a more
Table 1 Status of Some Diseases
Diseases Largely Cured or Avoided
Diseases Alleviated 
Asthma 
Diabetes
Cholera Heart Disease
Diphtheria Schizophrenia
Erysipelas Syphilis and other venereal diseases
Lobel pneumonia 
Measles Diseases Which Still Present Challenges
Meningococcal meningitis AIDS
Pertussis (whooping cough) Alzheimer’s disease
Plague Arthritis
Poliomyelitis Cancer
Rheumatic fever Cirrhosis
Scarlet fever Common cold
Smallpox Genetically transmitted diseases
Staphylococcal septicaemia Genital herpes
Subacute bacterial endocarditis Huntingdon’s chorea
Tuberculosis Influenza
Typhoid fever Multiple sclerosis
Vitamin deficiency Parkinson’s disease
Pulmonary fibrosis 
Senility, geriatric problems
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fundamental level, this reflects an important feature o f cancer b iology, namely: the 
cancerous transformation of a healthy body cell (carcinogenesis) is not a single step process 
and generally requires many years before enough abnormalities accumulate to the point of 
undermining the regulatory and safety mechanisms of normal cell growth.
1.3 The Development o f Neoplasms— Carcinogenesis
Although over one hundred distinct forms of cancer have been identified, they can generally 
be classified by their tissue origin (Figure l ) .3 As indicated, the important distinction is that 
between a benign and a malignant neoplasm. Generally speaking, a neoplasm (literally, 
“new growth”) is any abnormal growth of cells and the term tumour is usually used 
synonymously with neoplasm. In particular, a benign neoplasm is a growth that remains 
confined to its original location whereas a malignant neoplasm is capable o f both invading 
adjacent tissues and o f spreading (or disseminating) to other tissues of the body 
(to metastasise, the process of metastasis). Therefore, in contrast to malignancies, benign 
Figure 1 Classification of Cancer bv Tissue Origin
( cause local pressure \
\  damaging normal cells/
BENIGN
(growth)
CANCER
( synonymous with \  
neoplasm or turnout
resemble tissue origin
remain localized
encapsulated
lining tissue 
(epithelial)
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(glandular)
ADENOMA
MALIGNANT-----
(malignancy)
\metastasise
( invade, destroy and replace normal! tissues forming secondary tumours/
show cellular abnormalities 
disorganised growth 
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- connective tissue 
(bone, muscle, etc.)
originate from bone 
marrow stem cells
CARCINOMA
ADENOCARCINOMA
SARCOMA
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(resemble blood cells)
resemble embryonic _ 
tissues
LYMPHOMA 
(resemble lymph cells)
►  BLASTOMA
resemble germ cells
NAMED after 
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tumours are generally not life-threatening (except, for example, brain tumours) and can 
usually be completely removed by surgery (ablation).
At the cellular level, the primary event (tumour initiation) in the development of a malignant 
neoplasm (carcinogenesis) most likely involves the damage or destruction (mutation) of the 
genetic material (DNA), probably in the stem cell population of the tissue involved .9 These 
initiated cells remain latent until promoted into an increased state of proliferation (tumour 
promotion). At this stage additional mutations can occur and eventually one variant cell will 
have the effect o f further increasing the growth potential of the neoplasm (tumour 
progression) . 10 Due to this proliferative advantage, the descedants o f a cell bearing such a 
mutation tend to outgrow the other cells in the tumour (clonal selection). This clonal 
selection process is repeated several times during tumour progression, resulting in the 
formation o f increasingly hyperproliferative tumour cells .11
Moreover, there is a general movement towards a more aggressive behavioural pattern 
against surrounding tissues.12 In the case of malignant neoplasms this is often manifested by 
the ability to invade and spread throughout the body (to metastasise) rather than remain 
confined (in situ ) to their site of origin.13 The first stage of this process involves the invasion 
and infiltration o f surrounding normal tissue with the eventual penetration of small blood 
and lymphatic vessels (i.e. the capillaries). Once a passage to the circulatory system has 
been established there can be release of neoplastic cells, either as single entities or small 
clumps (emboli). At this stage the disseminated tumour cells must survive any natural 
defence mechanism (e.g. cells of the immune system) and be able to penetrate the junctions 
of the circulatory system before they can arrest in the capillary beds of distant organs and 
finally develop into a secondary tumour (see Figure 2). Luckily, the vast majority of tumour 
cells which enter the circulation are eliminated by such barriers apd it has been estimated 
that less than one in ten thousand successfully establish a metastatic tumour.
1.4 Factors in Cancer Causation14
Substances that aggravate a cell into a neoplastic state are generally termed carcinogens.15 
Carcinogens which induce the critical mutation(s) 16 in the first stage of tumour formation are 
called initiating agents, whereas others which enhance carcinogenesis by stimulating cell 
proliferation17 are called promoting agents18 (see Figure 3 for chemical examples). The 
hormones provide examples which act solely as promotors— particularly oestrogen, a
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Figure 2 Invasion and the Metastasis Process
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horm one w hich  has been shown to be a major factor in the developm ent o f  endometrial 
carc inom a.19 D ietary  fat is another example o f  a sole p rom oting  agen t and has been 
implicated in carcinom as of the breast, colon, prostate, ovary and uterus (endom etrium ).20 
H ow ever  there  are various dietary elements which studies suggest to be o f  benefit in 
reducing  the risk o f  breast21 and colorectal cancers:22 e.g. high grain f ib re ,23 fruits and 
vegetables,24 and foods rich in vitamins A, C and E .25
“Lifestyle” has been attributed as one of the most com m on causes o f  cancer and, apart from 
stress and  d ietary  factors, includes: smoking, alcohol use, reproductive  history, sexual 
behaviour, and exposure to sunlight.26 From this list, tobacco smoking is unquestionably the 
major identifiable cause of all cancers (30 %). Not only is it directly responsible for the vast 
m ajority  ( 8 0 - 9 0  %) o f  lung cancers , but also fo r  cancers  o f  the m outh , pharynx, 
oesophagus, urinary bladder, pancreas, and kidney.27 Heavy alcohol consumption,
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Figure 3 Structures of Some Representative Carcinogens
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particularly in combination with cigarette smoking, has also been linked with these cancers28 
and can result in chronic cell damage of the liver (cirrhosis), leading to excess cell 
proliferation, and hence liver cancer.
Genetic factors also play a part in cancer causation.29 Although, inherited cancers represent a 
small fraction (perhaps 1-2 %) of total cancers,30 dominant genetic inheritance accounts for 
about 40 % of retinoblastomas31 and 20-40 % of Wilm’s tumours (embryonal renal tumours) 
and neuroblastomas.32 In these cases, a strong predisposition to cancer is transmitted direcdy 
from parent to child, and development of cancer is inherited like any other trait, such as hair 
or eye colour. A lso the transmission of a single dominant gene can result in a cancer family 
syndrome,33 for example, but luckily these are quite rare. Such disorders tend to result from 
defective maintenance of the genetic material, i.e. from their inherent genetic instability.34
A further class o f  carcinogens would include chemicals or other agents that interfere with 
the normal function of the immune system.35 This includes the genetic disorders from viral 
infection and inherited immunodeficiences36— as opposed to acquired  immunodeficiences
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which are mostly due to factors such as imm unosuppressive agents or viruses, e.g. AIDS 
caused by viral (HIV) infection. Indeed viruses, and in particular oncogenic viruses are 
known to be associated with the generation of various human cancers .37 These nonceUular 
m rracellu lar parasites exhibit oncogenic activity by utilising the genetic material of host 
cells, thereby subverting normal cellular function.
1.5 Cancer Genetics
The control of  gene expression is considered  central to the unders tand ing  of cancer 
(see Figure 4). Specifically, it is abnormalities in the regulatory program me of a normal cell 
that transforms it into a neoplastic state. For this to occur, there must be specific alterations 
within critical regulatory genes, viz.: proto-oncogenes and tumour suppressor genes.38 The 
proto-oncogenes are normal genes of the cell which play a major role in numerous aspects 
of cell growth and differentiation. These “pre-cancerous” genes require to be triggered into a 
state of abnormal function (a process called mutation) and thereby becom e fully-fledged 
oncogenes able to cause the pathological process of cancer. However, tumour suppressor 
genes have an indirect cause on cancer, whereby their function to inhibit tumour progression 
is switched-off or lost altogether.39 Thus, the activation of oncogenes and inactivation of 
tumour suppressor genes represent complementary events in the carcinogenic process.
Figure 4 Gene Expression  
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The oncogenes found in tumour cells result from particular alterations in either the normal 
regulation, or structural (i.e. functional) integrity of the proto-oncogenes that are already 
native to the cell (so-called cellu lar  proto-oncogenes) .40 These abnormal alterations are 
generally termed mutations (see Table 2) and may also elevate the levels of a product 
(via gene am plification )41 to the point o f subverting any normal cellular function. 
Interestingly, the oncogenes of retroviruses42 are derived from such host-cell genes,43 and 
this has led to the identification of various oncogenes associated with human tumours.
Table 2 Common Events in the Mutagenesis of DNA
M utagenic Event General Description
Point mutation
Genetic code becomes altered due to substitution of a nucleotide base pair (i.e. the 
basic unit, “alphabet”, of the genetic language). Also can get “frame shift mutations” 
due to either a deletion or insertion of one or more base-pairs. So-called since the 
’’words” of the genetic code become off-set and thus become garbled.
DNA rearrangement
This is where a proto-oncogene can be activated by recombination with other, 
previously unlinked, DNA sequences. Such a gene transfer usually occurs from viral 
transfection of cellular genomes and may disrupt regulatory sequences leading to 
abnormal gene expression. Alternatively, gene integration leads to recombinant 
fusion oncoproteins, often truncated, with aberrant functioning within a cell.
Chromosomal
translocation
A type of genetic rearrangement whereby regions of chromosomes become removed 
from their normal environment (i.e. locus) and become inserted into an abnormal 
position in a different chromosome. This transposition process results in oncogenes 
in a similar manner as described above but only involves cellular DNA (not viral).
Similarly, defective tumour suppressor genes45 result from the mutagenic events described 
above but, unlike the oncogenes, can also result from inheritance of previously damaged 
forms. Noteworthy are the tumour supressor genes p 5 3  and RB  which are frequently 
inactivated in most types of human cancers.46,47 Thus, in combination with the oncogenes, 
these “cancer-associated” genes contribute substantially to the pathogenesis o f cancer 
(for a representative listing see Table 3).48
CHAPTER «2» Cell Communication—An Overview
The human body consists of about 5 x 1013 cells, o f which there are approximately 100 
different kinds, and a clear marvel of biology is in the proper functioning of such a complex 
system .49 Ultimately this requires stringent control mechanisms so that not only proximal 
but remote cell types can communicate with each other. Thus, this section will concentrate 
on the signalling processes of cells, particularly in relation to cancer, and will lead on to a 
growth control pathway that forms the conceptual backbone of this research project.
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T ab le  3 O n co g en es & T u m ou r S u p p ressor  G enes in H u m a n  C ancers
Tumour Oncogenes Tumour Suppressor Genes
r. ■ 50 Breast carcinoma c-myc, erbB-2 RB. p53, chromosomes 1. 3. 11, 18
Burkitt’s lymphom a51 BNLF-1, c-myc
Colon/rectum carcinoma52 ms K DCC, MCC, p53, chromosomes 5, 
18
Lung carcinoma33 ras K. c-myc, L-myc, N-myc RB, p53, chromosome 3
54Neuroblastoma N-myc chromosome 1
Neurofibrosarcoma35 N F \, p53
2.1 Factors of Cell Growth
Cell growth and replication (i.e. division)56 is classically divided into four stages, 
collectively known as the cell cycle (Figure 5).37 In situations where G l is very long, cells 
may be considered as being arrested and are said to be in a quiescent state (denoted by G0). 
Connective tissue cells remain arrested in G0 unless triggered by some “external factor”. For 
skin fibroblasts this may be in response to damage made by a cut or injury. In this case, the 
“ factor” involved is called platelet-derived growth factor (PDGF) and is released by blood 
cell fragments (i.e. platelets) during the blood clotting process.55 It is this which stimulates 
proliferation of local skin cells. Such control substances are known as growth factors and 
they belong to diverse set of signalling molecules that also include the hormones.
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An underlining theme in understanding the regulatory action of growth factors is 
exemplified in their endocrine, autocrine and paracrine modes of action (see Figure 6).59 
This understanding augments and extends the action given by the mobile endocrine (or
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hormone) system. Thus, the global effect of the classical hormones often requires the local 
action of these polypeptide mediators.
Figure 6 Diagrammatic Representation of Secretion M odes60
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2.2 Aspects of Growth Factors
Due to their function in influencing the cell to divide, i.e. to undergo mitosis, growth factors 
are often referred to as mitogens. However, although they do exert a mitogenic action in 
growth control processes, this is not their sole function. Indeed they are multifunctional in 
nature and may be regarded as simply the alphabet or symbols o f  a biological regulatory 
language (see Table 4).61 Elucidation of the gram m ar and syntax o f  this language is one of 
the most challenging aspects of modern biology and an attempt to give a deciphered acount 
of this will be given in the next sections.
Often it is the case that growth factors {e.g. PD GF62 and others63) regulate gene expression 
by controlling the synthesis and degradation of the extracellular matrix. The extracellular 
matrix is com posed of collagens, glycoproteins and proteoglycans, and provides not only a 
physica l support  to the tissues but also m ain ta ins  ce llu la r  v iab ili ty , stability  and 
homeostasis.64 Thus, it comes as no surprise that abnormalities in growth factor action can 
lead to the development and progress of cancer.65 In part, this is due to aberrant stimulation 
of a cell to produce proteolytic enzymes, e.g. plasminogen activator or collagenase.66
An important principle to put forward is that the type o f  cell that makes a growth factor does 
not normally respond to that factor. Rather, growth factors are produced in order to signal a
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Table 4 Names and Abreviations of Growth Factors
Common Growth Factor Name Alternative Functional Name(s)
Activins (A, AB, B) FSH releasing protein (FRP)
Colony-stimulating factor 1 (CSF-1) Macrophage colony-stimulating factor (M-CSF)
Epidermal growth factor (EGF) Urogatrone
Erythropoietin (epo; EP) Haemopoietin Erythrocyte stimulating factor (ESF)
Fibroblast growth factors (FGF)
Acidic fibroblast growth factor (aFGF) 
Basic fibroblast growth factor (bFGF) 
Brain-derived growth factor (BNDF; BDGF) 
Heparin binding growth factor (HBGF) 
Endothelial cell growth factor (ECGF) 
Retina-derived growth factor (RDGF) 
Eye-derived growth factor (EDGF)
Kidney angiogenic factor (KAF)
Adrenal growth factor (AGF)
Corpus luteum angiogenic factor (CLAF) 
Ovarian growth factor (AGF)
Placental angiogenic factor (PAG) 
Hepatocyte growth factor (HGF) 
Myogenic growth factor (MGF) 
Cartilage-derived growth factor (CDGF) 
Bone growth factor (BGF) 
Seminiferous growth factor (SGF) 
Prostatropin (PGF) 
Tumour-derived growth factor (TDGF) 
Hepatoma-derived growth factor (HDGF) 
Melanoma-derived growth factor (MDGF) 
Mammary tumour-derived growth factor (MTGF)
Gastrin-releasing peptide (GRP) Mammalian bombesin
Granulocyte colony-stimulating factor (G-CSF)
Macrophage/granulocyte inducer 
type 1, granulocyte (MG-1G) 
Pluripotent colony-stimulating factor (pluripoetin) 
Granulocyte-macrophage 
colony-stimulating factor- p (GM-CSF(3)
Granulocyte-macrophage 
colony-stimulating factor (GM-CSF)
Macrophage-granulocyte inducer 
Colony-stimulating factor 1 (CSF-2)
Inhibin
Insulin-like growth factor I (IGF-I)
Somatomedin A 
Somatomedin C 
Basic somatomedin
Insulin-like growth factor II (IGF-II) Multiplication stimulating activity (MSA)
Interferon-a (IFN-a) Leukocyte (Le) interferon Type I interferon
Interferon-13 (IFN-J3) Fibroblast (F) interferon Type I interferon
Synthesis and Biological Evaluation of Anticancer Agents Page 12
Interferon-y (IFN-y)
Immune interferon 
T interferon 
Type II interferon
Interleukin-1 (LL-1)
Interleukin-1 a 
Interleukin-1 b 
Lymphocyte activating factor (LAF)
Interleukin-2 (IL-2) T-cell growth factor (TCGF)
Interleukin-3 (IL-3)
Mast cell growth factor 
P-cell stimulating factor 
Multi-colony-stimulating factor 
Burst promoting activity 
WEHI-3 haematopoietic growth factor 
Thy-1 inducing factor 
Histamine cell-producing stimulating factor 
20a-dehydrogenase-inducing factor
Interleukin-4 (IL-4)
B-cell stimulating factor 1 (BSF-1) 
T-cell growth factor (TCGF) 
B-cell growth factor 1 (BCGF-1) 
Mast-cell growth factor (MCGF)
Interleukin-5 (IL-5)
T-cell replacing factor (TRF-1)
B-cell growth factor II (BCGFII)
B-cell differentiation factor p, (BCDFp) 
Eosinophil differentiation factor (EDF)
IgA enhancing factor (IgA-EF)
B-cell maturation factor (BMF)
B-cell growth and differentiation factor (BGDF)
Interleukin-6 (IL-6)
B-cell stimulatory factor-2 (BSF-2) 
Interferon-P2 
26-kDa protein 
Hepatocyte stimulatory factor 
Hybridoma/plasmacytoma growth factor 
Interleukin-HPl 
Macrophage granulocyte inducer type 2
Lymphotoxin Tumour necrosis factor-P (TNF-(3)
Mullerian inhibiting substance (MIS) Anti-Miillerian hormone (AMH) Mullerian inhibiting factor (MIF)
Nerve growth factor (NGF)
Platelet-derived endothelial cell growth factor (PD-ECGF)
Platelet-derived growth factor (PDGF) (PDGF-AA, PDGF-AB, PDGF-BB)
Transforming growth factor-a (TGF-a) Sarcoma growth factor (SGF)
Transforming growth factor-(3 (TGF-p)
Cartilage inducing factor-A (CIF-A) 
Cartilage inducing factor-B (CIF-B) 
BSC-1 growth inhibitor (BSC-1 GI) 
Differentiation inhibitor (DI) 
Polyergin
Tumour necrosis factor (TNF) Cachectin Tumour necrosis factor- a  (TNF-a)
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different cell type. In cancer, a cell can produce a growth factor that it also responds to 
(called autocrine growth stimulation) leading to continual cell proliferation.67 Pertinent cases 
of this situation are given by: the viral oncogene v-sis  and PDGF (causes sarcomas in 
monkeys),68 the oncogenes hst and int-2 (members o f the FGF family which are sometimes 
amplified in human tumours),69 and EL-3 (which is translocated in some human 
leukaemias).70
Another important concept to address is the contextual nature o f growth factors, i.e. the 
cellular response will depend on other effectors and receptors which are present or have 
been set into action. For example TGF-p, in a particular fibroblastic cell line, will inhibit 
cell proliferation in the presence of EGF but stimulate proliferation in the presence o f  
PDGF.71 A lso the action of growth factors depends on the state o f development or 
differentiation of a target cell (see reference 72 for examples involving TGF-p action). Thus, 
peptide growth factors should be considered as a regulatory apparatus within a more 
complex array and serve simply as a means to convey information from one cell to another. 
It is the responsibility of the target cell from the whole context o f these messengers to 
determine the actual cellular response.
2.3 Signal Transduction— An Overview
The biological action of growth factors are mediated by cell surface receptors, i.e. piasma 
membrane proteins. These serve as external sensors, acting to transmit information from 
outside the cell to its interior. Such a response is usually exhibited by the initiation o f a 
cascade o f enzymatic biochemical reactions that ultimately results in changes in gene 
expression and cell division (Figure 7). As indicated, activation of a receptor often leads to 
the phosphorylation o f intracellular proteins. This is a common regulatory event within a 
cell73 and not only serves to alter enzymatic action, as in this receptor-signalling system, but 
in the metabolic pathways o f a cell74 increases a substrates reactivity. In essence, 
phosphorylation “moves” a substrate from one state to another. Thus, an enzyme which 
catalyses the transfer of a phosphate groups from ATP to another molecule is called a kinase 
(from the Greek for motion or action, kiriema). If the recipient molecule is a protein and is 
phosphorylated on the amino acid tyrosine, then the enzyme is called a protein tyrosine 
kinase (PTK).
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Figure 7 Schematic of Intracellular Signal Transduction
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The PTKs can be divided into three categories, v iz .: receptor-linked PTKs, or receptor 
tyrosine kinases (RTKs), which are found bound to the cell membrane; non-receptor linked, 
cytosolic PTKs, which are found in the more fluid portions of the cytoplasm; and non­
receptor-linked PTKs, which are also found bound to the cell membane. A  notable example 
of a RTK would include the epidermal growth factor receptor (EGF-R). This belongs to a 
family o f growth factor receptors which possess intrinsic tyrosine kinase activity.75 The 
structural organisation of this receptor76, and family members77, is composed of several 
distinct domains: an extracellular domain for ligand binding; a transmembrane a-helical 
domain; and a cytosolic PTK domain for ATP and substrate binding (Figure 8).
In cancer, such growth factor receptors have often been altered in their normal functioning. 
This could be due to an abnormally high expression o f the cellular receptor itself, as in the 
case of the erbB -2  oncogene,78 an EGF-R like product in breast and ovarian carcinomas. 
Alternatively, a number of receptors become oncogenic as a consequent o f structural 
changes (or truncation) of their ligand-binding domains. These non-receptor-linked 
membrane-bound PTKs remain active even in the absence o f growth factor stimulation and 
would include the oncogenes ret,19 trk?° and the Src-family81 o f PTKs.
At least four distinct protein targets have been recognised to be initially phosphorylated by 
the RTKs in the signal transduction processes o f the cell (Figure 9). These would include: 
phosphatidylinositol 3-kinase (PI 3-kinase) and phospholipase C (PLC), which regulate the
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molecular weight compounds or ions. It is these so-called second messengers that activate a 
cascade of biochemical events which eventually leads to an end response. Figure 10 
illustrates the most important types but excludes the calcium ion (Ca2+) which is also a 
highly utilised second messenger in the signal transduction processes of the cell.
As the phosphorylation of signalling proteins on tyrosine is essential for regulation of 
growth and differentiation, any excessive tyrosine phosphorylation would be expected to be 
detrimental to normal cellular activity. Indeed, the level of tyrosine phosphorylation in a cell 
is modulated by a family of enzymes called protein tyrosine phosphatases (PTPs) which 
specifically dephosphorylate tyrosine residues on their target proteins.82 Furthermore, it is 
perhaps not surprising that PTPs are also involved in the pathogenesis o f certain human 
diseases, including cancer.83
As for the PTKs, the PTPs can be grouped into discrete categories, namely those that are 
cytosolic or membrane-bound (non-receptor-like), and those that span the plasma membrane 
(receptor-like). But, despite the division, all PTPs share a common catalytic core of ca. 250 
amino acids comprised of ca. 21 invariant residues, many of which appear to be essential for
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Figure 10 Important Second Messengers
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phosphatase activity.84 Unfortunately, this area of research is still in its infancy and little is 
known about the specific biological roles of these proteins. However, the study of PTPs 
should provide important insights into the understanding of normal growth and development 
as well as the molecular basis of cancer. The beginings of this understanding is exemplified 
by the demonstration that certain PTPs (CD45 and Cdc25)85 cause cells to enter mitosis as 
opposed to merely quenching signals that have been generated by the PTKs. Thus, PTPs 
have also been implicated as positive regulators of cellular processes.
Although phosphorylation and dephosphorylation events on tyrosine residues are an 
essential regulatory feature of many signal transduction pathways, it is not the sole amino 
acid to be utilised. Thus phosphate esters are also formed on serine and threonine residues 
which, as for tyrosine, are controlled by kinases (protein-serine/threonine kinases or PSKs) 
and phosphatases (protein serine/threonine phosphatases or PSPs).86 In some cases the 
phosphoramidate counterparts of the basic amino acids histidine,87 lysine,88 and arginine39 
have been known to occur, and recently “dual specific” kinases (DSK s)90 and phosphatases 
(DSPs)91 have been described, so-named due to their ability to act both on tyrosine and 
serine/threonine residues.
Thus the enzymatic machinery of the signal transduction processes is complex and is finely 
tuned in order to compensate for each other’s actions. Accordingly this is a complex area 
and it is beyond the scope of this thesis to give a detailed narrative on all aspects of cell 
communication. However an attempt has been made in Table 1.5 to summarise the 
(presently) known essential features of signal transduction and the reader should refer to the 
reviews for further information.
2.4 Signalling Guides— Modulators of Protein Interaction
The recent progress in deciphering the signalling pathways of a cell has highlighted key 
protein motifs that are intimately involved in the modulation of protein-protein interactions. 
These so-called protein modules are highly conserved sequences and examples, which 
include Src homology domains (SH2 and SH3) and pleckstrin homology domain (PH), are 
found in a wide variety of intracellular signalling proteins, either singly or in combination.92 
The SH2 domains function as motifs capable of binding to short protein sequences that bear 
phosphorylated tyrosine residues, whereas the SH3 domains prefer to bind to sequences 
with one or more proline residues (the PH domain is less understood). In any case the result
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Table 5 Signal Transduction Processes—An Overview
Second Messengers in Signalling Pathways
Second Messenger Main Substrates Affected Reviews
cyclic AMP (cAMP)
cAMP is generated by the adenylyl cyclase (AC) family of isozymes.
Functions in muscle contractility, glycogenolysis, lipolysis, 
steroidogenesis, ion channel/pump modulation, and growth factor & 
inflammatory responses. Also cAMP controls a PSK family of 
cytosolic enzymes: called cAMP-dependent protein kinases (PKAs).
93
94
cyclic GMP (cGMP)
cGMP is formed by guanylyl cyclase: an enzyme which can be 
receptor-linked (controls water/Na+ loss in kidney) or cytosolic 
(involved in muscle contractility) but is also activated by NO. 
Also cGMP controls a family of PSKs: cGMP-dependent protein 
kinases, types I and II; and directly controls retinal ion channels.
95
96
Phospholipid hydrolysis 
products (IP3, DAG)
A phopholipase C (PLC) cleaves phosphatidyIinositol-4,5- 
bisphosphate (PIP2), a minor component of the cell membrane, to 
DAG and IP3. DAG remains membrane-bound and with Ca2+ activates 
PSPs: e.g. protein kinase C (PKC) which, in turn, modulates AC, 
cAMP phosphodiesterases (PDEs), and ion channels/pumps. IP3 
migrates to, binds, and then activates receptors on the endoplasmic (or 
sarcoplasmic) reticulum stores thereby allowing rapid Ca + release.
97
98
Calcium ions (Ca2+)
Ca2+concentrations play a fundamental role in muscle contraction, 
secretion, mitosis, chemotaxis, glycogenolysis, and steroidogenesis. Is 
mediated: extracellularly, via voltage-sensitive, receptor-operated, or 
second-messenger channels; intracellularly, via IP3-receptors or 
ryanodine channels of endoplasmic reticulum Ca2+ stores. Important 
Ca2+ binding proteins include calmodulin and in muscle cells troponin 
C which bind and then modify the activity of other receptor proteins.
99
Nitric oxide (NO)
NO is a physiological mediator and is generated from arginine by 
Ca2+-dependent nitric oxide synthases: iNOS (which is important in 
macrophage host-defences), and nNOS & eNOS (which are important 
in the regulation of blood pressure and CNS transmission).
100
is temporal localisation of a protein substrate to its host and enables the regulation of
cellular events such as protein trafficking or relocalisation, and the enhancement of catalytic 
activity. Very recently an alternative phosphotyrosine-binding domain (designated PTB) has 
been identified but as yet its function and occurrence remains to be fully elucidated.101
2.5 Signalling and Transcription
To finalise fully a general discussion on signalling pathways, one should connect these 
intracellular pathways to the factors that directly influence gene expression, Le. the 
transcription factors or gene promotor/enhancer proteins. These are factors which contain 
specific nucleotide regulatory sequences for a particular gene and are able to control DNA
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Table 5 Signal Transduction Processes—An Overview (continued)
Generic Enzyme Signalling Pathways
Enzyme Family Brief Description Reviews
Receptor-linked 
PTKs (RTKs)
RTKs such as EGF-R or PDGF-R are well recognised to participate in 
mediating cellular processes (proliferation, differentiation, division) 
by initiating a set of signalling molecules (PI3-kinase, S6 kinase, PIC 
or PLC-y , GAP, Grb2, SHPTP-2 (a PTP), Src family) plus signalling 
cascades (e.g. Ras, MAP kinase & JAK-STAT)—see below.
102
G-protein 
coupled receptors
i
Hormones, neuropeptides/neurotransmitters and vasoactive peptides 
are known to transmit their signal via G-protein coupled receptors.
These comprise a large superfamily of receptors which operate 
through guanine nucleotide binding (G) proteins (e:g. Ras) and are 
known to activate multiple effector systems (e.g. ion channels, AC; 
activation of PIC, PKC, and the MAP kinase cascade; plus possibly 
the JAK-STAT pathway-below entries). Structurally, they consist of a 
cluster of 7-transmembrane helical domains that describe a pocket for 
ligand binding-with intracellular loops involved in G-protein coupling
103
Kinases in 
phospholipid signalling
PIP2 (PtIns(4,5)P2) hydrolysis is a mitogenic signal implicated in both 
the normal and pathological control of cell growth. This is regulated 
by an inositol lipid-specific PLC called a phosphinositidase C (PIC) & 
generates IP3 (Ins( 1,4,5)P3, which releases Ca2+) plus DAG (which 
activates PKC). Many other phosphorylated forms of membrane- 
bound inositol lipids play several distinct (but still undefined) roles in 
cell signalling. Phosphatidylinositol 3-kinase (PI 3-kinase)—a DSK 
activated by RTKs (via PLCy), G-protein coupled receptors (via 
PLCp), and T-Ras—produces a set of 3-phosphorylated lipids from 
PIP2 (PIP3 or PtdIns(3,4,5)P3; PtdIns(3,4)P2; PIP or PtdIn(3)P) which 
have been correlated with cell proliferation and motility. One of these 
products PIP3 is a specific activator of certain isozymes of PKC.
104
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106
transcription by interaction with RNA polymerase III, a nuclear enzyme that synthesises
RNA from a DNA template. Such an interaction may be considered analogous to the 
interactions o f growth factors with their receptors and is exemplified by the c-fos gene 
product associating with the jun  protein (p39) thereby forming an activating protein (AP-1) 
which can stimulate synthesis at its designated DNA binding site.107
Today a great deal of effort is being directed at ascertaining these transcriptional events and 
burgeoning evidence is giving a better insight into the contextual (or pleiotropic) nature of 
the external instigators of such events, i.e. the growth factors.108 For example, signal 
convergence can occur from different growth factor receptors via the MAP kinase pathway 
and ends in the regulation of the activity of a transcriptional factor, serum response element 
(SRE), known to regulate activity at the c-fos gene.109 In some cases, activation of a
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Table 5 Signal Transduction Processes—An Overview (continued)
Generic Enzyme Signalling Pathways
Enzyme Family Brief Description Reviews
MAP kinase cascade
Mitogen-activated protein (MAP) kinases and their cloned gene 
products (called extracellular regulated kinases, ERKs) are activated 
by a wide variety of external signals through many cell-surface 
receptors via c-Raf-l (e.g. RTKs, serpentines, cytokines and others). 
They represent a ubiquitous unit of phosphorylation events that couple 
upstream input signals to a variety of outputs: e.g. negative growth 
control, differentiation, proliferation and stress responses; whereby 
each kinase is regulated by a partner kinase, i.e.: MAP kinase 
(MAPK) by MAPK kinase (MAPKK, or MEK for MAPK/ERK 
kinase); MAPKK by MAPKK kinase (MAPKKK, or MEKK).
110
111
112
Ras signalling network
Ras, a small G-protein, acts as a molecular switch which can 
interconvert between an active GTP-bound form (T-Ras) and an 
inactive GDP-bound form (D-Ras). This interconversion is stimulated 
by a few distinct GTPase activating proteins (GAPS) and is facilitated 
by GDP-releasing factors (GRFs). Ras may be activated to T-Ras by 
RTKs, cytokine receptor aggregates with cytosolic tyrosine kinases 
(Lck, Lyn), or by individual cytosolic tyrosine kinases (Src, Abl, Neu). 
T-Ras also activates c-Raf-\, and thus the MAP kinase cascade.
113
114
115
JAK-STAT pathways
This is a newly recognised pathway whereby the direct activation of 
transcriptional factors occurs via growth factor or cytokine receptor 
stimulation. Thus cytosolic STATs (signal transducers and activation 
of transcription) become transiently associated to activated receptors, 
whereby tyrosine phosphorylation induces STAT homo- & hetero- 
dimerisation and initiates dimer migration to the nucleus (by some 
unknown mechanism). Cytokine receptors lack intrinsic PTK activity 
& recruit members of the JAK (Janus kinase) family to act as adaptor 
proteins thereby forming aggregates able to phosphorylate the STATs.
116
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transcription factor requires the dual or multiple action of different pathways of the cell, 
e.g. the full activation of the transcription factor AP-1 requires both the calcium and PKC 
dependent pathways in activated T-cells."8 Futhermore, depending on the specific physical
interactions among the STATs, JAKs, and receptors, a repertoire o f differing STAT 
complexes may be formed. A few of these have been shown to elicit different DNA  
sequence specificities and thus illustrate a further mode of contextual regulation.119
CHAPTER «3» Signalling at the Epidermal Growth Factor-Receptor
Unequivocally, cancer is a genetic disease and disruption in the regulation of proto­
oncogenes and tumour suppressor genes is the fundamental cause for the onset and 
progression o f the neoplastic state. In general, most o f these cancer-associated genes are 
integral participants in the signalling pathways of a cell (Table 6). In that sense, cancer may
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Table 6 Functions of Oncogene & Tumour Suppressor Gene Products
Cellular Function (or Class) Representative Gene (and/or Product)
Growth factors
sis (PDGF B-chain), 
fgf-5, hst & int-2 (all FGF-like) 
EGF, EPO, IL-2, IL-3, CSF-1, GM-CSF
Growth factor receptors
erbB (EGF-R), erbB-2 (heregulin-like receptor) 
fins (CSF-R), kit (SCF-R), trk (NGF-R) 
met, ret, ros
Intracellular transducers
abl, lek, Src family, & yes (all PTKs)
Ref family, pim , & mos (all PSKs) 
gsp & Ras family (all G-proteins) 
sos (a GRP); NF-l (a GAP-like suppressor gene) 
grb, crk, nek, & she (all adaptor proteins)
Nuclear transcription factors fos/jun (AP-1), myc, myb, rel, E2A, 
RB,p53 &VVT1 (all suppressor genes)
Steroids receptors (transcriptional regulation) erbA\ RAR
Cell adhesion/matrix control DCC, APC & NF2 (all suppressor genes)
Cell survival bcl-2 (inhibits apoptosis)
be considered a disease of intracellular signalling and that the overexpression, mutation, or 
inactivation of such gene products will subvert a normal cell into an unhealthy state.120 For 
this reason, there has been a surge of activity in recent years to develop signal transduction 
inhibitors in order to circumvent or reverse such oncogenic processes.
3.1 Rationale for Targeting EGF-R
Within the plethora of signal transduction processes there are many conceivable areas of 
intervention. However, particular interest has centred on the signalling pathways associated 
with the epidermal growth factor receptor (EGF-R) since an abundance of experimental 
evidence has implicated its involvement in many human cancers.121 Clinical evidence, 
amongst others, shows that high levels of EGF-R are often found in epithelial tumours of the 
breast, bladder, oesophagus, and lung, as well as gynecological malignancies of the ovary, 
cervix and vulva. Related studies have shown that the gene encoding EGF-R (c-erbB) is 
often amplified or overexpressed in human squamous cell carcinomas, mammary 
carcinomas and bladder carcinomas. Further genetic investigations have shown oncogene 
products to be homologous to EGF-R (erbB-2 or HER-2/neu, plus erbB-2 and erbB-4) and 
these oncoproteins are overexpressed in carcinomas of the breast, stomach, ovary, and
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lung.122 Moreover, the growth factors which activate EGF-R signalling (EGF and TGF-a) 
are commonly co-produced with EGF-R in either an autocrine or paracrine fashion 
(.cf. Figure 1.6) to give continual growth stimulation of various human tumours including: 
glioblastomas, oesophageal squamous-cell carcinomas and adenocarcinomas of the lung, 
stomach, colon, pancreas, kidney, ovary and breast.123 In addition, it has been observed that 
certain tumour cells are more dependent on the EGF-R signalling pathway for proliferation 
than their normal counterparts (e.g. breast carcinoma cells).124
All this information has provided a strong impetus for the development o f anticancer agents 
targeted at the EGF-R growth control pathway. However, there are many possible points of 
pharmacological intervention along this pathway, from inhibiting growth factor binding 
through interference with the phosphorylation of regulatory proteins and transcription 
factors via specific protein kinases and phosphatases. Therefore, in order to devise a precise 
target, tliis mitogenic signal transduction process should be studied in more detail.
3.2 EGF-R Kinase Activation
A variety of viral and cellular ligands are known to activate EGF-R but among these the 
most important include the mammalian polypeptide growth factors:125 epidermal growth 
factor (EGF), transforming growth factor-alpha (TGF-a), and amphiregulin (produced by 
human MCF-7 adenocarcinoma breast cells).126 Ligand binding of these growth factors to 
the extracellular domain of EGF-R (see Figures 7 and 8) stimulates a conformational change 
that allows the transmembrane a-helical anchor to either rotate or slide within the cell 
membrane. In this model, this leads to adjacent receptors to cluster and is referred to as 
allosteric receptor oligomerisation (or dimerisation).127 This then leads to the ability for 
intimate receptors to phosphorylate each other on tyrosine residues located within their 
adjacent carboxy-terminal segments128 (a process called autophosphorylation or cross­
phosphorylation; Figure l l ) . 129 These autophosphorylation sites serve the function o f  
creating suitable docking regions for down-stream signal transduction proteins that contain 
SH2 domains. Importantly, this provides the necessary activation step required for substrate- 
binding to the intracellular PTK domain.
However, very recently, an alternative model for EGF-R activation has been proposed and 
suggests that dimerisation is not a prerequisite for receptor activation.130 Moreover, the 
functional state of the EGF-R is a preformed but inactive dimer form that only becomes
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Figure 11 Ligand-Induced Dimerisation and EGF-R Activation
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activated on ligand binding. Futhermore, it is postulated that the stereochemical 
requirements enforced by the closely bound ligands induce a mutual rotation (or twist) of 
the receptor monomers that enables an appropriate orientation for PTK activation to occur. 
In any case, the result is a fully functional cytosolic region of the EGF-R with intrinsic PTK 
activity and enables the subsequent tyrosine phosphorylation o f many SH2-containing 
intracellular proteins (see Figure 9 for examples).
3.3 Signalling Cascades at EGF-R
The activation of EGF-R can initiate a variety of signalling cascades and, in general, the 
intervening regulatory steps still remain to be fully elucidated. However, recent progress has 
deciphered at least three main pathways that link the action of extracellular growth factors 
such as EGF and TG F-a to the transient induction of nuclear oncogenes that encode 
transcriptional regulatory proteins. Two of these signalling cascades have been illustrated in 
Figure 12 (see Table 5 and also “List of Abbreviations” if necessary). As indicated, the 
cytoplasmic STAT proteins become transiently associated with EGF-R during activation, 
and phosphorylation at their C-termini allows STAT dimerisation. Following this the STAT 
dimers translocate to the cell nucleus, by some unknown mechanism, whereby they bind 
directly to specific DNA sequences, e.g. the SEE (sis inducible element) site found on the 
c-fos gene (this is a base sequence previously recognised to induce sis gene expression).131
Alternatively, EGF-R activation triggers PLC-y mediated PIP2 hydrolysis to generate the 
second messengers DAG and EP3. Recendy it has been highlighted that this step requires a
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Figure 12 Two Signalling Cascades at the EGF-R
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further protein called phosphatidylinositol transfer protein (PITP).132 In any case, the product 
D A G  stim ulates a PSK called protein kinase C (PKC) w hile IP3 releases intracellular 
calcium  from endoplasmic reticulum (ER) stores by acting on specific IP 3-receptors (IP3-R).
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Through serine/threonine phosphorylation events, PKC leads to the activation o f the 
transcription factors AP-1 and SRE which can then assist gene expression.
PKC is also mediated by calcium and initiates many, and as yet unmapped, kinase cascades. 
In addition, it has the function o f down-regulating the EGF-R by phosphorylating a 
threonine residue (Thr654)— this is a common regulatory event to alter the signalling activity 
at this receptor.133 Not shown in Figure 12 is the conversion o f DAG into a C20-fatty acid 
called arachidonate, a prostaglandin (PG) precursor, which can regulate cytosolic signalling 
or, as a PG, be transported out of the cell to act at specific adenylyl cyclase (AC) coupled 
receptors. Futhermore, changes in calcium levels modulate various calcium- and voltage- 
dependent ion channels for growth related processes and, while still poorly defined, this has 
recently been associated with the phenomenon of apoptosis.134
One of the most noteable achievements in recent years has been the connection o f Ras, a 
small GDP/GTP-binding (G) protein, to the EGF-R or PDGF-R signal transduction 
pathways. The significance of this finding is that mutations in the Ras protein have long 
been associated with a large proportion (around 30 %) o f all human carcinomas and, in 
particular, with 90 % of pancreas and 50 % of colon cancers.135 This is yet more convincing 
evidence to concentrate on inhibiting EGF-R signalling pathways.
The sequence o f events in this pathway is illustrated in Figure 13. Thus EGF-R activation 
promotes binding o f a non-catalytic unit called growth factor binding protein (Grb2) via its 
SH2 domain. This so-called adaptor protein is constitutively bound to a GDP releasing 
factor (a GRP) called son-of-sevenless (Sos) via its two SH3 domains. This brings Sos to the 
membrane whereby it activates D -Ras into its active T -Ras state by facilitating the 
exchange o f GDP for GTP (c/. “Ras signalling network” in Table 5). Not indicated, is the 
fact that the Grb2-S0.s complex may also bind to EGF-R indirectly using an additional 
phosphorylated adaptor protein, She, which binds through either its SH2 domain or, more 
likely, through its PTB domain.136 In any case, T-R as  associates with a MEKK called 
c-Raf-l (a PSK) which, when bound to the cell membrane, becomes activated and thus able 
to initiate the MAP kinase cascade (see Table 5). At the end o f this sequence, MAP kinases 
regulate the expression of various transcription factors, including SRE which regulates c -fas 
expression, as well as affecting other components of the cell, e.g. PSKs, the cytoskeleton, 
and inflammatory mediators such as cytoplasmic phospholipase A2 (cPLA2).
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Figure 13 EGF-R Activation of MAP Kinase Cascade via Ras
binding
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CH APTER «4» Cancer Treatment & Chem otherapy
If an individual has the unfortunate diagnosis o f having cancer, a variety c f  possible  
treatment options may be considered (see Table 7). The choice o f treatment is determined by 
the type o f cancer and the extent to which the disease has progressed. Generally the limiting 
factor is m etastasis and, more often than not, drug resistance results from a given  
chem otherapeutic drug. Above all this, the present day anticancer drugs are grossly  
unselective and interfere with rapidly dividing cells such as the haematopoeitic, intestinal 
epithelial, and hair follicle cells. These results have lead researchers to develop alternative 
treatment strategies (see later sections).
4.1 Cancer Treatment
Cancer treatments in the clinic are continually improving and often require the combination 
of surgeon, radiotherapist, clinician and oncologist. Together with the correct choice o f  
chemotherapy a w hole range o f success stories have resulted. A  list o f these could include: 
acute lymphocytic leukaemia o f childhood, Hodgkin’s disease, Burkitt’s lymphoma, Ewing’s 
sarcom a (a form  o f  bone cancer), W ilm ’s tumour (a kidney cancer in children), 
rhabdomyosarcoma (a cancer o f the muscle tissue), choriocarcinoma (a malignancy o f the
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Table 7 Current Cancer Treatments
Treatment
Method
Discussion
Surgery137
This is the first line of attack against most cancers. If operable (unlike brain 
tumours) removal of a benign tumour (or carcinoma in situ if diagnosed early) 
results in a complete cure. Thus early diagnosis is essential but unfortunately about 
70% of cancers have already metastasised and therefore cannot be eliminated by 
surgery alone. Nevertheless, clinical staging of the primary tumour mass still forms 
an integral part of treatment, in combination with radiation and chemotherapy.
1Radiotherapy
This is primarily used for the treatment of localised cancers that have spread beyond 
the scope of surgical removal and is used in combination as such. For some cancers 
it is the preferred treatment due to their sensitivity to DNA damage (via radical 
formation). However, its effectiveness is limited by the fact that radiation is not 
selective for cancer cells and is often highly toxic to the patient leading to anaemia, 
nausea, vomiting, diarrhoea, skin damage, hair loss, and sterility.
139Chemotherapy
Surgery and radiotherapy are frequently limited by metastasis of cancer cells and 
often the adminstration of chemotherapeutic drugs is required. Unfortunately, most 
clinically used drugs act by damaging DNA or by interfering with DNA synthesis 
and, like radiation, unselectively kill rapidly dividing cells giving the same adverse 
side effects (see previous entry). The goal of the physician is to regulate doses such 
that cancer cell death is maximised while maintaining normal cell survival.
Drug Resistance140 
and Combination 
Chemotherapy
Often a drawback of chemotherapy is drug resistance whereby a small proportion of 
tumour cells remain and thus reform a tumour. In certain cases the genetic instability 
of cancer cells also renders them resistant to many drugs (multidrug resistance). 
This may be combatted by administering a spectrum of chemotherapeutic agents 
with alternative modes of action and toxicity patterns (combination chemotherapy). 
This has resulted in most of the progress in chemotherapy over the last few decades.
Bone marrow 
transplantation141
An approach to bypass the toxicity of cancer therapies to rapidly dividing 
haematopoeitic cells is to perform bone marrow transplantations thereby allowing 
higher drug or radiation doses. This is often employed for the treatment of 
leukaemias & lymphomas, but also for solid tumours. Unfortunately, during & after 
this operation the immune system is impaired & there is a high risk of infection.
Hormone therapy142
Some cancer cells still can respond to growth factors and manipulation of hormone 
levels can be an effective means of cancer treatment. For eample: breast cancers can 
be treated with tamoxifen (an antagonist at the oestrogen receptor); endometrial 
cancer is inhibited by progesterone (a natural inhibitor of proliferation in the 
menstrual cycle); prostate cancer can be suppressed by stopping androgen (e.g. 
testosterone) production at the testes; leukaemias and lymphomas may be controlled 
by glucocorticoids-usually prednisone, a natural antiproliferative of lymphoid cells.
Immunotherapy143
Immunotherapy is an attempt to stimulate the natural defence mechanisms of the 
body to eliminate cancer cells. In the treatment of human colon carcinomas the 
general immune stimulant, levamisole has been proved useful in combination with 
the chemotherapeutic agent, fluorouracil. More specific immunostimulants would 
include: tumour-infiltrating lymphocytes (possess antitumour activities) in 
combination with their cytokine growth factors, interleukin-2 (an interferon) or 
tumour necrosis factor; monoclonal antibodies, alone or for drug targeting.
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placenta), testicular cancer, certain ovarian cancers, and oestrogenic sarcoma. 
Unfortunately, these have a relatively low incidence and the major types of cancers which 
occur in adults (breast, lung, colon, and prostate) remain largely incurable. Nevertheless, 
early diagnosis and prompt treatment by the forenamed arsenal o f specialists, in 
combination with chemotherapy, still holds the best hope for a patient’s long-term survival.
4.2 Classical Chemotherapeutic Agents
The beginings o f  chemotherapy can be traced back to the times of Paul Ehrlich 
(1854-1915)144 who coined the term “chemotherapy” as the classical cure o f infectious 
diseases (1891).145 Although his seminal work (ending 1910) provided a “magic bullet” 
against syphilis (not cancer), the arsenobenzyl compound called salvarsan (1), was 
undoubtedly the first true chemotherapeutic agent. Importantly, this led to an organisation of
pharmaceutical research which has not changed materially to the present day and is
/
inextricably linked to cancer research. Since that time the emergence of various forms of 
chemotherapeutic agents targeted at cancer has resulted.
OH
As
HO
Today the choice o f clinically proven chemotherapeutic agents is continually being 
reassessed as rapid developments in this field occur. The current status (from Goodman and 
Gilman)146 o f compounds worthy of being characterised as chemotherapeutic agents (with 
acceptable toxicity limits) has been classed and summarised in Table 8. These classes of 
drugs are still predominantly used in cancer chemotherapy today and each class often 
reflects its mode o f  action. For an overall perspective on cancer chemotherapy and 
chemistry o f anticancer agents the reader is refered to the literature.147
Ironically, the alkylating agents are very potent carcinogens and mutagens. As inferred by 
their name, they become covalently bound to a diverse set of cellular constituents, disrupt 
the normal function o f the cell and therefore exhibit an overall cytotoxic effect. The nitrogen 
mustards act as D N A  cross-linkers:148 as do the aziridines, the alkane sulfonates, the 
nitrosoureas, and several of the platinum complexes. Repair mechanisms within the cell
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease
Name Structure Cancer Application
Alkylating Agents
Mechlorethamine (HN2)
Nitrogen Mustards: 
CH3N(CH2CH2C1)2 Hodgkin’s disease, non- 
Hodgkin’s lymphomas
Cyclophosphamide (CP)
0
II
HO ~  P— N(CH2CH2a ) 2
n h 2
Acute and chronic 
lymphocytic leukaemias, 
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, 
multiple myeloma, 
neuroblastoma, breast, ovary, 
lung, Wilm’s tumour, 
rhabdomyocarcoma
Meiphalan 
(L-sacolysin, L-PAM)
^ ^ ^ N ( C H 2CH2q )2
r x  j
H
Multiple myeloma, 
breast, ovary
Uracil mustard (Dopan)
0
J L  N(CH2CH 2Q) 2 
HN Y
.  x j
H
Chronic lymphocytic 
leukaemia, Hodgkin’s disease, 
non-Hodgkin’s lymphomas, 
ovary, primary 
thrombocytosis
Chlorambucil
^ ^ / N(CH2CH2a ) 2
X J
H02C(CH2)3
Chronic lymphocytic 
leukaemia, Hodgkin’s disease, 
non-Hodgkin’s lymphomas
Myleran CH3S 0 20(CH2)40S02CH3 Chronic myeloid leukaemia
Carmustine (BCNU)
Nitrosoureas:
v  N N 
1 H
N * o
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, 
primary brain tumours, 
multiple myeloma, 
malignant melanoma
Lomustine (CCNU)
R =' \ ^
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, 
primary brain tumours, 
small-cell lung
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease (continued)
Semustine (MeCCNU)
R=
Primary brain tumours, 
stomach, colon
Streptozocin
(streptozotocin)
H O ^
OH
H O ^  f
NHCON(NO)CH3
Malignant pancreatic 
insulinoma, malignant 
carcinoid
Dacarbazine (DTIC; 
dimethyltriazenoimidazole 
carboxamide)
m . c o n h 2
< f T _ ^N (CH 3h
g  N = N
Malignant melanoma, 
Hodgkin’s disease, 
soft-tissue sarcomas
Antimetabolites
Methotrexate
(amethopterin)
Folic Acid Analogues:
o  c o 2h
^  1 1 *  HO^C
h3n  n  013
Acute lymphocytic leukaemia, 
choriocarcinoma, mycosis 
fungoides, breast, 
head and neck, lung, 
osteogenic sarcoma
Fluorouracil 
(5-fluorouracil; 5-HT)
Pvrimidine Analogues:
A 'O N 
H
Breast, colon, stomach, 
pancreas, ovary, head and 
neck, urinary bladder, 
premalign ant skin 
lesions (topical)
Cytarabine 
[cytosine arabinoside; 
l-( P-D-arabinofuranosyl)- 
cytosine, araQ]
n h 2
HO
Acute granulocytic and acute 
lymphocytic leukaemias
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease ( continued)
Mercaptopurine 
(6-mercaptopurine; 6 -MP)
Purine Analogues: 
Nw H
Acute lymphocytic, acute 
granulocytic, and chronic 
granulocytic leukaemias.
Thioguanine 
(6-thioguanine; TG) xV >h 2n ^ n > ' n
Acute lymphocytic, acute 
granulocytic, and chronic 
granulocytic leukaemias.
Natural Products
Vinblastine (VLB) 
[Rl=CH3 ,R 2= o c h 3, 
R3=COCH3]
Vincristine (VCR)
[R' = CHO, r 2= o c h 3, 
R3=COCH3]
Vindesine (VDS) 
[Rl=CH 3 ,R 2= N H 2, 
R3=H]
Vinca Alkaloids:
OH
t t r U S Q
c h 3ooc  |  r  1 J n
Rl HO COR2
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, 
breast, testis
Acute lymphocytic leukaemia, 
neuroblastoma, Wilm’s 
tumour, rhabdomyosarcoma, 
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, 
small cell-lung
Lymphomas, blastic crisis of 
chronic granulocytic 
leukaemia, systemic 
mastocytosis
Etoposide (VP-16) 
Teniposide (VM-26)
Epipodophvllotoxins:
c h 3^ 2 ^ 0
e * V P 1 6
ch3o ^ V ^ och3
OH
Testis, small-cell lung and 
other lung, breast, Hodgkin’s 
disease, non-Hodgkin’s 
lymphomas, acute 
granulocytic leukaemia, 
Kaposi’s sarcoma
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease ( continued)
Dactinomycin 
(actinomycin D)
Antibiotics: 
ch 3 ----------------- 0 ---------------- 6?
"v 0 I 0 j
N * N (D-ValH L-Pro)-(X)-NCH 3CH ‘f t
0  N x= Sarcosine
H jc /  C• N - p n "  (D-ValHL-ProMX>-NCH3CH'Pr
V -s :  0  H 0  1
O NH, CH3 J----------------- 0 -----------"^q
Choriocarcinoma, Wilm’s 
tumour, rhabdomyosarcoma, 
testis, Kaposi’s sarcoma
Daunorubicin (R= H) 
(daunomycin; 
rubidomycin)
Doxorubicin (R= OH) 
(adriamycin)
0  OH 
OCH3O OH 0
CH3- r ^ 7  
r  n h 2
OH
Acute granulocytic and acute 
lymphocytic leukaemias
Soft-tissue, oesteogenic, and 
other sarcomas; Hodgkin’s 
disease, non-Hodgkin’s 
lymphomas, acute luekaemias, 
breast, genitourinary tract, 
thyroid, lung, stomach, 
neuroblastoma
Bleomycin (mixture of ca. 
70% bleomycin A 2 and 
30% bleomycin B2)
CONH, NH,
0
N N a t ,  ch3
W  8 HOrSr V"™
' V  ° — . OH JL f
0H 1 S X N * , 
OH OCONHj ^ (, *h
CONH
[A,: R=*S(CH3)j 4  B j  R= CH,NHC(=NH)NH,]
Testis, head and neck, skin, 
oesophagus, lung, and 
genitourinary tract; Hodgkin’s 
disease, non-Hodgkin’s 
lymphomas
Mitomycin (mitomycin C)
0  ^  OCONH2
H2N t V \  ' 0 C H 3
h 3c x ^ Y ^ n ^ J ] ^ n h
0
Stomach, cervix, colon, 
breast, pancreas, bladder, 
head and neck
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease (continued)
Plicamycin (mithramycin)
HO
o ^T ^-4
0H
/ 0 —  OH
JL .JL
$  ' cHO. 0 0
x °  <&!HO CH, 1 
OH
Testis, malignant 
hypercalcaemia
L-Asparaginase
Enzymes:
Acute lymphocytic leukaemia
Hormones and antagonists
Prednisone
Adrenocorticosteroids:
C H ^ V
HO
Acute and chronic 
lymphocytic leukaemias, 
Hodgkin’s disease, non- 
Hodgkin’s lymphomas, breast
Medroxyprogesterone 
acetate (no double-bond)
Megestrol acetate (contains 
double-bond, 
as shown)
Progestins:
<xf T y < *
c h 3
Endometrium, breast
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease (continued)
Diethylstilbestrol
HO
Oestrog
(
f v S
S s ^  h 3c
ens:
■H3
Breast, prostate
Ethinyl oestradiol
c h 3 P h
Breast, prostate
Tamoxifen
Antioestrogens: 
(CH3)2N(CH2)2Q ^  ^  ^  ^
Breast
Testosterone propionate
Androgens:
p u  OCOCH2CH3
r— A
x Z P
Breast
Fluoxymesterone
0 X
aH 3j H
H0V / \ L ^ 4 ll,‘013
c h 3t  t  y
F
Breast
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Table 8 Chemotherapeutic Agents Useful in Neoplastic Disease ( continued')
Miscellaneous Agents
Cisplatin ( cis-DDP)
Platinum Coordination Complexes:
C k .  , n h 2 
c r n h 2
Testis, ovary, bladder, head & 
neck, lung, thyroid, cervix, 
endometrium, neuroblastoma, 
osteogenic sarcoma
Hydroxyurea
Substituted Urea: 
0
H2N n  
H
Chronic granulocytic 
leukaemia, polycythemia vera, 
essential thrombocytosis, 
malignant melanoma
Procarbazine 
(N- me thy Ihy drazi ne, MEH)
Mcihxlhydn
H
h 3c x  1
N V
H
1 
o
nvarive:
0  1 
a A
H
Hodgkin’s disease
Mitotane (o,/?'-DDD)
Adrenocorti
X
2Ql $WU 
CHC
c x y
ressant:
X
0
Adrenal cortex
Aminoglutethimide
O ^ N  O 
H
Breast
cannot cope with such adducts and often DNA strand scission occurs. A lso, alkylation o f  
D N A  decreases its ability to act as a template for transcriptional processes.149 Although 
alkylation can occur at any time, its biological consequences are more severe when it occurs 
during D NA synthesis150 and alkylating agents are said to be proliferation dependent. 
Luckily, this has good implications for selecting out hyperproliferative cancer cells over 
their normal counterparts.
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An alternative way of binding to DNA is in a noncovalent fashion and this is exhibited by 
the so-called intercalating agents. All such drugs possess planar regions capable of stacking 
between the paired bases in DNA. This forms a tight drug-DNA interaction that is critical to 
their cytoxic, mutagenic, and carcinogenic effects.151 Examples of these would include the 
acridines, [e.g. amsacrine or m-AMSA; (2)], anthracyclines (daunorubicin and doxorubicin), 
dactinomycin, bleomycin and plicamycin (see Table 8).
A further mechanism of action is given by the antimetabolites. These interfere with the 
production o f nucleic acids by antagonising the synthesis o f D N A  precursors (i.e. the 
deoxyribonucleoside triphosphates) and therefore inhibit DNA (i.e nucleotide) synthesis. 
Alternatively, or in addition, they may act as purine or pyrimidine base surrogates and, by 
deceiving polymerases, become incorporated into RNA or DNA, and thereby disrupt nucleic 
acid function. Both these mechanisms are demonstrated by 5-fluorouracil, the thiopurines 
(6-mercaptopurine and thioguanine) and also the modified nucleoside sugar, cytarabine (see 
Table 8).
Other chemotherapeutic agents act by disrupting a stage in cell division whereby delicate 
chromosomal changes in conformation and position are occurring. Thus inhibitors of 
enzym es that unwind and expose regions o f  D N A  for transcriptional processes 
(topoisomerase inhibitors) show anticancer properties. Notable examples would include the 
epipodophyllotoxins, etoposide and teniposide (see Table 8), and is the principle effect of 
amsacrine152 (2) in creating D N A  strand breaks and cross-links. The vinca alkaloids, 
vinblastine and vincristine, represent a class o f microtubule inhibitors which disturb the 
functioning o f protein polymers (composed o f tubulin dimers)153 that are involved in 
chromosomal segregation. These act by binding to free tubulin dimers and result in the net 
depolymerisation o f microtubules, destruction o f  the mitotic spindle, and arrest o f
H
(2)
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metaphasic cells. In contrast, a revived antitumour agent known as taxol [paclitaxel; (3)]
acts by stablising the equilibrium in the direction of assembly,155 rather than dissembly. 156
OH
OH
HO
Tumour cells that arise from sexually differentiated tissues (breast, endometrium, prostate) 
normally contain hormone receptors and thus are able to respond to physiological hormones 
that naturally affect growth. This is the rationale behind the drugs that affect the endocrine 
system in steroid therapy. Examples include the glucocorticoids, oestrogens, progestins and 
androgens (see Table 8). On one hand it may be necessary to administer a hormone which 
inhibits growth and, on the other, to remove the effect of the growth stimulation made by 
endogenous hormones. This latter case may be acheived by organ removal (e.g.  
ovariectomy), prevention of hormone synthesis (e.g. aminoglutethimide is an aromatase 
inhibitor), or blocking hormone action [e.g. use o f antioestrogens, such as tamoxifen; or 
antiandrogens, such as cyproterone acetate (4) or flutamide (5)].
O
CH
O
F,cD a
(5)
OoN
O
A representative summary of the previously described modes of action o f the clinically 
useful chemotherapeutic agents has been given in Figure 14. As indicated these agents 
mostly intervene at the DNA level. However, this overall picture is changing and different
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points o f intervention are emerging as viable targets for the fight against neoplastic 
processes. This will be discussed in the next section.
Figure 14 Modes of Action of Representative Anticancer Agents
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4.3 New Approaches to Cancer Chemotherapy
Most of the chemotherapeutic agents previously descibed have one major drawback— their 
toxicity to the patient. The root of the problem lies in the rather unselective manner in which 
they exert their anticancer activity. Obviously superior agents and new directions in drug 
discovery and treatment therapies must be developed. Potentially, novel anticancer agents 
may be obtained from a number of sources, as exemplified by the classical agents 
(Table 9 ).157 But, ideally, future anticancer drug discovery should be based on more rational 
and mechanism-based approaches.
Table 9 Methods to the Discovery of Current Anticancer Agents
Targeted
Synthesis
Screening of 
Natural Products
Screening of 
Chemicals
Analogue
Synthesis
Serendipity & 
Rationaf Appln
Antimetabolites: 
Methotrexate 
Thioguanine 
Mercaptopurine 
Fluorouracil 
Cytarabine 
PALA
Hormones: 
Steroids 
Tamoxifen 
Flutamide 
Leuprolide 
Octreotide
Dactinomycin 
Vincristine 
Vinblastine 
Plicamycin 
Daunorubicin 
Doxoxrubicin 
Mitomycin C 
Bleomycin 
Streptozocin 
Taxol
Busulfan
Dacarbazine
Procarbazine
Hydroxyurea
Thiotepa
Carmustine
Lomustine
Mitoxantrone
Altretamine
Pentostatin
Cyclophosphamide
Chlorambucil
Melphalan
Ifosfamide
Etoposide
Teniposide
Carboplatin
Mechlorethamine
Asparaginase
Mitotane
Cisplatin
Levamisole
Interferons
In recent years, biological approaches to treating cancer have received a lot of attention
(consult Table 10 for a referenced listing). This is an area where future breakthroughs will 
probably occur and so it is important to place these in context with other new therapeutic 
agents and regimes. Thus, using the technologies o f recombinant D N A 158 and gene 
therapy,159 one line of attack is to develop immunotherapy protocols160 whereas others utilise 
the natural “magic bullets” o f the body {i.e. the antibodies) to facilitate drug action 
(tumour-directed monoclonal antibodies, MoAbs). Today, radionuclide MoAb-conjugates 
are used to localise tumours diagnostically as well as for the purpose o f radiotherapy.161 
Morever, in 1992, the first MoAb-based diagnostic agent for tumour y-camera imaging 
(OncoScint CR/OV) received approval by the Federal o f Drug Administration162 and 
currently a number of antitumour MoAb-based therapeutics are in clinical trials.163
An important therapeutic strategy for the treatment of cancer involves the use of antisense or 
antigene oligonucleotides.164 These are genetically engineered or chemically synthesised
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Table 10 Biological Approaches to Cancer Treatment
Type o f Treatment L it Type o f Treatment L it
Immunotherapies 165 MoAb-Based Therapies 168
Biomodulators 166 immunotoxin (IT) therapy 169
Interferon Therapy 167 ADEPT 170
Gene Transfer Therapies
Adoptive Immunotherapies 
(interleukin therapies)
V-DEPT
G-DEPT
171
172
LAK-Cell Therapy 173
Clinical approaches and drug 
deliverv
chemosensitivity testing 174
TIL-Therapy 175 liposome-encapsulation 176
CSF-Therapy 177 biodegradable microspheres 178
TNF-Therapy 179 implantable devices 180
to regulate gene expression selectively by acting as complementary sequences to either 
target mRNA (the antisense approach) or to target DNA (the antigene approach). The idea is 
to block an oncogene that is involved in cell immortalisation or cell transformation in the 
neoplastic process.
This is an area o f great excitment and exem plifies the so-called mechanism-based  
approaches to the design of novel anticancer agents.181 A further important example of this 
would include the exploitation o f a characteristic of solid tumours, i.e. their low-oxygen  
(hypoxic) enviroment and enables the design of prodrugs which can become cytotoxic upon 
bioreduction, e.g. Tirapazamine™ or SR 4233 (6).182 Moreover, this may lead the way to the 
treatment o f the major types of solid cancers that have eluded the chemotherapist in the 
past.183
0
1
t
o
(6)
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Thus, the search for new compounds for the treatment o f cancer has been revolutionised by 
our burgeoning knowledge of the “workings” of a cell and how previously known anticancer 
agents exert their effects. Armed with such information, the drug discoverer has been able to 
“design” more effective analogues and many examples have been described in the recent 
literature.184 However, such an exploitation of the classical chemotherapeutic agents will 
only partially circumvent the problems of cytotoxicity and drug resistance which are 
commonly encountered in the clinic today. Clearly, we must use the advancing knowledge 
o f the regulatory mechanisms o f a cell, together with any highlighted molecular (hence 
genetic) differences between normal and deranged cell types, to enable us to design 
selectivity into a potential anticancer agent.
4.4 Signalling & EGF-R Inhibition
As outlined previously, signalling at the EGF receptor represents a formidable target for 
drug intervention and many excellent reviews exist in this area.185 Within the EGF-R 
signalling pathways (see Section 3.3) many specific pharmacological targets present 
themselves (see Table 11 and references therein). For the purpose o f this research work, the 
focus o f this discussion will be on the potential chemotherapeutic utility in developing 
signal inhibitors targeted at the EGF receptor. Theoretically, blocking signalling at or near 
the cell membrane should provide a more selective strategy than going further downstream. 
Indeed, signalling is better understood within this region. Unfortunately, there is the 
possibility that this will not affect a self-perpetuating oncogenic signal or one that is 
activated by other pathways. The mutated forms of the Ras family illustrate a point in this 
matter since these G-proteins are switched “on” irrespective o f the activity at any given 
receptor. Thus, the inhibition of EGF-R would serve no function in these cases. However, it 
should be stressed that any excess activity of the normal forms of the Ras family will still 
contribute significantly to the condition of cancer (this is also true for c-Src, see reference in 
Table 11). Hence, these facts further implicate signal amplification at the EGF-R as being a 
significant factor towards the neoplastic state of a cancer cell (cf. Section 3.1).
In light o f the above, the logical choice is to inhibit activity at the EGF-R. As indicated in 
Table 11, one line of attack is to develop growth factor antagonists or receptor-directed 
antibodies. Unlike the former case, the antibody based agents have shown some success in 
clinical trials and tend to induce internalisation of the receptor. This down-regulation
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Table 11 Signal Transduction Targets of the EGF-R Pathways
Possible Target to Inhibit Literature Examples Ref.
Growth factor action at EGF-R
Growth factor antagonists (Suramin) 
EGF-R raised monoclonal antibodies (MoAb) 
Growth factor or MoAb toxin-conjugates
186
187
188
PTK activity at EGF-R SEE TEXT FOR DISCUSSION
Cytoplasmic PTKs c-Src is a viable target 189
SH2/SH3 domains None cited to date. 190
Ras activation 
(via Grb2JSos & Sos/Ras)
Develop farnesylation inhibitors (as Ras is 
attached to membrane via a famesyl group) 
“Grbstatins” & “Sostatins”, which interfere 
with the complexes opposite, also suggested
191
192
c- Ref- 1 and MAP kinases None-cited to date 193
PKC Suramin, phorbol esters, & bryostatins 194
PLC-y ether lipids 195
PI 3-K myo-Inositol analogues & wortmannin 196
Transcription factors (SRE, AP-1) None cited to date 197
of EGF-R signalling may also be achieved indirectly by stimulating or inhibiting the 
specific action of PSPs or PTPs.198 For example, a cytosolic PTP isozyme denoted by 
PTP1C is known to form a high-affinity complex with EGF-R.199 It is proposed that PTP 1C 
dephosphorylates specific autophosphorylation sites and the augmentation of this process 
should provide an inhibitory effect on EGF-R signalling. Furthermore, agonist action on 
somatostatin receptors is known to stimulate tyrosine phosphatase activity and to inhibit the 
EGF-stimulated growth of pancreatic cancer.200 Therefore, the development of somatostatin 
analogues is another indirect way of controlling signalling at the EGF receptor.
By far the most studied approach to the development of EGF-R signalling inhibitors is based 
on blocking the inherent PTK activity at the receptor itself. Conceivably such PTK 
inhibitors can exert their action in a number of ways, viz.'. to prevent the dimerisation 
process; to inhibit the autophosphorylation process; to block the ATP-binding site within the 
receptor PTK domain; and/or to inhibit substrate-binding to the PTK domain (see Figures 8 
and 11). Although all these are valid targets, it is debatable whether or not the dimerisation 
process is critical to receptor activation (see Section 3.2). Futhermore, the ATP-binding site 
is a highly conserved structural region in all protein kinases and an inhibitor designed to
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only compete with ATP would be expected to exhibit low selectivity and could lead to 
undesirable side-effects, probably toxicity. However, the substrate-binding site is a variable 
region between PTKs and RTKs, and this should increase molecular selectivity and thus 
give a favourable toxicity profile for substrate-directed inhibitors or  ATP/substrate mixed 
inhibitors. Preferably these PTK inhibitors should possess higher receptor-binding affinities 
prior  to autophosphorylation in order to block this activation step and any subsequent 
phosphorylation o f endogenous protein-substrates thereafter.
As chemotherapeutic agents, the PTK inhibitors should invoke a “calming” effect on the 
amplified signals within a cancer cell. In other words, PTK inhibitors should be able to 
“persuade” the cell to enter G0 and block any internal signal that enforces a 
hyperproliferative state. Thus, unlike the cytotoxic chemotherapeutic agents o f today, they 
should exert an overall cytostatic effect and provide a greater efficacy. In addition, this 
cytostatic effect should be able to cause tumour mass shrinkage since the “natural” loss of 
tumour cells by necrosis (or apoptosis) should outweigh any cell gain.201
Moreover, the strategy is to exploit the contextual and redundant nature o f signalling 
processes (c f . Section 2.2) in order to acheive a therapeutic selectivity between tumour cells 
and normal cells. In addition, the strategy is to revert a tumour cell into a more differentiated 
form by blocking an overpowering oncogenic pathway to such a degree as to leave the intact 
normal cellular pathways to take over. In that sense, a PTK inhibitor will not merely be a 
new antiproliferative tool but an antisignalling agent with the capacity to control cellular 
processes such as differentiation, apoptosis, angiogenesis, and metastasis. Therefore, the 
PTK inhibitors should be an extremely valuable addition to the pharmacopoeia o f the 
clinician in his/her fight against the multiple forms and stages o f the neoplastic state (see 
Figure 15).
CHAPTER «5» ProteinTvrosine Kinase (PTK) Inhibitors
On the whole, the search for PTK inhibitors has been semi-empirical in nature. Often this 
has involved the initial discovery o f a “lead” compound from some natural source and/or 
correlating a design to one of several common motifs characteristic to PTKs or their protein 
substrates, and then manipulating its “chemical make-up” in order to obtain an attractive 
pharmacological profile. The reason for this is that prior to 1991, no X-ray model for a 
protein kinase was available to the scientific community. Nevertheless, there has been a
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Figure 15 The Evolving Pharmacopeia of the Clinician
TOPOISOMERASE INHIBITORS
Topoisomerase I (Camptothecin)
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Radiosensitizers (nitro-imidazoles) anthraquinones)
Cytotoxins (Podophyllotoxins VP-16 <k VM-26 
mitomycins <& elUpticines) 
Bioieductives (Bleomycin &. SR4233)
TRANSCRIPTION
INHIBITORS
Acdnomycins (Act. A) 
Dactinomycin
CYTOSKELETAT,-----------
INHIBITORS
Vinca alkaloids (Vincristine, Vinblastine)
Taxol & Rhizoxin 
Colchicine
ANTIMETABOLITES —•v
Dihydrofolate reductase inhibitors \ ,
(Methotrexate) 7*“^
Thymidylate synthase inhibitors I
(5-FU, folinic acid, CB3717 <£ analogues, I ^ 
polyglutamates & Methotrexate) /
STEROIDAL INHIBITORS
Danazol &. Ammoglutethimide
NUCLEUS
CYTOPLASM
MEMBRANE ACTIVE AGENTS
Ether lipids (Et-18-OMe)
An thracy clines
VIRAL/GENE THERAPIES
V-D EPT/G-DEPT, viral vaccines 
antisense and and gene oligonucleotides
DNA INTERCALATORS
Acridines (Amsacrine)
Anthracyclines (Doxo-, Epi- <4 fda-rubicin) 
Anthraquinones (Mitoxantrone) 
Anthrapyrazoles
ALKYLATING AGENTS
Azin dines (Mitomycin C)
N-mustards (Chlorambucil, Melphalam, 
Urethane & Triazene types) 
Phosphoramides (Cyclo-, N-mustard. & 
Aziridinyl types e.g. CP, 
Ifosfamide. TSPA <& TEPA) 
Niroso-ureas (CCNU, DCNU, PCNU)
Triazenes (Dacarbcaxne, Procarbazine) 
Melamines (HMM)
Azolotetrazinones (mitozolomide)
Diazoalkanes (Azaserine, Azotomycin, DON) 
Alkyl halides (DBD, Mielobromol)
Oxiranes (Ttroxirone)
Alkyl sulphonates (Myleran)
S-mustards &. Aikyl phosphates 
Benzo- & Naphthoquinoes 
Piperazinediones and 5- or y-lactones
PLATINUM COMPLEXES
Cisplatin, Carboplatin <& tproplatin
IMMUNOTHERAPIES
Ricin A-chain, MoAbs
MoAb-conjugates (radionuclide, cytotoxic drug) 
SIGNAL INHIBITORS Immunotoxin (IT) therapy, ADEPT
Suramin & Tamoxifen Biomodulators, cytokine therapies
Signal inhibitors (PTK Inhibitors) adoptive immunotherapies, immunostimulants
series of hopeful candidates in the last five or so years and these are outlined below— for 
further information and earlier references the reader should refer to review articles in this 
area. 202 Today two X-ray structures for a kinase exist. One constitutes the catalytic unit o f a 
PSK and has been used to generate a homology model for the EGF-R kinase. 203 More 
recently, an X-ray o f the PTK domain of the insulin receptor (IR) has been published. 204 
These data have generated much excitement in cancer research since comparison o f these 
two models should greatly facilitate the rational design o f highly selective PTK inhibitors.
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5.1 Flavonoids and Isoflavanoids
In 1975 a flavonol called quercetin (7) was found to inhibit malignant cells. Later this 
activity was shown to be due to the inhibition of tyrosine phosphorylation activity at the 
v-src gene product and lead to the first systematic search for PTK inhibitors based on 
similar plant products between 1985 and 1988. This screening programme identified a set of 
isoflavonoids including orobol (8 ) and its regioisomer genistein (9) plus a further set of 
flavonols, but these were not significantly more potent than quercetin (7).
OH
HO
OH
OH
OH O
HO
R‘
(8 ) R i = O H ,R 2= H
(9)R *=H , R2= OH
Quercetin is competitive against ATP both in vitro and in vivo (IC50= 6 to 11 |IM ) but shows 
hardly any PTK selectivity and inhibits several other enzymes involved in cell signalling. 
On the other hand, genistein (9) is a competitive inhibitor with respect to ATP and can 
inhibit EGF-R at concentrations which do not effect PSKs. It has also exhibited cytostatic 
activity in experimental models but this may not be directly due to EGF-R inhibition. In 
spite o f these ambiguities, these base structures have been used to develop other more 
selective inhibitors, e.g. from independent studies, the potent flavonoid derivatives ( 1 0 ) and 
(11) have been identified .205 The compound (11) showed a 4-fold greater differential 
cytotoxic action against v-Abl transformed cells over their non-transformed counterparts and 
was a very poor ATP-inhibitor at the EGF-R kinase.
OCH
NH<
NH<
HO
O
(10) (11)
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Another class o f PTK-inhibitors structurally related to the isoflavones include the 
benzopyranones and benzothiopyranones, typified by derivatives (12). These provide the 
first examples to act as selective ATP-competitive inhibitors at the v-A b l oncoprotein 
(ID50=1 to 7 J IM ), compared to EGF-R or PKC, and illustrate that PTK selectivity can be 
achieved in non-substrate-type competitors.206 Recently, a naturally occurring isoflavonoid 
called kievitone (13) was identified to be a potent antiproliferative agent o f breast cancer 
cell lines and has been shown to inhibit PTK activity at the EGF receptor. However, its 
mode o f action remains to be determined as flavonoids in general inhibit numerous 
signalling molecules with varying degrees of selectivity.
5.2 Quinones and Antibiotics
Several antibiotics of the benzoquinonoid ansamycin group exhibit moderate antitumour 
activity. The compound herbimycin A (14) has been studied the most and reverses 
malignant cell morphologies which have been induced by certain PTK oncogenes, including 
y e s , a b l , and erb B . An additional favourable characteristic is that the induction of 
differentiation was observed in K562 human leukasmic cells. Its activity is attributed to PTK 
inhibition o f p60v*jrc and it has also been reported to inhibit EGF-R autophosphorylation. 
Herbimycin A (14) may be useful clinically as an adjuvant to other anticancer agents as it 
can reverse a malignant phenotype at higher concentrations, while displaying only partial 
cytotoxicity, and can establish a regular growth pattern on removal.
A large number o f anthraquinones and naphthoquinones exhibit moderate to good PTK 
inhibition o f p56 lckt e.g. emodin (15). Very recently a polycyclic bisanthraquinone called 
hypericin (16) has demonstrated potent EGF-R PTK inhibition and, although it is also a 
potent inhibitor o f PKC, has been used as an adjuvant to treat brain tumours.207 The known 
anthracycline antineoplastic antibiotic doxorubicin (see Table 1.8 under “Natural Products”) 
has also been shown to inhibit a number of PTKs in a manner that is competitive to ATP.
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(12) X= O or S (13)
OH O OH
(14)
(15) O
OH O OH
OH O
However, its value as a selective PTK inhibitor is limited due to its inhibition of PKC.
The indolecarbazole antibiotic staurosporine (1 7 )  has been shown to be a potent 
non-selective inhibitor of various kinases, including PTKs. However, the related analogue 
K252a (18) exhibits selectivity for the Trk family of oncogenes, having no inhibitory 
activity for EGF-R or src. Unfortunately, (18) is about ten-fold more efficient for the normal 
Trk proteins than their oncogenic forms. Also, N-benzoylstaurosporine (19) is known to 
inhibit PDGF-R autophosphorylation and c-fos gene expression in intact cells .208
(17) R=
OCH,
NHCH,
(19) R= o c h 2
, N S  
H,C COPh
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The aminoglycoside antibiotic neomycin (20) is known to act as a PTK inhibitor and 
prevents autophosphorylation of a PDGF class of receptor.209 A notable example o f an 
antibiotic which can act as a very potent PTK inhibitor to members of the Src family is the 
macrocycle radicicol (21), which shows inhibition o f p53/56lyn with an IC50 value of 
27 nM.210 However, its selectivity to other PTKs and signalling enzymes is not fully 
established.
NH-
OH N H
HO
H,C H\
HO
NH.
HO
HO
OH
OH
OH (20) (21)
5.3 Nucleoside. Peptide and Amino Acid Analogues
Nucleoside-based analogues were among the first agents explored as potential inhibitors of 
ATP binding to PTKs. The known PSK inhibitor 5'-[4-(fluorosulfonyl)benzoyl]adenosine or 
5'-FSBA (22) has been shown to form covalent bonds to lysine residues within the active 
site of PTKs.211 However, these agents tend to lack selectivity and potency, possibly due to 
problems in traversing the cell membrane.
HoN
AspArgVal
o
r y
IleHisProPheHisLeu
(23)
Apart from the many tyrosine-containing peptides m odelled around PTK auto­
phosphorylation sites, an interesting analogue (23) o f angiotensin I has been designed 
whereby the 4-hyrdoxyphenyl group normally phosphorylated has been replaced by 
4-pyridyl-l -oxide.212 The rationale was that phosphorylation on the N-oxide would activate
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the pyridine ring for nucleophilic attack by a lysine residue in the ATP-binding site 
(cf. 5'-FSBA) and thus act as a potential suicide inhibitor. Unfortunately, the peptide 
analogue (23) proved to be an extremely weak competitive inhibitor. However, a different 
type of isosteric replacement within angiotensin II gave a more successful PTK inhibitor, 
the dehydrophenylalanine derivative (24). Also there has been success among a series of 
amino acid-like derivatives, whereby 'Boc-Tyr-aminomalonic acid (25) was found to be the
most effective inhibitor of PTK activity at the insulin receptor. 213
5.4 Bisubstrate Inhibitors
Compounds that are designed to incorporate structural aspects o f both ATP and a tyrosyl- 
containing protein have been termed bisubstrate (or multisubstrate) inhibitors. In general, 
the most successful design strategy has emphasised the ATP moiety as a base structure to 
which a tyrosine-like portion is appended. The nucleoside analogues (26a) and (26b) 
illustrate this concept whereby the triphosphate chain of ATP is replaced in some isosteric 
manner or form. However, when tested in PTK assays, both these compounds are purely 
competitive with respect to ATP. Nevertheless, unlike the best 5'-FSBA sulfonamide 
analogue (26a), the compound (26b) still exhibits selectivity for PTKs over PSKs.
AspAr; ValHisProPhe
(24) (25)
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Bisubstrate inhibitors also have the potential to mimic the postulated transition state of the 
y-phosphoryl transfer o f the terminal phosphate group of MgATP to a tyrosine moiety and
potent and selective inhibitor of EGF-R, and exhibits no inhibitory effect for p60v'5rc or the 
PSKs, PKC and PKA. The analogue (28), which utilises a glutarate group as a “triphosphate 
spacer”, also gave a similar kinase activity, and it is believed that these types o f PTK 
inhibitors are truly multisubstrate in nature and present an experimental model to design 
potentially superior agents.
5.5 Miscellaneous PTK Inhibitors
Among the natural products with PTK inhibitory activity, lavendustin A (29) displays one of 
the most potent in vitro IC50 values of 12 nM against EGF-R and, at or near this 
concentration, does not inhibit PKA or PKC. The less potent methyl ester (30) is more 
easily taken up by the cell and inhibits EGF-R autophosphorylation and internalisation. The 
truncated version (31) also exhibits similar activity and, as for (29) and (30), is ATP 
competitive.
was the basis in the design of (27) and (28).214 The compound (27) has been found to be a
O O
(28) X
(29) R= H
(30) R= CH3
(31)
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Another natural product, piceatannol (32), inhibits a variety of PTKs by competing for the 
peptide-substrate binding site and has no effect on PKAs. Initial attempts at improving its 
potency failed but substituting a 3-pyridyl ring and methoxylated phenyl ring generated the 
more successful analogue (33). Interestingly, although (33) has a similar structure and 
potency as (32) it differs in its mode of action and is competitive with respect to ATP.
A novel class of PTK inhibitors, typified by (34), was shown to inhibit both EGF-R and 
c-Src kinase (without effecting v -A b l, PKA, or PKC) and further block EGF-R 
autophosphorylation and EGF-dependent proliferation in intact cells. Inhibition of PTKs by 
these thiazolidinediones is competitive with respect to ATP and the protein substrate. 
Apart from the ATP-competitive heterocycle amiloride (35), some other PTK inhibitors, 
although reasonably potent, lack selectivity and tend to elicit unknown modes of action. 
Examples o f these would include: the glutarimide antibiotic, epiderstatin (36); a naturally 
occurring tyrosine metabolite, (+)-aeroplysinin-l (37)— a potent inhibitor o f EGF-R; an
OH
HO,
OCH3
o c h 3
OH N
(32) (33)
(34) (35)
O O
(36) (37)
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opioid tyrosine mimic, (±)-phenazocine (38)— a fairly potent EGF-R inhibitor; halomethyl 
ketones, e.g. *Boc-Leu-CH2Br (39) inhibits EGF-R; and chlorpromazine (40), a lipid active 
inhibitor effective against c-Src kinase.
HO
(38) (39)
N(CH3)2
(40)
5.6 Recent Classes of PTK Inhibitors
A novel class of selective inhibitors of EGF-R kinase is based on 2,2'-dithiobis( 1 //-indole-3 - 
propanoic acids), as typified by the most potent compound (41).215 Generally, the esterified 
form (42) is considered less inhibitory to the isolated enzyme but shows better cellular 
growth inhibition, possibly due to more efficient membrane permeability. Based on this 
observation, a series of amide analogues was prepared. 216 The iV-benzylamide derivative 
(43) was found to be the most potent (IC50= 0.85 JIM ) in an in vitro assay against EGF-R 
kinase or ppbO7’^  but its inhibition of other kinases remains to be determined.
(41) R= H
(42) R= CH3
(43) R= NHCH2Ph
(44)
Synthesis and Biological Evaluation o f Anticancer Agents Page 53
Based on the aglycone moiety of the non-selective PTK inhibitor staurosporine (17) a 
collection o f ATP-competitive dianilinophthalimide derivatives was designed and found to
For example the compound (44) displayed a high selectivity for inhibiting EGF-R and 
erbB-2 autophosphorylation as well as c-fos expression (y-abl, c-src, and PDGF-R kinase 
activity were unaffected). Furthermore (44) demonstrated an in vivo antitumour activity in 
nude mice and offers a promising therapeutic lead.218
The truncated lavendustin A compound (31) has also proved to be a useful lead and has 
generated a series of amino derivatives, e.g . the methyl ester (45), which are non­
competitive with respect to both ATP and the peptide-substrate at the EGF-R kinase.219 This 
study provided information on the importance of a hydrophobic auxiliary binding group and 
demonstrated that (45) had a significantly lower inhibitory activity for PKC or PKA. 
Furthermore the study implies that the ester functionality may not be necessary for activity 
and a hydrolytically stable alternative should be sought. Based on the data given, probably 
an amide or ether linkage substituted with a phenyl or benzyl group would be advisable.
A novel class o f potent and selective inhibitors of EGF-R kinase has recently been 
described. 220 Its most potent member, the acrylophenone (46), displays significant selectivity 
over other kinases such as v -a b l , c -src , and PKC, as w ell as exhibiting potent 
antiproliferative properties towards intact cells and antitumour activity in nude mice. 
However the mechanism of action does not involve blocking autophosphorylation and needs 
to be investigated in more detail.
The most interesting set of compounds recently found to possess PTK inhibitory activity are 
based on bicyclic nitrogen heterocycles. The isoquinolines (47) and (48) were designed as 
conformationally locked mimetics of the known p56/c* inhibitor (49) and represent potential 
new leads for this kinase. 221 An important lead compound for PTK inhibitors that act against
be potent and selective inhibitors of EGF-R kinase in enzyme-free and intact-cell assays. 217
O N(CH3)2
(45) (46)
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OH OH
(47) X= OCH3
(48)X =N H 2
(49)
O
NH
(50)
the pp60c'J7C kinase is the fused pyrimidinone (50) and acts in a mixed non-competitive, 
potent, and selective manner.
The quinoxaline (51) selectively inhibits PDGF-R kinase in intact cells and does not inhibit 
EGF-R or c-src  kinases.222 Undoubtedly the most potent and selective PTK inhibitors belong 
to the 4-anilinoquinazoline class. For example, the chloro derivative (52) has an IC50 value 
of 3 nM against the EGF-R kinase and is ATP-competitive.223 The bromo derivative (53) has 
an IC50 in the low picomolar range against the EGF-R kinase and is clearly an exceptionally 
potent PTK inhibitor. 224
(51)
H3CO
H3CO
H3CO,
H3CO
(52) X= Cl
(53) X= Br
5.7 Erbstatin and the Tvrphostins
Among the PTK inhibitors discovered from natural product screening, erbstatin (54a) has 
been the most useful prototype used for drug design. It was isolated from an Actinomycete 
broth and has an in vitro  IC50 value of 3 p,M against EGF-R . 225 However, the action of 
erbstatin is ambiguous and probably effects other kinases apart from the PTKs. Also, its
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antiproliferative activity is partly due to inhibition of DNA topoisomerase I and II and its 
action in vivo requires Fe(III) chelators (e.g. feroxy mi thine) .226 Presumably, erbstatin (54a) 
is prone to oxidative degradation. Accordingly, much synthetic effort has been directed at 
developing stable analogues.
OH
NH3
OH
NHCHO
OH OH
(54a) (54b) (55)
The methyl cinnamate (54b) was found to inhibit EGF-R kinase activity and EGF-R 
autophosphorylation in intact cells with equal potency to erbstatin, and was about four times
t
more stable in aqueous solution .227 The pyridone-based analogue (55) has also been 
designed and inhibits EGF-R non-competitively with respect to ATP and the protein- 
substrate. 228 In the same study, erbstatin (54a) was shown to inhibit the EGF-R kinase as a 
partial competitive inhibitor with respect to both ATP and the protein-substrate. This 
implies erbstatin binds at a site distinct from the ATP and protein-substrate binding sites of 
the enzyme, and thereby lowers the binding affinities of the enzyme for both substrates by 
some, still undefined, manner.
The most promising and well studied PTK inhibitors based on erbstatin (54a) are known as 
the “tyrphostins”, for tyrosine phosphorylation inhibitors. Together with Shiraishi et al.,229 
this area has been pioneered by Levitzki and his co-workers.230 Between these two groups, 
three main structural archetypes have been synthesised and each o f these bear a diverse 
range o f functionality (Figure 16). The key pharmacophoric feature appears to be a 
p-hydroxycinnam onitrile (Structure A) or, more generally, a 3 -arylpropenonitrile 
(Structure B). This importantly includes the cis relative arrangement between the aryl and 
nitrile groups and is exem plified in the conformationally constrained indanones 
(Structure C)— the corresponding trans-forms of the tyrphostins are thought to be less 
active. On the whole, reducing out the double-bond, removing phenolic hydroxyl groups, or 
replacing the p-hydroxyphenyl ring with a heteroaryl ring, abolishes PTK inhibitory action.
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Figure 16 Tvrphostin Archetypes
Structure A Structure B Structure C
NP R2
(n— 0,1, or 2) R= alkyl or H  
Ar= aryl or heteroaryl
(n= 0, 1, or 2)
R*= OH, OR, alkyl, and/or CH2SAr
„ 2_  alkyl, alkenyl, aryl, heteroaryl, aralkyl,
K ”  ' CN, c o n h 2, c s n h 2, c o 2r ,  c o r ,  c h o
n h 2
The tyrphostins are designed to be low molecular weight PTK inhibitors competitive for the
favourable. However, in general, they exhibit a mixed-type competitive response against 
ATP and peptide binding ( i.e. are bisubstrate inhibitors) but, fortunately, this does not affect 
their selectivity .231 In fact, the tyrphostins are not only effective at distinguishing between 
PTKs and other signalling enzymes, but also among the PTKs themselves (see Table 12 for 
pertinent examples). Importantly, there is significant selectivity over the insulin-receptor 
(IR) kinase and this should circumvent the potential problem of signal inhibitors being toxic 
to cells of the pancreas.
The biological activity of the tyrphostins generally correlates well to their PTK potency. 
This is exem plified by the tyrphostin (58) (Table 12) which inhibits EGF-dependent 
autophosphorylation at EGF-R kinase, EGF-stimulated DNA synthesis, and tyrosine 
phosphorylation o f endogenous protein substrates. However, penetration into cells is often 
slow and experiments indicate that (58) is either unstable and/or is easily metabolised. An 
improvement on this is the analogue (62) (Table 12). This is related to the potent but non- 
selective inhibitor (64) and Shiraishi’s compound (65),229 a potent and selective PTK 
inhibitor o f EGF-R. Thus, compound (62) preferentially inhibits erbB-2  kinase and Trk 
kinase over EGF-R and PDGF-R kinases. Clearly, while the tert-butyl groups add stability 
to (62), predicting the selectivity between related kinases remains a learning process.
peptide-binding site such that their selectivity and hence toxicity w ill be therapeutically
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Table 12 Selectivity of Some Tyrphostins
PTKs and IC50 values (pM)
Tyrphostin EGF-R erbB-2 PDGF-R Trk p 2 i  t fc r -A U DR
H O y ^
H O ^ ^  CN (56)
35 25 >100 75 4000
I
HO y
0
^  CN 
H (57)
3
: *........
>100 3.6
X
^ . c s n h 2
CN
(58)
0.8 3 >100 6 640
I O
/-^C O N H Ph
CN
(59)
0.7 42 6 75 >100
H0 CONH(CH 2)3Ph
J i  J  CN
(60)
0.7 35
: v:|  YfflSfiS':
>100
CH 30  CONH2
J L  J  CN Ho y
(61)
19 0.35 40
, - , 
.
75 >100
y ^ C S N H ,
J CN
(62)
>500 1.0 >100 10
■
\  CN 
\ = <  1) CN
N
H (63)
18.5
■ ’ :
0.8
-
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(64) (65)
Pertaining to metabolic stability, it is preferable to design PTK inhibitors devoid of phenolic 
hydroxyl groups and the diaryl compounds ( 6 6 ) and (67) represent a significant 
development in this respect. These “second generation” tyrphostins have been used in vivo 
and inhibit EGF-dependent growth of EGF-R rich squamous cell carcinomas in nude
mice. This contradicts the notion that phenolic hydroxyl groups are essential for PTK 
inhibitory activity for a given tyrphostin (see above). Another contradiction is the existence 
of potent and selective heteroaryl tyrphostins, e.g. (68 ) selectively inhibits PDGF-induced 
mitogenesis and PTK activity in bone-marrow fibroblasts, 233 and a structurally related 
analogue (63) is highly selective for the PDGF-R kinase (Table 12). All these facts add 
another dimension to the design of potentially useful PTK inhibitors.
NH2
(6 6 ) X= 3,4-dimethoxy
(67) X= 3,5-dichloro
(68)
In general terms, the tyrphostins and related PTK inhibitors have a great therapeutic 
potential to control a whole range of proliferative diseases where PTKs are implicated, e.g. 
many human cancers, psoriasis and other skin conditions, atherosclerotic diseases, and 
inflammatory conditions (see Table 13).234 However, before becoming clinically useful, the 
tyrphostins will have to display better pharmacological profiles such as bioavailability, cell 
permeability, metabolic stability, and non-toxicity. Furthermore, they need to overcome the 
significant problem of drug resistance, as this all too frequently occurs for the conventional 
anticancer drugs in the genetically unstable fertile environment o f a tumour cell 
population.235
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Table 13 Potential Therapeutic Application of PTK Inhibitors
Disease PTK Implicated Mechanism of PTK involvement PTK Inhibitor
Certain cancers 
(squamous cell 
carcinoma)
EGF-R Amplification of gene and 
overexpression of EGF-R
Compounds (44), (52), 
(58), (60), and (66)
Psoriasis EGF-R
Overexpression of 
amphiregulin or TG F-a 
gene, leading to autocrine 
stimulation of EGF-R
Compounds (58) and (60)
Mammary and ovary 
carcinoma erbB-2
Gene amplification and 
overexpression of erbB-2 
kinase receptor
Compounds (61) and (62)
Atherosclerosis, 
restenosis, pulmonary 
fibrosis
PDGF-R
Amplification of PDGF-R 
by pathological release of 
PDGF (restenosis)
Compounds (51) and (64)
Gliomas, glioblastomas PGDF-R
Amplification of PDGF-R; 
coexpression of PDGF and 
PDGFR in the tumour
Compounds (51) and (64)
Chronic myelogenous 
leukaemia (CML) p21 ( f cr'Abl and p 1 S5Bcr'Abl
Chromosome 
rearrangement that results 
in fusion of Bcr and 
pl40c* ^ ,  ieading to 
enhanced kinase activity
Compound (63)
Nevertheless, the PTK inhibitors, and the tyrphostins in particular, are making an impressive
impact on anticancer drug design. Not only can they serve as molecular tools to unravel the 
signalling processes of the cell, but can act as signal blockers capable of “sensitising” a 
tumour cell to the effects o f traditional cytotoxic agents.236 Indeed, they have already been 
shown to act as effective anticancer agents in their own right.237 Moreover, once signalling 
“cross-talk” is better understood238 and further X-ray structures for kinases become 
available, PTK inhibitors may be tailored more appropriately in order to exploit the 
contextual nature o f signalling processes within tumour cells in a favourable manner over 
their normal cellular forms. In this way, the challenge is to design a predictive and 
efficacious signalling agent for the purpose of fighting against the age-old disease of cancer.
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0 RESULTS & DISCUSSION 0
“Write the things which thou hast seen, 
and the things which aret 
and the things which shall be hereafter”;
The Revelation o f St. John the Divine, Chapter 7, Verse 19.
CHAPTER «6» Preliminary Tyrphostins Studied
At the onset o f this project the most promising approach to the discovery o f PTK inhibitors 
was that described for the so-called tyrphostins (see Section 5.7). As an appropriate start it 
was necessary to confirm and extend the work carried out by Levitzki and co-workers,23** 
and therefore synthesise hydroxylated aromatic tyrphostins (see Figure 16; Structure A). An 
additional purpose was to “design out” the undesirable feature o f  phenolic hydroxyl 
groups— a structural motif renowned for the instability and easy metabolism of compounds. 
Thus it was decided to explore the effects of replacing these hydroxyl groups with halogens 
or substituting in a whole new heteroaromatic moiety. Moreover, the impetus was to 
“discover” an interesting new “lead” and so a range of alternative aromatic moieties was 
investigated.
However, the purpose of this project was not only to synthesise potential PTK inhibitors but 
also to test them in an appropriate biological assay. Indeed, an additional aim was to 
develop structure-activity relationships for a tyrphostin’s antiproliferative activity in a 
tumour-derived cell line— previously, Yaish et a/.230a demonstrated that several o f their 
compounds inhibited EGF-dependent proliferation o f fibroblasts. For this purpose, the 
MCF-7 breast adenocarcinoma cell line was chosen as an apt model system. The reason for 
this was two fold: the growth o f MCF-7 cells is stimulated by EGF in culture and is 
inhibited by EGF-R derived monoclonal antibodies;239 and other mitogens such as oestrogen 
and the insulin-like growth factors (IGFs) are important for proliferation o f MCF-7 cells .240 
Thus, signalling via the EGF-R kinase not only plays an important role in the proliferation 
of this tumour type but also depends on other growth factors. Therefore, it was important to 
determine the ability o f these inhibitors to block growth of tumour cells where multiple
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interactions control cell proliferation and to assess whether effects on MCF-7 cell growth
evaluation o f these types of PTK inhibitors will be discussed here and some o f this work has 
recently been published. 241
The MCF-7 and some o f the H ER-14 cell-line assays were carried out by me at the CRC 
Medical Oncology unit, Beatson Institute, Glasgow University. Unless stated otherwise, the 
more detailed cell assays, including EGF-R kinase inhibition and cytotoxicity testing, were 
perfomed by Dr Valerie G. Brunton and co-workers. For the readers information, the 
protocols followed have been appended as an Experimental— Biology section.
6.1 Synthesis of Hvdroxvlated 3-Phenvlpropenonitriles
The tyrphostin base structure is sometimes referred to as a benzylidenemalononitrile (or 
benzalmalononitrile, BMN) and, as inferred by its name, is normally made from the reaction 
between a benzaldehyde and an activated methylene derivative of malononitrile (Scheme 1). 
Classically this is called a Knoevenagel condensation242 and an excellent general review on 
ylidenemalononitriles is given by Freeman.243 The reaction belongs to the general class of 
base-catalysed aldol-type condensations and is usually performed in an alcohol and, for 
aromatic aldehydes, involves the use of a weak secondary amine or its equivalent salt.
Depending on the starting materials, a judicious choice o f base, solvent, reaction 
concentration, and temperature should be considered in order to obtain a clean conversion. 
With the correct choice of conditions the product w ill normally precipitate out or, better 
still, crystallise out o f solution. In general, piperidine was used as the base, ethanol as the 
solvent, and yields ranged from 60 to 90 %. However, for some cases the reactions were 
extremely temperamental and gave complex mixtures, presumably v ia  some kind of
could be attributed to inhibition of EGF-R kinase function. The synthesis and biological
Scheme 1 The Knoevenagel Condensation
amine catalyst
X
O /  (e-S • piperidine)
+ r --------------------------► X
alcoholic solvent 
(e.g. ethanol)
(X= OH, OR, halogen, etc.) (X= OH, OR, halogen, etc.)
£ =  electron withdrawing group, e.g. CN, CONR2, C 0 2R, COR, Ar, N 0 2, S (0 )nR, etc.
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M ichael-type addition product (or &fs-adduct) o f the initially formed a,(3-unsaturated 
compound.
The first tyrphostins prepared contained the mono-, di-, and tri-hydroxylated phenyl 
portions. Thus, condensation of 4-hydroxybenzaldehyde with malononitrile, 1,1,3-tricyano-
2 -aminopropene (malononitrile dimer), cyanothioacetamide, ethyl cyanoacetate, and 
cyanoacetamide gave the 3-(4-hydroxyphenyl)propenonitrile series [(69)-(73)]— hereinafter 
called the p-hydroxyphenyl series. Similar reactions with 3 ,4-dihydroxybenzaldehyde led to 
the dihydroxyphenyl series [(56), (58), and (74)-(76)], and the trihydroxyphenyl series 
[(57) and (77)-(80)] were formed from 3,4,5-trihydroxybenzaldehyde. Apart from 
compounds (71), (72), (75), (79) and (80), these tyrphostins had previously been reported by 
Gazit e ta l.230e
(69) R= CN
(70) R= C(NH9)=C(CN)2
(71) R= CSNH2
(72) R= C 0 2Et
(73) R= CONH2
H0I ^ R
HO
(56) R= CN
(74) R= C(NH2)=C(CN)2 
(58) R= CSNH2
(75) R= C 02Et
(76) R= CONH2
HO
OH
(57) R= CN
(77) R= C(NH2)=C(CN)2
(78) R= CSNH2
(79) R= C 0 2Et
(80) R= CONH2
Synthesis o f the p-hydroxyphenyl series was reasonably straightforward except for the 
malononitrile dimer product (70) and the thioamide (71) which tended to give low yields 
(below 30 %). This turned out to be a general trend and also occurred in the 
dihydroxyphenyl and trihydroxyphenyl series. In particular, synthesis of the known 
tyrphostin (58) proved problematic. The best procedure employed precluded light, used a 
minimum amount of piperidine, and isolation was performed via silica chromatography. 
Further purification by crystallisation was avoided due to the generation of impurities. 
Indeed, all the thioamide dervatives [(71), (58), and (78)] were light and air sensitive. 
Moreover, the dihydroxyphenyl and trihydroxyphenyl series all tended to go dark on 
standing at room temperature or at 4 °C. The best method o f storage avoided light and air, 
since it was suspected that these hydroxylated series may readily oxidise to quinones. 
Clearly this instablity is not a desirable feature to have in a potential cytostatic agent since 
normal cell toxicity is likely to be increased.
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6.2 Biological Evaluation of Hvdroxvlated 3-Phenvlpropenonitriles
The antiproliferative activities of the compounds synthesised above were assessed in the 
breast adenocarcinoma cell line MCF-7 using [3H]thymidine incorporation as a measure of 
DNA synthesis. In other words, the growth of MCF-7 cells in the presence o f an inhibitor 
was compared to that in the absence of the inhibitor (a control system). Unhindered growth 
should allow a greater incorporation of the radioactive label into the D NA  of new cells, than 
that of cells stunted by any inhibitor, and thus the quantity of radioactivity measured over a 
period o f time should differ between the two test systems. The difference is best expressed 
as a percentage and gives a so-called typical dose-response curve, for example see 
compounds (69), (56), and (57) in Figure 17. The range of inhibitor concentrations used in 
these assays was: 1, 10, 20 and 50 f iM  and the concentration at which a 50 % inhibition of 
[3H]thymidine incorporation occurs is defined as the IC50 value. This is indicated for 
compound (57). The other compounds have IC50 values greater than 50 JIM .
Figure 17 Typical Dose-Response Curves
125
so
osu
7 5 -
2 5 -
IQ ' IC5 0 —30.1 pM 
Inhibitor Concentration (jiM)
100
■O (69)
-•----- (56)
4 ----- (57)
Silmilar dose-response curves were obtained for the other compounds in the series and the 
data have been collated in Table 14. Also given are IC50 values for a cell free system  
whereby the only parameter to consider is enzyme inhibition of the EGF-R kinase (tyrosine
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phosphorylation of a synthetic polypeptide is measured). This allows a direct comparison of 
the data between inhibiting signalling events at the EGF-R kinase with the observed 
antiproliferative activity against intact tumour cells.
Structure No. R IC5o(MM)a 
M CF-7 cells
IC50 (|4M)b 
EGF-R kinase
__  R (69) CN >50 560c
(70) C(NH2)=C(CN)2 >50 0.125c
(71) c s n h 2 >50 40
J L  CN
HO (72) C 02Et >50 >500
(73) c o n h 2 >50 >800°
HO R (56) CN >50 35c
(74) C(NH2)=C(CN)2 >50 2.5c
(58) CSNH, 31.3 2.4°A . CN
HO (75) C 02Et 43.4 35
(76) c o n h 2 40.9 10c
(57) CN 30.1 3C
II ' (77) C(NH2)=C(CN)2 46.3 o oo oA .  A  CN 
HO y (78) c s n h 2 32.6 1.7
(79) c o 2b 35.3 8
OH (80) c o n h 2 >50 4.2
“intact cell assay bCeli free assay
cVaIues taken from Gazit eta l. Value taken from Anafi etal.
As can be observed in Table 14, the compounds exerted a range o f antiproliferative 
activities against the MCF-7 cell line with IC50 values ranging from 30 to above 50 |xM. 
From the collection of novel structures, compounds (75) and (79) displayed a reasonable 
correlation between EGF-R kinase inhibition and antiproliferative activity. However, the 
activity o f compound (80) is disappointing in the MCF-7 assay. In general, the functional 
groups which contributed the most to potency tended to be the thioamide (R = CSNH2) and 
malononitrile dimer (R= C(NH2)=C(CN)2) moieties.
From one series to the next, there is a significant enhancement of antiproliferative activity of 
MCF-7 cells over the /?-hydroxyphenyl series, although this increase in activity is not so 
prominent when comparing the dihydroxyphenyl series to the trihydroxyphenyl series. In 
contrast, the inhibition of the EGF-R kinase shows a much more linear structure-activity 
relationship when the number of hydroxyl groups is increased on the phenyl group for a 
given analogue in a series. This agrees with the findings of Levitzki and co-workers.2301
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However, not in agreement is the fact that there is no general correlation o f antiproliferative 
activity o f the MCF-7 cells with enzyme inhibiton o f the EGF-R kinase. Previously, this 
correlation had been observed for the EGF-dependent proliferation o f fibroblasts.
This result is not entirely surprising as other mitogens such as oestrogen and the IGFs are 
involved in MCF-7 cell growth, and signalling via the EGF-R kinase may not be the major 
pathway responsible for growth. Alternatively, the tyrphostins may act with low selectivity 
and so inhibit other growth pathways of the cell or, indeed, act in some unknown manner 
(cf. Faaland et a/.245). Indeed, the tyrphostin 2-cyano-3-(4-hydroxyphenyl)propenonitrile 
(69) has been reported to prevent mitochondrial oxidative phosphorylation in animal and 
plant systems,246 and this inhibition of a V TK -independent function has recently been 
confirmed for other tyrphostins.247 Futhermore, the general toxicity o f this class of BMNs is 
well.known as numerous reports mention their associated cytotoxic and irritant properties, 248 
and a detailed animal exposure o f BMNs, including LD50 values,249 has been reported by 
Jones.250 Moreover, (2-chlorobenzylidene)malononitrile (8 1 ) and (2-nitrobenzylidene)- 
malononitrile (82) are severe irritants, and (81) has even found use as a riot control agent 
and in chemical warfare. In any case, this study has demonstrated that care must be taken in 
interpreting the mode of antiproliferative activity in tumour cells as the compounds may be 
altering the activity of multiple enzymes or pathways in a ceil to exert their antiproliferative
(81) X= Cl
(82) X = N 0 2
6.3 Preliminary Tvrphostin Stability Study
As noted earlier and in Section 5.7 (Introduction) a major concern with the hydroxylated 
3-phenylpropenonitriles is their biological and chemical instability. Even before reaching 
the metabolic processes of a cell, it is conceivable that compounds o f this type may undergo 
hydrolysis o f the nitrile group or undergo quinone formation.251 Conceptually, the main 
reason for this is probably the pow erful “p u sh -p u ll” sy stem  o f the
3-(4-hydroxyphenyl)propenonitrile generating a quinonoid-type structure able to facilitate 
protonation and subsequent nucleophilic attack (Scheme 2). This hydrolysis is particularly
effects.
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pertinent for the thioamide group since this will generate hydrogen sulphide as a toxic side- 
product and may account for such compounds exhibiting higher IC50 values than their ester 
or amide counterparts ( c f  Table 14).
Scheme 2 Possible Reactions of p-Hvdroxphenvl Series of Tyrphostins
proton transfer
c o n h 2
c r f ^ r -  
®J . 0  N'„HO
Thus, it was important to ascertain the stability o f a tyrphostin in aqueous solution. 
Consequently, 2-cyano-3-(3,4-dihydroxyphenyl)propenonitrile (6 9 )  was dissolved in 
distilled water (125 jig ml-1) and monitored by UV/visible spectra (200-520 nm). The initial 
UV spectrum gave a main peak at 370 nm (Figure 18A) but during 2.5 h an additional peak 
formed and rose to a maximum near 435 nm (Figure 18B), after which the initial peak 
gradually diminished to a minimum near 345 nm over 24 h (Figure 18C). A similar result 
was obtained in the absence of light and clearly, the compound (69) is readily converted into 
one or more degradation products. Silica TLC (EtOAc/MeOH; various ratios) confirmed 
this observation and at least two products were formed which tended to be more polar than 
the parent compound. However, isolation of these proved to be extremely difficult and all 
attempts failed.
It was thought that at least one of these degradation products would be a quinone o f some 
kind. Thus it was decided to attempt the synthesis of the orr/zo-quinones (83) and (84) in 
order to determine if these were responsible for the in vitro  activity observed (see 
Scheme 3). Several oxidation methods were tried and included: sodium periodate252 on 
compounds (56) or (58), and diphenylseleninic anhydride253 on compound (69). Also, as
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Figure 18 UV Spectra Illustrating the Degradation of 
2-Cvano-3-(3.4-dihvdroxvphenvDpropenonitrile (69)
3.0000
(arbitrary
units)
2.3920
i.7840
1.1760
0.5680
-0.0400 4 
200.0 250.0 300.0 450.0 ("*0 500.0350.0 400.0
3.000 435 nM
1.784
1.176
250.0 300.0 450.0350.0 400.0 500.0
1.5000 435 nM
1.1900
0.8800 345 nM
0.5700
0.0500 4 
200.0 250.0 300.0 400.0 450.0350.0 580.0
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the ferric ion is known to form the para-quinone of erbstatin (cf. Introduction), iron(III) 
choride catalyst plus (56) or (58) dispersed in dichloromethane or partitioned between an 
aqueous and organic layer were tried. However, all these attempts failed to produce the 
required ortho-quinones and so this work was abandoned.
(69) X= H, R= CN
Very recently, the observation of a tyrphostin’s instability in aqueous solution was reported
UV/visible profile as shown above for compound (69) and gave an initial main peak at 
340 nm which shifted to 440 nm (cf. above). Moreover, the degree o f inhibition of ppbCF'^ 
kinase and EGF-R kinase by these tyrphostins was shown to be linked to their instability 
and compound (76) displayed an enhanced inhibition in the presence of catalytic amounts of 
Mn2+, Fe2+, or F e3+. This implies that oxidation products (possibly quinones) may be 
formed and, although no characterisation data were given, these compounds were isolated 
and shown to be at least 5 -fold more potent than the parent compounds.
6.4 Synthesis and Biological Evaluation of 3-f3.5-DihalophenyPpropenonitriles 
From the information given above it was desirable to eliminate the presence of the phenolic 
hydroxyl groups altogether and replace these by an isostere which was not so activating. For 
this purpose a set of 3-(3,5-dihalophenyl)propenonitriles was synthesised. The substitution 
pattern on the phenyl ring was decided based on the data mentioned above for the 
hydroxyphenyl series. Thus, groups at the ortho  and p a ra  positions relative to the 
attachment of the propenonitrile moiety were avoided due to the possible mesomeric effects 
that could aid nitrile hydrolysis (cf. Scheme 2), as well as the known toxicity of compound
(81). Furthermore the ortho and para positions do not seem to contribute significantly to a 
compound’s potency (cf. Table 14). Substitution at the meta  positions seemed the more 
logical choice.
Scheme 3 Attempted Formation of Ort/io-quinones
X= H: [PhSe(O)] 20
(56) X= OH, R= CN
(58) X= OH, R= CSNH2
(83) R= CN
(84) R= CSNH2
to occur for the amide derivatives (76) and (80).254 Both of these compounds gave a similar
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Thus, the 3-(3,5-dichlorophenyl)propenonitrile series— hereinafter called the dichlorophenyl 
series— was synthesised by reacting malononitrile, cyanothioacetamide, and ethyl 
cyanoacetate with 3,5-dichlorobenzaldehyde in the presence o f catalytic amounts of 
piperidine to give (85), (8 6 ), and (87), respectively. All attempts at making the amide and 
malononitrile dimer adducts failed. Again formation and isolation o f the thioamide 
derivative ( 8 6 ) proved problematic. However, after chromatography the product could be 
purified by a low temperature crystallisation, unlike the analogues (58) or (78).
Cl
CN
Cl
F
CN
F
(85) R= CN (88 ) R= CN
(86) R= CSNH2 (89) R= CONH,
(87) R= C 0 2Et (90) R= C 0 2Et "
The difluorophenyl series [(8 8 ), (89), and (90)] was similarly prepared by the condensation 
of 3,5-difluorobenzaldehyde with malononitrile, cyanoacetamide, and ethyl cyanoacetate. 
H owever, all attempts at obtaining analytically pure m alononitrile dimer and 
cyanothioacetamide members of this series failed, and the impure samples isolated were 
considered unsuitable for testing. Futhermore, unlike the dichlorophenyl series, the 
compounds of the difluorophenyl series were best formed in isopropanol with the use of a 
very slight catalytic amount of piperidine. This was necessary to allow precipitation of the 
fluorinated compounds (which are too soluble in ethanol) and avoided the production of side 
products.
As for the hydroxylphenyl series, the biological activities of these compounds were assessed 
in MCF-7 intact-cell assays, but at concentrations of 0.1, 1.0, 10, 50, and 100 ( IM . The 
results are summarised in Table 15 and analogues which contain two cyano groups (R= CN) 
tended to be more potent than others in the series. In particular, compound (85) showed an 
encouraging IC50 (MCF-7) value of 11 jiM  and is at least 3-fold more potent than the 
corresponding analogues (56) and (57) in the hydroxyphenyl series. Moreover, this was in 
good correlation with the IC50 (EGF-R kinase) value of 0.1 JIM .
Clearly compound (85) represents a promising successor to the tyrphostins (56) and (57). 
Indeed, a short term stability study in aqueous solution demonstrated that no untoward side
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Table 15 Biological Activities of Halogenated 3-PhenvlpropenonitriIes
Structure No. R IC50 (M-M)a 
MCF-7 cells
ICso(HM)b 
EGF-R kinase
(85) CN 11 0.11 I X (86) c s n h 2 37 n.d.
T (87) C 0 2Et 68 n.d.
a
(88) CN 35 n.d.1 I X (89) c o n h 2 86 n.d.V
F
(90) 0 0 2Et 49 n.d.
*Intact cell assay. bCell free assay (n.d.= not determined)
products are detectable by UV/visible or TLC analysis over a 24 h period. However, direct 
UV spectrophotometry is probably an inadequate technique for detailed analysis o f the 
stability o f this tyrphostin, since a degradation product may possess a chromophore similar 
to that of the parent compound— an HPLC technique would be preferable. Also, the activity 
of (85) in other kinase assays (e.g. IR, PDGF-R, ppbO0-^ )  should be studied, as well as its 
selectivity over PSKs such as PKC and PKA.
6.5 Synthesis and B iological Evaluation of 3-Heteroarvlpropenonitriles 
In order to develop tyrphostin analogues less prone to hydrolytic or metabolic processes, a 
series of 3-heteroarylpropenonitriles was synthesised. Gazit et al.230e had previously reported 
that heteroaromatic tyrphostins were inactive; however only a very small number of  
compounds were synthesised. Thus, a series of Knoevenagel condensations (Scheme 1) 
were carried out with 2-pyridinecarbaldehyde to give (91); 3-pyridinecarbaldehyde led to
(92)-(95); 2-imidazolecarbaldehyde yielded (96)-(100); 2-thiophenecarbaldehyde generated 
(101)-(105); and 3-thiophenecarbaldehyde produced (106)-(110).
C 0 2Et
(91) (92) R= CN
(93) R= CSNH2
(94) R= C 0 2Et
(95) R= CONH2
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(96) R= CN (101) R= CN (106) R= CN
(97) R= C(NH2)=C(CN)2 (102) R= C(NH2)=C(CN)2 (107) R= C(NH2)=C(CN),
(98) R= CSNH2 (103) R= CSNH2 (108)R =C SN H 2
(99) R= C 0 2Et (104) R= C 0 2Et (109) R= C 0 2Et
(100) R= CONH2 (105) R= CONH2 (110) R= CONH2
Formation o f other members of the 2-pyridyl series, apart from compound (91), proved 
extremely problematic. The reactions of 2-pyridinecarbaldehyde with malononitrile, 
l,l,3 -tricyano-2-am inopropene (m alononitrile dimer), cyanothioacetam ide, and 
cyanoacetamide all gave black inseparable amorphous mixtures. Changing the reaction 
conditions (under nitrogen, absence of light, low temperature) seemed not to effect the 
outcome. The only success was acheived with the reaction between 2-pyridinecarbaldehyde 
and m alononitrile in the presence o f a n on -nu cleop hilic  am idine base, 
l,8-diazabicylco[5.4.0]undec-7-ene (DBU). Although a compound was isolated, albeit in 
very low yield, and could be crystallised, it could not be assigned to the required structure.
A plausible structure consistent with the data obtained is illustrated for the indolizine (111). 
The mass spectrum of (111) showed distinct ions at m/z (El) 245 (assigned 100 % in 
intensity) and 246 (55 % relative intensity). For structure (111), the molecular ion for 
C 15H 10N 4 would be at 246. Moreover, this formula tallied well with the 200 MHz *H and 
13C NMR spectra which illustrated the presence o f 10-aromatic methine hydrogens and 
carbons, plus at least four quaternary carbons (Figures 19 and 20).
4
14
15
16
8 CN
(111)
Importantly, the NMR spectrum showed the presence of two distinct aromatic coupling 
systems, each comprising of four contiguous protons, and it is likely that these signals are 
derived from two 2-substituted pyridine-like rings (see Figure 19). Consistent with the
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Figure 19 *11-200 MHz Spectrum of Compound (111)
4
CN14
15
16
(HD
11-H 7-H
5-H17-H
f\
4-H 3-H2-H
15-H
16-H
/ K
14-H,
r
T T T T
proposed structure was the fact that the protons 2- and 16-H displayed additional long-range 
couplings to their respective partners, 7- and 11-H. The coupling constant for the (2-H/7-H) 
and (16-H/l 1 -H) proton pairs were 5J  0.5 Hz and 0.7 Hz, respectively.
The full carbon spectrum of compound (111) is given in Figure 20A. Significantly, only one 
nitrile carbon is observed in the 110 to 120 ppm region. By close inspection of the DEPT 
13C NMR spectrum a further quaternary carbon signal seems to be apparent but is obscured
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by a strong methine signal (Figure 20B). Futhermore, this signal is relatively broad and is 
likely to be experiencing the phenomenum of relaxation. Therefore, in structure (111) this 
signal may correspond to 9-C, a quaternary carbon flanked by two nitrogens but, for the full 
carbon assigments of compound (111) additional NMR data (e.g. 2D) is required.
Clearly, formation o f the imine product (111) involves the amine intermediate (112). 
However, the formation of (112) must require a reduction at some stage. This is inevitable 
for any  product with the formula C9H7N 3 which is being generated from pyridine-
2-carbaldehyde (C6H5NO) and malononitrile (C3H2N 2). This creates some difficulties at 
stipulating a likely mechanism since reductive reaction conditions were not employed. 
Nevertheless, if a hydride source is generated in situ, conceptually the overall reaction may 
be considered as a redox process. Indeed, this is the case for the Cannizzaro reaction255 
whereby aromatic aldehydes, under basic conditions, are converted to their correponding
i
carbinols and acids. Thus, in this situation, the hydride source will likely be analogous to the 
hydride source in the Cannizzaro reaction256 and, although alternative candidates may be 
envisaged, an example is presented in Scheme 4.
CN
(112)
A postulated mechanism for the formation of the intermediate (112) is outlined in Figure 5. 
Initially, it is likely that a normal Knoevenagel condensation product (A ) forms which 
would be expected to be a good hydride acceptor and thereby be reduced to its more 
saturated counterpart (B). Subsequent intramolecular attack o f the pyridine nitrogen 
lone-pair on a nitrile grouping followed by a series of proton transfers will generate the ring 
closed structure (112). Although this unexpected side-reaction requires to be validated by 
experiment, this study provides an interesting basis for future investigation.
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Figure 20 DEPT 13C 200 MHz Spectra of Compound (111)
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Scheme 4 Proposed Hydride Source in the Formation of Indolizine (112^
At
OH
H a
A r ' I 'H  
OH
Cannizzaro Reaction Hydride Source
A r " ^ H
0 ^
NC CN
O
Ar'
NC
*H
‘CN
DBU
Proposed Hvdride Source
NC \ ©  CN
Hydride Source
Scheme 5 Mechanistic Outline to the Formation of Indolizine (1121
N CHO
CH2(CN)2
DBU/EtOH
[H]' source 
— ----------------------------------
(see Scheme 4)
intramolecular 
ring closure
tautomerism
CN
(112)
proton
transfer
HN CN CN
In comparison to the discussion above, the synthesis of the 3-pyridyl series [(92)-( 95)] was 
much more straightforward, although attempts at obtaining the 3-pyridinecarbaldehyde 
adduct with 1,1,3-tricyano-2-aminopropene failed. Also, the synthesis o f the 2-imidazolyl 
series [(96)-(100)], 2-thienyl series [(101)-(105)], and 3-thienyl series [(106)-(110)], did not 
pose any serious problems. Consequently, together with the unknown (111), these were all 
biologically tested in the MCF-7 intact-cell assay, as well as the cell-free assay against the 
EGF-R kinase (Table 16).
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Table 16 Biological Activities of Heteroarvlpropenonitriles
Structure No. R IC5 0  (jIM)a 
MCF-7 cells
IC5 0  (|lM)b 
EGF-R kinase
N ^  R
(91) C02Et 39.3 n.d.
See structure ( 111) >50 n.d.
ryv
J  CN 
N
(92)
(93)
(94)
(95)
CN
c s n h 2
C 02Et
c o n h 2
32.3
>50
>50
>50
225°
77
>500
n.d.
c u .
H
(96)
(97)
(98)
(99)
(100)
CN
C(NH2)=C(CN)2
c s n h 2
C 02Et
c o n h 2
26.3 
>50
29.4 
>50
; >50
532c
n.d.
56
>100
n.d.
'a x
(101)
(102)
(103)
(104)
(105)
CN
C(NH2)=C(CN)2
c s n h 2
C 02Et
c o n h 2
20.0
>50
49.9
>50
>50
>100
>100
>100
>100
n.d.
crs*
(106)
(107)
(108)
(109)
(110)
CN
C(NH2)=C(CN)2
c s n h 2
co2a
c o n h 2
43.0
39.1 
22.7 
40.9 
>50
n.d.
n.d.
250
>100
n.d.
aIntact cell assay bCell free assay (n.d.= not determined) 
‘Values taken from Gazit et. a l .230c
On the w hole the biological results were disappointing and there was no significant 
correlation between antiproliferative activity and EGF-R kinase inhibition. Futhermore none 
of these compounds seemed to possess the capacity to inhibit the enzymatic activity of the 
EGF-R kinase to the same extent as the dihydroxphenyl or trihydroxyphenyl series. For 
example the thioamide derivatives (98) and (103) showed reasonable IC50 values of 77 and 
56 JIM, respectively, against the EGF-R kinase, but this did not approach the 1-5 pM values 
exhibited by the best hydroxyphenyl analogues, cf. (58) and (78) in Table 14. It is clear, 
therefore, that the hydroxybenzylidene nucleus is needed for potent inhibitory action of the 
tyrphostins against the EGF-R tyrosine kinase. However, as noted previously, there is a 
major concern for this type o f tyrphostin and probably potency and instability are 
inextricably linked with each other. Thus, it was decided to search for other heterocyclic
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moieties that are able to exhibit low micromolar IC50 values. This will be discussed in 
Chapter 8 .
6.6  Propenoic Acid and Other Tyrphostin Derivatives
the /7-hydroxyphenyl nucleus. Thus, it was planned to make a series o f ester and acid 
derivatives based on alternative aryl groups. Particular interest was directed at exploring 
nitroaromatic tyrphostin analogues, as only a limited number of these had been reported. 
Initially, only methyl and ethyl cyanoacetate were available as starting materials. Thus, in 
order to determine appropriate conditions to form the corresponding acid derivatives, the 
cinnamic esters (113)-(118) were formed and used as model systems. .
Due to the acid and base sensitivity of the nitrile group, a hydrolytic route to the acid 
derivatives of the above esters was avoided. Thus, it was required to use neutral conditions 
and the method initially chosen involved the SN2 cleavage of methyl esters using anhydrous 
lithium iodide in refluxing DMF .257 However, although a variety of conditions were used, 
this method gave complex mixtures with no identifiable product after extensive attempts at 
purification. Interestingly, the use of anhydrous lithium brom ide  on methyl 2-cyano-3- 
(4-nitrophenyl)propenonitrile (115) induced a demethoxycarbonylation and gave a low yield 
of the frarts-cinnamonitrile (1 1 9 )— as identified by 90 MHz ! H NMR spectroscopy 
(see Scheme 6 ). This result is not surprising considering the powerful electron-withdrawing 
effect of the 3-(4-nitrophenyl)propenonitrile system since it will facilitate nucleophilic 
attack and subsequently stabilise any anionic intermediate. Furthermore, dipolar aprotic 
media are frequently used to effect this transformation.258
Previously, Levitzki and co-workers230b had synthesised acid and ester derivatives based on
N 0 2
(117) R= Me
(118) R= Et
(113) R= Me
(114) R= Et
(115) R= Me
(116) R= Et
Scheme 6 Demethoxvcarbonvlation of Compound (115) 
y x  .C 0 2Me 
I LiBr, DMF
L ^  CN reflux, under N 2
(115) (119)
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Another S N2 method employed the use of potassium trimethylsilanolate and was applied to 
the simplest tyrphostin model (113).259 This method quickly and efficiently formed the 
potassium cinnamate salt (120) in 90 % yield (Scheme 7), but was found inappropriate for 
the nitroaromatics (115)-(118). This is probably due to nucleophilic attack o f the powerful 
silanolate anion on the nitroaromatic rings.
After these disappointing results a milder non-nucleophilic method o f cinnamic acid 
formation was sought and the use of trimethylsilyl iodide (TMS-I) made in situ from 
sodium iodide and trimethylsilylchloride was tried. 260 However, this method also met with 
failure and only starting material could be isolated, even when TMS-I was preformed from 
hexamethyldisilane and iodine.261 Similar results were obtained with the use o f  
bis(tributyltin)oxide— a mild procedure reported to cleave methyl esters selectively among 
co-existing functional groups of methyl penicillonates.262 Clearly, an alternative mechanism 
of ester cleavage had to be investigated.
Originally, the idea had been to form te rt-butyl ester derivatives of the tyrphostins by the 
Knoevenagel condensation and then generate the acid derivatives by a classical SN1 
fragm entation, exp ellin g  isobutylene, using excess trifluoroacetic acid in 
dichloromethane. 263 However, the methods described previously were adopted since, at that 
time, the te r t-butyl cyanoacetate starting material was unavailable. When this material 
became available, a series o f terr-butyl cinnamate esters were formed and consequently 
transformed into their acid counterparts (Scheme 8 ). U se o f trifluoroacetic acid in 
dichloromethane was temperamental and required only a brief exposure to the solvent 
system. Trimethylsilyl triflate proved to be a milder method of fragmentation.264 But the best 
protocol employed the use o f formic acid265 whereby the terf-butyl esters could be briefly 
heated at reflux in a minimum amount of this solvent and on cooling the acid derivatives 
tended to crystallise out.
Scheme 7 Demethvlation of Compound (113)
Me3SiOK, THF (dry) 
under N 2, RT, 0.5 h
(113) (120)
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Scheme 8 Formation of Propenoic Acid Tyrphostin Derivatives
C 0 2Bu'
H C 02H at reflux
 ►
then RT, 0.5 h
C 0 2H
(121) X= 3,4-dihydroxy
(123) X= 3,5-dichloro
(125) X= 3,5-difluoro
(127) X= 4-nitro
(129) X= 3,4-dimethoxy-6-nitro
(131) X= 3,4-methylenedioxy-6-nitro
(133) X= 3-methoxy-4-hydroxy-5-nitro
(122) X= 3,4-dihydroxy
(124) X= 3,5-dichloro
(126) X= 3,5-difluoro
(128) X= 4-nitro
(130) X= 3,4-dimethoxy-6-nitro
(132) X= 3,4-methylenedioxy-6-nitro
N,
NH
(134)
C 0 2Bu'
CN reflux to RT, 0.5 h
H C02H
N,
■ * r Y
NH CN
c o 2h
(135)
After this work, other analogues based on the tyrphostins were sought. It was proposed to 
form a series o f 4-oxo-2-thioxo-l,2,3,4-tetrahydropyrimidines (Scheme 9). The rationale 
behind this was two fold: firstly, to incorporate a less hydrolytically labile  
thioamide/thiourea functionality since, from previous work, the thioxo-group seemed to be 
important for potency, and secondly, to design a novel heterocyclic target that would 
enforce a cis-geometry about the aromatic and cyano portions (cf. Levitzki et a l .230f). 
Scheme 9 Formation of 4-Oxo-2-thioxopvrimidines
S
X
(i) K2C 0 3, EtOH
H ,N
S
X
NH,
A r ^ ^ O r
CN
C0 2a  (ii) AcOH, reflux
Originally, it was planned to make a range of derivatives and incorporate the most active 
aromatic groups so far encountered in the project. However, this three component reaction 
could not be applied generally and only the reported synthesis o f compound (136) could be 
successfully achieved, albeit in a low yield .266 In particular, nitroaromatic systems proved to 
be problematic and reacting thiourea with the compounds (115), (117) or (129), or indeed 
the dichlorophenyl derivative (87), under a variety of conditions did not produce the desired 
product.
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Consequently, this area of work was not investigated any further. However it should be 
noted that compound (137) was formed from the isolated potassium salt (136) by an 
oxidative process. Although 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) was initially 
used for this purpose, the best method employed vigorously heating the acidified product of 
(136) at reflux in glacial acetic acid in order to achieve an air-assisted mild oxidation.
Another area o f interest was to develop other heterocyclic systems. For this purpose, the 
malononitrile dimer adduct of 2-nitrobenzaldehyde was formed (138). The rationale was to 
convert the nitro group into an amino group and then induce a cyclisation to the quinoline 
system (139). Such reductive cyclisations of benzylidene compounds with ortho-nitro 
groups have been documented before.267 However all attempts based on catalytic 
hydrogenations {e.g. 5 % palladium on carbon)268 were unsuccessful. Hydrolytic reduction 
methods (e.g. zinc or tin metal in mineral acid) were precluded due to the sensitivity of the 
nitrile grouping— although, in hindsight, the use of zinc or iron dust in acetic acid could 
have been tried.
H,N HoN
Other miscellaneous tyrphostin-based analogues were also made via  the Knoevenagel 
condensation. These have been collated with the ester and acid tyrphostin derivatives in 
Table 17. A lso displayed are the IC50 values measured for the compounds in the MCF-7 
antiproliferative assay (no EGF-R kinase assays were performed in these cases).
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Table 17 MCF-7 Data for Acid &  Other Tyrphostin Derivatives
Structure No. R IC50OJM) Structure No. R IQ qGjm)
CN
(113)
(114)
Me
a
30
3 ° ° 2R
(77)
(121)
(122)
a
lBu
H
43
31
33
CN
a
(87)
(123)
(124)
a
lBu
H
68
49
38 CN
F
(90)
(125)
(126)
a
lBu
H
49
67
30
CN
(115)
(116)
(127)
(128)
Me
a
lBu
H
13
17
58
50
Me°  C°2»
> L  j s .  CN
MeO N02
(129)
(130)
lBu
H
25
31
CN
o  n o 2
(131)
(132)
lBu
H
30
46
Me0 C° 2R 
n o 2
(117)
(118) 
(133)
Me
a
lBu
40
10
7
/ V " Y ro2R
\ ^ N H  CN
(99)
(134)
(135)
a
lBu
H
>50
42
63
n h 2
( r v v V ™
1 CN CN
n o 2
(138) 15
S
X
HN NH
(136) 
K" salt
33
s
XHN NH
1  J  CN
MeO V
(137) 12
CN
C X ^ O
(139) 43
J X &
(140) 28
In some cases, the terf-butyl esters tended to be more active than their acid counterparts. 
This may be due to the more hydrophobic derivatives being more able to penetrate the cell 
membrane. However, there are a few exceptions to this statement. For example, in the 
3,5-dihalophenyl series, there is a distinct advantage to possessing an acidic side group, 
cf. compounds (87), (90), and (123)-(126). Also, in the 4-nitrophenyl series [(115), (116),
(127), and (128)], as the alkyl group (R ) gets smaller the potency increases, although it is
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it is not beneficial to have an acidic functionality. The imidazole derivatives [(99), (134), 
and (135)] all tend to lack potency. Similarly, both the anthracene (139) and the Meldrum’s 
acid adduct (140) of 4-nitrobenzaldehyde, did not afford interesting results.
A strikingly clear trend in Table 17 is shown by the 5-nitrovanillin derivatives [(117), (118), 
and (133)] where as the size and hydrophobicity of the alkyl group (R ) is increased so does 
the potency. For the the thioxopyrimidines, (136) and (137), the presence o f a double bond 
seems to be important for potency and this, as a series, could show promise. However, in 
order to ascertain the likelihood that the observed antiproliferative activity is due to 
inhibiting the signalling function at the EGF receptor, the most potent members of Table 17, 
Le. compounds (114)-(116), (133), (137), and (138), should be checked against the EGF-R 
kinase cell-free assay. Unfortunately, this was beyond my expertise and was not carried out. 
Nevertheless, for future reference, it would be advisable to develop the thioxopyrimidine 
series and incorporate alternative aromatic moieties into this base structure. Also, 5-nitro­
vanillin derivatives, cf. (133), with an aralkyl hydrophobic side chain (R ) should be made.
CHAPTER «7» Heteroaromatic Tyrphostin Derivatives
From the results given above, nitroaromatic tyrphostins generally exhibit a higher potency 
than the tyrphostins that possess a simple phenyl moiety (cf. Tables 14 to 17). This could 
mean that one should search for other nitroaromatic tyrphostins or an alternative electron- 
deficient system. For this latter case the most suitable system would be that of a nitrogen- 
heterocycle. However, as the formation of a 2-pyridine series of tyrphostins was unfruitful 
and the 3-pyridine series showed poor potency, it was decided to form a set of tyrphostins 
based on the quinoline nucleus. Futhermore, a set of nitro-substituted heterocycles was 
synthesised and tested for their biological activity. Thus, work relating to electron-deficient 
systems will be discussed in this chapter.
7.1 Nitrofuranvlpropenonitrile Series
Earlier in the project various attempts at performing the Knoevenagel condensation 
(Scheme 1) on 2-nitrofuran-5-carbaldehyde were made. These were based around using neat 
piperidine and relatively dilute reaction concentrations at room temperature (Methods A and 
B). However these methods were generally unsuccessful or gave complex mixtures which 
were difficult to separate. So in order to ascertain an optimum procedure, a systematic 
investigation of reaction conditions was performed. This resulted in a new method based on
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the observation that the product tended to be less soluble in the chosen alcohol solvent than 
the starting materials (Method C). This allowed the required product to precipitate or 
crystallise out so that it could not react any further. It was also important to minimise the 
reaction time as well as the quantity of piperidine catalyst. Indeed, this procedure is 
applicable to other activated nitroarylcarbaldehydes and, in this case, gave rise to the
3-(2-nitrofuran-5 -yl)propenonitrile series (141)-(148). The acid derivative (149) was made 
from (148) using formic acid according to the conditions given in Scheme 8 .
(145) R= COoMe
(141) R= CN
\  CN (146) R= C 0 2Et 
NC (142) R= > = <
I ~ \  H2N 0 4  (1 4 7 )R = C 0 2"Bu
0 2N q '  K (143) R=CONH-.
(148) R= C 0 2'Bu
(144) R= CSNH2
(149) R= C 0 2H
In this series, the most difficult analogues to make were the products derived from  
malononitrile dimer (142), cyanoacetamide (143), and cyanothioacetamide (144). Both 
(142) and (143) required careful purification by silica chromatography, and it was found 
best not to use piperidine as a catalyst for the preparation of the thioamide (142). For this 
latter case it was surmised that there was enough basic character in the amino portion of the 
thioamide group to act as a self-catalyst for the condensation reation— a thioamide group is 
more like an a-thioxo-amine group due to poor orbital overlap. However, some other related 
reactions could be conducted without the presence o f base catalyst. Thus an alternative 
reason may simply be the fact that 2-nitrofuran-5-carbaldehyde is a highly activated system  
for this type of reaction.
The observation that no base catalyst was required led to a brief *H NMR study of a related 
activated aldehyde (2-nitrothiophene-5-carbaldehyde) in deuteriated methanol. It was 
postulated that the aldehyde would be in an equilibrium between its free unsolvated and 
solvated form, i.e . as a dimethyl acetal. Indeed, this was observed and probably the 
condensation reactions as descibed above are facilitated by the alcohol solvent. The 
proposed role o f piperidine as a catalyst is to form an iminium intermediate with an 
aldehyde and thereby make it more susceptible to nucleophilic attack. Thus, in this case, an
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alkyl oxonium intermediate such as (150) could be involved in the reaction mechanism but 
clearly this is still open for investigation.
(150) X= O or S
Returning to the nitrofuranyl tyrphostin series, the condensation products (141)-(149) were 
subsequently tested in the MCF-7 intact-cell assay and the IC50 values obtained have been 
collated in Table 18. The amide (143) and tert-butyl ester (148) were the most potent 
compounds. However, unlike the other series so far encountered, the thioamide (144) and 
the 2-amino-1,1-dicyanopropene conjugate (142) were not the most potent members of this 
series. Also, a clear structure-activity relationship is presented for the ester derivatives
(145)-(148), with the rm-butyl ester (148) being the most potent with a significantly low  
IC50 value of 4  JIM. This same pattern was observed in the 5-nitrovanillin derivatives [(117), 
(118), and (133)] whereby an increase in hydrophobicity is correlated to an increase in 
potency— cf. Table 17. Again a loss in potency is observed for the acid derivative (149) and 
reflects the ease at which acids are able to traverse cellular membranes.
Table 18 MCF-7 Data of 3-(2-Nitrofuran-5-vl)propenonitriIes
Structure No. R IC5 0  (jiM)
(141) CN 39
(142) C(NH2)=C(CN)2 41
NO (143) c o n h 2 9(144)
(145)
(146)
c s n h 2
0 0 2Me
C02Et
39
49
53
(147) C 02nBu 25
(148) 0 0 4
(149) c o 2h 30
This series was not investigated any further since more potent compounds were generated 
from 2-nitrothiophene-5-carbaldehyde. Also a promising series based on the quinoline 
nucleus had been discovered— see following sections. This aside, a clear recommendation 
for the nitrofuranyl tyrphostins would be to synthesise ester or amide derivatives with 
branched and unbranched alkyl chains. Also the incorporation of aralkyl groups would be 
advisable (particularly isosteres of tyrosine). Both these suggestions should not only aid the
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compound to traverse the cell membrane but the hydrophobic side chains should be able to 
act as auxiliary binding groups in their own right.
7.2 Synthesis of 3-fNitrothienvl>)propenonitriles
From initial undergraduate work carried out in our group it was apparent that certain 
tyrphostins derived from a nitrothiophene showed excellent biological activities (IC50 values 
less than 1 JIM). Thus, it was o f interest to synthesise a range of substituted nitrothiophenes 
in order to establish structure-activity relationships. Therefore, using readily available 
starting materials, a set of 5- and 4-substituted 2 -nitrothiophenes were synthesised—  
hereinafter called the 2-nitrothien-5-yl series (151)-(159) and 2-nitrothien-4-yl series (160)- 
(166).
(155) R= C 0 2Me
(151) R= CN
\  CN (156) R= C 0 2Et 
NC (152) R= > = <
J \  I R H2N 0 1  (157) R= C 0 2"Bu
o 2n ^ N s ^ ^  R  (153) r =  C O n h 2
(154) R= CSNH2
(158) R = C 0 2:Bu
(159) R= C 0 2H
_ _ / ===(  (161) R= V=<
fj  S CN H2N CN
° 2N ' ^  ^  (162) R= CONH2
(163) R= CSNH2
(160) R= CN
CN (164) R= C 0 2Me
(165) R= C 0 2Et
(166) R= C 0 2nBu
The method developed for the nitrofuranyl series was used to form these products— other 
methods tended to be less effective and more cumbersome. However, as encountered before, 
formation of the malononitrile dimer product (152) gave difficulties. This was overcome by 
using THF as the solvent, instead o f ethanol, which allowed the desired product to 
precipitate out as the reaction progressed. The esters (155)-(158) and (164) -(166) could all 
be crystallised directly from the reaction medium. The acid (159) was made from the
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terr-butyl ester (158), in a similar manner as described before by using hot formic acid and
series, generally isopropanol or ethyl acetate were used. However, the amide (162) had to be 
purified by column chromatography.
Having synthesised two isomeric series it was desirable to explore other substitution 
patterns. This was achieved after synthesising the appropriate nitrothiophene carbaldehydes. 
Thus, for one series, 4-nitrothiophene-2-carbaldehyde (168) was made by the P-nitration of 
thiophene-2-carbaldehyde (167) at -10 to 20 °C with a mixture of fuming nitric acid and 
concentrated sulfuric acid (Scheme 10) .269 An approximate 3:2 ratio o f the p- and y-nitrated 
products was obtained, as indicated by 90 MHz *H NMR spectroscopy. The desired isomer 
(168) was separated by column chromatography but needed a series o f careful low  
temperature crystallisations in order to obtain an analytically pure product.
In this reaction it was critical to maintain a temperature below -10 °C and to add the 
nitrating solution slowly with ample stirring, otherwise purification was problematic and the
yield obtained was 33 %. Under the conditions o f the Knoevenagel condensation  
(Method C), the aldehyde (168 ) was subsequently used to form a set o f 2-substituted
4-nitrothiophenes, compounds (169)-(175)— hereinafter called the 4-nitrothien-2-yl series. 
Again the malononitrile dimer product (170) was formed in low yield and it was preferable 
not to use piperidine as catalyst in the formation of the thioamide (172).
could also be crystallised from this solvent. For crystallisation of other members in these
/.HNO 3/CH2SO4
Scheme 10 [3-Nitration of Thiophene-2-carbaldehvde
o 2n
(167) (168)
ratio of desired product to unwanted isomer plus overall yield diminished greatly. The best
(169) R= CN
(171) R= CONH
(172) R= CSNH2
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The synthesis o f the other starting aldehyde (1 7 8 ) required a different strategy 
(Scheme l l ) .270 This involved an initial orf/io-dichloromethylation o f 2-nitrothiophene (176) 
to give (177) followed by hydrolysis of the dichloromethyl moiety with 85 % formic acid. 
This last step required a little perseverance but the right reaction conditions were finally 
determined. Overall, this gave an ortho-formylation and is a good general method for 
introducing a carbaldehyde group to an electron-deficient aromatic system— as opposed to 
the Reimer-Tiemann reaction271 which under different conditions works well on 
electron-rich systems such as phenols or pyrroles.
Scheme 11 ort/io-Formvlation of 2-Nitrothiophene
(53%) (70%)
(i)CHCl3,'BuOK CHC12   CHO
n 4 DMF/THF, -70 °C ^ 4 85 % HCQ2H  ^ n
\ s / " ~ N 0 2 (ii) AcOH/MeOH X j / ' "  N 0 2 under N 2, reflux \ ^ - ~ N 0 2
r
(176) (177) (178)
The initial reaction type has been termed by M^kosza et a l.m  as a “vicarious nucleophilic 
substitution (VNS) of hydrogen”. However, as it stands, this VNS description is probably 
confusing since hydrogen, as the hydride anion, does not actually act as the leaving group. 
Indeed, the reaction proceeds by an ortho or para  attack on a nitro-aromatic by a carbanion 
which possesses a leaving group capable of a base induced (3 -elimination.273 Under the 
anionic conditions, this generates an orf/io-dichloromethylene ac/-nitronate intermediate 
(179) that on acidification gives 3-dichloromethyl-2-nitrothiophene (177).
a
^ _ y ~ c x
o ©// v®,>
O ©
(179)
Subsequently, the novel aldehyde (178 ) was subjected to a series o f Knoevenagel 
condensations to give the compounds (180)-(185)— hereinafter called the 2-nitrothien-3-yl 
series. Synthetically, this set of compounds did not pose too much problems and their 
biological evaluation, together with the isomeric series discussed above, will be presented in 
the next sections.
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N C - /
R
N 0 2
(182) R= CONH
(183)R =C SN H 2
7.3 Biological Evaluation of 3-fNitrothienvDpropenonitriles
The biological activities o f the various nitrothienyl series have been summarised in 
Table 19. Initially, the MCF-7 assay was conducted at inhibitor concentrations of 1 to 
100 }IM. However, as potencies of less than 1 pM were indicated, several assays were 
conducted at inhibitor concentrations down to 1 nM, and it was encouraging that some 
compounds even displayed inhibitory activities below this value.
As can be seen in Table 19 (MCF-7 column), most of the nitrothiophenes are highly potent 
antiproliferative agents. However, some compounds within a series displayed unexpectedly 
disappointing inhibitory actions, for example the methyl esters (155) and (164). The reason 
for this is not clear but it was found that methyl esters tended to be very insoluble in both 
organic and aqueous solvents. Thus, precipitation during an assay could account for these 
seemingly erroneous results.
For the EGF-R kinase assay, the IC50 values measured did not approach that observed for 
the MCF-7 cell assays. This indicates that the potent antiproliferative activity observed in 
the MCF-7 assay is not necessarily all due to inhibiting enzyme action at the EGF-R kinase. 
Nevertheless, a number compounds showed a reasonable correlation. For example, the 
nitrile (R = CN) derivatives [(151), (160), (169), (180)] consistently gave encouraging 
results in this respect. Also, the malononitrile dimer (R = C(NH2)=C(CN)2) products [(152), 
(161), (181)] and the thioamide (R = CSNH2) derivatives [(154), (163), (183)] displayed a 
reasonable correlation.
By comparing Tables 17 to 19, an interesting general trend seem s to be apparent for 
tyrphostin ester derivatives. Thus, for certain sets of tyrphostins such as the 
dihydroxyphenyl series [(77), (121), (122)], the nitrovanillin series [(117), (118), (133)], or 
the nitrofuranyl series [(145)-(148)], increasing the ester alkyl chain length tends to increase 
potency. However, for other sets of tyrphostins (particularly those with definite electron-
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Table 19 Biological Activities of Nitrothienvlpropenonitriles
Structure No. R IC5 0  ([1M)“ 
MCF-7 cells
IC5 0  (|lM )b 
EGF-R kinase
(151) CN 18.4 50
(152) C(NH2)=C(CN)2 12.0 12.25
(153) c o n h 2 1.9 >500
j n  ?* (154) c s n h 2 <1 37.5(155) C 02Me >100 >500
R (156) C 02Et <1 34
(157) C 02nBu 17.8 >500
(158) C 02'Bu <1 75
(159) c o 2h >50 150
(160) CN <0.001 23
R (161) C(NH2)=C(CN)2 <0.001 7
(162) c o n h 2 0.9 >500
' a . (163) c s n h 2 <0.001 10.5
0 2 N - <  JJ (164) C 02Me >20 >500sr (165) c o 2b <0.001 9
(166) C 02"Bu >20 >500
(169) CN 0.91 2
02N (170) CCNHjK^CCN^ <0.001 160
V  PVT (171) c o n h 2 <0.001 47
t \  T (172) c s n h 2 <0.001 >500(173) C 02Me <0.001 18
S R (174) c o 2h <0.001 >500
(175) C 02nBu <0.001 >500
(180) CN <0.001 15.3
.R (181) C(NH2)=C(CN)2 0.025 14.6
(182) c o n h 2 <0.001 400
(183) c s n h 2 0.8 22.7CN< A (184) C 02Me 6.0 50
S " ^ N 0 2 (185) co2a <0.001 100
(186) C 02wBu <0.001 >500
“Intact cell assay 1Cell free assay
deficient character) such as the nitrothienyl series [above], 4-nitrophenyl series 
[(115), (116), (127), (128)], or difluorophenyl series [(90), (125), (126)], decreasing the 
chain length tends to increase potency. Although this contrasting structure-activity 
relationship is open to interpretation, it may be speculated that the site or, possibly, mode of 
action between these two classes of tyrphostins is different.
Due to this discrepancy and that the nitrothiophene set of tyrphostins exhibit highly potent 
antiproliferative properties, a more detailed biological analysis on their mode of action was
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required. The data so far obtained indicates that some nitrothiophene compounds are able to 
block the phosphorylation o f a synthetic polypeptide by inhibiting activity at the EGF-R 
kinase in a cell-free enzyme assay. It was therefore necessary to ascertain the inhibition o f  
the EGF-R kinase in an intact-cell assay. For this purpose a similar assay to that performed 
for MCF-7 cells was carried out, except that fibroblast (HER-14) cells that have been 
transfected with the human EGF receptor were used. As before, the antiproliferative activity 
was assessed by using [3H]thymidine incorporation as a measure o f D N A  synthesis and 
gave a similar dose-response curve as shown in Figure 17.
It is important to understand in these assays that HER-14 cells remain arrested in G0, Le. are 
quiescent, unless acted upon by two types of growth stimulators (c /. Section 2.1—  
Introduction). One o f these is donor calf serum (DCS) and the other is EGF. DCS is 
ineffectual at a 0.1  % concentration but is growth stimulatory at 10 % and does not use 
EGF-R signalling to achieve this effect. Thus, parallel experiments were performed in which 
cells are grown in medium supplemented with 0.1 % DCS plus EGF274, or just medium  
containing 10 % DCS. Ideally, selective EGF-R PTK inhibitors w ill only block EGF- 
stimulated growth and will have no effect on growth stimulated by 10 % DCS. This 
behaviour is exem plified  in Figure 21 for the known tyrphostin, 2-cyano-3- 
(3,4-dihydroxyphenyl)propenothioamide (58)275 which was used as a control in these assays.
Figure 21 Inhibition of EGF* & Serum- Dependent Proliferation of 
HER-14 Cells bv 2-Cvano-3-(3.4-dihvdroxyphenvl)propenothioamide (58)
■ 10 % DCS
□ 0.1 % DCS 
+ EGF
CSNH<
[cone.]
0  n m n ' i ' i m m  i n i i n wq1 n m n  
. 01  . 1 1 10 100 1000
Synthesis and Biological Evaluation o f Anticancer Agents Page 91
The compounds (152), (154), (156), and (160) were tested in the HER-14 assay but, 
although significant antiproliferative activity was observed with IC50 values in the range of  
20 to 80 pM, there was no observed selectivity (see Figures 22A to 22D). Unfortunately, 
these activities are not near the nanomolar values measured for the breast carcinoma MCF-7 
cells. These results imply that another mode of action other than inhibition o f EGF-R  
signalling is occurring.
Further investigations (carried out by Dr Valerie G. Brunton) assessed the ability of few  o f  
nitrothiophenes [(152), (154), (156), (160)] to inhibit EGF-R autophosphorylation in intact 
cells.276 From this study, only the ethyl ester (156) was identified to inhibit this process but 
only at a concentration (100 |iM) that was (probably) toxic to the cells and thus does not 
represent a specific effect on EGF-R function. As an unselective toxic action was suspected, 
Dr Brunton then went on to assess the ability of a selection of nitrothiophenes to inhibit 
EGF-R kinase activity in a cytotoxicity assay against a panel o f  four squamous cell 
carcinoma cell lines derived from tumours of the vulva, tongue, cervix and uterus (see 
Table 20). These cell lines were chosen as they are well characterised for their EGF-R  
status, with the A 431 and HN5 cells having highly overexpressed levels o f receptor and the 
CaSki and SiHa cell lines having levels around those found in normal cells.
Table 20 Cytotoxicity Data for Nitrothiophene Tyrphostins in a Panel of 
Squamous Cell Carcinoma Cell Lines______________
IC5 0  values ( |IM ) ±  standard deviations
Compound Structure and 
Number for ArCH=C(CN)R
Values in brackets after each cell line represent 
the number of EGF receptors (x 106 per cell)
Ar R No. HNS (5.195) A431 (1.554) CaSki (0.785) SiHa (0.114)
OjN^fX
CN
C(NH2)=C(CN)2
c s n h 2
c o 2r
(151)
(152) 
(154) 
(156)
20.7 ±0.5 
8.411.1
66.919.7 
5.410.3
28.011.4
6.110 .2
71.615.2
4 .610 .2
25 .812 .7
9 .2 1 0 .2
82.918.3
6 .912 .8
25.413.8
13.411.0
82.1110.0 
4 .611 .3
CN
C(NH2)=C(CN)2
C 0 2Et
(160)
(161)
(165)
40.415.8
>100
>100
. 28.411.9 
>100 
>100
40 .016 .4
>100
>100
44.615.0
>100
>100
V iS ^ N 0 2
C(NH2)=C(CN)2
c s n h 2
(180)
(183)
5.112.4
0.2710.08
4 .710 .8
0.1110.02
4 .7 1 1 .2
0.3210.02
7.811.1
0.3510.04
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Figure 22 Inhibition of EGF- and Serum- Dependent Proliferation of 
HER-14 Cells bv Nitrothiophenes (152). (154). (156). and (160)
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In theory, cell lines that overexpress the EGF receptor will be more dependent on the 
EGF-R pathway for growth and thus will be more susceptible to an EGF-R selective  
inhibitor. Consequently, the potency of such an inhibitor should be greater in these cell lines 
as compared with ones that express lower numbers of EGF receptors, and should result in a 
gradual differential response from one cell line to another. However, although the 
compounds (152), (156), (180), and (183) were significantly potent in this assay, the results 
showed that nitrothiophenes were unselective (IC50 values remained constant).
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7.4 Further Studies on Nitrothiophenes
The studies described above indicate that the nitrothiophenes are not displaying a selective 
inhibitory action on EGF-R kinase function. Nonetheless, these compounds exert an 
impressive cytotoxic effect against the breast carcinoma MCF-7 cells. Thus, although these 
compounds were originally designed to be cytostatic, it was of interest to investigate this 
mechanism of cell kill further.
From the information so far obtained it is more likely that the nitothiophenes exert their 
cytotoxic effect in a non-selective manner. With consideration to their structure, a plausible 
reason for this could be the presence of an aromatic nitro group, since it is known that nitro- 
reduction within a cell can generate DNA damaging species (usually radicals of some 
kind— see references on Tirapazamine™ (6 ) in Section 4.3). Futhermore, it has been 
reported that a number of nitrothiophenes277 give initial one-electron reduction potentials in 
the order o f -200 to -550 mV. This lies within the range for cellular reductions and so 
nitrothiophenes have the potential to act as bioreductively activated cytotoxins or 
radiosensitisers.
To test this suggestion, a selection of nitrothiophenes [(152), (156), (161), (165)] was 
evaluated for their ability to induce DNA strand breaks in A 431 cells. This work was carried 
out by Dr Lloyd R. Kelland at the Institute o f Cancer Research (Belmont, Surrey, 
SM2 5NG, UK) and used alkaline filter elution as described previously for cw-platin.278 In 
summary, this study demonstrated that compounds (1 5 2 ) and (156) gave significant 
induction of DNA strand breaks at 100 |IM, and compound (152) even partially displayed 
this activity at 50 JIM. However, compounds (161) and (165) showed much less effecient 
activities. In contrast, the known typhostins (58) and ( 6 6 ) exhibited no induction of DNA  
strand breaks.
Having established that some nitrothiophenes can cause DNA damage, preliminary work 
carried out by a colleague279 demonstrated that compounds belonging to the 2-nitrothien-5-yl 
and 2-nitrothien-3-yl series displayed one-electron reduction potentials280 within the range 
likely to be reduced by cellular reducing agents, whereas compounds belonging to the
2-nitrothien-4-yl and 4-nitrothien-2-yl series did not. This result was not entirely surprising 
since, for electron withdrawing groups, an ortho- or para-  substitution pattern is more able 
to accept and stabilise an additional electron than a meta- substitution pattern.
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Interestingly, compounds (152) and (156) not only exhibited acceptable one-electron 
reduction potentials (-420 ± 20 m v and -330 ± 50 m V, respectively)280 but also caused 
significant DNA damage as described above. Futhermore, it is notable that compounds
(161) and (165) of the 2-nitrothien-4-yl series, which were inactive in the cytotoxicity panel 
at 100 fiM (see Table 20) and did not induce DNA damage, gave reduction potentials 
outwith the range possible for cellular reduction (-1 2 1 0 ± 3 0 m V  and -7 2 0 ± 1 0 m V ,  
respectively) .280 Such evidence agrees with the possibility that bioreduction contributes at 
least partially to the observed cytotoxicty of the compounds (152) and (156).
Due to the novelty and increasing interest in this class of compounds, a few promising 
candidates were selected to be screened against a panel of 60 human tumour cell lines held 
at the US National Cancer Institute.281 Under a similar protocol to that performed for the 
MCF-7 cell line, tumour cells are subjected to a series of drug concentrations and the 
concentration which produces an apparent 50 % decrease in the number of tumour cells 
(relative to an untreated control) is defined as the GI50 value. The results for compounds
(152), (156) and (160) are given in Figure 23. For each graph the vertical line represents the 
log of the mean GI50 value based on all the 60 cell lines. Thus, bars to the right represent 
activity greater than the mean [lower log (GI50)] while bars to the left represent activity 
lower than the mean [higher log (GI50)].
As can be observed in Figures 23A and 23C, there was a very narrow range o f GI50 values 
for compounds (152) and (160) in the different cell lines, indicating no preference for any 
particular tumour class. In contrast, compound (156) displayed a significant variation in 
sensitivity between the cell lines (Figure 23B). The leukaemia cell lines were particularly 
sensitive to the compound as were the majority of the colon cancer, melanoma and breast 
cancer cell lines, while the CNS derived lines and the non-small cell lung cancer lines were 
particularly resistant to compound (156). Furthermore, in order to search for similarities 
between drugs of known mechanism of action and the test compounds (152), (156), and
(160), the data obtained was subjected to a COMPARE analysis. 282 This indicated that these 
compounds had unique profiles of sensitivity in the 60 cell lines as compared to a panel of  
anticancer agents with well defined modes of action.
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Figure 23 Mean GIg0 Values from US National Cancer Institute Panel of
Human Cancer Cell Lines for Compounds (152). ( 156). and (160)
A: Compound (152)
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Figure 23 Mean GIcq Values from US National Cancer Institute Panel of
Human Cancer Cell Lines for Compounds (152). (156). and (160)
NC
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Figure 23 Mean GI50 Values from US National Cancer Institute Panel of
Human Cancer Cell Lines for Compounds (152). ( 156). and (160)
CN
C: Compound (160)
CN
LEUKEMIA
CCRF-CB4 -4.63
HL-aOfTB) -0 7
K-662 
MOLT-4 
RPMW22B 
SR -0 3
NOM-SMALL CELL LUNQ CANCER 
A64B«CTCC > -0 0
BCVX *-4J0
H0M2 
H0P42 
NCW4226 
NCLH23 
NCLH322M 
NCLH460 
NCJ-H522 
COLON CANCER 
COLO 205 
HCG-2996 
HCT-116 
HCT-15 
H720 
KM12 
SW-620 
CMS CANCER 
SF-2M 
SP-295 sr-Mfl 
SNB-19 
SN3-75 
U251
MELANOMA
LOX IMVI 
MALME-3M 
Ml 4
SK-MEL-2 
SK-MEL-2B 
SK-MEL-6 
UACC-257 
UACC-62
OVARIAN CANCER 
(GR0V1 
OVCAR-3 
OVCAR-4 
OVCAR-6 
OV CAR-6 
SK-OV-3
RENAL CANCER 
786-0 
ACHN 
CAW-1 
RXF-393 
SN12C 
TK-10 
UO-31
PROSTRATE CANCER 
PC-3 
OU-145
BREAST CANCER 
MCF7
MCF7/A0R-RES -4.43
M0A-MB-23VATCC -LM
HSS78T -435
MDA-MB-435 -4.64
MDA-N -4.70
ST-649 -434
T-47D -4.64
•431
*•430
•432
•4.13
•431
•432
•434
•437
-4.79
-437
•434
-4.49
-436
-4.41
3.36
-4.22
-4.30
•431
•4.47
-4.75
•437
•4.79
-4.M
•4.72
•4.75
•4.62
•4.64
•4.54
•433
•4.71
•433
•4.47
•4.71
*4.61
-4.76
•4.46
•4.34
•4.75
•4.42
-4.62
aB
Cc
□
13
MG MID
DELTA
RANGE
•432
030
032
+3 +2 +1 0 •2 -3-j
Synthesis and Biological Evaluation o f Anticancer Agents Eoge 98
It is clear, therefore, that the nitrothiophenes represent an interesting (possibly novel) class 
of cytotoxic agent and may be promising candidates for future drug development. However, 
their exact mode(s) of action still remains to be determined and their overall selectivity does 
not look too encouraging. Nevertheless, from the study described above and in the previous 
sec tio n , particu lar a tten tion  should  be d irected  at e th y l 2 -cyan o-
3-[5-(2-nitrothienyl)]propenoate (156) due to its differential effects on various tumour cell 
lines. Currently this compound has been accepted by the NCI to undergo an in vivo 
evaluation and, if bioreduced, has the possibility o f being solid tumour selective, although 
its sensitivity to rapidly dividing cells of the body still remains a concern. However, for the 
other nitrothiophenes [(152), (160), (161), (163), (163), (165), (169), (173), (180), (181), 
(183)] found signficantly active against the EGF-R kinase assay (see Table 19), the next step 
would be to test these against appropriate human tumour xenografts, first in vitro and then in 
vivo . Further recommendations would be to determine if the inhibition o f DNA synthesis is 
reversible or not and to ascertain whether high dosing induces cell death {e.g. by lysis, 
apoptosis, necrosis, etc). This should allow the degree of cytotoxicity to be assessed in 
greater detail. It would also be advisable to test these compounds for damage against redox 
or metabolic (mitochondrial) processes of the cell because of their susceptibility to reduction 
{cf. closing discussion in Section 6.2). Indeed, they should be assayed against enzymes 
responsible for cellular reductions {e.g. DT diaphorase, P450 cytochromes, etc.). Clearly, 
this is an area open to further investigation and the results so far obtained have been 
submitted for publication.283
7.5 Synthesis of Ouinolinvlpropenonitrile Series
In Section 6.5, the synthesis and biological evaluation of heterocyclic tyrphostin derivatives 
was described. As an extension to this work and to explore alternative heteroaromatic 
systems, a series of quinoline derivatives was synthesised. Like the nitroaromatics described 
earlier in this chapter, these heterocycles are electron-deficient (but to a lesser degree). This 
may avoid the instability that is apparent in the hydroxylated phenyl series {cf. Section 6.3) 
and the cytotoxicity that is observed in the nitrothienyl series (to some extent). Although 
potency may diminish, it should be borne in mind that potency per se is less important than 
selectivity and the purpose of this project was not to develop yet another cytotoxic agent but 
to strive for a cytostatic antisignalling agent.
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The synthesis o f quinoline based tyrphostins was carried out under the conditions of the 
Knovenagel condensation (c/. Scheme 1). Thus, using a selection o f activated methylene 
derivatives, the 2-quinolinyl series (187)-(192) was generated from 2-quinoline- 
carbaldehyde. Similarly, the 3-quinolinyl series (1 9 3 X 1 9 7 )  was produced from
3-quinolinecarbaldehyde; and the 4-quinolinyl series (198)-(202) was synthesised from
4-quinolinecarbaldehyde. The formation of the malononitrile products (187), (193), and 
(198) for use as charge transporters in electrophotographic photoconductors has recently 
been reported.284 These compounds, together with the derivatives (188), (194), and (199), 
have also been prepared in order to study the mesomeric effects o f an electron withdrawing 
sidearm on the ultraviolet spectrum of quinoline.285
R
(193) R= CN
(194) R= C(NH2)=C(CN)2
(195) R= CONH2
(196) R= CSNH2
(197) R= C 0 2Et
(198) R= CN
(199) R= C(NH2)=C(CN)2
(200) R= CONH2
(201) R= CSNK2
(202) R= C 0 2Et
(187) R= CN
(188) R= C(NH2)=C(CN)2
(189) R= CONH2
(190) R= CSNH2
(191) R= C 0 2Et
(192) R= C 0 2But
Out of these three series the formation of the 2-quinolinyl series posed the most problems 
(cf. 2-pyridyl series, Section 6.5). Although preparation of the compounds (187), (191), and 
(192) did not create too many difficulties, the malononitrile dimer (188) and amide (189) 
products were preferably made in THF while using DBU as the base catalyst. However, 
under reasonably concentrated conditions with a minimal amount o f piperidine, the 
compound (188) could be made and precipitated from ethanol. This was not the case for the 
formation of the amide (189) which was extremely problematic and gave complex mixtures. 
The reason for this was not clear but careful elimination o f water, using 4 A molecular 
sieves, and an immediate purification by column chromatography, yielded the desired 
product, albeit in very low yield.
In contrast, although DBU was also used for some members of the 4-quinolinyl series, the 
amide (200) was produced in reasonable yield and could be crystallised. Apparently, a
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heteroarylcarbaldehyde with an ortho azine-nitrogen is susceptible to further reaction under 
the conditions employed. One possibility is activation of the double-bond for fo's-adduct 
formation, although other alternatives may be envisaged, e.g. nitrogen lone-pair attacking a 
carbonyl or nitrile carbon centre.
In the 3-quinolinyl series, the preparation o f compounds (193) and (195)-(197) was 
reasonably straightforward. The malononitrile dimer product (194) was formed in very low  
yield but this was mainly due to the small scale of the reaction and product loss during 
crystallisation. The formation o f the rm-butyl ester (192) in the 2-quinolinyl series, was 
carried out in order to obtain its acid counterpart. However, all attempts at treating (192) in 
formic acid or other media favourable for SN1 reactions failed and gave intractable 
mixtures. In comparison, formation of the acid derivatives in the 3- and 4-quinolinyl series 
is possible {via the terf-butyl esters) and the formic acid reactions are reasonably facile and 
effective (see note286). The reason for this is again unclear but is probably connected to the 
problems encountered previously in the preparation of the 2 -quinolinyl series.
7.6 Biological Evaluation of Ouinolinvlpropenonitrile Series
Initially, a selection of tyrphostins incorporating a quinoline portion, as synthesised above, 
were evaluated in the MCF-7 antiproliferative assay (Table 21; “[3H]Thymidine” column). 
This gave encouraging results since a number of substituted quinolines, notably (187),
(188), and (196), displayed IC50 values less than 1 JIM. Also, this set o f compounds (as a 
whole) exhibited activities significantly higher than those encountered for the 
hydroxyphenyl series {cf. Section 6.2) or, indeed, the other heterocyclic series previously 
described {cf. Section 6.5).
Consequently, the compounds were tested for their ability to inhibit EGF-R kinase function 
directly (Table 21). This demonstrated that the most potent derivatives in each quinoline 
series contained the 2 -aminoethene-l,l-dicarbonitrile moiety [R= C(NH2)=C(CN)2]. Thus, 
compounds (188), (194), and (199), gave respective IC50 values o f 1.7, 27.0, and 4.7 (IM. As 
can be seen, for each R group, the 2-substituted quinolines were generally more potent than 
their 3- or 4-substituted counterparts and the 3-substituted series were the least potent.
However, there did not seem to be a consistent correlation between antiproliferative activity 
and EGF-R kinase inhibition. This indicated that a non-selective mode of growth
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Table 21 Biological Activities of Ouinolinvlpropenonitriles
Compound IC5 0  Values (pM )
Structure No. R pHJThynidinea M TTb EGF-R kinasef
(187) CN <1 >100 58
h CN (188) C(NH2)=C(CN)2 <1 77 1.7
(189) c o n h 2 49 34 79
(191) c o 2r n.d 17 240
(192) C 0 2Bu n.d 14 145
__ D (193) CN 24.8 76 400
(194) C(NH2)=C(CN)2 n.d 52 27
(195) c o n h 2 23.9 n.d >500
> CN (196) c s n h 2 <1 >100 300
(197) c o 2r >50 >100 >500
R
1 (198) CN 21.0 78 170
f ^ ^ C N (199) C(NH2)=C(CN)2 n.d 55 4.7
(2 0 0 ) c o n h 2 26.8 41 140
(2 0 1 ) c s n h 2 n.d 49 38
I (2 0 2 ) c o 2r 48.4 n.d 330
^  N
aMCF-7 antiproliferative assay bMCF-7 cytotoxicity assay
cCell free assay on HN5 membrane fractions (n.d.= not determined)
inhibition was occurring, possibly toxicity, and the compounds required further
investigation. For this purpose the compounds were assessed in a cytotoxicity assay against 
the MCF-7 cell line (see Table 21; “MTT” column). As indicated, there was a wide range of 
IC50 values (as low as to 14 pM and above 100 pM  ) but again no obvious correlation could 
be made between cytotoxicity and EGF-R kinase inhibition. Futhermore, although a 
reasonable correlation was apparent for the compounds (188), (194), and (199), there was no 
general pattern between potency and R group substituents or with the position of 
substitution on the quinoline ring system.
These findings raised the possibility that the observed antiproliferative effects o f the 
quinoline-derived tyrphostins may be unrelated to EGF-R kinase inhibition. Thus, as 
performed for the nitrothiophenes, the most promising candidates [(188), (194), (199)] were 
assessed against transfected fibroblast (HER-14) cells {cf. Section 7.2). The dose-response 
curves obtained are given in Figure 24. Each graph displays parallel experiments that were 
carried out in which quiescent HER-14 fibroblasts were stimulated to undergo DNA  
synthesis in either 0.1 % DCS supplemented with EGF, 274 or just 10% DCS over a
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Figure 24 Inhibition of EGF- and Serum- Dependent Proliferation of
HER-14 Cells bv Quinolines (1881. (194). and (199)
NC NC
CN
(188)
2 0 -
.01 .1 1 10 100 1000
B
100 -
ao
muocxuoua ,CN
4 0 - CN CNo
h
ao
O
(194)
.01 .1 101
C^ 1 0 0 -
ao
• a .
ca
tmO
Ok
tmoua
CN CN
’CN
NH;
4 0 -
o
b
§ 2 0 “ 
£  ft -
N
(199)
piM
100 100001 101 1
KEY: □ 10% DCS ■ 0.1% DCS + EGF
Synthesis and Biological Evaluation of Anticancer Agents Page 103
16 h period. Thus, all compounds were shown to preferentially inhibit EGF-dependent 
phosphorylation at 100 pM , although to a lesser degree as compared to the tyrphostin (58) 
{cf. Figure 21). The 3 -substituted quinoline (194) even showed preferential inhibition at 20 
JIM (Figure 24B). Therefore, this study suggests that the mechanism o f action of these 
compounds is at least partially linked to the EGF-R signalling pathway.
In an attempt to determine if  there was a link between the molecular properties of this set of 
quinoline tyrphostins and PTK activity, detailed ab initio calculations were carried out by 
Dr R. Zwaans and Dr C. Thomson at the University o f St. Andrews (North Haugh, St. 
Andrews, Fife, K Y I6 9ST) . 287 Although sophisticated computer-aided techniques were used, 
conclusions were difficult to formulate and will not be discussed in detail here. However, it 
was suggested that three small negatively charged areas are required to attach compounds 
containing the 2-aminoethene-l,l-dicarbonitrile moiety [(188), (194), (199)] to the catalytic 
site of the enzyme and allow the quinoline portion to rotate freely in an appropriately 
orientated position.
Further biological studies (carried out by Dr Valerie G. Brunton) investigated the effect that 
the compounds (188), (194), and (199) had on inhibiting the EGF-stimulated tyrosine 
phosphorylation of the EGF-R kinase as well as other cellular proteins in HER-14 cells. 
This showed that the 2- and 3- substituted quinolines [(188) and (194)] did not reduce 
EGF-R autophosphorylation at concentrations as high as 100 JIM. In comparison, the
4-substituted quinoline (199) at 100 }JM completely abolished EGF-induced tyrosine 
phosphorylation but this was probably due to a toxicity effect at this concentration 
(cf. Figure 24C). However, an interesting observation made from this study was that all 
three compounds were able to inhibit selectively the EGF-dependent phosphorylation o f an 
unknown protein o f around 50 kDa in mass— compounds (188) and (194) at 100 jiM, and 
compound (199) at 50 |XM.
These findings, therefore, imply that the selected quinoline compounds may not be acting on 
the EGF-R kinase itself but on at least one downstream protein involved in EGF-R 
signalling. However, the action o f these compounds on EGF-R cannot be totally discounted 
since in intact cells they may be acting as inhibitors competitive for the ATP binding site 
and so would have to compete with very high intracellular levels o f ATP ( c f  Osherov 
e ta l .288). This would mask any effect the compounds had on receptor autophosphorylation.
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However their action may still be sufficient to inhibit the association and/or phosphorylation 
of EGF-R kinase substrates that are involved in the mitogenic response to EGF. Such 
substrates may include the She family of adaptor proteins which are known to associate with 
and be phosphorylated by activated EGF receptors (see Section 3.3; Introduction). 
Unfortunately, although the She protein has a molecular weight o f around 50 kDa, more 
detailed experiments showed that the EGF-dependent phosphorylation o f She in HER-14 
cells was unaltered by either compound (188), (194), or (199).289
The suggestion that the quinoline compounds (188) and (199) are affecting EGF-R kinase 
signalling was also indicated in the results obtained from their cytotoxicity profile against a 
panel o f squamous cell carcinoma cell lines which express differing levels o f the EGF 
receptor (Table 22). Thus, the high receptor-expressing cell lines were more sensitive to the 
quinolines than the cell lines expressing lower receptor levels (cf. Table 20 in Section 7.2). 
Although encouraging this outcome can not be used as direct evidence for inhibition o f  
EGF-R kinase function either at the receptor itself or downstream in its signalling cascades.
Table 22 Cytotoxicity Data for Quinoline Tyrphostins (188) and (199) in a
Fanel of Squamous Cell Carcinoma Cell Lines
IC 50 values (fiM ) ±  standard deviations
Compound Structure 
and Number
Values in brackets after each cell line represent 
the number of EGF receptors (x 106 per cell)
HN5 (5.195) A431 (1.554) CaSki (0.785) SiHa (0.114)
r r ^ Y ^ l  CN CN
__ _
^  N ^  CN 
(188) NH2
38.3 ±7.5 45.7 ±7.5 69.0 ±17.1 >100
NC CN
iTy S
4 ?  (199)
N
8.9 ±2.4 6.3 ±1.0 36.3 ±3.8 >100
In each cytotoxicity assay, the 4-substituted quinoline (199) displayed greater potency than 
the 2 -substituted quinoline (188) and so was selected to be evaluated for its potential to 
induce DNA strand breaks. This work was carried out by Dr Lloyd R. Kelland at the 
Institute o f Cancer Research (Belmont, Surrey, SM2 5NG, UK) and showed that cells
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treated with compound (199) displayed no evidence of DNA damage— cf. opening 
discussion in Section 7.3. Thus, the mechanism of cytoxicity remains unknown at present.
It is clear, therefore, that further work is required to elucidate the mechanism of action of 
this group o f substituted quinoline tyrphostins and to establish whether this is related to 
inhibition of EGF-R kinase function or not. This is particularly pertinent for the most active 
compounds (188), (194), and (199) which, although possessing an additional cytotoxic 
action, selectively inhibit the EGF-dependent phosphorylation of a 50 kDa protein. An 
initial recommendation would be to determine if these three compounds are acting as 
substrate-based ATP inhibitors at the EGF-R kinase in cell-free assays. Also, their 
selectivity towards other signalling enzymes should be investigated as well as their effect on 
the mitochondrial processes of the cell.
As suggested in the closing discussion for the nitrothiophenes (Section 7.3), the compounds 
(188), (194), and (199) should also be assessed in a panel o f human xenograft models in 
order to establish sensitivity patterns. The 2-substituted quinoline (188) has already been 
screened by the US National Cancer Institute for its antiproliferative activity against a panel 
of 60 tumour cell lines. The mean GI50 graph (Figure 25) shows that the majority of non­
small cell lung cancer tumours are resistant to compound (188), whereas the majority of the 
colon, CNS, melanoma and renal tumours are relatively sensitive. 290 Thus, this study has 
demonstrated that a certain degree o f selectivity may be achieved with this type o f  
antiproliferative agent and some o f the results presented here have been submitted for 
publication.291
7.7 Attempted Synthesis of Polvsubstituted Quinoline Derivatives
From the biological results obtained for the quinoline-based tyrphostins, the 2-substituted 
series gave the most potent compounds. Thus it seemed appropriate to develop a synthetic 
route to substituted 2-quinolinecarbaldehydes (2 0 7 )  in order to explore the effect 
substituents had on the biological activity o f the tyrphostins (208) derived from these 
starting materials (Scheme 12). This work was initiated nearing the end o f  the PhD project 
and was not completed due to time restrictions but is included here due to its logical 
connection to the previous sections.
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Figure 25 Mean GI50 Values from US National Cancer Institute Panel of
Human Cancer Cell Lines for Compound (188)
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Scheme 12 Proposed Synthesis of Substituted 2-OuinolinecarbaIdehvdes
X-
CHO
n o 2
(X= 3,4-dimethoxy)
H2N-R, PhCH3
TsOH, reflux, 4 h 
(Dean-Stark)
R
CH'
n o 2
(203)R ='B u
(204)R=4-C1C6H4
Ni2B, EtOH 
reflux, NH2NH2
o
NOH
NOH
(206)
KOH, EtOH 
reflux, 6 h NH2 
(205) not formed
acid
hydrolysis
X - ~
N CHO
Knoevenagel
condensation 
(cf. Scheme 1)
(207) (208)
Scheme 12 outlines the Friedlander quinoline synthesis292 and requires the initial imine 
protection o f an orr/io-nitrobenzaldehyde before reduction o f the nitro group to form the 
orr/io-aminobenzaldimine derivative (205). The reason for this is that unprotected 
orr/zoaminobenzaldehydes are generally unstable and are proned to further reactions. Thus 
treatment o f the intermediate (205) with the aldoxime derivative o f glyoxal under basic 
conditions should generate the quinoline system (206). This step illustrates the Borsche 
modification293 o f the Friedlander quinoline synthesis and allows the incorporation o f an 
oxime protected aldehyde functionality in the 2 -position for further derivatisation.
As an appropriate starting material, 6 -nitroveratraldehyde was chosen (X= 3,4-dimethoxy) 
and was converted under Dean-Stark conditions to the benzaldimines (203) and (204). The 
subsequent reduction o f the nitro group to form the aniline (205) proved to be problematic. 
At the time, the method of choice was to use nickel boride in the presence of hydrazine 
since it has been reported to leave sensitive functionality such as amides, esters, nitriles, or
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carbaldehydes, unreduced.294 However, when the N -tert-buty limine (203) was added to a 
freshly prepared ethanolic suspension of nickel boride (from N i(O A c)2 and NaBH4) 
followed by the addition of hydrazine, only the hydrazone derivative (209) could be 
isolated. This was also the case for the imine (204) and any alternative reaction condition 
which were employed.
When the hydrazone (209) was treated with nickel boride in the presence of hydrazine only 
starting-material could be isolated. Apparently this system is resistant to these reduction 
conditions. Interestingly, the only success in making a nitro-reduced product was achieved 
when unprotected 6 -nitroveratraldehyde was treated with nickel boride in the presence of 
excess hydrazine. This reaction produced the hydrazone (209) in 17 % yield together with
3,4-dimethoxy-6-aminobenzaldazine (210) in 73 % yield, after silica chromatography.. 
Presumably, the nitrobenzaldazine (211 ) is formed as an intermediate and is more 
susceptibile to reduction than its hydrazone counterpart (209). The symmetrical azine (210) 
was consistent with NMR data and was identified via  its mass spectra (M+ 358)— cleaves 
into monomeric units at M + 179 and/or loses N2 to give a main fragment at M + 165.
In retrospect the problems encountered are not entirely surprising and probably the use of 
sodium sulphide as a reductant, although unpleasant to work with, would have been 
advisable. Nevertheless, under the reaction conditions given in Scheme 12, a final attempt 
was made to form the quinoline system (2 0 6 ) (X = 3,4-dim ethoxy) using the 
aminobenzaldazine (210). Unfortunately this met with failure and there was no more time to 
pursue this route any further.
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(209) (210)
(211)
CHAPTER «8» Further Tvrphostin Investigations
As mentioned in the Introduction (Section 5.7) tyrphostin derivatives devoid of phenolic
functionality represent good candidates for lead development. Notable examples would 
include the 2,3-diarylpropenonitriles (66) and (67). Thus, for the purpose o f reproducing the 
results o f Levitzki et al. these and other therapeutically promising tyrphostin derivatives 
[(59) and (61)]2308 have been prepared. In addition, an aim of this project was to perform 
stereochemical studies and also to attempt the synthesis o f geometric isomers o f the 
tyrphostins in order to establish the stereochemical requirement preferred for biological 
activity. This and other related work will be described in this chapter.
8.1 Synthesis of the Tvrphostins (59) and (61)
As shown in Table 12, the tyrphostin (59) is about 50-60 times more potent towards 
inhibiting the EGF-R kinase over its highly homologous counterpart (erbB-2). The reverse 
situation is true for the tyrphostin (61). These two compounds, therefore, represent an 
interesting situation for further biological evaluation and, for this purpose, were requested 
by Dr J. Bartlett, Department of Surgery, Glasgow Royal Infirmary, Glasgow.
The preparation of the N-phenyl amide tyrphostin derivative (59) initially involved the 
synthesis o f iV-phenylcyanoacetamide (213) (Scheme 13). Although amide coupling
Scheme 13 Synthesis of iV-Phenvi 2-Cvano-3- 
f3.4-dihvdroxvphenvl)propenamide ( 59)
O (61 %) 
aniline, 16 h
90-100 °C
CN CN
(212) (213)
EtOH, 5 h 
piperidine (caL)
(40%)
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methodologies to cyanoacetic acid were envisaged, the procedure adopted involved heating 
neat methyl cyanoacetate (212) with aniline at ca. 100 °C in the absence o f solvent.2306 The 
evaporation o f methanol drove the reaction forward and the product crystallised out on 
cooling making the procedure simple and effective. The subsequent Knoevenagel 
condensation between the amide (213) and 3,4-dihydroxybenzaldehyde afforded the desired 
target (59) in 40 % yield after crystallisation.
The synthesis o f the tyrphostin (61) required a more complex route and is outlined in 
Scheme 14. Vanillin (214) was first converted into the 5-substituted compound (215) in a 
Mannich-type reaction whereby formaldehyde and dimethylamine form an iminium  
intermediate that acts as an electrophilic source of the (iV,iV-dimethylamino)methyl group.295 
The reaction works well on electron-rich systems and is probably facilitated by the mildly 
basic conditions generating a phenoxide intermediate.
Replacement o f the dimethylamino group in compound (215) with a more appropriate 
leaving group was achieved by heating this compound in acetic anhydride at reflux. This 
gave the acetate intermediate (216) which was isolated directly from the reaction mixture by 
fractional distillation and then treated with concentrated hydrochloric acid to afford the 
chloromethyl derivative (217). The best yield obtained for these two steps was 50 %. It was 
important not to use aqueous base in the work-up procedure in isolating compound (217). 
When aqueous 0.1 M sodium hydroxide was used this generated, not surprisingly, the 
methyl alcohol (219), as identified by 90 MHz *H NM R  spectroscopy. A lso two other 
products were obtained after chromatography, although in impure form, with RF values less 
than 0.2 (Silica/EtOH). Spectroscopy indicated that these contained many exchangeable 
protons and it is conceivable that at least one of these was the acid or carbinol product of a 
Cannizzaro reaction (cf . Section 6.5) .296
CHOMeO
HO
OH
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Scheme 14 Synthesis of 2-Cvano-3-r4-hvdroxy-3-methoxv-5- 
(2■benzothiazolvlthiomethvDphenvIlpropenamide (61)
MeO
(214)
q j q  HCHO/HNMe2 
aqueous EtOH
reflux, 3 h 
(RT, 19 h)
(79 %)
MeO CHO
HO
RT, 8 h 
CH2G 2, 
(34 %)
N
MeO
HS —^
CHO
(50 %) 
c.HCl
RT, 3 h
MeO. CHO
NCn^C O N H 2 
EtOH, 6 h ^
piperidine (cat) 
(61 %)
HO
(215)
NMe*
MeO
Ac20  
reflux, 25 h
CHO
OAc 
(216) isolate
CONH,
MeO
The next step in the synthesis of compound (61) required the displacement o f the chloro 
group in compound (217) by 2-mercaptobenzothiazole to give the 5-aryl thioether (218).2308 
This conversion was difficult to optimise but it was found best to slow ly add the thiol and 
triethylamine together in dichloromethane. The highest yield obtained was 34 % after 
column chromatography. The synthesis of the target tyrphostin (61 ) was completed by 
perfoming a Knoevenagel condensation between the aldehyde (218) and cyanoacetamide in 
the usual manner.
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8.2 Attempted & Proposed Synthesis of Tyrphostin Geometric Isomers 
So far it has been assumed that the product which is formed in the Knoevenagel 
condensation is the one with the aromatic ring syn relative to the nitrile grouping 
(cf. Scheme 1). Indeed, mechanistic considerations242 together with experimental data297 
agree with this assumption. It has also been presumed that the most active geometric form 
for a tyrphostin is that for this s y n -arrangement. Although there is some evidence to 
substantiate this latter statement,230f it may be the case that small traces o f the an ti-isomer 
are contributing to the observed biological activity.
Thus, it was o f interest to develop a general synthetic route to the anti-isomers o f the 
tyrphostins. A  strategy initially investigated has been generalised in Scheme 15 and involves 
the formation of an epoxide (B) from an alkene (A) in a stereoselective syn -manner by using 
meta-chloroperoxybenzoic acid (wcpba). Presuming only the syn -isomer originally existed 
this will lead to a racemate of the diastereoisomer (B ) .298 In theory, an ti-nucleophilic attack 
on the epoxide (B ) with the anion of trimethylsilane, followed by s y n -elimination of 
trimethylsilanolate, 299 will invert the relative stereochemistry about the epoxide (B) and 
therefore afford the desired isomer (C) .300
However, when this strategy was conducted on the epoxide (220), prepared from compound 
(116) using racpba in dichloromethane, a complex mixture o f products was obtained 
(Scheme 16). As indicated trimethylsilyllithium was pre-formed by treatment o f 
hexamethyldisilane with methyllithium and was then added to the epoxide in DM PU301 
dropwise at ca. 10 °C under an inert atmosphere. Although the reaction conditions could not 
be altered to improve the result, two products of the reaction after column chromatography 
were identified to be the a-keto ester (221) and the amide (222) (Scheme 16).
According to the !H NMR and infra-red spectra, the a-keto ester (221) exists in its enol 
form and displays rotameric behaviour. In retrospect, the production o f this product is not 
entirely surprising and probably involves the mechanism as given in Scheme 17. However, 
the mechanism of formation of the amide (222) is not all that obvious. Nevertheless, an 
attempt has been made in Scheme 18. It is proposed that the source of the amide group is via 
hydrolysis of the nitrile group during the work-up stage of the reaction. The
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Scheme 15 Proposed Method of Double-Bond Isomerism
s ^  Ph(m-Cl)
o-
/
H \
Ph(m-Cl)
■syn-epoxidation^
CN
(A) CN syn to Ar
SiMe
R CN
H
5yn-eiimination 
(step-wise 
or concerted)
(-LiO SiM e3)
CN
(B) CN anti to Ar
SiMeCN
(B)
anti-opening (+LiSiM e3)
Ar
© -
101
CN
Kev: R= alkyl or ester group 
Ar= aromatic group
incorporation o f the nitrile group at the benzylic position in compound (224) is possibly as a 
result of an mtermolecular reaction on the epoxide (2 2 0 ) as it is conceivable that the cyanide 
nucleophile is readily generated under the reaction conditions employed (c/. Scheme 16). A  
plausible sequence o f events (Scheme 18) would thus form the a-keto ester intermediate 
(223) which would then be able to fragment, under the influence o f a nucleophile, to the 
stabilised acetonitrile anion (224). Hydrolytic work-up would therefore produce the amide 
(222).
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Scheme 16 Attempted Double-Bond Isomerism of Tyrphostin (116)
0 ,N
(116)
C02Et
mcpba
CH2CI2, 4 h
(79 %) 0 2N
CO 2a
(220) 
(DMPU, under N2)
(i) add LiSiMe3 at ca. -10°C 
[from (Me3Si)2 + MeLi]
(ii) RT, 2.5 h then N I^ C l^
c n r
(221) (15 %)
CO^Et
OoN
CONB,
(222) (19 %)
Scheme 17 Mechanism of Formation of the a-Keto ester (221) 
©
CN
(220)
CN
©
(CN-  or) Me3Sil
(- CN')
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after NH4CI 
quench
0 ,N
C02Et
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Scheme 18 Proposed Mechanism of Formation of the Amide (222)
NCI
CN CN
(220)
(Nu = nucleophile, e.g. Me3Si , or NC“)
Nu
CN
„  hydrolytic 
\L1L) work-up
{ -  CO, -  C 0 2)
(224) (223)
Although not carried out at the time, a test of this reaction mechanism would involve 
treatment of the epoxide (2 2 0 ) with a cyanide salt in order to establish if  an acetonitrile 
product akin to the anion (224) could be generated. If so this could be an interesting method 
for the formation o f arylacetonitriles.
However, due to the problems encountered, this method o f inverting the stereochemistry 
about an olefin (Scheme 15) was abandoned and other alternative strategies were sought. 302 
It was decided to avoid other protocols which utilised epoxides, such as those which involve 
intermediates found in a Homer-Wadsworth-Emmons303 or Wittig-type olefination,304 since 
these often involve strong anionic nucleophilic conditions and so are likely to be 
inappropriate for such functionalised compounds. The conclusion was that the desired 
geometric isomer of a tyrphostin probably had to be made in a stereocontrolled manner and 
two such approaches have been proposed in Schemes 19 and 20. Due to time limitations 
these routes were not initiated. Nonetheless, they should provide an interesting basis for 
future research and are included here due to their potential practical use.
In summary, Scheme 19 illustrates a strategy which makes use o f the stereoselective 
reductive addition o f diisobutylaluminium hydride (DEBAL or rBu2A l-H ) or pre-formed 
alanate com plex (DIBAL plus methyllithium) to alkynes follow ed by the retentive 
substitution o f the metal centre by an electrophile.305 From a literature survey, alternative
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reagents and procedures could be envisaged to be used in a similar protocol and examples 
would include: use of zirconium complexes;306 use of iron complexes;307 and the technique 
of hydrocyanation.308 However, DIBAL seemed more preferable due to its availability and 
ease o f use. A different strategy involves the formation of /raws-alkenylsilanes via  an 
aldol-type condensation (Scheme 20). These isomers should predominantly form for large 
trisubstituted silyl groups and may be substituted with a nitrile group as shown. Under 
Friedel-Crafts conditions, such electrophilic desilylations309 have been reported to occur 
with retention of configuration about the double-bond310 and can be rationalised in a similar 
fashion to proto-desilyation. 311
Scheme 19 Proposed Synthesis of Tyrphostin Geometric Isomers
via Substituted Alkvnes
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Scheme 20 Proposed Synthesis of Tyrphostin Geometric Isomers
via trans-Alkenvlsilanes
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8.3 Synthesis and Biological Evaluation of 2.3-Diarvlpropenonitriles 
At the request of colleagues at the CRC Beatson Laboratories (Glasgow University) the 
so-called “second-generation” tyrphostins (66) and (67) were synthesised for the purpose of 
biological evaluation (Scheme 21). These 2,3-diarylpropenonitriles have previously been 
reported to be made by condensing the appropriate arylcarbaldehyde with  
3-pyridylacetonitrile (225) using potassium carbonate as a base (yields not disclosed) .312 
However, this method of preparation was found to be temperamental and often gave low  
yields of products. Thus, it was decided to obtain significant amounts o f the compounds ( 66) 
and (67) by using sodium hydride as a base. In this case, the pre-formed sodium salt of 
3-pyridylacetonitrile (225) was added to the appropriate arylcarbaldehyde and afforded the 
desired products ( 66 ) and (67) in respective yields of 54 % and 24 %, after crystallisation.
Due to the precautions and lengthy procedure involved in the use o f sodium hydride, 
together with the relatively low yields obtained, an alternative protocol was sought Initially, 
piperidine was used as a base in a Knoevenagel condensation whereby the reactants under 
concentrated conditions were heated at reflux (Method C). However, this method failed and 
it was surm ised that piperidine was not su fficien tly  basic to deprotonate 
3-pyridylacetonitrile (225). Changing the base to potassium terf-butoxide, used in catalytic 
to stoichiometric amounts according to a similar procedure, consequently produced the 
desired products but the reaction was complicated by side-products and yields were 
generally low. Based on the idea that a secondary amine is important for activating 
arylcarbaldehydes, via an iminium intermediate, it was then decided to use piperidine and 
potassium terf-butoxide in combination. This led to a general procedure (Method D) that 
efficiently and quickly generated the desired compounds (66 ) and (67) in high yield— 94 % 
and 80 %, respectively (see Scheme 21).
Scheme 21 Synthesis of 2.3-Diarvlpropenonitriles
CN (225) Piperidine/KO*Bu 
EtOH, A, 0.5 h
NaH.THF 
under N2, 2-3 h
5
(6 6 ) X= 3,4-dimethoxy
(67) X= 3,5-dichloro 
(226) X= H
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Having esablished that the method worked w ell on both the electron-rich and 
electron-deficient benzaldehyde precursors to compounds (6 6 ) and (67), the method was 
applied to forming the unsubstituted compound (226) (Scheme 21). Futhermore, the 
generality o f this method was exemplified in the formation o f the 2,3-diarylpropenonitriles
(227)-(2 3 2 ) .  Thus, com pounds ( 2 2 7 ) - ( 2 2  9 )  w ere m ade by reacting
3,4-dimethoxybenzaldehyde with either 2-pyridyl-, 2-thienyl-, or 3-thienylacetonitrile. For 
the preparation o f the derivatives (228) and (2 2 9 ), it was found best to purify the 
thienylacetonitrile starting materials over activated charcoal prior to performing the 
condensation reaction. This was also found to be the case for the 3-thienyl derivative (232). 
Unfortunately, all attempts at completing the 2-quinolinyl series [(230)-(232)] by making a 
2 -thienyl analogue, failed.
(227) Ar= 2-pyridyl (230) Ar= 2-pyridyl
(228) Ar= 2-thienyl (231) Ar= 3-pyridyl
(229) Ar= 3-thienyl (232) Ar=  3-thienyl
An additional purpose to forming the compounds (226)-(232) was to explore alternative 
tyrphostin derivatives akin to ( 66) and (67), and thus evaluate their biological activities. The 
IC50 values obtained against the MCF-7 cell line in a growth inhibition assay using 
[3H]thymidine as a measure of DNA synthesis have been collated in Table 23. As can be 
seen, the diaryl tryphostin derivatives are all reasonably potent antiproliferatives with many 
being comparable to the known tyrphostin (6 6 ). In particular the compounds (227) and 
(229)-(231) display significantly low IC50 values and are good exam ples for future 
investigation.
Although time limits prevented a complete study o f these diaryl derivatives in the EGF-R 
kinase cell free assay, recent results (performed by Dr Valerie G. Brunton) indicated that the 
quinolines (230)-(232) exhibit IC50 values greater than 500 |1 M. These compounds are, 
therefore, not blocking phosphorylation events at the EGF receptor, implying that the 
observed growth inhibitory effects are due to some other mechanism. Nevertheless, this 
work has provided some interesting tyrphostin derivatives (2 ,3 -diarylpropenonitriles) for 
future biological evalution and, in addition, a relatively facile method for their preparation.
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Table 23 MCF-7 Data for Some 2.3-DiarvlDropenonitriles
IC50 (MCF-7) Values1 for Ar>CH=CH(CN)Ar2
aGrowth Inhibition values are given below compound numbers
(67)
(not determined)
S.4 Stereochemical. Crvstallographic & Biological Studies
As m entioned in the Introduction (Section 5.7), the tyrphostin (66) has been shown to 
exhibit promising in vivo activity. In addition, it has been claim ed to give a long lasting 
inhibitory effect in cell culture and prolongs the survival o f tum our-bearing m ice.232 
However, it has been briefly noted that tyrphostin (66) is able to undergo a light-induced 
trans/cis  isom erism ,313 generating some speculation as to which isom er is actually 
attributable to the observed biological activity. For this reason, it was decided to investigate 
this isom erism  process in more detail and therefore synthesise the individual geometric 
isomers. This was achieved by irradiating a dilute acetonitrile solution of the tyrphostin (66) 
with a 500 w  halogen lamp for 26 h (Scheme 22).
Scheme 22 Light-induced cis/trans Interconversion of Tyrphostin (66)
MeO
MeO
N 500 w  halogen
lamp, C H 3CN 
(< 60 °C, 26 h)
MeO
MeO
(66) (233)
Synthesis and Biological Evaluation of Anticancer Agents Page 120
In this reaction, care must be taken not to allow the solvent to reach boiling point and it was 
found best to immerse a cold-finger condenser into a well stirred solution o f compound ( 66). 
At equlibrium, an approximate 60:40 mixture of (233) to (6 6 ) was present (by 90 MHz *H 
NMR spectroscopy) and the desired isomer (233) was isolated in good yield (43 %) after 
column chromatography. Interestingly, this reaction also afforded the epoxide (234) in 8 % 
yield. Since the reaction was carried out in the presence o f air, the most likely reason for this 
outcome was probably due to the generation and subsequent [2 + 2 ] cycloaddition of singlet 
oxygen to the double bond (Scheme 23).314 In the presence of a proton source (e.g. from the 
acetonitrile solvent or, more likely, from any water present) 315 the oxygenated species (235) 
is likely to be protonated and then converted with the epoxide (234). This amounts to an 
overall reduction and would be concomitant with the oxidation o f either acetonitrile to 
hydroxyacetonitrile, or water to hydrogen peroxide.316
MeO
CN
MeO
(234)
Having synthesised and isolated the compounds (66 ), (233), and (234) it was then necessary 
to determine their relative stereochemistry, unambiguously. Through the expertise of Dr 
David S. Rycroft (Glasgow University) this was achieved via  detailed l H and 13C NMR  
spectroscopic analysis of their *13/^  and l H/13C coupling constants, DEPT spectra, 2D 
5q/8h direct and long-range correlation experiments, as well as their NOE difference 
spectra. The !H and l3C NMR data obtained (including NOE results) for CDC13 solutions of 
(Z X 66), (£)-(233) and (Z H 234) have been summarised in Tables 23 to 25.
However, before discussing the results, it should be noted that it seem s more sensible to 
ignore the Cahn-Ingold-Prelog sequencing rules for designating a (Z) or (E) assignment and 
focus only on the configurational relationship between the aromatic rings. Thus, the 
geometric isomers (Z H 6 6 ) and (£)-(233) will hereinafter be called  tra n s  and c is ,  
respectively, while the epoxide (Z)-(234) will be referred to as trans. This definition should 
eliminate any confusion that might occur later in the discussion when relating these 
structures to trans- and cw-stilbenes.
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Scheme 23 Mechanism of Formation of the Epoxide (234)
MeO
MeO
MeO
MeO
proton
source
MeO
MeO
(e.g. + H 20)
l Oi
N (-HjOa) MeOMeO
CN
MeOMeO
(234)
As shown in Table 24, when 3-H was irradiated in compound (6 6 ) all four ortho protons of 
the aromatic rings (5-, 9-, 11-, and 15-H) displayed NOEs. The resulting spectrum of this 
NOE difference experiment is given in Figure 26 and indicates that compound (6 6 ) exists in 
a rrarcs-configuration. Similar arguments identified the epoxide (235) to be trans (Table 26) 
and both cases were substantiated by the fact that NOEs between the two aromatic rings 
were not observed. This would be expected in a cw-arrangement and was seen in compound 
(233) between the aromatic protons (5-H, 9-H) and (11-H, 15-H). Importantly, the cis- 
assignment for compound (233) was reinforced by the fact that irradiation o f 3-H caused 
NOEs at 5- and 9-H but not at 11- and 15-H (Table 25).
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Table 24 NMR Data of trans-Isomer ( 66)—CDCK solution
MeO
CNMeO 7
Position
number 5  a ° c
R o tas shewing lcng 
range oxidations
Cabon
nuUpfid^ 1H/^CaxipiingslHz) 8 a H
R o ta
nuitipiirify R o ta  couplings (Ha^
1 117.91 3 d 14.4
2 105.03 15 dd 5 3
3 143.56 5,9 dt 154.6 4.9 7.49 s
4 126.17 8 d 8.6
5 110.63 3,9 dt 157.8 4.9 7.72 d 22.
6 149.05 6-OMe, 5, 8 dquin 7.4 3.9
7 151.63 7-OMe, 5, 8, 9 m (obscured)
8 110.91 dd 158.3 1.9 6.93 d 8.4
9 124.92 3,5 dt 160.1 6.3 7.38 ddd 8.4 2.2 0.5
10 130.82 3, 11, 14 qd 6.5 1.6
11 146.82 13 ddd 178.8 11.5 5.5 8.90 dd 2.5 0.8
13 149.59 11 ddda 180.3 11.0 6.9 3.0 8.60 dd 4.8 1.6
14 123.55 13 ddd 164.4 8.6 0.9 7.37 ddd 8.1 4.8 0.8
15 133.07 dtd 161.6 6.0 1.0 7.93 ddd 8.1 2.5 1.6
GOIVfe 55.96 q 144.8 3.97 s
TOMe 55.99 q 145.0 3.95 s
R o ta
madatadj
% cf
Saturation
Observed NOEs Scaled for 1(X) % Saturaldon
3-H 5-H 8-H 9-H 11-H 13-H 14-H 15-H 60M e 7-OMe
3-H 69 7% -1 % 7% 13% 8%
5-H 64 5% 4%
8-H 47 13% 5%
9-H 33 * 14%
11-H 71 6%
13-H 51 5%
14-H 29 7% 15%
15-H 39 5% 14%
aRelative to TMS at 0.00 (CDC13 appears at 8C 77.15).
* The experimental integral was -2 %, but this result is dominated by the proximity of 3-H to the position 
of irradiation.
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Table 25 NMR Data of c£s-Isomer (233)—CDCU solution
MeO CN
9MeO 7
13
Position
number 8 a ° c
Protons Aowing long 
range°C oxidations
Gabon
iniHipKrify 1H/°Cq«pting?(Hz) V
Proton
milliplid^ Roton coupling? (Hzj
1 119.83 3 d 8.9
2 107.86 3 dt 4 2
3 146.06 5 ,9 dt 157.6 4.5 7.40 s
4 125.55 8 d 7
5 111.66 3,9 dt 157.6 6.2 6.55 d 1.9
6 148.68 6-OMe, 5, 8 d quin 6.7 4.0
7 151.07 7-OMe, 5. 8, 9 m (obscured)
8 110.95 d 160.1 6.77 d 8.4
9 124.61 3,5 dddd 162.3 6.6 5.8 0.9 6.84 ddd 8.4 1.9 0.3
10 129.59 3, 11, 14 dtd 9.3 7.1 1.7
11 149.98 13 ddd 180 11 6 8.67 dd 2.3 0.9
13 150.02 11 dddd 180 11 7 3 8.62 dd 4.9 1.7
14 123.77 13 dm 165 7.37 ddd 7.9 4.9 0.9
15 136.52 11 dm 165 7.77 ddd 7.9 2.3 1.7
60Me 55.45. q 144.7 3.54 s
7-OMe 55.93 q 145.0 3.87 s
Proton % of
Sanitation
Observed NOEs Scaled for 1<30 % Saturalion
3-H 5-H 8-H 9-H 11-H 13-H 14-H 15-H 6-OMe 7-OMe
3-H 67 5% 2% 6%
5-H 56 6% 2% 1% 4%
8-H 28 5%
9-H 21 11% 1% 0.5%
11-H 34 1%
13-H 49 3%
14-H 23 6% 11%
15-H 25 1% • 9%
6-OMe 67 22% 0.3% 1% 0.3%
7-OMe 67 15% 4%
“Relative to TMS at 0.00 (CDC13) appears at 8C 77.18). 
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Table 26 NMR Data of /raws-Epoxide (234)—CDC1? solution
MeO
CN
MeO 7
Position
number V
DEPT
u CmuItiplkity
Rolens showing long 
iangp^CcondalKns 5 0H
Prolan
multiplicity Proton couplings (Hz)
1 120.82 s 3
2 46.72 s 3
3 54.81 d 5.21 s
4 123.87 s 3,8
5 112.23 d 3 6.64 d 2 2
6 148.91 s 6-OMe, 8
7 149.77 s 7-OMe, 5,9
8 111.05 d 6.82 d 8.4
9 122.64 d 3 6.93 dd 8.4 2 2
10 130.83 s 3
11 148.87 d 8.65 dd 2.6 0.7
13 149.90 d 8.59 dd 4.8 1.5
14 123.39 d 7.26 ddd 8.1 4.8 0.7
15 135.46 d 7.59 ddd 8.1 2.6 1.5
60Me 55.78 q 3.66 s
7-OMe 55.78 q 3.87 s
Rolan
inarfiafcd
% af
Safciration
Observed NOEs Scaled for H30 % Saturaldon
3-H 5-H 8-H 9-H 11-H 13-H 14-H 15-H 60M e 7-OMe
3-H 66 15% 16% 15% -1% 15%
5-H 53 10% 5%
8-H 41 6%
9-H 33 13%
11-H 55 9%
13-H 43 13%
14-H 35 10% 13%
15-H 36 7% 11%
6-OMe 67 -1% 20% 0.3% 1% 0.3%
7-OMe 67 20%
“Relative to CDC13 at 8C 77.00.
bLong-range (and direct) correlations were observed for (234) present as a 15 % impurity in a sample of (66). 
cRelative to TMS at 0.00.
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Figure 26 NOE Difference Spectrum of Tvrphostin (66) 
with Irradiation of double bond proton (3-H)
MeO
CN
MeO 7
11-H
5-H
3-H
9-H
15-H
9 .0 8 . 5 8 . 0 7 . 5 7 . 0
Additional evidence for the geometric assignments of the compounds (6 6 ) and (233) was 
derived from their proton-coupled 13C NMR spectra (see Tables 24 and 25). In particular, 
the vicinal couplings 3/(3-H ...l-C N ) of 14.4 Hz in structure ( 6 6 ) and 8.9 Hz in structure 
(233) were in respective agreement o f a trans- and cis- mutual arrangement between the 
cyano group (1-CN) and olefinic proton (3-H) about the double bond. To act as a reference 
system, the dinitrile product (236) was synthesised from 3,4-dimethoxybenzaldehyde and 
malononitrile. In this case the corresponding trans- and cis- couplings were 14.1 Hz 
(S^n 113.6 ppm) and 8.4 Hz ( 8^  114.5 ppm), respectively. In fact, 3/ ( 1H ...13C) values are 
widely used to assign the stereochemistry of Knoevenagel condensation products242 and, as 
expected, the magnitude o f trans -couplings are generally greater than cw-couplings due to 
better orbital overlap. 317
Synthesis and Biological Evaluation o f Anticancer Agents Page 126
CNMeO
CN
MeO
(136)
In collaboration with Dr Kenneth W. Muir and A. Ashgar Torabi (Glasgow University) the 
stereochemistry o f the compounds ( 6 6 ) and (233) was confirmed by single crystal X-ray 
analysis. 318 The structures obtained are displayed in Figures 27 and 28 together with their 
crystallographic data— 50 % probability ellipsoids are used to represent atomic positions, 
except for hydrogen atoms which are depicted by spheres of arbitrary radius. A selection of 
bond lengths/angles may be found in Table 27 (atom labels refer to Figures 27 and 28).319
Interestingly, the c/j-isomer (233) exists in the solid state in two near identical forms 
(A and B; Table 27)320 and, for both shown in Figure 28, the most striking feature is that the 
pyridyl ring is twisted out-of-plane to the rest o f the molecule in a near perpendicular 
manner. In contrast, the fra/w-isomer (6 6 ) adopts a near flat conformation (Figure 27). 
However, a common feature for both isomers is that the (3,4-dimethoxyphenyl)- 
propenonitrile carbon skeleton [(MeO)2C6H3C=CCN] remains close to planarity.
In order to assess how typical these cis and trans structures were, Dr Muir surveyed the 
Cambridge Structural Database for 1,2-diarylethenes [Ar-C=C-Ar] containing a central 
C=C double-bond in which both carbons carry a single six-membered aromatic ring (Ar).321 
In summary, this search identified 105 trans and 22  cis structures. Since it was of interest to 
determine the orientation of the aromatic rings (Ar) with respect to the double bond, each o f 
these structures was defined by two torsion angles (p! and % (of the type C=C -C ^-C^) and 
thus represented in a plot o f versus  (p2. Analysis of tran j-Ar-C=C-Ar molecules 
(Figure 29) indicated that many are either centro-symmetric (with cpt = -(pj) or close to C2 
point symmetry (with cpj *  9  2). For cz'j-Ar-C=C-Ar molecules (Figure 30) the data 
suggested that acceptable inter-ring distances occur when at least one aromatic ring (Ar) is 
twisted out o f conjugation with the C=C double bond (% > 45°)— the other ring twists by 
variable amounts (q>2 = 15-90°).322
Using these plots it may be concluded that the trans-isomer was not unusual (Figure 29). In 
comparison, the planarity (9 ! close to zero) of the [(MeO)2C6H3C=CCN] unit for the 
cw-molecules was somewhat unusual (Figure 30) and may reflect the resonance stabilisation
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Figure 27 X-ray Crystal Structure and Data of trans -Isomer (66)
M e(X  y ^ v  A v  .N
trcws-C 16H14N 2O2, Mj.= 266.30 
MeO" ^  orthorhombic, space group Pbca
crystallised from diisopropyl ether, 0 °C a= 8.0279(8), b= 26.098(2), c= 13.3235(1) A
crystal specimen: transparent needle |3= 90°, V= 2791.4(5) A3, Z= 8
(0.80 x  0.25 x  0.15 mm) D c= 1.267 g cm'3, n(M o-Ka)= 0.79 mm' 1
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Figure 28 X-rav Crystal Structure and Data of cis -Isomer (233)
MeO CN
MeO czj~CjgHj4N202» M r— 266.30 
monoclinic, space group P2{/c
crystallised from diethyl ether, -1 0  °C a= 9.7755(5), b= 25.6816(9), c= 11.4330(6) A
crystal specimen: transparent plate |3= 93.625(4)°, V= 2864.5(2) A3 , Z= 8
(0.48 x  0.42 x 0.30 mm) D c= 1.235 g cm*3, |i(M o-£a)=  0.77 mm*1
Molecule A ftop view)
C(A18)
0(A15)
C(A24)
0(A14)
C(A25)
C(A15)
C(A26) N(A23)
C(A14)C(A17) C(A16) C(A22)
C(A12) C(A21)C(A2)
C(A11)
C(A12)
C(A3)C(A1)
N(A1)
Molecule B (side view)
C(B18)
C(B17)
0(B 15)
U(B14)
C(B12)
C(B16)
C(B2) 
6 C(B1)
N(B1)
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Table 27 Selected X-Rav Data of trans - and cis -isomers. (66) and (233)
Jond A n g les4 trans cis-A c cis-B c
N(l)—C(3) 1.139(5) 1.141(3) 1.138(3)
N(23)—C(22) 1.329(6) 1.339(3) 1.332(3)
N(23)—C(24) 1.324(6) 1.332(3) 1.323(3)
0(14)—C(14) 1.351(4) 1.357(3) 1.366(3)
0(14)—€(17) 1.424(6) 1.437(3) 1.440(3)
0(15)—C(15) 1.363(4) 1.369(2) 1.364(3)
0(15)—C(18) 1.434(6) 1.425(3) 1.419(3)
C(l)—C(2) 1.338(5) 1.341(3) 1.338(3)
C(l)—C (ll) 1.454(5) 1.454(3) 1.449(3)
C(2)—C(3) 1.461(6) 1.433(3) 1.432(3)
C(2)— C(21) 1.457(5) 1.497(3) 1.495(3)
C (ll)—€(12) 1.392(5) 1.385(3) 1.390(3)
C (ll)—€(16) 1.398(5) 1.406(3) 1.407(3)
C(12)—€(13) 1.368(6) 1.377(3) 1.378(3)
C(13)—C(14) 1.374(5) 1.381(3) 1.375(3)
C(14)—C(15) 1.403(5) 1.402(3) 1.404(3)
C(15)—C(16) 1.357(5) 1.368(3) 1.368(3)
C(21)—C(22) 1.382(5) 1.371(3) 1.387(3)
C(21)—€(26) 1.383(5) 1.373(3) 1.375(3)
C(24)—C(25) 1.365(7) 1.349(4) 1.372(3)
C(25)—C(26) 1.359(6) 1.377(3) 1.383(3)
Bond Anglesb trans cis-Ac c£s-Bc
C(22)—N(23)— C(24) 117.8(5) 116.6(3) 116.6(2)
€(14)—0(14)—€(17) 117.9(4) 117.1(2) 117.7(3)
C(15)—0(15)—C(18) 117.0(4) 117.4(2) 117.0(2)
C(2)—C( 1)— C( 11) 133.3(4) 132.0(2) 131.7(2)
C( 1)—C(2)— C(3) 120.4(4) 116.4(2) 117.6(2)
C(l)—C(2)— C(21) 124.6(4) 128.7(2) 128.8(2)
C(3)—C(2)— C(21) 115.0(3) 114.8(2) 113.5(2)
N(l)—C(3)—C(2) 177.0(4) 178.4(3) 178.2(3)
C(l)—C(ll>—C(12) 118.1(4) 117.5(2) 118.2(2)
C(l)—C(11)— C(16) 125.7(4) 124.9(2) 124.3(2)
C(12)—€(11)—C(16) 116.2(4) 117.7(2) 117.5(2)
C(ll)—€(12)—C(13) 121.8(4) 122.0(2) 121.8(2)
C(12)—C(13)— C(14) 120.9(4) 119.8(2) 120.1(2)
0(14)—C(14)—€(13) 126.1(4) 125.4(2) 125.3(2)
0(14)—C(14)—C(15) 115.4(4) 115.2(2) 115.3(2)
C( 13)—C( 14)— C( 15) 118.6(4) 119.4(2) 119.4(2)
0(15)—C(15)—C(14) 114.5(4) 114.8(2) 115.2(2)
0(15)—C(15)— C(16) 125.7(4) 124.8(2) 124.7(2)
C(14)—C(15)—€(16) 119.8(4) 120.3(2) 120.1(2)
C(11)—C(16)— C(15) 122.7(4) 120.8(2) 121.1(2)
C(2)—C(21)— C(22) 122.8(4) 120.9(2) 119.5(2)
C(2)—€(21)—€(26) 122.4(4) 121.5(2) 122.7(2)
C(22)—C(21)—€(26) 114.8(4) 117.5(2) 117.7(2)
N(23)—C(22)—C(21) 125.1(5) 123.9(3) 124.1(2)
N (23)-€(24)—€(25) 122.0(5) 123.7(3) 124.2(2)
C(24)—€(25)—C(26) 119.2(5) 118.9(3) 118.4(3)
C(21)—C(26>—C(25) 121.1(5) 119.3(3) 119.0(2)
Torsion Angles6 trans c is - \c c£s-Bc
€(17)—0(14)—€(14)—C(13) 4.4(5) 1.4(3) ' -4.3(3)
C(18)—0(15)—C(15)—C(16) 10.3(5) -8.4(2) -8.0(2)
C(11)—C(l)—C(2)—C(3) -2.8(4) -179.7(4) 179.6(4)
C(2)—C(l)— C(11)—C(12) 178.6(7) -178.6(4) -177.7(4)
C(2)—C(l)— C(11)—C(16) -2.7(5) 2.0(3) 0.5(2)
C(11)—C(l)—€ (2 )—C(21) 178.1(7) 1.6(2) -0.3(2)
C(l)—C(2)— C(21)—€(22) -23.5(5) -107.4(3) -106.7(3)
C(l)—C(2>—C(21>—C(26) 157.5(6) 75.3(3) 75.0(3)
C(3)—C(2)— C(21)—C(22) 157.4(6) 73.9(3) 73.3(3)
C(3)—C(2)— C(21)—C(26) -21.6(4) -103.4(3) -105.0(3)
0(14)—C(14)—C(15)—0(15) 0.4(3) -0.5(2) -0.4(2)
aIn Angstroms (A) bIn degrees (°) 
aCrystals of the cw-isomer contain two crystallographically independent molecules, A and B.
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Figure 29 Plot of /ran,y-l,2-DiarvIethenes rAr-C=C-Arl Defined hv 
Torsion Angles (pJL and cp, (of the type C=C-
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Figure 30 Plot of cfo-1.2-Diarvlethenes fAr-C=C-Arl Defined bv 
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gained through an electron-donating group [(MeO)2C6H3] being in conjugation with an 
electron-withdrawing group [CN]. However, only a small number of c is -compounds were 
found, with only a few being substituted similarly to compound (233)— see cluster 
marked A in Figure 29. Thus care must be taken in designating this cw-structure as unusual.
On the whole, the crystallographic data suggest (not unexpectedly) that the pyridyl ring is 
more prone to twist out o f conjugation with the central double bond than the 
dimethoxyphenyl ring and this is more likely to occur for the cw-isomer (233) than the 
trans-isomer (6 6 ). However, the NOE results (Tables 23 and 24) demonstrate that the 
dimethoxyphenyl ring readily twists in and out of alignment with the double-bond (within 
the NMR timescale at ambient temperatures) since irradiation o f 3-H causes NOEs at all 
four ortho protons in ( 6 6 ) [5-, 9-, 11-, and 15-H] and at both 5- and 9-H in (233).323 Thus, 
given the present evidence it is difficult to draw detailed conclusions about the 
conformational preference for either isomer and thus shed any light on any plausible 
bioactive conformation.
When the trans/cis isomerism (Scheme 22) was repeated for the 3-thienyl compound (229), 
three distinct compounds were observed by TLC. Unfortunately, subsequent seperation by 
column chromatography and crystallisation of the presumed czj-isomer (aromatic groups 
mutually cis)  only afforded the corresponding tranj-isom er (229). A ll attempts failed 
thereafter and presumably the cw-isomer reverts back to its trans counterpart in the 
purification process. Nevertheless, a product akin to the epoxide (234), as identified by 
90 MHz chromatography, could be isolated and the frarw-isomer (229) was able to be 
crystallised in a form suitable for X-ray crystallography— see Figure 31 and Table 28.319 As 
expected a near co-planar arrangement was found for the dimethoxyphenylpropenonitrile 
portion [(MeO)2C6H3C=CCN] and the structure (229) adopts a very similar conformation to 
the trans -isomer (6 6 )— compare torsional angles of aromatic groups relative to the double- 
bonds (cf. Tables 27 and 28).
Pertaining to the isomeric tyrphostins ( 66 ) and (233), it was o f interest to study the effect 
daylight had on each compound. This was achieved by monitoring each isomer every 24  
hours in d6-DMSO by 200 MHz *H NMR spectroscopy (Figure 32). The composition o f the 
mixture was determined by measuring the integrals o f the methoxy signals at §h 3.89 and 
3.86 for ( 66 ), and 8 H 3.79 for (233). In both cases, a near identical mixture was obtained
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Figure 31 X-rav Crystal Structure and Data of trans-Tsomer (229)
MeO
MeO'
crystallised from diethyl ether 
crystal specimen: pale-yellow cuboid 
(0.55 x  0.38 x  0.20 mm)
fra7W-C15H 13N 0 2S, M r= 271.34 
monoclinic, space group P2{ln
a= 10.5062(5), b= 11.0185(7), c= 12.4749(8) A  
(3= 107.36(4)°, V= 1378.3(1) A3, Z= 4 
D c= 1.308 g cm'3, (i(M o-ira)= 2.2 mm' 1
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Table 28 Selected X-Rav Data of trans-isomer (27ff\
Bond Lengths (A)
S(23)— C(22) 1.705(2) S(23)—€(24) 1.702(3)
N(l)—C(3) 1.137(3) 0(14)— C(3) 1.357(2)
0(14)— C(17) 1.428(3) 0(15)—€(15) 1.366(2)
0(15)—C(18) 1.419(3) C(l)—C(2) 1.341(3)
C(l)—C (ll) 1.456(3) C(2)—C(3) 1.443(3)
C(2)—C(21) 1.477(3) C (ll)—C(12) 1.381(3)
C(ll>—C(16) 1.415(3) C(12)— C(13) 1.386(3)
C(13)— C(14) 1.380(3) C(14)—C(15) 1.409(3)
C(15)— C(16) 1.371(3) C(21)— C(22) 1.354(3)
C(21)— C(25) 1.437(3) €(24)—€(25) 1.349(3)
Bond Angles (°)
C(22)— S(23)— C(24) 91.5(1) €(14)—0(14)—€(17) 117.9(2)
C(15)— 0(15)— C(18) 117.2(2) C(2)—C(l)— C(11) 132.2(2)
C(l)— C(2)— C(3) 122.2(2) C(l)—C(2)—€(21) 123.2(2)
C(3)— C(2)— C(21) 114.2(2) N(l)— C(3)— C(2) 177.3(3)
C(l)—C (ll)—C(12) 118.3(2) C(l)—C (ll)—€(16) 123.8(2)
C(12)— C(11)— C(16) 117.8(2) C (ll)—C(12)—C(13) 121.8(2)
C(12)— C(13)— C(14) 120.1(2) 0(14)—€(14)—€(13) 125.6(2)
0(14)—C(14)—C(15) 115.3(2) C(13)— C(14)—€(15) 119.2(2)
0(15)—C(15>—C(14) 115.1(2) 0(15)—C(15)—C(16) 124.6(2)
C(14)—€(15)—€(16) 120.2(2) C (ll)—€(16)—C(15) 120.9(2)
C(2)—C(21)— C(22) 124.3(2) C(2)—C(21)—C(25) 124.1(2)
C(22)— C(21)— C(25) 111.6(2) S(23)—C(22)—C(21) 112.4(2)
S(23)— C(24)— C(25) 112.5(2) C(21)—C(25)—€(24) 112.0(2)
Torsion Angles (°)
C( 17)— 0 ( 14)—C( 14)—C( 13) 2.7(2)
C(18)— 0(15)—C(15)—C(16) -4.8(2)
C( 11)—C( 1)—C(2)- € (3 ) 2.5(2)
C(2>—C (l)—C(11)—€(16) 5.0(2)
C(11)—C (l)-C (2 } -C (2 1 ) 176.9(4)
C(l>—C(2>-C(21)—C(22) 152.1(3)
C( 1)—C(2>—C(21)—€(25) -26.9(2)
C(3>—C(2)—€(21)—C(22) -27.3(2)
C(3)— C(2)—C(21)—C(25) 153.6(3)
0(14)—€(14)—C(15)—0(15) 0.5(2)
C(25)—C(21)—C(22)—S(23) 0.8(2)
C(22)— C(21)—C(25)—C(24) -0.2(2)
S(23>—C(24)—C(25)—C(21) -0.4(2)
C(24)— S(23)—C(22)—C(21) -0.9(2)
C(22)— S(23)—C(24)—C(25) 0.8(2)
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Figure 32 Light-induced trans/cis Interconversion of Tvrphostins (66) and
(2 3 3 ).
At time zero: pure trans -isomer (66) in d6-DMSO 
(% of composition as a function of time)
lOu
7 5 -
(233)
2 5 -
0 24 48 72 96 120
Time (hours)
At time zero: pure cis -isomer (233) in d6-DMSO
(% of composition as a function of time,
100
75 -
g  5 0 -
2 5 - ■6 (rans-\somQT 
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within 5-6 days, with the ds-isomer (233) predominating by a ratio of 7:2, which showed 
that both forms can mutually equilibrate in the presence of light. By conducting a similar 
light study in d8-THF, it was demonstrated that the equilibrium ratio was solvent dependent 
since ( 66 ) and (233) gave a 4:5 mixture, respectively, over ca. 8 days.
When each isomer was stored in the dark at ambient temperatures (over 17 hours) either as a 
d6-DMSO solution or in the solid state, no trans/cis interconversion was observed. Also, no 
isomerised products or impurities were detected when ( 6 6 ) and (233) were exposed to light 
in the solid state (over 16 hours), and no discolouring of the transparent crystals of the cis- 
isomer (233) were observed for longer periods (two weeks in daylight hours). Thus, this 
study highlights the importance of not storing stilbene-like tyrphostins as stock solutions, 
especially in DMSO, and it would be advisable to reconstitute these drugs in the dark 
immediately prior to biological testing.
The stablity of the tyrphostin ( 6 6 ) in solution has previously been questioned by colleagues 
at the Beatson Institute (Glasgow University) and it was suggested that the parent drug 
seemed to be in equilibrium with a “main degradation product (mdp)” in DMSO .324 Indeed, 
in later work, this “mdp” was isolated by reverse phase HPLC (55% H20/45%  MeOH) and 
was identified by us to be the ds-isomer (233) using NMR spectroscopy. Futhermore, it 
was demonstrated by Dr Howard L. McLeod and colleagues (Beatson Institute, Glasgow  
University) that the ds-isomer was also formed in the plasma of nude mice, together with at 
least 6 other metabolites, after administration of the trans-compound (6 6 ). However, the 
results of Yoneda e t a lP 2 could not be reproduced in this study and the tyrphostin ( 66 ) did 
not show a promising in vivo profile against tumour-bearing nude mice.
Nevertheless, an interesting finding was that the isomeric tyrphostins ( 6 6 ) and (233) gave 
IC50 values o f 11 and 38 JIM, respectively, when tested in an antiproliferative assay against 
the HN5 cell line .325 This finding supports Levitzki’s premise230f that trans -forms of the 
tyrphostins (aromatic and nitrile groups mutually cis) are more potent than their cis- 
counterparts. However, the true reason for this result is not clear but, since the tyrphostin 
(66 ) is a mixed-type inhibitor231 and therefore competes for the ATP-binding site, it may be 
speculated that a flat conformation analogous to the adenine portion of ATP is important to 
attain a high binding affinity (c/. Burke202). This situation is sterically dissallowed for the 
ds-isomer (233) and so would be expected to be less active. On the other hand, it may be
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the directional nature of the nitrile group that is important for substrate binding interactions 
via hydrogen-bonding or by some electrostatic attraction, for example. Whatever the reason 
the present study has provided interesting data towards the interpretation of the biological 
data of the known tyrphostin (6 6 ) and is currently being compiled for publication both in a 
chemical and biological context. 326,327
Synthesis and Biological Evaluation o f  Anticancer Agents Page 137
EXPERIMENTAL—CHEMISTRY
M a t e r ia l s  a n d  In s t r u m e n t a t io n
All chemicals and solvents were purchased from Aldrich Chemical Company (Gillingham, 
Dorset, UK) except 2-nitrothiophene-4-carbaldehyde which was purchased from Lancaster 
Synthesis Limited (Morecambe, Lancashire, UK). Organic solutions were dried with 
anhydrous Na2S 0 4 or M g S 0 4 and concentrated under 40 °C using a rotary evaporator. 
Unless otherwise stated, ether refers to diethyl ether and petroleum ether refers to the 
fraction which distills between 40-60 °C. RF values were obtained by performing qualitative 
thin-layer chromatography (TLC) using Merck G F ^  silica gel plates. Compounds were 
detected by viewing under UV and/or developing with iodine.
Mps are uncorrected and were determined on a Reichert-Kofler hot-stage apparatus. IR 
spectra were recorded as KBr discs on a Philips analytical PU9800 Fourier Transform IR 
spectrometer. IR frequencies, v , are given in wave numbers (cm-1) and the relative 
intensities (weak, medium and strong) are denoted by w, m, and s, respectively. Stated 1H 
(200 Mz) and 13C (50 Mz) NMR data were obtained from Briiker AM 200SY or WP200SY  
instruments and the numbering systems refer to the appropriate structures in the Appendix. 
All chemical shifts are quoted in ppm on the 8 scale using the residual protons from the 
deuteriated solvent as reference. Mass spectra (MS) were performed (as El) on an 
AEI/Kratos MS 12 (low resolution) and an AEI/Kratos MS 902S (high resolution) 
instrument. Elemental compositions for C, H and N were determined on a Carlo Erba 
Strumentazione Elemental Analyzer-MOD 1106 with a Hewlett Packard 3394A Integrator. 
The presentation of the experimental data is according to the 1994 recomendations of the 
Journal o f  the Chemical Society (Perkin Transaction 1) 328
General Notes and Methods Used
Method A . A round-bottomed flask was charged with equimolar amounts o f aryl 
carbaldehyde and malononitrile derivative (1-4 mmol) followed by absolute ethanol 
(3-15 ml) and a magnetic stirrer. After addition of neat piperidine (1-3 drops from a pasteur 
pipette) the reaction was stirred at room temperature until precipitation o f the product had 
occurred (1-18 h). Failing this water and/or diethyl ether was added and the precipitate was 
collected and dried under suction. This procedure worked well with malononitrile and the 
alkyl cyanoacetate esters.
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Method B . A 25 ml round-bottomed flask was charged with the appropriate aryl 
carbaldehyde (1.5 mmol) and malononitrile derivative (1.5 mmol) together with absolute 
ethanol (5 ml) and a magnetic stirrer. As a precaution the contents were occasionally heated 
and filtered to obtain a clear solution or else each reactant was separately dissolved in a 
minimum amount of ethanol, filtered and mixed later. The solution obtained was stirred at 
room temperature and 10% piperidine in ethanol (up to 1 ml) was added dropwise. The 
reaction was then stirred for up to 24 h or until TLC (silica gel/diethyl ether) showed 
completion. The precipitate was filtered, washed and dried under suction with diethyl ether. 
This procedure was preferred for the less soluble malononitrile derivatives, l,l,3-tricyano-2- 
aminoacetate and cyanothioacetamide.
Method C . Equimolar amounts of an appropriate aryl carbaldehyde and malononitrile 
derivative (10-100 mmol) were dissolved in a minimum amount of ethanol (1-10 ml). After 
keeping the solution hot for ca. 5 min, piperidine in ethanol (5 to 50 %; 1-5 drops) was 
added, while stirring, and the mixture was left to cool to room temperature (unstirred). The 
crystals were filtered, washed (diethyl ether) and dried under suction. This procedure 
worked well with nitroaryl carbaldehydes Le. activated systems.
Method D . Neat piperidine (1 drop per ml of solvent used) was added to a hot stirred 
solution o f the appropriate aryl carbaldehyde ( 10-100  mmol) in a minimum amount of 
ethanol (1-10 ml). After keeping the solution hot for ca. 5 min and while stirring, an 
equimolar amount of the appropriate 3-substituted acetonitrile derivative was added 
followed by cautious addition of a catalytic amount of potassium rm-butoxide (ca. 10 mg). 
After the initial exotherm subsided, the solution was left to cool to room temperature 
(unstirred). The crystals were filtered, washed (diethyl ether) and dried under suction. This 
procedure worked well with less activated reaction systems and in particular for the
3-arylacetonitriles.
Experimental Procedures— Chapter 6
2-Cyano-3-(4-hydroxyphenyl)propenonitrile  ( 6 9 ) — U sin g  M ethod A,
4-hydroxybenzaldehyde (0.50 g, 4.1 mmol) and malononitrile (0.27 g, 4.1 mmol) reacted to 
give a yellow preciptate after 1 h: (0.68 g, 98 %), m.p. 155-163 °C (from EtOH) (lit. ,2300 
180 °C); Rp 0.69 (diethyl ether); (Found: M +, 170.0487. C10H 6N 2O requires M, 170.0494); 
vmax(KBr discVcm ' 1 3400m (OH), 3025w (Ar-H), 2200s (CN), 1610m, 1580s, and 1560s
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(Ar and C=C), 850m and 840m (Ar-H); 8 H(200 MHz; DMSO-d6) 9.77 (1 H, br, OH), 8.09 
(1 H, s, 3-H), 7.85 (2 H, d, 3J 8.4 Hz, 5-H and 9-H), 6.30 (2 H, d, 3J  8.4 Hz, 6-H and 8-H); 
8C(50M H z;DM SO -d6) 169.6(7-C), 159.1 (3 -CH), 134.5 (5- and9-CH), 120.4(4-C), 118.1 
(6- and 8-CH), 116.2 and 115.5 (2 x  CN), 69.8 (2-C); m/z 170 (M+, 100%), 142 (M+ -  CO,
56), 119 (M +-  CO, -  CN, 60), 91 (M+-  CO, -  H-CsC-CN, 46), 76 (16), 63 (32), 51 (25.5).
3-Amino-2,4-dicyano-5~(4-hydroxyphenyl)penta-2,4-dienonitrile (7 0 )— U sin g  
Method A, 4-hydroxybenzaldehyde (0.50 g, 4.1 mmol) and 1,1,3-tricyano-2-aminopropene 
(0.54 g, 4.1 mmol) were reacted in ethanol (5 ml) with piperidine (1 drop) and after 4 h the 
product was precipitated with water and collected: (0.17 g, 18 %), m.p. 182 °C (from 
ethanol/water) (lit. ,2300 225 °C); R¥ 0.38 (diethylether); (Found: M+, 236.0716. C 13H 8N 30  
requires M, 236.0734); v max(KBr discVcm ' 1 3400s (OH), 3330s and 3240s (NH2), 2200s 
and 2220s (CN), 1640s, 1605s and 1560s (C=C), 835m (Ar-H); 8H(200 MHz; DMSO-d6)
9.0 (3 H, v.br, OH and NH 2), 7.94 (1 H, s, 3-H), 7.93 (2 H, d, 3J  8.6  Hz, 5-H and 9-H), 6.97 
(2 H, d, 3J  8.6  Hz, 6 -H and 8-H); m/z 236 (M +, 40 %), 210 (M+ -  CN, 6 8 ), 194 (M + -  
H C=CH -0, 3), 192 (M + -  CN, -  H20 , 4), 181 (M + - H 2C=CH -C=0, 13), 116 (M+ - C O ,-  
C(NH2)=C(CN)2, 12.2), 165 (8 ), 152 (3.5), 143 (9), 142 (4.5), 139 (4), 107 (100), 89 (28), 
84 (23), 77 (34), 63 (25), 56 (44), 51 (30.5).
2-Cyano-3-(4-hydroxyphenyl)propenothioamide (7 1 )— U sing M ethod A, 
4-hydroxybenzaldehyde (0.50 g, 4.1 mmol) and cyanothioacetamide (0.41 g, 4.1 mmol) 
were reacted in ethanol (3 ml) with piperidine (1 drop) and after 2 h the product was 
precipitated with water: (0.31 g, 38 %), m.p. 189-193 °C; R ¥ 0.64 (diethyl ether); (Found: 
M+, 204.0368. C 10H8N 2OS requires M, 204.0379); vmax(KBr discycm ' 1 3360s (OH), 3290s 
and 3170s (CSNH2), 2220 (CN), 1640 (C=S), 1605m, 1585s and 1565s (Ar and C=C), 845s 
and 830s (Ar-H); 8H(200 MHz; DMSO-d6) 10.70 (1 H, br, OH), 9.99 (1 H, br, N H 2), 9.45 
(1 H, br, N H 2), 8.29 (1 H, s, 3-H), 7.93 (2 H, d, 3 J  8 .6  Hz, 5-H and 9-H), 6.98 (2 H, d, 3J
8 .6  Hz, 6-H and 8-H); Sc (50 MHz; DMSO-d6) 192.9 (C=S), 162.0 (7-C), 147.9 (3-CH),
133.3 (5- and 9-CH), 122.8 (4-C), 116.5 (6- and 8 -CH), 117.2 (CN), 107.8 (2-C); m/z 204 
(M+, 83%), 203 (M+ -  H, 100), 171 (M+ -H S , 19), 116 (M + -C O , -  CSNH2, 16), 115(11), 
114 (15), 77 (8), 60 (34), 51 (22).
Ethyl 2-Cyano-3-(4-hydroxyphenyl)propenoate (7 2 )— U sin g  M ethod A,
4-hydroxybenzaldehyde (0.50 g, 4.1 mmol) and ethyl cyanoacetate (0.46 g, 4.1 mmol) were
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reacted in ethanol (3 ml) with piperidine (1 drop) to give a white precipitate after 2 h: 
(0.85 g, 96 %), m.p. 169-170 °C (from EtOH); RF 0 .60 (diethyl ether); (Found: M +, 
217.0737. C 12H n N0 3  requires M ,  217.0736); v max(KBr disc)/cm'' 3300s (OH), 2990w  
(Ar-H), 2230m  (CN), 1730m and 1710m (C =0), 1585s (Ar and C=C), 835m (Ar-H); 
8h(200 MHz; DMSO-d6) 10.68 (1 H, br, OH), 8.03 (1 H, s, 3-H), 7.80 (2 H, d, 3J 8.4 Hz,
5-H and 9-H), 6.78 (2 H, d, 3J  8.4 Hz, 6 -H and 8 -H), 4.10 (2 H, q, J/ 6.8  Hz, CH2), 1.13 
(3 H, d, 3J  6.8  Hz, CHj); 8C(50 MHz; DMSO-d6) 163.0. (C =0), 162.7 (7-C), 154.7 (3-CH), 
134..0 (5- and 9-CH), 122.6 (4-C), 116.5 (6 - and 8 -CH), 116.5 (CN), 97.1 (2-C), 62.0 
(CH2), 14.1 (CH3); m/z 217 (M+, 91%), 188 (M+ -C H 2CH3, 14), 173 (M+ - H 20 , - C N ,  5), 
144 (M + -  C 0 2CH2CH3, 55), 118 (M + -  C 0 2CH2CH3, -  CN, 26), 105 (2.5), 100 (20), 94 
(9), 90 (22), 89 (93), 79 (2), 77 (3), 74 (6), 63 (23).
2-C yano-3-(4-hydroxyphenyl)propenam ide  ( 7 3 ) — U sin g  M ethod A,
4-hydro’xybenzaldehyde (0.50 g, 4.1 mmol) and cyanoacetamide (0.34 g, 4.1 mmol) were 
reacted in ethanol (5 ml) with piperidine.(l drop) After 5 h the product was obtained by 
precipitation on ice: (0.45 g, 58 %), m.p. 243 °C (from EtOH) (lit.,2300 250 °C); RF 0.32 
(diethyl ether); (Found: M +, 188.0598. C 10H 8N 2O2 requires M, 188.0610); v max(KBr 
disc)/cm"' 3450s and 3370s (N H ,), 3190s (OH), 2230m (CN), 1655m (C =0), 1600s and 
1570m (Ar and C=C), 840m (Ar-H); 8h(200M Hz; DMSO-dg) 10.62(1 H, br, OH), 8.11 (1 
H, s, 3-H), 7.81 (1 H, br, NH 2), 7.70 (1 H, br, NH2), 7.92 (2 H, d, 3J  8.3 Hz, 5-H and 9-H),
6.98 (2 H, d, 3J 8.3 Hz, 6 -H and 8-H); 8C(50 MHz; DMSO-d6) 163.5 (C =0), 161.9 (7-C),
150.7 (3-CH), 133.0. (5- and 9-CH), 123.0. (4-C), 117.5 (CN), 116.3 (6 - and 8-CH), 101.5 
(2-C); m/z 188 (M +, 100%), 172 (M+ -  N H 2, 25), 144 (M+ -  CONH2, 39), 118 (M+ -  
CONH2, -  CN, 61), 114 (13), 104 (3.5), 93 (3), 91 (5.5), 89 (81), 65 (27), 64 (16), 63 (53), 
51 (26).
2-Cyano-3-(3,4-dihydroxyphenyl)propenonitrile ( 5 6 ) — U sin g  M ethod A,
3,4-dihydroxybenzaldehyde (1.10 g, 8.0 mmol) and malononitrile (0.55 g, 8.3 mmol) were 
reacted in ethanol (6  ml) under reflux with piperidine (1 drop) for 0.5 h. This gave a yellow  
precipitate which was crystallised from ethanol/water: (1.18 g, 80 %), m.p. 220 °C 
(decomp.) (from EtOH/H20 )  (lit.,230c 225 °C); R F 0.72 (diethyl ether); (Found: M+, 
186.0415. C 10H 6N 2O2 requires M, 186.0401); v max(KBr discVcm ' 1 3460s and 3285s (2 x  
OH), 2220s and 2225s (2 x CN), 1610m, 1595m and 1570s (Ar and C=C), 905m and 825m
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(Ar-H); 8H(200 MHz; acetone-d6) 9.00 (2 H, v.br, 2 x  OH), 7.97 (1 H, s, 3-H), 7.65 (1 H, d, 
4J9.h 2.25 Hz, 5-H), 7.47 (1 H, dd, 4J5.H 2.25 Hz, }J8_H 8.4 Hz, 9-H), 7.00 (1 H, d, 3J9.„ 8.4 
Hz, 8 -H); 8 C(50 MHz; acetone-d6) 160.7 (3-CH), 153.2 (7-CH), 146.5 (6 -CH), 128.1 
(9-CH), 124.8 (4-C), 116.7 (5- or 8-CH), 116.5 (8- or 5-CH), 116.6 and 114.6 (2 x  CN),
77.1 (2-C); m/z 186 (M+, 100%), 158(M + -C O , 36), 130 (M+ - 2 xC O , 52), 103(M +- 2 x  
CO, -  HCN, 39), 93 (2), 89 (4), 87 (18), 76 (52), 62 (30.5).
3 -Amino-2,4-dicyano-5-( 3,4-dihydroxyphenyl)penta-2,4-dienonitrile (74)—
Using Method A, 3,4-dihydroxybenzaldehyde (0.50 g, 3.62 mmol) and 1,1,3-tricyano- 
2-aminopropene (0.47 g, 3.61 mmol) were reacted in ethanol (5 ml) with piperidine (1 drop) 
for 3 h. The product was precipitated on ice to give a yellow solid: (0.39 g, 43 %), m.p. 
229 °C (from EtOH/H20 )  (lit. ,2300 235 °C); ftp 0.26 (diethyl ether); (Found: M +, 252.0640. 
C i3H 8N 40 2 requires M, 252.0373); vmax(KBr discycm ' 1 3380s (2 x  OH), 3330s and 3220s
i
(NH2), 2220s and 2200s (CN), 1650s, 1610s and 1570s (C=C), 310w (Ar-H); 8 h(200M H z; 
DMSO-d6) 10.01 and 9.10 (4 H, br, 2 x  OH and N H 2), 8.19 (1 H, s, 3-H), 7.95 (1 H, b r s,
5-H), 7.47 (1 H, br d, 3Jm  8.5 Hz, 9-H), 7.07 (1 H, d, 3J9.H 8.5 Hz, 8 -H); m/z 252 (M+, 
100%), 210 (M + -  CN, 14), 198 (M + -  CN, -  CO, 11), 196 (M + -  2 x  CO, 28), 195 (M+ -  
CO, -  NH2, 31.5), 135 (M+ -  CN, -  C(NH2)=C(CN)2, 3), 235 (25), 226 (47.5), 180 (32), 
169(27), 152 (20), 141 (23), 130(14.5), 127(6), 115(10), 114(34), 105(11.5), 88 (36).
2-Cyano-3-(3,4-dihydroxyphenyl)propenothioamide (58)— Using Method B and 
in the absence o f light, 3,4-dihydroxybenzaldehyde (2.085 g, 15.10 mmol) and 
cyanothioacetamide (1.510 g, 15.08 mmol) were reacted in ethanol (10 ml) for 5.5 h with 
10% piperidine in ethanol (3 drops). The greenish-yellow precipitate was filtered, washed 
with isopropanol and dried under suction with diethyl ether. This was subsequently purified 
through a silica column with ethyl acetate/petroleum ether (bp 30-40 °C) elutions to give: 
(1.631 g, 49 %), m.p. 206-207 °C (from EtOAc/pet. ether; bp 30-40 °C) (lit.,230c 213 °C); 
ftp 0.58 (diethyl ether); (Found: M+, 220.0365. C 10H 8N 2O2S requires M , 220.0373); 
vmax(KBr discycm ' 1 3380s (2 x  OH), 3290s and 3185s (NH2), 2215m (CN), 1630m (C=S), 
1610s and 1575s (Ar and C=C), 870m (Ar-H); 8 H (200 MHz; DMSO-d6) 9.90 (2 H, br, 2 x  
OH), 9.92 (1 H, br s, NH2), 9.40 (1 H, br s, NH 2), 8.01 (1 H, s, 3-H), 7.61 (1 H, d, 4Jg.H 1.97 
Hz, 5-H), 7.35 (1 H, dd, 4JS.H 1.97 Hz, 3J8_„ 8.34 Hz, 9-H), 6.94 (1 H, d, 3J9.H 8.34 Hz,
8 -H); 5C(50 MHz; DMSO-ds ) 193.0 (C=S), 151.0 (7-C), 148.2 (3-CH), 145.9 (6 -C), 125.9
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(9-CH), 123.2 (CN), 117.2 (4-C), 116.5 (5- or 8 -CH), 116.2 (8 - or 5-CH), 107.4 (2-C); m/z 
220 (M+, 96%), 203 (M + -  CO, + H, 31), 187 (M+ -  HS, 15), 132 (M + -  CO, -  CSNH2 , 4), 
131 (9.5), 130 (40), 77(14.5).
Ethyl 2-cyano-3-(3,4-dihydroxyphenyl)propenonitrile (75)— Using Method A,
3.4-hydroxybenzaldehyde (0.50 g, 3.62 mmol) and ethyl cyanoacetate (0.41 g, 3.62 mmol) 
were reacted in ethanol (3 ml) with piperidine (1 drop). After 1 h a precipitate was not 
observed and thus the reaction was heated for 2 h which yielded the title product (0 .7 4  g,
87.4 %) on cooling to room temperature, m.p. 160-165 °C (from EtOH); R F 0.67 (diethyl 
ether); (Found: M +, 233.0684. C 12H u N 0 4 requires M , 233.0680); v max(KBr disc)/cm _1 
3470m and 3140m (2 x OH), 2205m (CN), 1700s (C =0), 1615w and 1580s (Ar), 860m and 
745s (Ar-H); 5H(200 MHz; DMSO-d6) 10.85 (2 H, v.br, 2 x  OH), 8.27 (1 H, s, 3-H), 7.83 
( lH .b r  s, 5-H), 7.54 (1 H, br d, 3J8.H 8.2 Hz, 9-H), 7.07 (1 H, d, 3J9_„ 8.2 Hz, 8-H), 4.42 
(2 H, q, 3J 7.0 Hz, CH2), 1.44 (3 H, t, 3J  7.0 Hz, CH3); m/z 233 (M +, 48 %), 188 (M+ -  CN, 
-C H 2CH3, 55), 160 (M+ - C 0 2 CH2CH3, 54.5), 141 (M+ -  2 x CO, -  2 x  H 20 ,  1), 114(M +
-  2 x CO, -  H2 0 ,  -  OCH2CH3, 100), 106 (M + -  C 0 2CH2CH3, -  H C =C -C =0, 5), 103
(34.5), 102 (16), 91 (2), 88  (7), 87 (6 ), 77 (13).
2-Cyano-3-(3,4-dihydroxyphenyl)propenamide (7 6 )— U sin g  M ethod  A,
3.4-dihydroxybenzaldehyde (0.50 g, 3.62 mmol) and cyanoacetamide (0.30 g, 3.62 mmol) 
were reacted in ethanol (8 ml) with piperidine (2 drops) After 1.5 h, no precipitate formed 
and so the solution was heated at reflux for 16 h and precipitation induced by the addition of 
diethyl ether to give: (0.34 g, 46 %), m.p. 220-222 °C (EtOH/Et20 )  (lit. ,2300 247 °C); ftp 0.22 
(diethyl ether); (Found: M +, 204.0527. C I0H 8N 2O3 requires M, 204.0520); vmax(KBr 
discycm ' 1 3460s, 3420s, 3320s and 3265s (OH, 2210m (CN), 1680m (C =0), 1605s and 
1575m (C=C, Ar); 8 H(200 MHz; DMSO-d6) 9.84 (2 H, v.br, 2 x  OH), 8.11 (1 H, s, 3-H),
7.73 and 7.60 (2 x  1 H, 2 x  br s, NH 2), 7.54 (1 H, d, 4Jg.H 2.12 Hz, 5-H), 7.26 (1 H, dd, 4J9_H
2.12 Hz, 3J8.h 8.3 Hz, 9-H), 6.87 (1 H, d , 3 Jg.H 8.3 Hz, 8-H); 8C(50 MHz; DMSO-d6) 163.7 
(C =0), 151.0 (3-CH), 150.9 (7-C), 145.8 (6 -C), 125.5 (9-CH), 123.5 (CN), 117.5 (4-C),
116.3 (5- or 8 -CH), 116.1 (8- or 5-CH), 101.2 (2-C); m/z 204 (M +, 100 %), 185 (M +-  H20 ,
-  H, 6.5), 176 (M+ -  CO, 6 ), 160 (M+ -  CONH2, 11.5), 134 (M+ -  CN, -  CON H2, 12), 132 
(M+ -  CO, -  CONH2, 5), 114 (M+ -  CO, -  CONH2, -  OH, -  H, 16), 104 (M + -  2 x  CO, -  
CONH2, 7), 103 (4), 102 (2.5), 88  (9), 87 (5), 78 (4), 77 (9), 76 (8.5).
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2-Cyano-3-(3,4,5-trihydroxyphenyl)propenonitrile (57)— U sin g  M ethod B,
3,4,5-dihydroxybenzaldehyde (0.109 g, 0.707 mmol) and ethanolic malononitrile (27.8 mg 
ml'1, 0.715 mmol) (1.7 ml) were mixed and while stirring piperidine (1 drop) was added. 
After 3 h, the orange precipitate was collected: (61.3 mg, 43 %), m.p. 157-160 °C (from 
EtOH) (lit.,230c 245 °C); RF 0.20 (diethyl ether); (Found: M +, 202.0384. C 10H 6N 2O3 requires 
M, 202.0390); v max(KBr discycm ' 1 3300m and 3170m (OH), 2955m (Ar-H), 2215s (CN), 
1605m, 1570s and 1545s (Ar and C=C); 5H(200 MHz; DMSO-d6) 8.02 (3 H, br, 3 x  OH), 
7.26 (1 H, s, 3-H), 6.97 (2 H, br s, 5- and 9-H); m/z 202 (M+, 20%), 174 (M + -  CO, 3), 128 
(M+ -  2 x  CO, -  H20 , 5), 118 (M+ -  3 x  CO, 100), 91 (M+ -  3 x  CO, -  HCN, 21.5), 90 (16), 
89 (4), 79 (1.5), 77 (3), 76 (16), 75 (11).
3-Amino-2,4-dicyano-5-(3f4,5-trihydroxyphenyl)penta-2,4-dienonitrile (77)—  
Using Method B, 3,4,5-dihydroxybenzaldehyde (0.10 g, 0.65 mmol) was added to 
1,1,3-tricyano-2-aminopropene (0.12 g, 0.91 mmol) in ethanol (3 ml). W hile stirring 10% 
piperidine in ethanol (1 ml) was added and after 4 h the dark red solution was subjected to 
column chromatography (silica/diethyl ether) to give an orange solid: (0.10 g, 42 %), m.p. 
180 °C (decomp.) (lit.,230c 275 °C); RF 0.39 (diethyl ether); v max(KBr d iscycm ' 1 3315s and 
3210s (NH2 and OH), 2220m (CN), 1630s (C=S), 1600s, 1570s and 1525s (Ar and C=C), 
875 and 800 (Ar-H); 6 H(200 MHz; acetone-d6) 7.8 (5 H, v.br, N H 2 and 3 x  OH), 7.65 (1 H, 
s, 3-H), 7.07 (2 H, br s, 5- and 9-H); m/z 268 (M+, 0.5), 242 (M+ -  CN, 1), 224 (M+ -  CN, -  
H20 ,  0.4), 176 (M + -  C(NH2)=C(CN)2, 2), 151 (M+ -  CN, C(NH2 )=C(CN)2, 2), 125 (Ar,
37), 97 (Ar -  CO, -  H, 33.5), 79 (95), 66  (17).
2-Cyano-3-(3,4,5-trihydroxyphenyl)propenothioamide (78)— Using Method B 
and in the abscence of light, 3,4,5-dihydroxybenzaldehyde (0.20 g, 1.30 mmol) was added 
to cyanothioacetamide (0.18 g, 1.80 mmol) in degassed ethanol (2  ml), under a nitrogen 
atmosphere. While stirring, 10% piperidine in ethanol (1 ml) was added and after 4 h the 
dark red solution was subjected to column chromatography (silica/diethyl ether) to give an 
orange solid: (0.21 g, 50 %), m.p. 98 °C (decomp.); RF 0.26 (diethyl ether); v max(KBr 
disc)/cm'‘ 3315s and 3210s (NH2 and OH), 2220m (CN), 1630s (C=S), 1600s, 1570s and 
1525s (Ar and C=C), 875 and 800 (Ar-H); 5 H(200 MHz; DMSO-d6) 9.42 and 8.81 (2 H, 
2a x  br s, N H 2), 8.2 (3 H, v.br, 3 x  OH), 7.81 (1 H, s, 3-H), 6.90 (2 H, br s, 5- and 9-H); m/z 
236 (M+, 55), 219 (M + -  NH3, 25), 209 (M+ -  HCN, 2), 203 (M + -  HS, 20), 176 (M + -
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CSNH2, 6.5), 148 (M + -C S N H 2, -C O , 8), 134 (M+ - C N , - 2  x C O ,-N H 2, 18.5), 118 (M +
-  CSNH2, -  CN, -  CO, 65), 102 (36), 91 (35), 76 (69).
Ethyl 2-cyano-3-(3,4,5-trihydroxyphenyl)propenoate (79)— U sing Method C, 
ethyl cyanoacetate (0.20 g, 1.8 mmol) was added to 3,4,5-dihydroxybenzaldehyde 
(0.20 g,1.30 mmol) in ethanol (1 ml) and were reacted with piperidine (1 drop) After 1.25 h, 
the reaction solution was directly applied onto a silica column and eluted with diethyl ether 
to give a yellow  solid: (0.13 g, 40 %), m.p. 76 °C (decomp.); R F 0.55 (diethyl ether); 
v^ C K B r d iscycm ’1 3365s (OH), 2985m (Ar-H), 2225m (CN), 1695s (C = 0), 1655s (Ar 
and C=C), 635m  (Ar-H); §h(2 0 0  MHz; DMSO-d6) 9.0 (3 H, v.br, 3 x  OH), 8.04 (1 H, s,
3-H), 7.17 (2 H, br s, 5- and 9-H), 4.31 (2 H, q, J77 .0 8  Hz, CH2), 1.32 (2 H, t, 7.08Hz, 
CH3); 5c (50 MHz; DMSO-d6) 163.0. (C=0), 155.3 (3-CH), 146.2 (6- and 8 -C), 141.5 (7-C),
121.4 (4-C), 116.7 (CN), 111.2 (5- and 9-CH), 95.9 (2-C), 61.9 (CH2), 14.2 (CH3); m/z 249 
(M+, 39%), 221 (M + -  CH2CH3, + H, 14), 204 (M+ -  OCH2CH3, 13.5), 193 (M + -  CO, -  
CH2CH3, +  H, 20), 165 (M* -  CO, -  CH2CH3, -  HCN, 46), 148 (M+ -  CO, -  HOCH2 CH3,
-  HCN, 57), 119 (M+ -  2  x  CO, -  CH2CH3, -  HCN, 100), 102 (49), 91 (50), 76 (53), 65 
(31).
2-Cyano-3-(3,4,5-trihydroxyphenyl)propenamide (8 0 )— U sin g  M ethod A,
3.4.5-dihydroxybenzaldehyde (0.20 g, 1.30 mmol) and cyanoacetamide (0.15 g, 1.8 mmol) 
were reacted in ethanol (2 ml) and while stirring piperidine (1 drop) was added. After 3 h, 
precipitation was induced on ice to afford a yellow solid: (0.25 g, 71 %), m.p. 260 °C 
(decomp.); RF 0.08 (diethyl ether); v max(KBr discycm ' 1 3410s (CONH2 and OH), 2965m  
(Ar-H), 2215w  (CN), 1680m (C =0), 1655s (Ar and C=C), 635m (Ar-H); 5 H(200 MHz; 
DMSO-d6) 7.87 (1 H, s, 3-H), 7.75 and 7.62 (2  H, 2 x  br s, N H 2), 7.05 (2 H, br s, 5- and 
9-H), 5.8 (3 H, v.br, 3 x  OH); 5C(50 MHz; DMSO-d6) 163.8 (C =0), 151.2 (3-CH), 146.1 
(6 - and 8-C), 139.1 (7-C), 122.2 (4-C), 117.4 (CN), 110.3 (5- and 9-CH), 101.1 (2-C); m/z 
220 (M+, 6.3%), 204 (M + - N H 2, 3), 176 (M+-C O N H 2, 6 ), 165 (M + -  CN, -  CO, 10), 135 
(M+ -  H, -  NC-CH2CONH2, 4), 153 (84), 125 (54), 97 (23), 79 (67), 67 (2.5).
2-Cyano-3-(3,5-dichlorophenyl)propenonitrile  ( 8 5 ) — U sin g  M ethod C,
3.5-dichlorobenzaldehyde (1.040 g, 5.94 mmol) and malononitrile (0.393 g, 5.95 mmol) 
were reacted in absolute ethanol (5 ml) with the addition o f 10 % piperidine in ethanol 
(10 drops). After 6.5 h the precipitate was collected (0.549 g, 41 %), m.p. 106-107 °C (from
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EtOH); ftF 0.91 (diethyl ether); (Found: M +, 221.9785 (for 35C1). CioH4N 2C12 requires M,  
221.9752 (for 35C1)); v max(KBr discycm ' 1 3080w, 3060m and 3035w (Ar-H), 2225m (CN), 
1590m and 1555s (Ar), 1225m/s, 865m/s (=C -H  deformation), 670m /s (=C-C1); 
8h(200 MHz; acetone-d6) 8.35 (1 H, s, 3-H), 7.97 (2 H, d, 4J  1 .54,5- and 9-H), 7.79 (1 H, t, 
4J  1.62,7-H); 8C(50 MHz; acetone-d6) 158.5 (3-CH), 136.5 (6-  and 8-C), 135.1 (4-C), 133.7 
(7-CH), 129.3 (5- and 9-CH), 114.0 and 113.0 (2 x  CN), 86 .8  (2-C); m/z  226 ((37C1)M+, 
9%), 224 ((35C1/37C1)M+, 46), 222 ((35C1)M+, 72), 197 ((35C1/37C1)M+ -  HCN, 33), 195 
((35C1)M+ -H C N , 20), 189 ((37C1)M+ - 37C1, 33), 187 ((35C1)M+ - 35C1 and (350 / 37Cl)M+ -  
37a, 100), 175 ((37a)M- -  2 x  CN, +  H, 9), 173 ((35C1/37C1)M+ -  2 x  CN, + H, 46), 171 
((35C1)M+ -  2 x  CN, + H, 72), 160 ((35C1)M+ -  35C1 or ( 35Cl/37a ) M + -  37C1, -  HCN, 8 ), 
152 (M+ -  2  x  Cl, 16), 124 (M+ -  2  x  HC1, -  CN, 18), 136 (M+ -  2 x  CN, -  H 35C1, 5), 111 
(5), 99 (12).
2-Cyano-3-(3,5-dichlorophenyl)propenothioamide ( 8 6 )— U sing Method C,
3,5-dichlorobenzaldehyde (0.497 g, 2.82 mmol) and cyanothioacetamide (0.284 g, 
2.84 mmol) were reacted in absolute ethanol (5 ml) with the addition of piperidine (3 drops). 
After 6 h the solution was concentrated in vacuo to an oil which was subjected to column 
chromatography through silica using a concentration gradient o f 4:1 to 2:1 petroleum 
ether/ethyl acetate. The yellow main fraction obtained (0.352 g) was crystallised at ca. 
-15 °C in diisopropyl ether triturated with n-pentane (0.120 g, 17 %), m.p. 126-128 °C (from 
*-Pr2C//z-pentane); RF 0.81 (diethyl ether); (Found: M +, 255.9661 (for 35C1). C10H 6N 2SC12 
requires M , 255.9629 (for 35C1)); v max(KBr disc)/cm ' 1 3416m, 3357m and 3196m (CSNH2), 
3073m (=C -H ), 2187m  (CN), 1629m/s (C=C), 1569 s (Ar), 1434m/s, 808m (=C -H  
deformation), 685m (=C-C1); 5 H(200 MHz; acetone-d^) 9.07 and 8.16 (2 x  1 H, 2 x  br s, 
NH2), 7.48 (2 H, d, 4J  1.81, 3-H), 7.36 (2 H, d, 4J  1.87, 5- and 9-H), 7.33 and 7.27 (2 x  1 H, 
2 x  t, 4J  1.89, 7-H); 5C(50 MHz; acetone-d6), 135.2 and 134.8 (6- and 8 -C), 131.7 (4-C), 
129.9 (3-CH), 129.0 (7-CH), 128.6 (5- and 9-CH), 117.7 (1-CN), 116.2 (2-C); m/z 260  
((37C1)M+, 6 %), 259 ((37C1)M+ -  H, 10), 258 ((35C1/37C1)M+, 31), 257 ((35C1/37C1)M+ -  H, 
41), 256 ((35C1)M+, 46), 255 ((35C1)M+ -  H, 52), 230 ((35C1)M+ -  CN, 5), 224 ((37C1)M+ -  
37C1, + H, 47), 223 ((37C1)M+ -  37C1,26), 222 ((35C1)M+ -  35C1 and (35C1/37C1)M+ -  37C1, +  
H, 72), 221 ((35C1)M+ -  35C1 and (35C1/37C1)M+ -  37C1, 31), 197 ((35C1/37C1)M+ -  CSNH2, 
15), 195 ((35C1)M+ -  CSNH2, 23), 187 OVT -  2 x  Cl, 100), 152 (M + -  2 x  Cl, -  H 2S, 18),
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135 (M+ -  HCN, -  H35C1, -  CSNH2, 6.5), 124 (M+ -  2 x  H Q , -  CSNH2, 24), 111 (12), 99 
(19).
Ethyl 2-cyano-3-(3,5-dichlorophenyl)propenoate (87)— U sing Method C,
3.5-dichlorobenzaldehyde (0.304 g, 1.74 mmol) and ethyl cyanoacetate (0.196 g,
1.73 mmol) were reacted in absolute ethanol (5 ml) with the addition o f 10 % piperidine in 
ethanol (3 drops). After 0.5 h the white dense precipitate was collected (0.439 g, 93 %), m.p.
117.5-118.5 °C (from EtOH); Rf  0.91 (diethyl ether); (Found; M+, 269.0010 (for 33C1). 
C12H9N 0 2C12 requires M, 269.0016 (for 33C1)); vmax(KBr discycm ' 1 3065m/w (=C-H ), 
2905m/w and 2935m /w (CHX), 2228m (CN), 1715s (C = 0), 1610s andl560m /s (Ar), 
1418m/s, 1278m /s and 1210m/s (C -O ), 865m (=C -H  deformation), 670m (=C-C1); 
5h (200 MHz; DMSO-d*; 333 K) 8.40 (1 H, s, 3-H), 8.06 (2 H, br s, 5- and 9-H), 7.84 (1 H, 
br s, 7-H), 4.39 (2 H, q, 3J  6.98 Hz, CH2), 1.38 (3 H, t, 3J  7.00 Hz, CH 3); Sc (50 MHz; 
DMSO-ds ; 333 K) 161.17 (C 0 2CH2CH3), 151.86 (3-CH), 134.98 (6 - and 8 -C), 134.79 
(4-C), 131.90 (7-CH), 128.79 (5- and 9-CH), 114.43 (1-CN), 106.18 (2-C), 62.77 (CH2),
13.98 (CH3); m/z 273 ((37C1)M+, 6 %), 272 ((37C1)M+ -  H, 5), 271 ((33C1/37C1)M+, 28), 270 
((35Cl/37a ) M + -  H, 8 ), 269 ((35C1)M +, 42), 268 ((33C1)M + -  H, 3), 243 ((35C1)M + -  CN,
37), 242 ((35C1/37C1)M+ -  C2H4, 20), 241 ((35C1)M+ -  C 2H4 and ( 35C!/37CI)Mf - C 2H5, 59), 
240 ((35C1)M+ - C 2 H5, 22.5), 236 ((37C1)M+ -  37C1, 11), 234 ( (35C1)M + - 35C1 and 
(35Q /37a ) M + -  37C1,27), 226 ((35C1/37Q M + -  OC2H5, 25), 224 ((35C1)M+ -  OC2H5, 38), 
199 (M* -  2 x  Cl, 22.5), 198 ((33C1/37C1)M+ -  C O jC jH j, 30), 196 ((33C1)M+ -  C 0 2C2H5,
38), 135 (M+ -  HCN, -  H33C1, -C O jC jH j, 11), 124 (M+ -  2  x  HC1, -  COjC^Hj, 24), 109 
(34), 99 (38).
2-C ya n o -3 -(3 ,5 -d if lu o ro p h en y l)p ro p en o n itr i le  (8 8 )— U sing Method C,
3.5-difluorobenzaldehyde (0.621 g, 4.37 mmol) and malononitrile (0.289 g, 4.37 mmol) 
were reacted in absolute ethanol (3 ml) with the addition o f 10 % piperidine in ethanol 
(2 drops). After 5.5 h the precipitate was collected, washed with ether (some material 
dissolved) and dried with petroleum ether (30-40 °C) (0.150 g, 18 %), m.p. 82-83 °C (from 
EtOH); R p 0.87 (diethyl ether); (Found: M+, 190.0351. C 10H 4N 2F2 requires M, 190.0346); 
v max(KBr d iscycm ' 1 3110w, 3090m/w and 3030w (Ar-H), 2230m (CN), 1615m (C=C), 
1585s and 1430s (Ar), 1330s, 1130s and 990s (C-F), 865m/s (=C-H deformation), 670m/s 
(=C -F deformation); 8H(2 0 0  MHz; acetone-d6) 8.39 (1 H, s, 3-H), 7.97 (2 H, br d, 3ip
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6.25 Hz, 5- and 9-H), 7.79 (1 H, tt, 3JF 8.93 Hz, *J5.H/9.H 2.22 Hz, 7-H); 8 C(50 MHz; 
acetone-d6) 164.0 (dd, 247.4 Hz, 3ip  19.4 Hz, 6 - and 8 -C), 159.0 (s, 3-CH), 135.0 (m,
4-C), 114.10 (d, 2JV 26.9 Hz, 5- and 9-CH), 114.0 (2 x CN), 109.8 (t, 3JF 24.3 Hz, 7-CH),
86.6  (s, 2-C); m/z 190 (M+, 77%), 163 (M + -  HCN, 100), 139 (M + -  H -O C -C N , 32), 1 12 
(M+ -  H 2C=C(CN)2, 15), 99 (12), 88  (6.5), 75 (9).
2 -C y a n o -3 - (3 ,5 -d i f lu o ro p h e n y l )p ro p e n a m id e  (89 )— U sing M ethod C,
3.5-difluorobenzaldehyde (0.176 g, 1.24 mmol) and cyano acetamide (0.104 g, 1.24 mmol) 
were reacted in absolute ethanol (5 ml) with the addition of 3 drops of ethanolic piperidine 
(1:10 dilution). After 7.5 h no precipitate formed and thus the reaction was concentrated in 
vacuo and the gum obtained was crystallised from isopropanol to give the title compound: 
(0.043 g, 17 %), m.p. 134-136 °C (from /-PrOH); RF 0.52 (diethyl ether); (Found: M+, 
208.0461. C 10H 6N 2OF2 requires A/, 208.0448); v max(KBr discycm ' 1 3440m, 3180m and 
3410m (CONH2), 3100m and 3020w (Ar-H), 2215m (CN), 1695s and 1675s (C =0), 1615m 
(C=C), 1600s, 1580s and 1435s (Ar), 1390s, 1340s, 1305s, 1130s and 990s (C-F), 870m/s 
and 850m (=C -H  defomations), 675m and 670m (=C -F deformations); 8H(200 MHz; 
acetone-d6) (CONH2 signals coincide with aromatic region), 7.27-7.06 (4 H, m, 3-H plus 5- 
and 9-H), 7.05-6.94 (2 H, m, ca.  triplet, 7-H); 5 C(50 MHz; acetone-d6) 163.9 (dd, ]J¥
244.7 Hz, 3Jf 19.1, 6 - and 8 -C), 117.4 (m, 4-C), 114.1 (m, 5- and 9-CH), (1-CN coincides 
with 5- and 9-CH), 103.7 (m, 7-CH), (2-C may overlap with 7-CH); m/z 208 (M+, 92%), 
207 (M + -  H, 100), 192 (M+ -  NH2, 19), 189 (M + -  F, 14), 164 (M+ -  CONH2, 53), 144 (M + 
-  CONH2, -  HF, 48), 138 (M + -  H-C=C-H, -  HCN, 32), 124 (M + -  CONH2, -  2 x  HF,
17.5), 113 (M + -  HC=C(CN)2, 22.5), 99 (12), 88 (12), 75 (12).
Ethyl 2-cyano-3-(3,5-difluorophenyl)propenoate (9 0 )— U sing M ethod C,
3.5-difluorobenzaldehyde (0.540 g, 3.80 mmol) and ethyl cyanoacetate (0.430 g,
3.80 mmol) were reacted in isopropanol (5 ml) with the addition 10 % piperidine in 
isopropanol (4 drops). After 1 h the white precipitate was collected (0.660 g, 73 %), m.p. 
97-98 °C (from EtOH); R ? 0.89 (diethyl ether); (Found: M +, 237.0609. C 12H9N 0 2F2 
requires M, 237.0601); v max(KBr discycm ' 1 3077m and 3035w (Ar-H), 2228w (CN), 1724s 
(C =0), 1612m/s (C=C), 1590m/s and 1442m/s (Ar), 1368m, 1326m, 1263s, 1239m/s and 
1000m (C -0  and C-F), 875m/s and 861m (=C-H defomations), 672m (=C-F deformation); 
5h(200 MHz; acetone-d6) 8.34 (1 H, s, 3-H), 7.70 (2 H, dm, 3JF 6.72 Hz, 5- and 9-H), 7.33
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(1 H, tt, 3JF 8.96 Hz, 4J}.H/9.H 2.30 Hz, 7-H), 4.37 (2 H, q, 3J  7.12 Hz, CH2), 1.36 (3 H, t, 3J
7.13 Hz, CH 3); 5c (50 MHz; acetone-d6) 163.8 (dd, 1JF 248.5 Hz, 3JF 13.0 Hz, 6- and 8-C),
162.1 (s, C 0 2 CH2CH3), 159.0 (t, 4JF 2.9 Hz, 3-CH), 135.7 (t, 3 JF 10.1 Hz, 4-C), 115.4 
(1 -CN), 114.3 (d, 2JF 26.5 Hz, 5- and 9-CH), 108.8 (t, 3JF 26.0 Hz, 7-CH), 107.2 (s, 2-C),
63.5 (CH2), 14.3 (CH3); m/z 237 (M+, 68%), 218 (M+ -  F, 18), 209 (M+ -  CH2CH2, 53), 192 
(M+ -  OCH2 CH3, 48), 190 (M + -  HCN, -  HF, 10), 171 (M + -  HCN, -  HF, -  F, 10), 164 
(M+ -  C 0 2 CH2CH3, 100), 144 (M+ -  C 0 2CH2CH3, -  HF, 73), 138 (M+ -  C 0 2CH2CH3, -  
CN, 63), 124 (M + - C 0 2CH2CH3, - 2  x  HF, 16), 113 (M + - C 0 2CH2CH3, H-CsC-CN, 20), 
99 (6), 87 (11), 75 (6 ).
E th y l 2 -c y a n o -3 - (2 -p y r id y l )p ro p e n o a te  ( 9 1 ) — U sin g  M ethod  A ,
2-pyridylcarbaldehyde (0.10 g, 0.93 mmol) and ethyl cyanoacetate (0.11 g, 0.94 mmol) were 
reacted in EtOH (1 ml) and while stirring piperidine (1 drop) was added. After 2 h, the 
yellow precipitate was collected: (0.12 g, 64 %), m.p. 81-87 °C (from EtOH); RF 0.24  
(diethyl ether); (Found: M+, 203.0829. C11H 11N 20 2 requires M, 203.0821); v^CK Er 
discycm ' 1 3100m  and 3030m (py-H), 2995w (C-H ), 2220m (CN), 1720s (C =0), 1600m  
(C=C), 8 10m, 795m, 760m, 645s (2-py and =C-H); 5 H(200 MHz; DM SO-d6) 8.34 (1 H, br 
d, 3J7.h 7.83 Hz, 6-H), 8.41 (1 H, s, 3-H), 8.03 (1 H, ddd, 3J6_H 7.83 Hz, 3JS.H 7.12 Hz, 4J9_H
1.17 Hz, 7-H ), 8.01 (1 H, br d, 3JS.H 4.69 Hz, 9-H), 7.62 (1 H, ddd, 3J7_H 7.12 Hz, 3Jm  
4.69 Hz, 4J6.h  1.90 Hz, 8-H); 8C(50 MHz; DMSO-d6) 163.0 (C =0), 153.0 (3-CH), 150.3 
(6 -CH), 137.7 (8-CH), 128.6 (9-CH), 127.1 (7-CH), 114.8 (CN), 149.6 (4-C), 105.7 (2-C),
62.6 (CH2), 14.1 (CH3); m/z  203 (M+, 1.2%), 158 (M+ -  OCH2 CH3, 44), 130 (M+ -  
C 0 2CH2CH3, 100), 103 (M+ - H C N ,- C 0 2CH2CH3 , 5), 78 (py, 40), 51 (53).
2-Cyano-3-(3-pyridyl)propenonitrile (9 2 ) — U s i n g  M e t h o d  B ,
3-pyridinecarbaldehyde (5.690 g, 53.12 mmol) was added to malononitrile (2.709 g,
41.01 mmol) in EtOH (20 ml) followed by 10 % piperidine in ethanol (2 ml). After 0.75 h, 
the orange precipitate was collected:(5.593 g, 88 %), m.p. 77-78 °C (from EtOH); f lF 0.32 
(diethyl ether); (Found: M+, 155.0467. C9H5N3 requires Af, 155.0483); Vn^OKBr discycm*1 
3030m and 3005m  (py-H), 2200s (CN), 1595m, 1590s and 1580s (C=C and py), 1410s 
(C=Npy), 695s (2-py and =C-H); S H(200 MHz; CDC13) 8.85 (1 H, br d, 4J%H 2.4 Hz, 5-H), 
8.77 (1 H, dd, 3] m  4.83 Hz, 4Jg_H 1.59 Hz, 7-H), 8.42 (1 H, dddd, 3Js.a  8.20 Hz, 4J5.H 
2.30 Hz, 4J7.h  1.60 Hz, 4J3.„  0.56 Hz, 9-H), 7.83 (1 H, br d, 4J9.H 0.5 Hz, 3-H), 7.62 (1 H,
Synthesis and Biological Evaluation of Anticancer Agents Page 149
ddd, 3J9.h 8.20 Hz, 3J7.H 4.86 Hz, 5J5.H 0.6 Hz, 8 -H); 5 C(50 MHz; CDC13) 156.6 (5-CH),
154.4 (7-CH), 152.1 (3-CH), 135.5 (9-CH), 126.8 (4-C), 124.1 (8 -CH), 112.8 and 111.9 
(2 x  CN), 85.2 (2-C); m/z 155 (M+, 100%), 128 (M+ -  HCN, 59), 104 (M * -  H-C^C-CN, 
85), 101 (M + - 2 x  H C N ,46),77  (p y -H , 8),73  (2 .5 ),64  (6 ),50  (74).
2 - C y a n o - 3 - ( 3 - p y r i d y l ) p r o p e n o t h i o a m i d e  (9 3 )— U sin g  M ethod B ,
3-pyridinecarbaldehyde (1.0 g, 9.34 mmol) and cyanothioacetamide (0.47 g, 4.67 mmol) 
were reacted in EtOH (3 ml) and while stirring piperidine (1 drop) was added. After 2 h, the 
dark red precipitate was collected: (0.54 g, 61 %), m.p. 170 °C (decomp.); RF 0.21 (diethyl 
ether); (Found: M+, 189.0379. C9H7N 3S requires M, 189.0391); v max(KBr discycm ' 1 3310m  
and 3230m (N H 2), 3060m (py-H), 2210m (CN), 1655s (C=S), 1585m and 1580s (C=C and 
py), 1410s (C =N py), 895s and 695s (2-py and =C-H); 8 H(200 MHz; DMSO-d6) 10.30 and
9.80 (2 x  1 H, 2 x  br s, NH2), 9.01 (1 H, d, *J 1.7 Hz, 5-H), 8.68  (1 H, m, 9-H), 8.43 (1 H, br 
d, 7-H), 8.17 (1 H, s, 3-H), 7.64 (1 H, dd, 3 ] %H 7.96 Hz, 3J7.H 4.79 Hz, 8-H); m/z 189 (M +, 
91.5%), 163 (M + -  CN, 5.5), 155 (M + - H 2S, 8.5), 146 (M+ -  HCN, -  NH2, 5), 129 (M + -  
CSNH2, 52), 122 (M+ -  NH2, -  H-CsC-CN, 3), 102 (M + -  HCN, -  CSNH2, 41.5), 90 (M+ -  
NC-CH-CSNH2, 3), 79 (16), 78 (12.5), 75 (23), 65 (5.5), 63 (22.5), 61 (10), 60 (94), 51 
(71).
E th y l 2 -c y a n o -3 - (3 -p y r id y l )p ro p e n o a te  ( 9 4 ) — U sin g  M ethod  A ,
3-pyridinecarbaldehyde (0.50 g, 4.67 mmol) and ethyl cyanoacetate (0.53 g, 4.67 mmol) 
were reacted in EtOH (3 ml) and while stirring piperidine (1 drop) was added. After 0.5 h, 
the yellow precipitate was collected: (0.59 g, 62 %), m.p. 73-74 °C (from EtOH); RF 0.45 
(diethyl ether); (Found: M+, 202.756. C n H 10N 2O3 requires M , 202.0737); v ^ fK B r  
discycm ' 1 3030m  and 3005m (py-H), 2225s (CN), 1720 (C =0), 1610s, 1585s and 1565m  
(C=C and py), 1415s (C=Npy), 820s, 765m and 705s (2-py and =C -H ); 8h (200 MHz; 
DMSO-d6) 9.13 (1 H, br s, 5-H), 8.79 (1 H, br d, 3J7_„ 4.6 Hz, 7-H), 8.51 (2 H, br s, 3- and 
9-H), 7.66 (1 H, br dd, 3J9.H 8.00 Hz, 3J7.H 4.84 Hz, 8 -H), 4.36 (2 H, q, 3J 7.08 Hz, CH2), 
1.35 (3 H, q, 3J 7.12 Hz, CH3); 5C(50 MHz; DMSO-d6) 161.4 (C =0), 153.3 (5-CH), 152.3 
(7-CH), 152.2 (3-CH), 136.5 (9-CH), 127.7 (4-C), 124.3 (8 -CH), 115.3 (CN), 105.0 (2-C),
62.7 (CH2), 14.0. (CH3); m/z  202 (M+, 30%), 173 (M+ -  CH 2CH3, 38), 157 (M+ -  
OCH2CH3, 58), 147 (M+ -  CH2CH3, -  CO, 2), 129 (M+ -  C 0 2CH2CH3, 39), 103 (M+ -  CN, 
- C 0 2CH2CH3, 20), 102 (22), 101 (7), 75 (46), 51 (52).
Synthesis and Biological Evaluation of Anticancer Agents Page 150
2-Cyano-3-(3-pyridyl)propenamide (9 5 )  —  U s i n g  M e t h o d  B ,
3 -pyridylcarbaldehyde (0.5 g, 4.67 mmol) was added to cyanoacetamide (0.4 g, 4.73 mmol) 
in EtOH (5 ml) followed by 10 % piperidine in ethanol (1 ml) After 0.5 h, the white 
precipitate was collected: (0.79 g, 98 %), m.p. 227-235 °C (from EtOH); RF 0.14 (diethyl 
ether); (Found: M +, 173.0616. C 9H7N 30  requires M , 173.0587); v max(KBr d iscycm ' 1 
3340m, 3130 m/s and 3280w (CONH2), 2120m (CN), 1720s (CONH2), 1675s (C=C), 1595s 
and 1490m/w (Ar), 1415m, 1380m and 1225m (C -X ), 695m /s and 635m (Ar-H  
deformations); 8H(200 MHz; DM SO-d6) 9.02 (1 H, d, 4J  2.04 Hz, 5-H), 8.76 (1 H, dd, 3J 
4.79 Hz, 4J  1.49 Hz, 7-H), 8.42 (1 H, dm, 3J  8.14 Hz, 4J 1.8 Hz, 9-H), 8.30 (1 H, s, 3-H),
8.07 and 7.94 (2 x 1 H, 2 x  br s, CONH2), 7.65 (1 H, dd, 3J  8.04 Hz, 3J  4.42 Hz, 8-H); 
5C(50 MHz; DM SO-d6) 162.3 (CONH2), 152.5 (5-CH), 151.4 (7-CH), 147.9 (3-CH), 136.0 
(9-CH), 128.2 (4-C), 124.3 (8-CH), 116.2 (1-CN), 109.0 (2-C); m/z 173 (M +, 70%), 172 (M+ 
- H ,  100), 156 (M+ -O H , 35), 147(M + -C N , 14), 145(M + -C O , 17), 129 (M+ -C O N H 2,
35.5), 118 (M+ -  CO, -  HCN, 15), 103 (M+ -  CONH2, -  CN, 41), 91 (6 ), 76 (79), 73 (7.5), 
63 (16.5).
2 - C y a n o - 3 - ( 2 - i m i d a z o y l ) p r o p e n o n i t r i l e  (9 6 )— U sin g  M ethod B,
2-imidazolecarbaldehyde (0.10 g, 1.04 mmol) and malononitrile (0.068 g, 1.05 mmol) were 
heated at 40 °C in EtOH (0.75) with 5 % piperidine in ethanol (1 ml). After 0.5 h the 
reaction was cooled and the addition of water gave a yellow precipitate: (0.081 g, 54 %), 
m.p. 165-169 °C (from EtOH); RF 0.20 (diethyl ether); (Found: M+, 144.0424. C7H4N4 
requires M , 144.0413); v max(KBr discycm ' 1 3145m and 3110m (HNim), 3015m (im-H), 
2230s (CN), 1610s (C=C), 790s and 775s (2-im and =C-H); 8 H(200 MHz; acetone-d6) 
13.23 (1 H, br s, 8 -NH), 7.96 (1 H, s, 3-H), 7.57 (2 H, br s, 6 - and 7-H); 5C(50 MHz; 
acetone-d6) 150.8 (3-C), 147.6 (4-C), 134.0 (6 - and 7-CH (broad)), 119.7 and 118.0. 
(2 x CN), 83.7 (2-C); m/z 144 (M +, 100%), 117 (M + -  HCN, 33), 90 (M+ -2  x HCN, 16), 77 
(.HC=C(CN)2, 5), 68 {bn, 41), 66  {NC-CH2-CN, 13), 63 (17), 53 (1), 52 (10).
3-Amino-2,4-dicyano-5-(2-imidazoyl)penta-2,4-dienonitrile (9 7 )  —  U s i n g  
Method B , 2-im idazolecarbaldehyde (0.10 g, 1.04 mmol) and l,l,3 -tr icyan o-2 -  
aminopropene (0.137 g, 1.05 mmol) were reacted in EtOH (0.75 ml) with 5 % piperidine in 
ethanol (1 ml). After 1 h, the yellow solid was collected: (0.125 g, 57 %), m.p. 173-177 °C 
(from EtOH); R F 0.15 (diethyl ether); (Found: M +, 210.0663. C 10H 6N 6 requires M ,
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210.0659); v max(KBr discycm ' 1 3395m (NH2), 3330m and 3285m (H N ^ ), 3135m and 3055 
(im-H), 2220s and 2200s (CN), 1660s and 1620m (C=C), 745m (im -H  and =C-H); 8 H(200 
MHz; DMSO-d6) 13.17 (1 H, br s, 8 -NH), 9.11 and 9.04 (2 x 1 H, 2 x  br s, NH2), 7.63 (1 H, 
s, 3-H), 7.38 (2 H, br s, 6 - and 7-H); 8C(50 MHz; acetone-d6) 166.7 (3-C), 146.9 (6 -C), 
140.6 (4-C), 138.3 (5-CH), 134.0(9-C (broad), 122.5 (8-C (broad), 116.0 (115.2 and 115.0,
3 x CN), 100.2 (2-C); m/z 210 (M+, 22.5%), 184 (M + -  CN, 100), 145 (M + -  NC-CH2-CN,), 
129 (M + -N C -C H 2-C N ,N H 2, 10), 118 (M+ -  H 2N-C=C-(CN)2, 9), 96 (15.5), 92 (10), 90 
(4), 81 (imCH2, 1), 77 (14), 68  (27), 52 (26).
2-Cyano~3-(2-imidazoyl)propenothioamide ( 9 8 ) — U sin g  M ethod  B ,
2-imidazolecarbaldehyde (0.10 g, 1.04 mmol) and cyanothioacetamide (0.10 g, 1.05 mmol) 
were reacted in EtOH (3 ml) with 5 % piperidine in ethanol (1 ml) After 1 h, water was 
added and the red solid was collected: (0.088 g, 48 %), m.p. 183 °C (decomp.); RF 0.72 
(diethyi ether); (Found: M+, 178.0401. C 7H6N 4S requires M , 178.0397); v max(KBr 
discycm -1 3320s (NH2), 3180s (HNim), 2210s (CN), 1615s (C=C), 800w and 710w (im -H  
and =C-H); 5 H(200 MHz; DMSO-d6) 13.12 (1 H, br s, 8-NH), 10.15 and 9.43 (2 x  1 H, 
2 x br s, NH2), 8.09 (1 H, s, 3-H), 7.45 (2 H, m, 6 - and 7-H); m/z 178 (M+, 100%), 161 (M+ 
- N H 2, 5), 150 (M + -  CN, 14.5), 118 (M + -  CSNH2, 89), 92 (M + -  CN, -  CSNH2, 54), 68 
(.im, 93), 77 (25), 68  (93), 52 (75).
Ethyl 2-cyano-3-(2-imidazoyl)propenoate  (9 9 ) — U sin g  M eth od  B ,
2-imidazolecarbaldehyde (0.10 g, 1.04 mmol) and ethyl cyanoacetate (0.12 g, 1.05 mmol) 
were reacted in EtOH (1 ml) with 5 % piperidine in ethanol (1 ml). After ca. 1 h, the white 
solid was collected: (0.186 g, 94 %), m.p. 195 °C (decomp.); R F 0.24 (diethyl ether); 
(Found: M+, 191.0712. C9H9N 30 2 requires M, 191.0735); vmax(KBr discycm ' 1 3145m and 
3105m (HNim), 3030m (im-H), 2920m (=C-H), 2220s (CN), 1720s (C =0), 1625s (C=C), 
795m and 760m (=C-H); 8H(200 MHz; acetone-d6) 12.92 (1 H, br s, 8 -NH), 8.09 (1 H, s,
3-H), 7.48 (2 H, br s, 6 - and 7-H), 4.32 (2 H, q, CH2), 1.32 (3 H, t, 3J 7.83 Hz, CH3); 
8C(50 MHz; acetone-d6) 163.2 (C =0), 140.9 (4-C), 140.0 (3-C), 134.0. (7-CH (broad)),
123.3 (6 -CH (broad)), 115.3 (CN), 100.0. (2-C); m/z 191 (M+, 14%), 146 (M + -O C H 2CH3, 
36), 118 (M + -  C 0 2CH2CH3, 57), 92 (M+ -  CN, -  C 0 2CH2CH3, 30), 68  (im, 33), 64 (34), 
52(18).
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2 - C y a n o - 3 - ( 2 - i m i d a z o y l ) p r o p e n o a m i d e  (1 0 0 )— U sin g  M ethod B, 
2-imidazolecarbaldehyde (0.10 g, 1.04 mmol) and cyanoacetamide (0.089 g, 1.03 mmol) 
were reacted in EtOH (1 ml) with 10 % piperidine in ethanol (1 ml) After 1.2 h, the white 
solid was collected: (0.059 g, 35 %), m.p. 178-180 °C (from EtOH); Rp 0.12 (diethyl ether); 
(Found: M +, 162.0544. C7H6N 40  requires M, 162.0522); v max(KBr discycm ' 1 3440m, 
3330m and 3180m  (CONH2), 3070m (Ar-H), 2210m (CN), 1770s (CONH2), 770m (Ar-H  
deformations); 5 H(200 MHz; DMSO-d6) 8-NH (not observed in range), 9.69 (1 H, s), 7.94  
(1 H, s), 7.79 (2 H, br s), 7.48 (3 H, d); 5C(50 MHz; DMSO-d6) 162.7 (CONH2), 140.5 
(4-C), 136.7 (3-CH), 127.4 (6- snd7-CH (broad)), 116.2 (1-CN), 103.1 (2-C); m/z 162 (M+, 
13%), 145 (M+ - N H 3, 10), 134 (M+ -  HCN, -  H, 8 ), 118 (M+ -C O N H 2, 54), 107 (M+ -  
CO, -  HCN, 6 ), 96 ([H 2C=C(CN)(CONH2)], 8), 92 (17), 79 ( [C 4 H3N2], 11), 68 
{[Cj H4N2 = imidazyl], 38).
2 -C y a n o -3 - (2 - th ie n y l)p ro p e n o n i tr i le  ( 1 0 1 ) — U s in g  M eth o d  B ,
2-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and malononitrile (0.29 g, 4.45 mmol) were 
reacted in EtOH (2.75) with 5% piperidine in ethanol (1 ml). After ca. 1 h, the pale orange 
solid was collected and crystallised from ethanol/water: (0.362 g, 51 %), m.p. 88-90 °C 
(from EtOH/H2 0 ); Rp 0.84 (diethyl ether); (Found: M+, 160.0076. C 8H4N 2S requires M,
159.9978); v max(KBr discVcm ' 1 3100m, 3090w and 3025m (th-H), 2230s (CN), 1570s 
(C=C), 1410s (C-S,,,), 740s (=C-H); 8H(200 MHz; CDC13) 7.91 (1 H, AB, 3J6.K i .ii 0.7 Hz,
3 -H), 7.90 (1 H, dAB, 3J1M 5.22 Hz, 4JfhH 1.0 Hz, 4J3rH 0.5 Hz, 8-H,), 7.82 (1 H, ddd, 3J1.H 
3.88 Hz, 4Jm  1.08 Hz, 5Jy a  0.53 Hz, 6 -H), 7.27 (1 H, dd, 3J(hH 3.91 Hz, 3JS.H 5.19 Hz,
7-H); Sc (50 MHz; CDC13) 152.3 (3-CH), 136.9 (8-CH), 134.0 (4-C), 128.4 (6-CH), 126.7 
(7-CH), 113.8 and 113.0 (2 x  CN), 80.5 (2-C); m/z 160 (M+, 100%), 134 (M* -  CN, 5), 116 
(M+ -  O S ,  8 ), 109 (M + -  H -O C -C N , 39), 100 (M+ -  CN, -  H 2S, 2), 89 (M + -  HCN, -  
O S ,  4), 77 (H C=C(CN )2,3 ) , 52 (HC=CH-CN , 1.5).
2,4-Cyano-3-amino-5-(2-thienyl)penta-2,4-dienonitrile (102)— Using Method A, 
2-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and l , l , 3 -tricyano-2 -aminopropene (0.59 g, 
4.45 mmol) were reacted in EtOH (3 ml) with piperidine (1 drop). After 1 h, the yellow  
precipitate (0 .812 g, 81 %) was collected and crystallised from ethanol/water: (0.417 g, 
42 %), m.p. 237-240 °C (from EtOH/H20); R¥ 0.48 (diethyl ether); (Found: M +, 226.0306. 
C n H 6N 4S requires M, 226.0319); v ^ K B r  disc)/cm'' 3380s and 3340s (NH2), 3225s and
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discycm ' 1 3380s and 3340s (NH2), 3225s and 3080m (th-H), 220s and 2210s (CN), 1665s 
and 1575m (C=C), 1410m (C -Sttl), 735m (=C-H); SH(200 MHz; acetone-d6) 8.6  and 8.4  
(2 x  1 H, 2 x  br s, NH2), 8.26 (1 H, AB, 3 7 6. h .8 -h  0 6  Hz- 3'H)> 8 1 0 (1 H, dAB, 3J1Ja 5.06 
Hz, 4J&h 1.16 Hz, 4J3_h 0.85 Hz, 8-H), 7.92 (1 H, ddd, 3J1.H 3.82 Hz, 1.22 Hz, 573_H 
0.56 Hz, 6 -H), 7.34 (1 H, dd, 3JfM 3.81 Hz, SJS,H 5.04 Hz, 7-H); Sc (50 MHz; acetone-dg)
166.2 (3-C), 146.5 (5-CH), 144.1 (4-C), 139.0. (10-CH), 136.5 (6 -C), 136.3 (8-CH), 129.4 
(9-CH), 115.6, 115.1 and 111.3 (3 xC N ), 98.9 (2-C); m/z 226 (M +, 100%), 200 (M+ -  CN,
56.5), 193 (M + -  HS, 13), 184 (M+ -  C N ,-N H 2, 2.5), 182(M + - C s S ,  18), 172 (M + -  2  x  
HCN, 8.5), 168 (M+ -  CNS, 23.5), 161 (M+ -C H (C N )2, 9), 156 (M+ -  CH, -  C=S, 4), 134 
(M+ -  H 2N-C=C(CN)2, 13), 97 (thCH2, 2 \  92 (H2N-C=C(CN)2,2 .5 ), 66  (CH2(CN)2, 12), 57 
(9), 45 (44).
2-Cyano-3-(2-thienyl)propenothioamide (10 3 ) — U s in g  M eth o d  A ,
2-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and cyanothioacetamide (0.45 g, 4.47 mmol) 
were reacted in EtOH (3 mi) with 10 % piperidine in ethanol (1.5 ml). After ca. 1 h, the dark 
red precipitate (0.651 g, 75%) was collected and crystallised from water/ethanol: (0.55 g, 
64 %), m.p. 163-167 °C (from H20/EtOH); f?F 0.83 (diethyl ether); (Found; M +, 193.9986. 
C8H6N 2S 2 requires M ,  193.9978); vmax(KBr discycm ' 1 3360s and 3260s (NH2), 3135s 
(th-H), 2200m (CN), 1620s (C=S), 1575s (C=C), 1410m (C -S th), 880s and 740s (=C-H), 
535s; 8h(200 MHz; acetone-d6) 9.26 and 8.67 (2 x 1 H, 2 x  br s, NH2), 8 .66  (1 H, AB, 3J(t_H 
g_H 0.7 Hz, 3-H), 8.05 (1 H, dAB, J/ 7.H 5.07 Hz, 4J&H 1.14 Hz, 4J2M 0.90 Hz, 8 -H,), 7.95 
(1 H, ddd, 3y7.H 3.82 Hz, 4J%_H 1.18 Hz, SJ2.H 0.60 Hz, 6 -H), 7.34 (1 H, dd, 3.82 Hz, 
3Jz_h 5.05 Hz, 7-H); 8C(50 MHz; acetone-d6) 193.2 (C=S), 145.4 (3-CH), 139.0 .(8-CH),
137.1 (4-C), 135.8 (6 -CH), 129.4 (7-CH), 116.8 or 111.1 (CN), 107.8 (2-C); m/z 194 (M+, 
100%), 168 (M + -  CN, 6.5), 149 (M+ -  H, -  C=S, 2), 134 (M+ -  CSNH2, 30), 122 (M + -  
HCN, -  C=S, -  H, 8.5), 106 (M+ -  HCN, -  CSNH2, 5), 94 (6 ), 90 (9), 76 (6 ), 60 (29), 52
(5.5), 45 (24).
Ethyl 2-cyano-3-(2-thienyl)propenoate  ( 1 0 4 ) — U sin g  M eth od  A,
2-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and ethyl cyanoacetate (050 g, 4.46 mmol) 
were reacted in EtOH (3 ml) with piperidine (1 drop). After ca. 0.5 h, the white precipitate 
was collected: (0.78 g, 85 %), m.p. 95-96 °C (from EtOH) (lit.,330 95-96 °C); Rp 0.65 
(diethyl ether); (Found: M +, 207.0357. C 10H9NO2S requires M ,  207.0345); v max(KBr
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discycm ' 1 3085s, 3070m and 3025m (th-H), 2985m and 2940m (CH2 and CH3), 2220m  
(CN), 1715s (C =0), 1600s (C=C), 1415m (C -S J , 735s (=C-H); 8H(200 MHz; acetone-d6) 
8.49 (1 H, br s, 3-H), 8.08 (1 H, dAB, 3 5.08 Hz, 3_^  1.0 Hz, 8-H), 7.99 (1 H, dAX,
3J1M 3.82 Hz, 7^g_H 1-2 Hz, J/ 3.H 0.60 Hz, 6-H), 7.27 (1 H, dd, 3JMi 3.87 Hz, Ji 8.H 5.02 Hz,
7-H), 4.32 (2 H, q, 3J 7.12 Hz, CH2), 1.33 (3 H, t, J7 7 .1 2  Hz, CH3); 5 C(50 MHz; acetone- 
d6) 163.0 (C =0), 147.6 (3-CH), 139.6 (8-CH), 136.8 (4-C), 136.7 (6 -CH), 129.5 (7-CH),
116.2 (CN), 99.8 (2-C), 62.9 (CH2), 14.4 (CH3); m/z 207 (M+, 100%), 178 (M + -  CH2CH3, 
5), 162 (M + -  OCH2CH3, 93), 134 (M+ - C 0 2CH2CH3, 85), 108 (M + - C N , - C 0 2CH2CH3, 
35), 90 (M + -  NC-CH2 -C 0 2CH2CH3, 33), 84 (th, 9), 63 (26), 45 (46).
2 -C y a n o -3 - (2 - th ie n y l )p ro p e n a m id e  (1 0 5 ) — U s in g  M eth o d  A ,
2-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and cyanoacetamide (0.45 g, 4.47 mmol) 
were reacted in EtOH (3 ml) with piperidine (2 drops). After 10 min, the orange precipitate 
was collected: (0.781 g, 99 %), m.p. 152-153 °C (from EtOH); R F 0.35 (diethyl ether); 
(Found: M +, 178.0202. C8H6N 2OS requires M , 178.0190); v max(KBr discycm ' 1 3470s, 
3360w, 3300w and 3235w (NH2), 3140s (th-H), 2210s (CN), 1700s (C =0), 1580s (C=C), 
1380s (C -S th), 745s (=C-H), 460s; 5 H(200 MHz; DMSO-d6) 7.89 and 7.78 (2 x  1 H, 2 x  br 
s, N H 2), 8.45 (1 H, s, 3-H), 8.12 (1 H, d, Ji 7.H 4.94 Hz, 8 -H), 7.90 (1 H, d, 3J1.H 3.28 Hz,
6 -H), 7.34 (1 H, dd, 8.H 4.4 Hz, 7-H); 8 C(50 MHz; DMSO-d6) 162.8 (C =0), 143.7 
(3-CH), 137.9 (8 -CH), 136.0 (4-C), 135.0 (6 -CH), 128.7 (7-CH), 116.8 (CN), 102.1 (2-C); 
m/z 178 (M+, 100%), 161 (M+ - N H 3,30 ), 145 (M+ - HS, 8), 134 (M + - CONH2, 36), 123 
(M+ -  HCN, -  CO, 2), 112 (M+ -  N H 2, -  HO, -  HS, 14), 108 (M+ -  CN, -  CONH2, 39), 90 
(18), 75 (9), 63(25.5), 50(14).
2 -C ya n o -3 - (3 - th ien y l)p ro p e n o n i tr i le  (1 0 6 ) — U s in g  M eth o d  A ,
3-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and malononitrile (0.29 g, 4.47 mmol) were 
reacted in EtOH (2.75 ml) 10 % piperidine in ethanol (1.5 ml). After ca. 1 h, the pale yellow  
solid was collected (0.70 g, 98 %) and crystallised from water: (0.084, 12 %), m.p. 84-85 °C 
(from H20 );  R f 0.84 (diethyl ether); (Found: M +, 160.0074. C8H4N 2S requires M,
159.9978); v max(KBr discycm ' 1 3125m, 3100w and 3235w (N H 2), 3140s (th-H), 2210s 
(CN), 1700s (C =0), 1580s (C=C), 1380s (C -Sth), 745s (=C-H), 460s; 5 H(200 MHz; CDC13)
8.18 (1 H, ddd, 4Jg_H 3.00 Hz, J/ 7.H 1.31 Hz, J/ 3_H 0.50 Hz, 5-H), 7.79 (1 H, dAX, 4/ 5.H
1.3 Hz, JJ3.H 0.3 Hz, 7-H), 7.78 (1 H, AB, 5 / 5. h ,8 .h  0-4 Hz, 3-H), 7.52 (1 H, ddd, 3JrH 5.25
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Hz, 4/ 5_h 3.01 Hz, 473.h 0.49 Hz, 8-H); S c (50 MHz; CDC13) 152.3 (3-CH), 136.9 (8 -CH),
134.0 (4-C), 128.4 (5-CH), 126.8 (7-CH), 113.8 and 113.0 (2 x CN), 80.5 (2-C); m/z 160 
(M+, 100%), 133 (M + -  HCN, 47), 116 (M+ - C=S, 4), 109 (M + -H -C =C -C N , 51), 89 (M + 
-  HCN, -  O S ,  3), 84 ( th, 2), 75 (7), 69 (16), 58 (19).
2-Amino-2,4-dicyano-3-(3-thienyl)penta-2,4-dienonitrile ( 1 0 7 )  —  U s i n g  
Method B , 3-thiophenelcarbaldehyde (0.50 g, 4 .46  mmol) and 1,1,3-tricyano-
2-aminopropene (0.59 g, 4.47 mmol) were reacted in EtOH (3 ml) with 10 % piperidine in 
ethanol (1 ml) After ca. 1 h, the yellow solid was collected (0.78, 79 %), m.p. 197-199 °C 
(from EtOH); RF 0.45 (diethyl ether); (Found: M +, 226.0315. Cn H 6N 4S requires M , 
226.0312); v max(KBr d iscycm ' 1 3340m and 3220m (N H 2), 3110w and 3090w (Ar-H), 
2220s and 2210s (CN), 1665s ((H2N)C=C(CN)2), 1580s (broad Ar), 795m and 625m (Ar-H  
deformations); 5 H(200 MHz; acetone-d6) 8.98 and 8.75 (2 x 1 H, 2 x  br s, NH2), 8.42 (1 H, 
dm, 4JrH i.31 Hz, 4/ 8.H 2.91 Hz, 5-H), 8.04 (1 H, s, 3-H), 7.87 (1 H, dt, 4J5.H 1.26 Hz, 3J^H
5.18 Hz, 7-H), 7.77 (1 H, dd, 4J}.H 2.93 Hz, 3J1M 5.18 Hz, 8-H); 8C(50 MHz; acetone-d6)
166.2 (H 2N-£=C(CN)2), 147.0 (5-CH), 136.8 (3-CH), 135.0 (4-C), 129.2 (7-CH), 126.8 
(8 -CH), 115.8 and 115.2 (H2N-C=C(£N)2), 100.6 (2-C), 50.9 (H2N-C=C(CN)2); m/z 226 
(M+, 100%), 200 (M+ -  CN, 63), 199 (M+ -  HCN, 45), 193 (M+ -  HS, 14), 182 (M+ -  O S ,  
21), 166 (M+ -  HCN, -  HS, 2), 161 (M + -H C (C N )2 ,7 ) , 139 (M + -  HCN, -  C = S ,-N H 2, 2), 
134 (M+ - H 2N-C=C(CN)2 , 9), 84 ([C4H4S= 3-thienyl], 3), 65 (7.5).
2-Cyano-3-(3-thienyl)propenothioamide ( 1 0  8 ) — U s in g  M eth o d  A ,
3-thiophenelcarbaldehyde (0.50 g, 4.46 mmol) and cyanothioacetamide (0.45 g, 4.47 mmol) 
were reacted in EtOH (2.75 ml) with 10 % piperidine in ethanol (1.5 ml). After ca. 1 h, the 
brown solid was collected (0.391 g, 45 %) and crystallised from ethanol/water: (0.226, 
16 %), m.p. 150-151 °C (from EtOH/H20); R? 0.84 (diethyl ether); (Found: M +, 193.9979. 
C8H6N 2S2 requires M, 193.9978); v max(KBr discycm ' 1 3360s and 3260m (NH2), 3140s and 
3055m (th-H), 2210s (CN), 1620s (C=S), 1590s (C=C), 1410m (C -S th), 790s (=C-H), 535s; 
8h(200 MHz; acetone-d6) 9.28 and 8.73 (2 x  1 H, 2 x  br s, N H 2), 8.48 (1 H, AB, 8.„ 
0.7 Hz, 3-H), 8.43 (1 H, ddd, 4Jm  2.92 Hz, SJ%H 1.31 Hz, 0.56 Hz, 5-H), 7.92 (1 H, 
ddd, •34 h 5.21 Hz, J75.H 1.33 Hz, 4/ 3.H 0.45 Hz, 7-H), 7.73 (1 H, ddd, 3J1Ai 5.22 Hz, 4J5.H
2.95 Hz, 44 h  0 -56  Hz- 8 -H); 8 c (50M H z; acetone-d6) 193.7 (C=S), 145.5 (3-CH), 136.4 
(8 -CH), 135.6 (4-C), 128.9 (5-CH), 127.6 (7-CH), 117.1 (CN), 109.9 (2-C); m/z 194 (M+,
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100%), 178 (M + -N H 2 , 4), 168 (M + -C N ,5 .5 ) , 161 (M+ -H S ,3 3 ) ,  1 5 0 (M +-C = S , 3), 140 
(M+ -  2 x  HCN, 3), 134 (M + -  CSNH2, 25.5), 126 (M+ -  NH 2, -  H-C=C-CN, 7), 107 (M+ -  
CN, -  CSNH2, + H, 7), 97 (4), 94 (3), 90 (14), 84 (th, 6.5), 76 (8), 60 (80), 52 (21), 45 (94).
Ethyl 2-cyano-3-(3-thienyl)propenoate  ( 1 0 9 ) — U s in g  M eth od  A ,
3-thiophenecarbaldehyde (0.50 g, 4.46 mmol) and ethyl cyanoacetate (0.50 g, 4.46 mmol) 
were reacted in EtOH (3 ml) with 1 piperidine (1 drop). After ca. 0.5 h, the white solid was 
collected: (0.782, 85 %), m.p. 66-67 °C (from EtOH); R F 0.70 (diethyl ether); (Found: M +, 
207.0361. C 10H 9NO2S requires M , 207.0345); v max(KBr discycm ' 1 3090m and 3030m  
(th-H), 2985m, 2940w and 2920w (CH2 and CH3), 2215m (CN), 1720s (C =0), 1600s 
(C=C), 1360m (C-Sth), 810s» 795m and 760m (=C-H), 635s; 5 H(200 MHz; DMSQ-d6) 8.43
(1 H, br s, 3-H), 8.63 (1 H, dd, 2.66 Hz, SJ7.H 1.14 Hz, 5-H), 7.91 (1 H, dd,
5.17 H z,.j 4 h 1.16 H z, 7-H), 7.84 (1 H, dd, 3J1M 5.13 Hz, 4J5_H 2.85 Hz, 8 -H), 4.33 (2 H, q, 
3J  7.11 Hz, CH2), 1.36 (3 H, t, 3J 7.10 Hz, CH3); 8C(50 MHz; DM SO-d6) 162.3 (C =0),
148.3 (3-CH), 138.4 (8-CH), 134.4 (4-C), 129.2 (5-CH), 126.4 (7-CH), 116.1 (CN), 100.0 
(2-C), 62.3 (CH2), 14.1 (CH3); m/z 207 (M+, 100%), 178 (M+ -  CH2CH3, 8 8 ), 161 (M + -  
OCH2CH3, - H ,  60), 151 (M+ - C H 2CH3, -C N , 7), 1 3 4 (M+ - C 0 2CH2CH3, 85), 110(M +-  
H-C=C-CN, -  OCH2CH3, -  H, 7), 108 (M+ -  CN, -  C 0 2CH2CH3, 55), 90 (M+ -  
NC-CH2-C 0 2CH2CH3, 33.5), 84 (th, 10), 63 (33), 45 (51).
2 -C y a n o -3 - (3 - th ie n y l )p ro p e n a m id e  (1 1 0 ) — U s in g  M eth o d  A ,
3-thiophenelcarbaldehyde (0.50 g, 4.46 mmol) and cyanoacetamide (0.38 g, 4.47 mmol) 
were reacted in EtOH (3 ml) with piperidine (2 drops). After 2 h, the reaction solution was 
poured onto ice and the white solid was collected: (0.559, 71 %), m.p. 104-106 °C (from 
EtOH/H20 ); 0.49 (diethyl ether); (Found: M+, 178.0199. C8 H6N 2OS requires M ,  
178.0190); v max(KBr discycm ’1 3450s and 3330s (N H 2), 3190s (th-H), 2200 (CN), 1645s 
(C =0), 1585s (C=C), 745m (=C-H); 8H(200 MHz; DMSO-d6) 8.42 (1 H, br d, 5-H), 8.25 
(1 H, br d, 7-H), 7.83 (1 H, s, 3-H), 7.90 and 7.80 (2 x  1 H, 2 x  br s, N H 2), 7.8 (1 H, br d,
8-H); 8C(50 MHz; DMSO-d6) 163.0 (C =0), 144.4 (3-CH), 135.6 (8 -CH), 134.6 (4-C), 128.9 
(5-CH), 126.4 (7-CH), 117.1 (CN), 104.1 (2-C); m/z 178 (M+, 100%), 161 (M + -N H 3, 19), 
136 (M+ -  CN, -  N H 2, 6 ), 134 (M+ -C O N H 2, 43.5), 112 (M + - C H 2(CN)2, 76), 108 (M + -  
CN, -  CONH2, 52), 97 (thCH2, M+ -  NC-CH-CONH2, + H, 3), 90 (M+ -  C=S, -  CONH2,
16.5), 84 (th, 5), 63 (14), 58 (14).
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2-cyano-3-(2-pyridylimino)indolizine ( 111)— A 25 ml two-necked round 
bottomed flask, fitted with equilibrating dropping funnel (1 0  ml) and temperature probe, 
was charged with 2-pyridinecarbaldehyde (1.003 g, 9.36 mmol), a magnetic stirrer and of 
absolute ethanol (5 ml). The reaction was cooled to -6.0 °C on an ice/salt water bath and 
while stirring an ethanolic solution (5 ml) of malononitrile (0.617 g, 9.34 mmol), doped with 
DBU (3 drops), was added dropwise over 10 minutes. On addition the reaction turned 
distinctly black in colour and was stirred at -3.0 and -6.0 °C for lh. After a further 1.5 h at 
room temperature the black solid which formed was collected (1.048 g, 72 %) and the 
mother liqours concentrated onto silica in vacuo  for preparation for column 
chromatography. Using a concentration gradient from 1:1 ethyl acetate/petroleum ether to 
100 % ethyl acetate a yellow product was isolated (0.154 g) and crystallised from 
isopropanol to give a product assigned to the title compound (44 mg), m.p. 167.5-168.0 °C 
(from /-PrOH); RF 0.59 (diethylether); v max(KBr discycm ' 1 3107m, 3078m, 3062m and 
2926m (=C-H ), 2218s (CN), 1630m (broad C=C), 1575m and 1563m (2-py), 1408s and 
1239s (C -N 2.py), 772s and 740s (=C-H); 8H(200 MHz; acetone-d6) 9.21 (1 H, s, 11-H), 8.69 
(1 H, ddd, 3y 15.H 4.6 Hz, 4/ , 6.H 2.0 Hz, sJ l7.H 1.0 Hz, 14-H), 8 .66  (1 H, dq, 3/ 3.H 7.1 Hz, 
4/ 4_h 1.1 Hz, 2-H), 8.38 (1 H, dt, 3716_H 8.1 Hz,4/ i5.h 1.1 Hz, 17-H), 7.93 (1 H, dddd, 3715.H
7.8 Hz, 3716.h 7.8 Hz, 47 I4.H1.8 Hz, 5/ n .H 0.7 Hz, 16-H), 7.55 (1 H, d t ,37^  8.8  Hz, 473.H
1.2 Hz, 5-H), 7.47 (1 H, ddd, 37 16.H 7.6 Hz, 37I4.H 4.9 Hz, 4/ 17.H 1.2 Hz, 15-H), 7.04 (1 H, 
ddd, 375_h 8 .8 , 3J3.h 6 .6 , % H 1.2 Hz, 4-H), 6.99 (1 H, d, 572.H 0.5 Hz, 7-H), 6.93 (1 H, td, 
3J2-W4-h 6 8  Hz, % H  1-5 Hz, 3-H); 8C(50 MHz; acetone-d6) 155.49 (s), 155.09 (d), 150.50 
(d), 137.28 (d, 132.23 (6d), 125.80 (d), 123.22 (d), 122.44 (d), 121.39 (d), 120.17 (d),
117.03 (CN), 114.57 (d), 105.38 (d), 86.23 (s); m/z 246 (M+, 55%), 245 (M + -  H, 100), 220 
(M+ -  CN, 8 ), 219 (M + -  HCN, 4), 194 (M+ -  H -C sC-C N , 1), 168 (M + -  [2-py ]+ i.e. 
[C5H4N ]+, 15), 142 (M+ -  [2-py f ,  -  CN, 9), 114 (M+ -  [2-py]-CH=NH, -  CN, 13), 105 (3), 
88 (4), 79 ([2-py-H ]+, 16.5), 51 (H-C^C-CN, 10).
Methyl 2-cyano-3-phenylpropenoate (113)— Using Method D, benzaldehyde 
(8.12 g, 0.077 mol) and methyl cyanoacetate (7.67 g, 0.077 mmol) were reacted in methanol 
(25 ml) with the addition of piperidine (10  drops) and potassium rm-butoxide (ca. 20  mg). 
After 29 h the crystals were collected (8.34 g, 58 %), m.p. 86-87 °C (from M eO H ); RF 0.83 
(diethyl ether); (Found: C, 73.12; H, 5.01; N, 7. 54; M +, 187.0642. Cn H 9N 0 2 requires C,
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73.32; H, 5.03; N, 7.77%; M, 187.0633); v max(KBr discj/cm ' 1 3070w, 3033w and 3008w  
(=C-H), 2954w (CH3), 2225w (CN), 1729s (C 0 2Bu‘), 1607m/s and 1571m (Ar and C=C), 
1267s, 1205s and 1190m/s (C-O), 768m/s and 684m (=C-H deformations); 8h(200M Hz; 
CDCIj) 8.13 (1 H, s, 3-H), 7.86 (2 H, dd, j 7 6. h/8-h  7 -7  Hz- 3h-w 1-6 Hz, 5- and 9-H), 7.41 
(3 H, m, 6 - and 7- and 8 -H), 3.81 (3 H, s, CH3); 8 C(50 MHz; CDC13) 162.8 (C 0 2CH3),
155.2 (3-CH), 133.4 (7-CH), 131.3 (4-C), 131.0 (5- and 9-CH), 129.2 (6 - and 8-CH), 115.4 
(1-CN), 102.5 (2-C), 53.3 (C 02CH3); m/i 187 (M+, 100%), 172 (M + -  CH3, 8 ), 156 (M + -  
OCH3, 98), 142 (M + -  HCN, -  H2 0 , 8 ), 128 (M+ -  C 0 2CH3, 98), 121 (M + -  CH3, -  H- 
O C -C N , 33), 101 (M+ -  C 0 2Me, -  HCN, 29), 77 ([Ph]+, M + -  H-C=C-CN, -  C 0 2Me, 56).
Ethyl 2-cyano-3-phenylpropenoate (114)— Using Method D, benzaldehyde (6.48 
g, 0.061 mol) and ethyl cyanoacetate (6.97 g, 0.062 mmol) were reacted in ethanol (20 ml) 
with the addition of piperidine (10 drops) and potassium rm-butoxide (20 mg). After 8 h the 
crystals were collected (6.54 g, 53 %), m.p. 63-65 °C (from EtOH) (lit. ,331 63-65 °C); RF 
0.87 (diethyl ether); (Found: C, 71.47; H, 5.48; N, 6 .8 8 ; M +, 201.0803. C12H u N 0 2 requires 
C, 71.63; H, 5.51; N, 6.96%; M, 201.0790); v max(KBr discVcm ' 1 3030w and 3002w (= C -
H), 2980w and 2940w (CHX), 2224w (CN), 1727s (CC^Bu1), 1607m/s and 1574m (Ar and 
C=C), 1257s, 1202s, 1189m/s and lO llm /s  (C -O ), 768m /s (= C -H  deformation); 
8h(200 MHz; CDC13) 8.50 (1 H, s, 3-H), 7.85 (2 H, dd, j 75.h/8-h 7 -8 Hz, J/ 7.H 1.5 Hz, 5- and
9-H), 7.40 (3 H, m, 6- and 7- and 8-H), 4.23 (2 H, q, 3J  7.14 Hz, £H 2CH3), 1.25 (3 H, t, 3J
7.14 Hz, CH2CH3); Sc (50 MHz; CDC13) 162.4 ( £ 0 2CH2CH3), 155.0 (3-CH), 133.3 (7-CH),
131.4 (4-C), 131.0 (5- and 9-CH), 129.2 (6- and 8 -CH), 115.5 (1-CN), 102.9 (2-C), 62.7 
(C 0 2CH2CH3), 14.1 (C 0 2CH2CH3); m/z 201 (M+, 89%), 172 (M+ -  CH2CH3, 86 ), 156 (M+ 
-  OCH2CH3, 92), 128 (M+ -  C 0 2CH2CH3, 100), 102 (M+ -  C 0 2CH2CH3, -  CN, 72), 77 
([Ph]+, M + -  H-C=C-CN, -  C 0 2CH2CH3, 85).
Methyl 2-cyano-3-(4-nitrophenyl)propenoate (1 1 5 )— U sing M ethod C,
4-nitrobenzaldehyde (1.453 g, 9.61 mmol) and methyl cyanoacetate (1.001 g, 10.10 mmol) 
were reacted in methanol (10 ml) with the addition of 5 % piperidine in methanol (5 drops). 
After 2 h the crystals were collected (1.541 g, 69 %), m.p. 173-174 °C (from EtOAc); RF 
0.88 (3:1 petroleum ether; bp 40-60 °C/diethyl ether); (Found: C, 56.65; H, 3.46; N, 11.83; 
M+, 232.0485. C n H8N 20 4 requires C, 56.90; H, 3.47; N, 12.06%; M, 232.0484); vmax(KBr 
disci/cm ' 1 3103w, 3078w and 3034w (=C-H), 3004w, 2982w and 2940w (CH3), 2250m
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(CN), 1717s (C 0 2Me), 1597m (Ar and C=C), 1529s (C -N 0 2), 1346s and 1156s (C -O ), 
853m/s (=C -H  deformation); 8 H(200 MHz; CDC13) 8.36 (2 H, d, 3J$.h /9_h 8.4 Hz, 6 - and 
8 -H), 8.34 (1 H, s, 3-H), 8.14 (2 H, d, j 7 6. h / 8- h  8 -4  Hz, 5- and 9-H), 3.98 (9 H, s, Me); 
Sc (50 MHz; CDC13) 162.0 (C 0 2Me), 152.1 (3-CH), 149.6 (7-C), 136.9 (4-C), 131.6 (6- and
8 -CH), 124.4 (5- and 9-CH), 114.5 ( 1-CN), 107.0 (2-C), 53.8 (CH3); m/z  232 (M+, 14%), 
202 (M+ -  N = 0 , 10), 186 (M+ -  N 0 2, 100), 174 (MH* -  C 0 2Me, 63), 159 (M+ -  N 0 2 , -  
HCN, 25), 127 (M + -  C 0 2Me, -  N 0 2, 45), 100 (M+ -  C 0 2Me, -  N 0 2, -  HCN, 14), 89 (12), 
76(14).
Ethyl 2-cyano-3-(4-nitrophenyl)propenoate  ( 1 1 6 )— U sin g  M ethod C,
4-nitrobenzaIdehyde (7.210 g, 47.71 mmol) and ethyl cyanoacetate (5.407 g, 47.80 mmol) 
were reacted in ethanol (30 ml) with the addition of piperidine (2 drops). After 2 h the 
crystals were collected (8.741 g, 74 %), m.p. 165.5-166.5 °C (from EtOH); Rp 0.82 (diethyl 
ether); (Found: C, 58.34; H, 4.07; N, 11.12; M +, 246.0645. C I2H 10N 2O4 requires C, 58.54; 
H, 4.09; N, 11.38%; M, 246.0641); vmax(KBr disc)/cm_1 3096w, 3078w and 3038w (=C-H), 
2992w, 2943w and 2905w (CH3), 2226w (CN), 1721s (C 0 2Bu‘), 1617m and 1594m (Ar and 
C=C), 1514s (C - N 0 2), 1347s and 1267s (C -O ), 860m /s, 766m  and 687m (=C -H  
deformations); 8H(200 MHz; acetone-ds ; 333 K) 8.48 (1 H, s, 3-H), 8.35 (2 H, dm, 3 3 s-h/9-H
8.95 Hz, 6- and 8-H), 8.20 (2 H, dm, 3J6. hjs.h 9.1 Hz, 5- and 9-H), 4.35 (2 H, q, 3J  7.09 Hz, 
£ H 2CH3), 1.33 (3 H, t, 3J  7.09 Hz, CH2QB3); S c (50 MHz; acetone-d6 ; 333K ) 160.8 
(CQ2CH2CH3), 152.3 (3-CH), 149.1 (7-C), 137.0 (4-C), 131.3 (6 - and 8 -CH), 123.8 (5- and
9-CH), 114.5 (1-CN), 106.6 (2-C), 62.5 (CH2CH3), 13.6 (CH2CH3); m/z 246 (M+, 77%), 
229 (M + -  OH, 9), 218 (MH+ -  Et, 100), 216 (M + -  N = 0 , 5), 201 (M H+ -  N 0 2 , 79), 199 
(M+ -  H N 0 2, 6 6 ), 188 (MH+ -  N = 0 , -  Et, 26), 174 (M H+ -  C 0 2Et, 20), 173 (M+ -  N 0 2 , -  
HCN, 26), 171 (M+ - E t , - N 0 2, 17), 155 (M+- 0 E t , - N 0 2,53 ), 127 (M + - C 0 2E t , - N 0 2,
57), 100 (M + -  C 0 2Et, -  N 0 2, -  HCN, 35), 89 (34), 76 (39).
Methyl 2-cyano-3-(3-methoxy-4-hydroxy-5-nitrophenyl)propenoate ( 1 1 7 )  —  
U sing M ethod B , 5-nitrovanillin (3-methoxy-4-hydroxy-5-nitrobenzaldehyde; 0.87 g, 
4.41 mmol) and methyl cyanoacetate (0.453 g, 4.57 mmol) were reacted in methanol (15 ml) 
with the addition o f piperidine (5 drops). After 29 h the reaction was concentrated to quarter 
volume which yielded the title compound (0.524 g, 36 %) on cooling to room temperature, 
m.p. 185.0-186.5 °C (from MeOH); Rp 0.69 (ethanol); (Found: C, 51.60; H, 3.45; N, 9.96;
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M+, 278.0547. C 12HioN20 6 requires C, 51.81; H, 3.62; N, 10.07%; M, 278.0539); vmax(KBr 
discVcm ' 1 3430m  (OH), 2954m and 2840w (CHX), 2214w (CN), 1723s (C 0 2Me), 1633m, 
1604m and 1586m/s (Ar or C=C), 1545s (C -N 0 2), 1435m, 1276m/s, 1236s, 1215s and 
1158s (C-O ), 760m  (=C-H deformation); 5 H(200 MHz; DMSO-d6) 8.51 (1 H, s, OH), 8.16 
(1 H, d, 4JS.H 2.14 Hz, 9-H), 7.99 (1 H, s, 3-H), 7.55 (1 H, d, 4J%H 2.17 Hz, 5-H), 3.80 (3 H, 
s, 6 -OMe), 3.72 (3 H, s, C 0 2Me); 5 C(50 MHz; DM SO-d6) 164.9 and 164.3 (C 02 CH3),
154.8 (8-C), 154.0 (3-CH), 130.64 (9-CH), 130.1 (6 -C), 118.6 (4-C), 110.2 (1-CN), 108.1 
(5-CH), 87.69 (2-C), 55.3 (OCH3), 52.4 (C 0 2CH3); m/z 278 (M+, 100%), 261 (M+ -  OH, 4), 
247 (M + -  H -N = 0 , 6 ), 230 (M+ -  H 2N 0 2, 11), 215 (M + -  H N 0 2, -  Me, 100), 204 (M + -  
HCN, -  H N 0 2, 3), 203 (MH+ -  C 0 2Me, -  OH, 3), 199 (M + -  H N 02 , -  MeOH, 10), 188 
(M+ -  H N 0 2 , -  Me, -  HCN, 20), 173 (M+ -  N 0 2, -  MeOH, -  HCN, 8), 158 (17), 144 (9), 
130(10), 116(11), 101 (17).
Ethyl 2-cyano-3-(3-methoxy-4-hydroxy-5-nitrophenyl)propenoate (118)— Using 
Method B, 5-nitrovanillin (3-methoxy-4-hydroxy-5-nitrobenzaldehyde; 0.47 g, 2.38 mmol) 
and ethyl cyanoacetate (0.273 g, 2.41 mmol) were reacted in ethanol (10 ml) with the 
addition o f piperidine (3 drops). After 5 h the reaction was concentrated to quarter volume 
which yielded the title compound (0.224 g, 34 %) on cooling to room temperature, m.p. 
159-162 °C (from EtOH); Rp 0.72 (ethanol); (Found: C, 53.14; H, 4.13; N, 9.37; M+, 
292.0690. C 13H l2N 20 6 requires C, 53.43; H, 4.14; N, 9.59%; M, 292.0695); v max(KBr 
disc)/cm -1 3426m  (OH), 2950m (CHX), 2208w (CN), 1732s and 1708m/s (C 0 2Et), 1604m 
(Ar or C=C), 1544s and 1527s (C -N 0 2), 1288s, 1236s, 1210s, 1155m/s and 1094m/s (C-O), 
760m (=C-H  deformation); SH(200 MHz; DMSO-ds) 8.47 (1 H, s, OH), 8.24 (1 H, d, 4J5.H
2.19 Hz, 9-H), 8.20 (1 H, s, 3-H), 7.79 (1 H, d, 4J%n 2.20 Hz, 5-H), 4.30 (1 H, q, 3J 1 W  Hz, 
f f l 2CH3), 1.33 (1 H, t, 3J 1.09 Hz, CH2£ H 3), 3.84 (3 H, s, OMe); 8C(50 MHz; DMSO-d6)
163.2 (C 0 2CH2CH3), 155.3 (8-C), 153.6 (3-CH), 152.2 (7-C), 137.28 (6 -C), 125.6 (9-CH),
117.3 (4-C), 116.0 (1-CN), 112.4 (5-CH), 94.7 (2-C), 61.8 (£ H 2CH3), 56.1 (OCH3), 14.2 
(CH2£ H 3); m/z 292 (M +, 63%), 278 (MH+ -  CH3, 11), 264 (M + -  CO, 8 ), 262 (M+ -  N = 0 , 
4), 247 (MH+ -  N 0 2 , 11), 229 (M+ -  N 0 2, -  OH, 6 ), 216 (M+ -  N 0 2, -  Et, 18), 202 (M + -  
C 0 2Me, -  OH, 5), 197 (M +- N 0 2 ,-O H ,-M e O H , 6 6 ), 180(35), 173 (M+ -  N 0 2, -  EtOH, 
-  HCN, 7), 149 (18), 135 (23), 84 (100).
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tert-Butyl 2-cyano-3-(3,4-dihydroxyphenyl)propenoate (121)— Using Method A,
3,4-dihydroxybenzaldehyde (1.238 g, 6.65 mmol) and tert-butyl cyanoacetate (0.942 g, 
6.67 mmol) were reacted in isopropanol (8 ml) with the addition o f piperidine (4 drops). 
After 3 h the precipitate was collected (1.241 g, 71 %), m.p. 201-203 °C (from i-PrOH); RF 
0.53 (diethyl ether); (Found: C, 64.17; H, 5.78; N, 5.11; M +, 261.0991. C14H 15N 0 4 requires 
C, 64.36; H, 5.79; N, 5.36%; M, 261.0995); v max(KBr disc)/cm'‘ 3245m/s (broad; 2 x  OH), 
2984m (CH3), 2232m (CN), 1717s (C =0), 1580s and 1514s (Ar ), 1372s, 1308s, 1291s, 
1256s, 1157s, 1121m/s and 1098m/s (C-O), 841m and 810m (Ar-H  deformations); 
8h(200 MHz; acetone-d6) 9.0 (2 H, v.br, 2 x  OH), 8.06 (1 H, s, 3-H), 7.74 (1 H, d, 4J%H
2.19 Hz, 5-H), 7.43 (1 H, dd, 4J5.H 2.19 Hz, 3Jm  8.36 Hz, 9-H), 7.07 (1 H, d, SJ9.H 8.32 Hz,
8-H), 1.55 (9 H, s, 'Bu); 8 C(50 MHz; acetone-d6) 162.6 (C =0), 154.6 (3-CH), 151.8 (7-C),
146.3 (6 -C), 127.6 (9-CH), 124.8 (4-C), 117.0 (1-CN and 5- or 8-CH), 116.6 (8 - or 5-CH),
100.5 (2-C), 83.3 (£(CH3)3), 28.0 (C(CH3)3); m/z 261 (M+, 2 %), 205 (M + -  Bu', + H, 21), 
188 (M + -  CN, -  B u‘, 20), 170 (M + -  2 x  CO, -  2 x  H 20 ,  + H, 1), 161 (M+ -  C 0 2Bu‘, + H, 
33), 133 (M+ -  C 0 2Bu‘, -  HCN, 30), 114 (M + -  2 x  CO, - H 20 ,  -O  Bu', 61), 105 (M+ -  
C 0 2Bu', -  HC=CH -C=0, 17), 104 (19), 103 (17), 88 (16), 77 (30), 57 ([Bw']+,79).
2-Cyano-3-(3,4-dihydroxyphenyl)propenoic acid  ( 1 2 2 )— A 25 ml round- 
bottomed flask was charged with rm-butyl 2-cyano-3-(3,4-dihydroxyphenyl)propenoate 
(0.456 g, 1.63 mmol) and dissolved in a minimum amount of 98 % formic acid (ca . 10 ml) 
by heating to reflux for 5 min. After this time the reaction was allowed to cool to room 
temperature (unstirred) and the precipitate was filtered, washed in ethyl acetate and ether to 
give the title acid (0.301 g, 82 %), m.p. 207.0-207.5 °C (from H C 02H) (lit.,230c 240 °C); 
(Found: C, 58.09; H, 3.34; N, 6.71; M +, 205.0377. C 10H 7NO4 requires C, 58.54; H, 3.44; N, 
6.83%; M , 205.0375); v max(KBr disc)/cm_1 3499m (sharp) and 3356m (broad; 2 x OH and 
C 0 2H), 2230m  (CN), 1671s (C =0), 1593s, 1578s and 1504s (Ar and C=C), 1296s and 
1253s (C-O ), 818m/w and 632m/w (Ar-H); 5 H(200 MHz; DMSO-d6) 10.3 and 9.7 (2 H, 
v.br, 2 x  OH), 8.11 (1 H, s, 3-H), 7.67 (1 H, d, 1.78 Hz, 5-H), 7.40 (1 H, dd, 4J5_H 1.78 
Hz, 3JS_H 8.35 Hz, 9-H), 6.93 (1 H, d, SJ9.H 8.28 Hz, 8-H); 5 C(50 MHz; DMSO-d6) 164.3 
(C =0), 154.5 (3-CH), 151.8 (7-C), 145.9 (6 -C), 126.7 (9-CH), 123.2 (4-C), 117.0 (1-CN),
116.5 (5- or 8 -CH), 116.1 (8- or 5-CH), 98.0 (2-C); m/z 205 (M +, 77%), 188 (M+ -  HCN,
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13), 161 (M + -  C 0 2, 87), 133 (M+ -  C 0 2, -  CN, 73), 114 (M + -  C 0 2H, -  CO, -  H20 ,  62), 
105 (M + -  C 0 2H, -  HC=CH-C=0, 100), 88 (43), 77 (76).
tert-Butyl 2-cyano-3-(3,5-dichlorophenyl)propenoate (123)— Using Method B,
3,5-dichlorobenzaldehyde (0.234 g, 1.34 mmol) and tert-butyl cyanoacetate (0.197 g, 
1.40 mmol) were reacted in absolute ethanol (5 ml) with the addition of 10 % piperidine in 
ethanol (10 drops). After 5 h the precipitate was collected (0.210 g, 53 %), m.p. 85.5-86.0 
°C (from EtOH); RF 0.95 (diethyl ether); (Found: C, 56.31; H, 4.38; N, 4.65; M +, 297.0351 
(for35Cl). C MH 13N 0 2C12 requires C, 56.40; H, 4.39; N, 4.70%; M, 297.0323 (for35Cl)); 
vmax(KBr disc)/cm_1 3096w, 3076w and 3016w (=C-H), 2980m and 2939w (CH3), 2222w  
(CN), 1722s (C =0), 1613s andl562m (Ar), 1420m/s, 1280m/s, 1256m/s, 1213m/s and 
1152s (C-O ), 865m and 816m (=C-H), 672m (=C-C1); 8H(200 MHz; CDC13) 8.00 (1 H, s,
3-H), 7.78 (2 H, d, 4J  1.65 Hz, 5- and 9-H), 7.49 (1 H, t, 4J  1.81 Hz, 7-H), 1.56 (9 H, s, lBu); 
§c (50 MHz; CDC13) 160.2 (C 0 2Bu‘), 150.5 (3-CH), 134.1 (6- and 8 -C), (4-C not observed),
132.3 (7-CH), 128.5 (5- and 9-CH), 114.6 (1-CN), 107.9 (2-C), 27.8 (Bu‘); m/z 299 
((35C1/37C1)M+, 3), 297 ((35C1)M+, 5), 255 ((35C1/37C)M+- 0 ‘Bu, 1), 253 ((35C1)M+ -  O'Bu,
1), 227 (M + -  2 x  Cl, 1), 226 ((35C1/37C1)M+ -  C 0 2lBu, 12), 224 ((35C1)M+ -  C 0 2‘Bu, 38), 
161 (M + -  HCN, -  H35C1, - C 0 2 ‘Bu, 12), 124 (M+ -  2  x  HC1, -  C 0 2‘Bu, 3), 109 (3), 99 (3), 
57 (['Bm]+, 100).
2-Cyano-3-(3,5-dichlorophenyl)propenoic acid (124)— A 10 ml round-bottomed 
flask was charged with ferr-butyl 2-cyano-3-(3,5-dichlorophenyl)propenoate (0.150 g, 
0.503 mmol) and dissolved in a minimum amount of 98 % formic acid ( ca. 2 ml) by heating 
to reflux for 10 min. After this time the reaction was allowed to cool to room temperature 
(unstirred) and the crystals were filtered, washed in ethyl acetate and ether to give the title 
acid (0.098 g, 80 %), m.p. 186-188 °C (from H C 0 2H); (Found: C, 49.43; H, 2.05; N, 5.67; 
M+, 240.9713. C10H 5NO2Cl2 requires C, 49.62; H, 2.08; N, 5.79%; M, 240.9697); v max(KBr 
discVcm’1 3422m (C 0 2H), 3072m (=C-H), 2226m (CN), 1703s (C =0), 1610s and 1563s 
(Ar), 1420m, 1284m, 1256m, 1215m (C-O), 862m/s and 787m  (=C -H  deformation), 
671 m/s (=C-C1); 8H(200 MHz; DMSO-d6) (acid proton not observed), 8.10 (1 H, s, 3-H),
8.00 (2 H, s, 5- and 9-H), 7.81 (1 H, br s, 7-H); S c (50 MHz; DM SO-ds) 162.4 (COzH),
148.8 (3-CH), 134.7 (6 - and 8 -C ), 128.0 (5- and 9-CH), 130.4 or 126.42 (7-CH); m/z 245 
((37C1)M+, 9%), 244 ((37C1)M+ -  H, 9), 243 ((35C1/37C1)M+, 50), 242 ((35C1/37C1)M+ -  H,
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30), 241 ((35C1)M+, 77), 240 ((35C1)M+ -  H, 32), 214 ((35C1)M+ -  HCN, 5), 208 ((37C1)M+ -  
37C1, 18), 206 ((33C1)M+ -  35C1 and (35C1/37C1)M+ -  37C1, 51), 199 ((35C1/37Q M + -  C 0 2 , 
62), 197 ((35C1)M+ -  C 0 2, 98), 170 (M+ - 2  x Cl, - H ,  28), 164 ((35CI/37C)M+ -  C O ,, -  
35C1,33), 162 ((33C1)M+ -  C 0 2, -  33C1, 100), 127 (M + -  C 0 2, -  2 x  Cl, 100), 109 (24), 99 
(44).
tert-Butyl 2-cyano-3-(3,5-difluorophenyl)propenoate (125)— Using Method B,
3,5-difluorobenzaldehyde (0.531 g, 3.03 mmol) and terr-butyl cyanoacetate (0.450 g,
3.19 mmol) were reacted in absolute ethanol (6  ml) with the addition o f 10 % piperidine in 
ethanol (5 drops). After 4 h the precipitate was collected (0.623 g, 78 %), m.p. 103-104 °C 
(from EtOH); R F 0.75 (diethyl ether); (Found: C, 63.12; H, 4.92; N, 5.05; M+, 265.0896. 
C14H 13N 0 2F2 requires C, 63.40; H, 4.94; N, 5.28%; M , 265.0914); v max(KBr disc)/cm'‘ 
3110w, 3088m /w, 3063w and 3028w (Ar-H), 2989m/w and 2945w ('Bu), 2226w (CN), 
1714s (C =0), 1620m and 1612m (C=C), 1592m/s, 1456m and 1438m (Ar), 1371m, 1315m, 
1281s, 1260m /s, 1150m/s and 996m (C -O  and C -F), 862m /s and 834m (=C -H  
deformations), 674m (=C-F deformation); 5H(200 MHz; CDC13) 7.89 (1 H, s, 3-H), 7.31 
(2 H, dm, SJF 6.02 Hz, 5- and 9-H), 6.82 (1 H, tt, 3JP 8.52 Hz, 2.21 Hz, 7-H), 1.41
(9 H, s, 'Bu); Sc (50 MHz; CDC13) 162.8 (dd, unresolved, 6 - and 8 -C), 160.3 (C 0 2Bu‘),
151.0 (t, unresolved, 3-CH), 134.2 (s, 4-C), (1-CN weak signal), 113.3 (d, 2JP 25.06 Hz, 5- 
and 9-CH), 108.0 (t, SJF 25.19 Hz, 7-CH), 84.5 (s, 2-C), 27.8 (Bu‘); m/z 265 (M +, 5%), 250 
(M+ - C H 3, 1), 221 (M* -  CN, -  F, + H, 3), 209 (M + -  Bu', +• H, 3), 192 (M + -O B u ‘, 34), 
164 (M* -  C 0 2Bu‘, 14), 144 (M + -  C 0 2Bu‘, -  HF, 12.5), 138 (M + -  C 0 2Bu‘, -  CN, 4), 124 
(M+ -  C 0 2Bu‘, -  2 x  HF, 3), 113 (M +-  C 0 2Bu‘, H-CsC-CN, 3), 87 (1.5), 57 ([B i/]+, 100).
2-Cyano-3-(3,5-difluorophenyl)propenoic acid  (126)— A 25 ml round-bottomed 
flask was charged with rerf-butyl 2 -cyano-3-(3 ,5 -difluorophenyl)propenoate (0.550 g,
2.07 mmol) and dissolved in a minimum amount of 98 % formic acid (ca . 5 ml) by heating 
to reflux for 15 min. After this time the reaction was allowed to cool to room temperature 
(unstirred) and the crystals were filtered, washed in ethyl acetate and ether to give the title 
acid (0.348 g, 80 %), m.p. 177-178 °C (from H C 0 2H); (Found: C, 57.11; H, 2.39; N, 6.49; 
M+, 209.0291. C 10H5NO2F2 requires C, 57.43; H, 2.41; N , 6.70%; M, 209.0288); v^O O Br  
disc)/cm4  3432m (C 0 2H), 3097m and 3039m (Ar-H), 2230m/w (CN), 1697s (C =0), 1608s 
(C=C), 1585s, 1428s and 1438s (Ar), 1325m/s, 1273s, 1233m, 1131m/s and 992m/s (C-O
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and C-F), 871m and 859m (=C-H deformations), 672m (=C-F deformations; 8H(200 MHz; 
DMSO-d6) (acid proton not observed), 8.36 (1 H, s, 3-H), 7.75 (2 H, dm, SJF 6.65 Hz, 5- and
9-H), 7.57 (1 H, tt, 3JP 8.06 Hz, 4J5.m _H 2.17 Hz, 7-H); Sc (50 MHz; DMSO-d6) 162.7 (s, 
C 0 2H), 162.4 (dd, 3JF 247.4 Hz, 3 JF 13.3 Hz, 6 - and 8 -C), 151.6 (t, unresolved, 3-CH),
134.8 (t, 3J¥ 10.2 Hz, 4-C), 115.5 (1-CN), 113.5 (d, 2/ F 26.4 Hz, 5- and 9-CH), 108.2 (t, 3JF
26.1 Hz, 7-CH), 107.0 (s, 2-C); m/z 209 (M +, 76%), 190 (M + -  F, 9), 165 (M + -  C 0 2, 100), 
144 (M+ -  C 0 2H, -  HF, 42), 138 (M + -  C 0 2H, -  CN, 77), 124 (M+ -  CO ,H , -  2 x  HF, 12), 
114 (M+ -  C 0 2, H-C=C-CN, 3), 99 (9), 75 (12).
tQTt-Butyl 2-cyano-3-(4-nitrophenyl)propenoate (1 2 7 )— U sing Method B,
4-nitrobenzaldehyde (2.183 g, 14.44 mmol) and rm -butyl cyanoacetate (2.103 g, 
14.90 mmol) were reacted in ethanol (10 ml) with the addition of piperidine (5 drops). After 
8 h the crystals were collected (1.541 g, 39 %), m.p. 148.0-148.8 °C (from EtOH); RF 0.88
i
(diethyl ether); (Found: C, 61.05; H, 5.11; N, 10.26; M+, 274.0951. C 14H 14N 20 4 requires C, 
61.31; H, 5.14; N, 10.21%; M , 274.0954); v max(KBr disc)/cm'' 3103w, 3078w and 3034w  
(=C-H), 3004w, 2982w and 2940w (CH3), 2230w (CN), 1717s (C 0 2Bu‘), 1686m, 1597m 
and 1620m (Ar and C=C), 1522s (C -N 0 2), 1345s, 1300s, 1291s and 1156s (C-O), 853m/s 
(=C-H deformation); 8 H(200 MHz; CDC13) 8.30 (2 H, dm, 8.89 Hz, 6 - and 8 -H),
8.19 (1 H, s, 3-H), 8.08 (2 H, dm, j / 6.H/8-H 8 80  Hz- 5‘ and 9’H)- ! - 5 6  (9  H- s . 'Bu)'. 
8C(50 MHz; CDC13) 160.1 (C 0 2C(CH3)3), 150.8 (3-CH), 149.4 (7-C), 137.1 (4-C), 131.3 
(6 - and 8 -CH), 124.2 (5- and 9-CH), 114.8 (1-CN), 108.9 (2-C), 84.7 (C (C H 3)3), 27.8 
(C(CH3)3); m/z 274 (M+, 4%), 259 (M+ -  O, + H, 1), 244 (M+ -  N = 0 , 0.3), 230 (MH2+ -  
N 0 2 , 2), 218 (MH+ -  Bu‘, 1), 201 (M+ - N 0 2 ,-H C N , 15), 188 (MH+ - N = 0 , - B u ' ,  3), 174 
(MH+ -  C 0 2Bu‘, 2), 171 (M+ -  Bu‘, -  N 0 2, 1), 155 (M+ -  OBu‘, -  N 0 2 , 7), 127 (M+ -  
C 0 2Bu‘, -  N 0 2 , 5), 100 (M + -  C 0 2Bu‘, -  N 0 2, -  HCN, 4), 89 (2), 76 (4), 57 ([Bu‘]+, 100).
2-Cyano-3-(4-nitrophenyl)propenoic acid  (128)— A 25 ml round-bottomed flask 
was charged with tert-butyl 2-cyano-3-(4-nitrophenyl)propenoate (1.034 g, 3.77 mmol) and 
dissolved in a minimum amount of 98 % formic acid (ca. 10 ml) by heating to reflux for 
5 min. After this time the reaction was allowed to cool to room temperature (unstirred) and 
the crystals were filtered, washed in ethyl acetate and ether to give the title acid (0.745 g, 
91 %), m.p. > 300 °C (from H C 02H) (lit.,230c 205 °C); (Found: C, 54.87; H, 2.73; N, 12.61; 
M+, 218.0334. C 10H 6N 2O4 requires C, 55.05; H, 2.77; N, 12.84%; M, 218.0328); v max(KBr
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discj/cm ' 1 3468m (broad CO 2H), 3113w, 3094w and 3032w (=C-H), 2218w (CN), 1686s 
(C 0 2H), 1639m and 1593m (Ar and C=C), 1522s (C -N 0 2), 1350s, 1298s and 1277s (C-O), 
853m/s (=C-H  deformation); 8H(200 MHz; DMSO-d6) 8.35 (2 H, br d, 3Js-h/9-h 8-- Hz, 6 - 
and 8 -H), 8.09 (1 H, s, 3-H), 7.96 (2 H, br d, SJ6.W$.H 8.7 Hz, 5- and 9-H); 8 C(50 MHz; 
DMSO-d6) 162.4 (C 0 2H), 148.1 (7-C), 144.9 (3-CH), 139.9 (4-C), 130.4 (6 - and 8 -CH),
124.1 ( 5 - and 9-CH), 113.6 (1-CN), 109.3 (2-C); m/z 218 (M+, 37%), 201 (M+ -O H , 14), 
188 (M+ -  N = 0 , 16), 174 (M+ -  C 0 2, 35), 172 (M+, -  N 0 2, 8 ), 144 (M+ -  H N 02, -  HCN, 
55), 128 (M+ -  C 0 2, -  N 0 2, 48), 116 (M+ -  C 0 2, -  NO, -  CO, 100), 101 (M+ -  C 0 2 , -  
N 0 2, -  HCN, 78), 89 (95), 75 (84).
tert-Butyl 2-cyano-3-(3,4-dim ethoxy-6-nitrophenyl)propenoate  (129)— Using 
Method B, 6 -nitroveratraldehyde (3,4-dim ethoxy-6-nitrobenzaldehyde; 2.214 g, 
10.48 mmol) and terr-butyl cyanoacetate (1.485 g, 10.52 mmol) was reacted in ethanol 
(40 ml) with the addition of piperidine (10 drops). After 19 h a precipitate was not observed 
and thus the reaction was refluxed for 0.5 h and concentrated to half volume which yielded 
the title acid (2.287 g, 65 %) on cooling to room temperature, m.p. 228-229 °C (from 
EtOH); R f 0.79 (diethyl ether); (Found: C, 57.13; H, 5.41; N, 8.62; M+, 334.1168. 
Ci6H i8N 20 6 requires C, 57.48; H, 5.43; N, 8.80%; M , 334.1165); v max(KBr disc)/cm _1 
3090w (=C-H ), 2979w and 2940w (CHX), 2232w (CN), 1715s (COjBu1), 1611m and 
1567m/s (Ar or C=C), 1524s (C -N 0 2), 1330m/s, 1285s, 1226s and 1160s (C-O), 883m, 
796m/w and 748m/w (=C-H deformations); 5H(200 MHz; CDC13) 8.58 (1 H, s, 3-H), 7.69 
(1 H, s, 8 -H), 7.29 (1 H, s, 5-H), 3.96 and 3.94 (6  H, 2 x  s, 2 x  OMe), 1.52 (9 H, s, B u1); 
5C(50 MHz; CDC13) 160.1 (C 0 2C(CH3)3), 153.2 (9-C), 152.0 (3-CH), 151.0 (7-C), 141.0 
(6-C), 121.8 (4-C), 114.9 (1-CN), 111.4 (8-CH), 108.6 (2-C), 108.1 (5-CH), 84.3 (C(CH3)3),
56.8 and 56.6 (2 x  OCH3), 27.8 (C(CH3)3); m/z 334 (M +, 6 %), 278 (MH+ -  B u \ 1), 261 (M + 
-  HCN, -  N 0 2, (or -  OBu1), 5), 232 (M+ -  N 0 2, -  B u1, 100), 215 (M+ -  OBu1, -  N 0 2, 11), 
164 (9), 136 (9), 57 ([Bu']+, 37).
2-cyano-3-(3,4-dimethoxy-6-nitrophenyl)propenoic acid  (130)— A 25 ml round- 
bottom ed flask  was charged with tert-butyl 2-cyano-3-(3,4-dimethoxy-6-nitro- 
phenyl)propenoate (1.437 g, 4.30 mmol) and dissolved in a minimum amount of 98 % 
formic acid ( ca . 10 ml) by heating to reflux for 5 min. After this time the reaction was 
allowed to cool to room temperature (unstirred) and the crystals were filtered, washed in
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ethyl acetate and ether to give the title acid (0.890 g, 74 %), m.p. 226-228 °C (from 
H C 02H); (Found; C, 51.72; H, 3.67; N, 9.87; M+, 278.0531. C12H 10N 2O6 requires C, 51.81; 
H, 3.62; N, 10.07%; M, 278.0539); v max(KBr disc)/cm -1 3328m/s (C 0 2 H), 3088m/w and 
2946m /w (=C -H ), 2230w  (CN), 1735s and 1702m/s (C 0 2H), 1654m /w, 1607m and 
1570m/s (Ar or C=C), 1527s (C -N 0 2), 1333m/s, 1292s and 1230s (C -O ), 884m, 794m and 
771m (=C-H deformations); 5h(200 MHz; DMSO-d6) 8.69 (1 H, s, 3-H), 7.83 (1 H, s, 8-H), 
7.57 (1 H, s, 5-H), 3.98 and 3.97 (6  H, 2 x  s, 2 x  OMe); 5 C(50 MHz; DM SO-d6) 162.8 
(C 0 2C(CH3)3), 153.7 (3-CH), 152.9 (9-C), 150.5 (7-C), 140.8 (6 -C), 122.0 (4-C), 115.3 
(1-CN), 112.3 (8-CH), 108.3 (5-CH), 107.9 (2-C), 56.8 and 56.5 (2 xO C H 3); m/z 278 (M+, 
14%), 234 (M + -  C 0 2, 10), 232 (M+ -  N 0 2 , 100), 217 (M + -  OCH3, -  N = 0 ,7), 205 (M+ -  
N 0 2 ,-H C N , 10), 188 (M + - N 0 2 , - C 0 2, 100), 164 (21), 136 (23), 102 (12).
tert-Butyl 2-cyano-3-(3,4-m ethylenedioxy-6-nitrophenyl)propenoate  (131)—  
Using Method B, 6 -nitropiperonal (3,4-methylenedioxy-6-nitrobenzaldehyde; 1.460 g,
7.48 mmol) and ferf-butyl cyanoacetate (1.060 g, 7.51 mmol) were reacted in ethanol 
(25 ml) with the addition of piperidine (10 drops). After 18 h a precipitate was not observed 
and thus the reaction was concentrated to quarter volume and left to crystallise. This gave 
the title compound on cooling to room temperature (0.845 g, 35 %), m.p. 116-117 °C (from 
EtOH); Rp  0.83 (diethyl ether); (Found: C, 56.35; H, 4.40; N, 8 .6 8 ; M+, 318.0856. 
C15H 14N 20 6 requires C, 56.60; H, 4.43; N, 8.80%; Af, 318.0852); v max(KBr discVcm ' 1 
3 1 13w and 3059w (=C-H), 2984w and 2908w (CHX), 2233w (CN), 1715s (C 0 2Bul), 1602m 
(Ar or C=C), 1522s (C -N 0 2), 1329s, 1286s and 1268s (C-O), 882m (=C -H  deformation); 
Sh(200 MHz; CDC13) 8.51 (1 H, d, 4J5_H 0.5 Hz, 3-H), 7.68 (1 H, s, 8 -H), 7.07 (1 H, d, 4JVA 
0.4  Hz, 5-H ), 6.21 (2 H, s, OCH20 ) ,  1.56 (9 H, s, Bu‘); 5 C(50 MHz; CDCI3) 159.9 
(C 0 2C(CH3)3), 155.0 (3-CH), 152.5 (9-C), 150.3 (7-C), 142.6 (6-C), 124.4 (4-C), 114.3 
(1-CN), 109.1 (2-C), 108.9 (8-CH), 106.0 (5-CH), 104.0 (OCH20 ) ,  84.4 (£(CH 3)3), 27.9 
(C (£H 3)3); m /z 318 (M+, 5%), 262 (MH+ -  B u \ 0.5), 245 (M+ -  HCN, -  N 0 2, (or -  OBu‘), 
11), 216 (M + -  N 0 2, -  Bu‘, 100), 199 (M+-O B u ‘, - N 0 2 , 21), 163 (7), 135 (10), 114 (5).
2-Cyano-3-(3,4-methylenedioxy-6-nitrophenyl)propenoic acid (132)— A 25 ml 
round-bottomed flask was charged with tert-butyl 2-cyano-3-(3,4-methylenedioxy-6-nitro- 
phenyl)propenoate (0.636 g, 2.00 mmol) and dissolved in a minimum amount of 98 % 
formic acid (ca , 7 ml) by heating to reflux for 5 min. After this time the reaction was
Synthesis and Biological Evaluation o f Anticancer Agents Page 167
allowed to cool to room temperature (unstirred) and the crystals were filtered, washed in 
ethyl acetate and ether to give the title acid (0.412 g, 79 %), m.p. 142-144 °C (from EtOH); 
(Found: C, 50.16; H, 2.30; N, 10.42; M +, 262.0222. C u H 6N 20 6 requires C, 50.39; H, 2.31; 
N, 10.68%; M, 262.0226); v max(KBr discycm *1 3424w (C 0 2H), 3069w (=C-H), 2233w  
(CN), 1718s (C 0 2H), 1599m (Ar or C=C), 1508s (C -N 0 2), 1329s andl276s (C-O), 883m 
and 818m (=C-H  deformations); 5 H(200 MHz; DMSO-d6) (C 0 2H not observed below  
9 ppm), 8.63 (1 H, s, 3-H), 7.90 (1 H, s, 8-H), 7.50 (1 H, s, 5-H), 6.39 (2 H, s, OCH20); 
5C(50 MHz; DMSO-d6) 162.7 (C 0 2C(CH3)3), 154.0 (3-CH), 152.4 (9-C), 150.0 (7-C),
142.4 (6 -C), 124.7 (4-C), 108.9 (8 -CH), 115.0 (1-CN), 108.0 (2-C), 105.8 (5-CH), 104.6 
(OCH20); m/z 262 (M +, 16%), 232 (M+ -  N = 0, 3), 218 (M+ -  C 0 2, 26), 216 (M+ -  N 0 2, 
100), 201 (M + -O C H 3 , - N = 0 ,  11), 189 (M + -  HCN, -  N 0 2, (or -  OBu1), 13), 163 (29), 
158 (32), 135 (32), 114(50).
t
tert-Butyl 2-cyano-3-(3-methoxy-4-hydroxy-5-nitrophenyl)propenoate (133) —  
Using Method B, 5-nitrovanillin (3-methoxy-4-hydroxy-5-nitrobenzaldehyde; 1.456 g, 
4.55 mmol) and terr-butyl cyanoacetate (1.043 g, 7.39 mmol) were reacted in ethanol 
(40 ml) with the addition of piperidine (10 drops). After 19 h the reaction was concentrated 
to quarter volume which yielded the title acid (0.524 g, 36 %) on cooling to room 
temperature, m.p. 166.5-167.5 °C (from EtOH); /?F 0.77 (diethyl ether); (Found: C, 56.00; 
H, 5.00; N, 8.63; M +, 320.0997. C 15H 16N 20 6 requires C, 56.25; H, 5.04; N, 8.75%; M , 
320.1008); v max(KBr disc)/cm_l 3080w (=C-H), 2981w and 2942w (CHX), 2234w (CN), 
1715s and 1685m/s (C 0 2Bul), 1613m and 1578m (Ar or C=C), 1548s (C—N 0 2), 1336m/s, 
1268s, 1233s and 1105s (C-O ), 919m, 875m, 769m and 626m (=C -H  deformations); 
8h(200 MHz; acetone-d6) 9.94 (1 H, s, OH), 8.32 (1 H, s, 3-H), 8.22 (1 H, d, 4J5_H 1.80 Hz,
9-H), 7.69 (1 H, d, 4J9.H 1.77 Hz, 5-H), 4.03 (3 H, s, OMe), 1.51 (9 H, s, B u‘); Sc (50 MHz; 
acetone-d6) 163.4 (C 0 2C(CH3)3), 153.4 (3-CH), 151.5 (8-C), 148.9 (7-C), 128.7 (6-C),
123.5 (4-C), 121.4 (9-CH), 116.55 (1-CN), 113.9 (5-CH), 103.6 (2-C), 84.2 (C(CH3)3), 57.2 
(OCH3), 27.7 (C(CH3)3); m/z 320 (M +, 12%), 290 (M+ -  N = 0 ,1), 264 (MH+ -  MeO, -  CN, 
(or -  Bu1), 100), 247 (M+ -  HCN, -  N 0 2, (or -  OBu‘), 20), 216 (M+ -  H N 0 2, -  H Bu\ 100), 
197 (M+ -  OBu‘, -  N 0 2, 11), 180(23), 149(13), 135 (17), 57 ([Bn']+, 56).
tert-Butyl 2-cyano-3-(2-im idazolyl)propenoate (1 3 4 )— U sing  M ethod B, 
2-imidazolylcarbaldehyde (0.121 g, 1.26 mmol) and (ert-butyl cyanoacetate (0.184 g,
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1.30 mmol) were reacted in isopropanol (2 ml) with 5 % piperidine in isopropanol (3 drops). 
After ca. 1 h, the white solid which formed was collected (0.146 g, 53 %), m.p. 164.5-165.0 
°C (from i-PrOH); RF 0.43 (diethyl ether); (Found: C, 59.98; H, 5.91; N, 18.99; M+, 
219.1005. C 11H 13N 30 2 requires C, 60.26; H, 5.98; N, 19.17%; M , 219.1008); v max(KBr 
discVcm ' 1 3134m/s, 3109m/s and 3031m (HNtm and im -H), 2990m and 2911m (=C-H), 
2228m/s (CN), 1719s (C =0), 1622s (C=C), 1442s, 1294s, 1244s and 1111s (C -N im and 
C-O), 797m/s and 760m/s (=C-H deformations); 5 H(200 MHz; acetone-d6/CDCl3) (8 -NH 
not below 12 ppm), 7.82 (1 H, s, 3-H), 7.23 (2 H, br s, 6 - and 7-H), 1.33 (9 H, s, Buc); 
8C(50 MHz; acetone-d6/CDCl3) 161.3 (C =0), 140.5 (4-C), 139.7 (3-C), 133.5 (7-CH  
(broad)), 122.4 (6-CH (broad)), 115.6 (CN), 102.3 (2-C), 83.3 (C(CH3)3), 27.8 (C(CH3)3); 
m/z 219 (M+, 4%), 163 (M + -  Bu1, + H, 11), 146 (M + -  OBu1, 24), 119 (M + -  C 0 2Bul, + H, 
100), 92 (M + -  CN, -  C 0 2But, 17), 68 (im, 13), 64 (25), 57 ([Bu‘]+, 18).
2-Cyano-3-(2-imidazolyl)propenoic acid  (135)— A 25 ml round-bottomed flask 
was charged with rm-butyl 2-cyano-3-(2-imidazolyl)propenoate (0.096 g, 0.438 mmol) and 
dissolved in a minimum amount of 98 % formic acid (ca. 2 ml) by heating to reflux for 
5 min. After this time the reaction was allowed to cool to room temperature (unstirred) and 
the precipitate was filtered, washed in ethyl acetate and ether to give the title acid (0.056 g, 
78 %), m.p. 189.5-190.5 °C (from H C 02H); (Found: C, 51.32; H, 3.07; N, 25.64; M+, 
163.0379. C 7H5N 30 2 requires C, 51.54; H, 3.09; N, 25.76%; M , 163.0382); v max(KBr 
discVcm ' 1 3428m/w (C 0 2H), 3173m/s and 3125m (H N ^), 3056m/w and 3015m/w (im-H), 
2926m/w and 2855m/w (=C-H), 2222m/w (CN), 1641m/s (C =0), 1609m/s (C=C), 1392s, 
1342s and 1304s (C -X ), 799s and 747m (=C-H); 5 H(200 MHz; acetone-d6) (8 -NH not 
observed below 12 ppm), 7.87 (1 H, s, 3-H), 7.25 (2 H, br s, 6 - and 7-H); 8C(50 MHz; 
acetone-d6) 163.7 (C =0), 141.1 (4-C), 139.9 (3-CH), 133.6 (7-CH (broad)), 122.7 (6-CH 
(broad)), 114.4 (CN), 102.8 (2-C); m/z 163 (M +, 2.5%), 119 (M + -  C 0 2, 100), 92 (M + -  CN, 
-  C 0 2H, 41), 68 (im, 65), 64 (34), 52 (28).
5-Cyano-6-(3,4-dimethoxyphenyl)-4-oxo-2-thioxo-l,2,3,4,5,6-hexahydro 
pyrimidine, potassium salt (136)266—  To a heated solution at reflux of 6 -nitroveratraldehyde 
(3, 4-dimethoxy-6-nitrobenzaldehyde; 2.230 g, 10.56 mmol), ethyl cyanoacetate (1.194 g, 
10.56), thiourea (0.804 g, 10.56 mmol) in absolute ethanol (20 ml) was added anhydrous 
sodium carbonate (1.460 g, 10.56 mmol) over 15 min. After 5.25 h the precipitate was
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filtered, washed in ethanol and tetrahydrofuran, and air dried to give the potassium salt of 
5-cyano-6-(3,4-dimethoxyphenyl)-4-oxo-2-thioxo-l,2,3,4,5,6-hexahydropyrimidine (3.19 g, 
80 %), m.p. 238-241 °C (from EtOH); v max(KBr discV cm ' 1 3322m /s and 3184m  
(HNC(S)NH), 2155m/s (CN), 1616s (broad; C = 0 of amide and C=S of thiourea), 1570m/s 
(thiourea stretch), 1620m and 1512m (C=C and Ar), 1423s, 1298m, 1280m/s, 1152m and 
1131m/s (C -N  and C-O stretches), 780m and 68 6m (=C-H deformations); 5H(200 MHz; 
DMSO-d6) 8.93 (2 H, br s, (NH)2C=S), 7.07 (1 H, d, 8.3 Hz, 9-H), 7.05 (1 H, s, 5-H),
6.83 (1 H, d, 3 8.20 Hz, V 5.H 2.20 Hz, 8-H), 3.77 (6  H, s, 6 - and 7-OMe); 8C(50 MHz; 
DMSO-d6) 175.8 (C=S), 160.6 (C =0), 148.6 and 148.0 (6 - and 7-C), 138.5 (3-C), 126.4 
(4-C), 118.3 (9-CH), (1-CN not observed), 111.7 (5-CH), 110.6 (8 -CH), 49.3 (2-C), 56.6 
(3-C), 55.7 and 55.6 (6- and 7-OCH3); m/z 307 (M+ -  22, [Af; ]+, 26%), 292 ([M ,}+ -  CH3, 
10), 276 -  OCH3, 16), 234 (HN)2C=S, 10), 232 ([M ; ]+ -  (HN)2C=S, -  H,
10), 216 {[M  y]+ -  HN-C=S, -  CO, 10), 151 (M+ -  HN-C=S, -  NC-C-CONH, 10), 137 (M+ -  
HN-C=S, -  H-C=C(CN)CONH, 10), 107 (12), 94 (20), 79 (15).
5-Cyano-6-(3,4-dimethoxyphenyl)-4-oxo-2-thioxo-l,2,3,4-tetrahydro 
pyrimidine (137)— The potassium salt of 5-cyano-6-(3,4-dimethoxyphenyl)-4-oxo-2-thioxo- 
1,2,3,4,5,6-hexahydropyrimidine (2.04 g, 5.43 mmol) was dissolved in distilled water 
(100 ml) and filtered prior to acidification with glacial acetic acid (5 ml). The solid formed 
was filtered, washed with water (2  x  20  ml) and ethyl acetate (2 x 10 ml), and dried over a 
sinter with diethyl ether. This solid (1.23 g) was dissolved in acetic acid (100 ml) and 
vigorously stirred at reflux (in the presence of air) for 2 h. On cooling the precipitate was 
filtered, washed in ethyl acetate (2 x  2 0  ml) and diethyl ether (2  x  2 0  ml) to give the title 
compound as a yellow powder (0.673 g, 37 %), m.p. 279-280 °C (from AcOH); RF 0.06 
(diethyl ether); (Found: C, 53.86; H, 3.84; N, 14.59; M +, 289.0532. C i3H 11N 30 3 S requires 
C, 53.97; H, 3.83; N, 14.52%; M, 289.0521); v max(KBr disc)/cm '' 3440m  and 3273m  
(HNC(S)NH), 2937m (CH3), 2224m/s (CN), 1678s (broad; C = 0  of amide and C=S of 
thiourea), 1575m/s (thiourea stretch), 1598s, 1548s and 1517s (Ar and C=C), 1439m/s, 
1273m/s, 1213m/s and 1016m (C -N  and C -O  stretches), 764m  (=C -H  deformation); 
8h(200 MHz; DMSO-d6) 13.17 (2 H, br s, (NH)2C=S), 7.37 (1 H, d, 3Ji .H 8.6  Hz, 9-H), 7.34 
(1 H, s, 5-H), 7.55 (1 H, d, 3J9M 8.3 Hz, 8 -H), 3.89 and 3.87 (6  H, 2 x  s, 6 - and 7-OMe); 
8C(50 MHz; DMSO-d6) 176.2 (C=S), 160.4 (C =0), 158.8 (3-C), 152.2 and 148.1 (6 - and
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7-C), 122.8 (9-CH), 120.9 (4-C), 115.3 (1-CN), 112.4 (5-CH), 111.3 (8 -CH), 89.8 (2-C),
55.9 and 55.8 (6 - and 7-OCH3); m/z 289 (M+, 100%), 274 (M+ -  CH3, 9), 258 (M+ -  OCH3,
8), 246 (M + -  CH3, -  CO, 6), 231 (M+ -  OCH3, -  HCN, 11), 215 (M+ -  (HN)2C=S, 10), 201 
(M+ -  2 x  OCH3, 8), 187 (M + -  HN-C=S, -  CO, 10), 164 (M+ -  HN-C=S, -  CN, -  C=C-H, 
18), 144 (M + -  HN-C=S, -  2 x  CO, -  CH3, 10), 115(12), 89 (7), 77 (7).
3 -Am ino-2,4-dicyano-5-(2-nitrophenyl)penta-1,3 -d ienon itrile  (138)— Using 
Method C, 2-nitrobenzaldehyde (1.563 g, 10.34 mmol) and l,l,3-tricyano-2-aminopropene 
(1.345 g, 10.18 mmol) were reacted in absolute ethanol (10 ml) with the addition of 10 % 
piperidine in ethanol (5 drops). After 4 h the crystals were collected (1.789 g, 66  %), m.p. 
200-202 °C (from EtOH); RF 0.40 (diethyl ether); (Found: C, 58.78; H, 2.67; N, 26.32; M+, 
265.0612. C 13H 7N 50 2 requires C, 58.87; H, 2.66; N, 26.40%; M, 265.0600); v max(KBr 
disc)/cm _1 3373m, 3333m and 3213m (NH2), 2223m/s and 2209m /s (H 2N-C=C(CN)2), 
1657s (H2N-C=C(CN)2), 1622m and 1604m (C=C), 1543s and 1523s (C -N 0 2), 1343s 
(C-N), 795m and 652m (=C-H deformations); 8 H(200 MHz; DM SO -d6) 9.30 and 9.23 
(2 x  1 H, 2 x  br s, NH2), 8.49 (1 H, s, 3-H), 8.35 (1 H, d, 3J 8.21 Hz, 6 -H), 8.35 (1 H, m, ca. 
dt, 3J  7.6 Hz, 8-H), 7.62 (2 H, m (ca. dt), 3J 7.6 Hz, 7- and 9-H); Sc (50 MHz; DMSO-d6)
164.0 (H 2N-C=C(CN)2), 152.6 (3-CH), 147.1 (5-C), 135.0 (6 -CH), 132.6 (8 -CH), 130.6 
(9-CH), 128.1 (4-C), 115.1 (1-CN), 114.4 and 113.8 (H2N-C=C(CN)2), 107.0 (2-C), 50.7 
(H2N-C=C(CN)2); m/z 265 (M +, 12%), 235 (M+ -  N = 0 , 11), 219 (M + -  N 0 2, 100), 192 (M + 
- N 0 2, -H C N , 35), 165 (M + -  N 0 2, -  2 x  HCN, 38), 153 (M + -  H N 0 2, -HC(CN)2, 38), 
138(M + - N 0 2, - 3 x  HCN, 12), 126(14), 1 0 4 (2 1 ),9 2 (4 3 ),7 6  (26).
2-Cyano-3-(9-anthryl)propenonitrile (139 )— Using Method B, 9-anthracene 
carbaldehyde (2.289 g, 11.10 mmol) and malononitrile (0.715 g, 10.82 mmol) were reacted 
with piperidine (4 drops) in chloroform (30 ml). After ca. 10 min a fine orange crystalline 
mesh formed which was collected (1.593 g, 58 %), m.p. 203-204 °C (from CHC13); RF 0.82 
(diethyl ether); (Found: C, 85.24; H, 3.98; N, 10.89; M+, 254.0863. C 18H 10N 2 requires C, 
85.02; H, 3.96; N, 11.02%; M , 254.0844); v max(KBr discVcm ' 1 3053w and 3016w (Ar), 
2229m /s (CN), 1621m (C=C), 1575m/s, 1552m/s and 1519m (Ar), 734s (=C -H  
deformation); 8H(200 MHz; DMSO-d6;338 K) 9.30 (1 H, s, 3-CH), 8.67 (1 H, s, 5-CH), 8.22 
(4 H, 2 x  d, 3J 8.54 Hz, 3J 8.09 Hz, 7- and 10-H), 7.62 (4 H, m, ca. two overlapping triplets,
8 - and 9-H); 8C(50 MHz; DMSO-d6;338 K) 161.7 (3-CH), 131.5 (5-CH), 130.6 (11-C),
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129.0 and 127.7 (6 - and 9-CH), 128.7 (6 -C), 125.7 and 124.2 (7- and 8 -CH), 124.0 andl 12.8 
(2 x CN), 91.9 (2-C); m/z 254 (M +, 8 6 %), 227 (M + -  HCN, 100), 200 (M + -  2 x  HCN, 15), 
187 (6 ), 174 (6 ), 150 (6 ), 113 (24), 100 (26), 87 (11).
5-(4-Nitrophenylene)-2-dimethyl-l,3-dioxane-4,6-dione (140)— Using Method 
C, 4-nitrobenzaldehyde (1.231 g, 8.15 mmol) and 2 ,2-dim ethyl-l,3-dioxane-4,6-dione 
(Meldrum’s acid; 1.124 g, 7.81 mmol) were reacted in ethanol (20 ml) with the addition of 
10 % piperidine in methanol (5 drops). After 2 h the crystals were collected (1.633 g, 75 %), 
m.p. 201-203 °C (from EtOH); RF 0.80 (diethyl ether); (Found: C, 56.13; H, 3.96; N, 4.83; 
M+, 277.0597. C 13H n N 0 6 requires C, 56.32; H, 4.00; N, 5.05%; M, 277.0586); v max(KBr 
disc)/cm_1 3 1 19w and 3014w (=C-H), 2989w and 2941 w (CH3), 1760m and 1729s (C =0), 
1630m and 1601m (Ar and C=C), 1528s (C -N 0 2), 1350s, 1306s, 1293s and 1198s (C-O), 
930m, 853m, 832m and 796m (=C-H deformations); 5 H(200 MHz; DMSO-d6) 8.54 (1 H, s, 
2-H), 8.36 (2 H, d, 3-/5_H/7.H 8.77 Hz, 4- and 8-H), 8.14 (2 H, d, ^ h / s - h  8 -67  Hz> 5‘ and
7-H), 1.83 (6  H, s, 0C(CH 3 )20 ); 5 c (50 MHz; DMSO-d6) 154.0 (2-CH), 150 (6-C), 132.6 
(5- and 7-CH), 123.2 (4- and 8-CH), 107.0 (1-C), 71.6 (0C(CH3)20 ) ,  27.4 (OC(CH3)20); 
m/z 277 (M*, 0.4%), 262 (M + -C H 3, 3), 219 (M + -  (CH3 )2C = 0 , 100), 202 (M+ -  
(CH3)2C (0H )0 , 80), 191 (M+ - C 0 2, - ( C H 3)2C, 8), 175 (M+ -  C 0 2, -  (CH3)2C =0, 8 ), 172 
(M+ -  H NO j, -  (CH3 )2C =0, 37), 146 (M + -  2 x  C 0 2, -  (CH3)2CH, 7), 129 (M + -  C 0 2, -  
N 0 2, -  (CH3 )2C = 0 ,20), 117 (M+ -  2  x  C 0 2, -  N = 0, -  (CH3)2C, 14), 101 (51), 89 (22), 75 
(39).
Experimental Procedures— Chapter 7
2-Cyano-3-[5-(2-nitrofuranyl)]propenonitrile (141)— Using Method C, a 100 ml 
round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (1.020 g, 7.23 mmol), 
absolute ethanol (7 ml), malononitrile (0.478 g, 7.24 mmol) and ethanolic piperidine (1:1,
1 drop). After 1.25 h the orange precipitate was filtered (1.187 g, 87 %) and a portion was 
crystallised from ethyl acetate: m.p. 173-174 °C (from EtOAc); RF 0.43 (diethyl ether); 
(Found: C, 50.78; H, 1.51; N, 22.35; M+, 189.0378. C8H3N 30 3 requires C, 50.81; H, 1.60; 
N, 22.22%; M , 189.0359); v max(KBr discVcm ' 1 3128m and 3071m (=C-H), 2232m (3 x  
CN), 1614m (Ar-C=C), 1558s (Ar), 1517s (N 0 2), 1470s and 1344s ( C - O ^ ) ,  842m, 814m, 
789m and 742m/w (=C-H); 8 H(200 MHz; acetone-d6) 8.29 (1 H, s, 3-H), 7.74 (1 H, d, ^ . h
4.03 Hz, 6 -H), 7.68 (1 H, d, 4.03 Hz, 5-H); 8C(50 MHz; acetone-d6) 153.1 (7-C), 149.0
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(4-C), 144.2 (3-CH), 124.7 (6 -CH), 115.4 (1-CN), 114.0 (5-CH), 112.7 (1-CN), 84.2 (2-C), 
(other CN visible at 113.96 in ] H... 13C coupled spectrum); m/z 189 (M +, 71%), 173 (M+ -  
O, 7), 160 (M+ -  HCN, 8 ), 159 (M + -  N = 0, 83), 131 (M+ -C N , -  N = 0 , 31), 115 (M+ -C N , 
- N 0 2, 51), 105 (100), 88 (65), 77 (27), 64 (47).
3-Amino-2,4-dicyano-5-[5-(2-nitrofuranyl)]penta-2,4-dienonitrile (142)— Using 
Method C, a 100 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde 
(1.203 g, 8.53 mmol) absolute ethanol (10 ml), 1.1.3-tricyano-2-amino-propene (1.127 g,
8.53 mmol) and ethanolic piperidine (1:1,.2 drops). After an initial heating to near reflux 
and 0.5 h at room temperature, the green precipitate was collected (1.714 g, 79 %), 
dissolved in THF and filtered. The liquors were subjected to column chromatography 
through a plug of silica using ethyl acetate/petroleum ether ( 1:1) and the main fraction was 
crystallised from acetone/ethyl acetate: m.p. 137-138 °C (from acetone/EtOAc); Rp 0.09  
(diethyl ether); (Found: C, 51.79; H, 1.97; N, 27.57; M+, 255.0285. CHH5N 5O3 requires C, 
51.71; H, 1.98; N, 27.44%; M , 255.0253); vmax(KBr d iscern ' 1 3372m, 3325m and 3217m  
(NH2), 3154m, 3130m and 3068m (=C-H ), 2223m/s and 2206m/s (3 x  CN), 1650m/s 
(H2N-C=C(CN)2), 1609m (Ar-C=C), 1558s (Ar), 1514s (N 0 2), 1350s ( C - O ^ ) ,  821m/w, 
812m and 738mAv (=C-H); 8 H(200 MHz; DMSO-d6) 9.23 (2 H, br s, N H 2), 8.11 (1 H, s, 3- 
H), 7.87 (1 H, d, 5y5.H4.01 Hz, 6-H), 7.59 (1 H, d, JJ(yH 4.03 Hz, 5-H); 5C(50 MHz; DMSO- 
dj) 164.1 (H2N-C=C(CN)2), 153.1 (7-C), 148.4 (4-C), 137.3 (3-CH), 122.8 (6 -CH), 115.4 
(l-C N ), 114.0 (5-CH ), 114.5 and 113.8 (H 2 N-C=C(CN)2), 103.4 (2-C ), 50 .4  
(H2N-C=C(CN)2); m/z 255 (M +, 36.5%), 225 (M + -  N = 0 , 2), 209 (M+ -  N 0 2, 100), 181 
(M+ -  N 0 2, -  CN, 53), 154 (MH+ -  N 0 2, -  2 x  CN, 60), 127 ([HC=C(CN)-C=C(CN)2]+, 
29), 100(14), 89(14).
2-Cyano-3-[5-(2-nitrofuranyl)]propenamide (143)— Using Method C, a 50 ml 
round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (1.155 g, 8.19 mmol), 
absolute ethanol (2  ml), cyanoacetamide (0 .688  g, 8.18 mmol) in hot ethanol (8 ml) and 
ethanolic piperidine (1:1 ,2  drops). After 1 h the black precipitate was filtered, subjected to 
column chromatography on silica with ethyl acetate/petroleum ether (30-40°) dilutions and 
gave: (0.327 g, 19 %), m.p. 190-193 °C (from EtOAc/Petroleum ether; bp 30-40 °C); 
/?F 0.21 (diethylether); (Found: C, 46.23; H, 2.56; N, 20.27; M +, 207.0492. C 8H5N 3 0 4 
requires C, 46.39; H, 2.43; N, 20.28%; M, 207.0475); v max(KBr disc)/cm'* 3432m, 3379m
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and 3317m (NH2), 3180m, 3142m and 3058m (=C-H), 2 2 2 1 w (CN), 1687s (C =0), 1614s 
andl563s (Ar), 1535s (N 0 2), 1474m/s (C-NH 2), 1349s {C -0 ^ rmt), 836m, 812m, 804m and 
738m (=C-H); 5 H(200 MHz; DMSO-d6) 8.11 (1 H, s, 3-H), 8.04 and 7.96 (2 H, 2 x  br s, 
NH2), 7.86 (1 H, d, 3J5.h 3.66 Hz, 6 -H), 7.58 (1 H, d, 3J6.H 3.62 Hz, 5-H); 8 C(50 MHz; 
DMSO-d6) 161.6 (C =0), 152.7 (7-C), 149.4 (4-C), 134.8 (3-CH), 121.6 (6 -CH), 115.2 
(1-CN), 114.2 (5-CH), 108.0 (2-C); m /z207 (M+, 37%), 191 (M+ - N H 2, 1), 162 (M+ -C O ,  
- N H 3, 13), 161 (M + - N 0 2, 100), 133 (M+- N 0 2, -  CN, 26), 118 (7.5), 105 (28), 89 (20),
78 (15).
2-Cyano-3-[5-(2-nitrofuranyl)]propenothioamide (144)— U sing Method C, a 
50 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (2.040 g, 
14.46 mmol), absolute ethanol (5 ml) and cyanothioacetamide (1.448 g, 14.46 mmol) 
dissolved in ethanol (10 ml). After the reaction reached ambient temperature the precipitate 
was filtered, washed with ethyl acetate, and dried with ether washings to give (2.550 g,
79 %), m.p. 189 °C (decomp.) (from EtOH); RF 0.63 (diethyl ether); (Found: C, 43.05; H, 
2.46; N, 18.72; M +, 223.0180. C8H5N 30 3S requires C, 43.05; H, 2.26; N, 18.82%; Af, 
223.0137); v max(KBr discVcm ' 1 3373m and 3275m (NH2), 3171m, 3142m  and 3027m/w  
(=C-H ), 2219w (CN), 1625s (C=S), 1560s (Ar), 1537s (N 0 2), 1472m/s (C-NH2), 1346s 
(C—Ofuj-Qix), 878s, 831 m/s, 810s and 738m/s (=C-H); 5H(200 MHz; DM SO-ds) 10.30 and
9.73 (2 H, 2 x  br s, NH 2), 8.04 (1 H, s, 3-H), 7.86 (1 H, d, J/ 5.H 4.01 Hz, 6 -H), 7.62 (1 H, d, 
} J(M 4.03 Hz, 5-H); 8 C(50 MHz; DMSO-d^) (C=S not within scale), 152.7 (7-C), 149.4 
(4-C), 131.1 (3-CH), 121.3 (6-CH), 115.1 (1-CN), 114.4 (5-CH), 113.0 (2-C); m/z 223 (NT, 
25%), 193 (M+ -  N = 0 , 3), 189 (M+ -  H2S, 8 ), 177 (M+ -  N 0 2, 100), 159 (M+ -  H2S, -  
H C N ,-H ,21.5), 149 (M+ -  N 0 2, -  CN, 49), 122(24), 105(55), 88(21).
M ethyl 2-cyano-3-[5-(2-nitrofuranyl)]propenoate (145)— U sing Method C, 
a 100 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (1.125 g,
7.97 mmol), methanol (4 ml) and methyl cyanoacetate (0.790 g, 7.97 mmol) diluted in 
methanol (5 ml). The reaction was heated with, methanolic piperidine (5 % piperidine, 
1 drop) and after 35 min the light orange precipitate was collected (1.464 g, 83 %). A  
portion o f this was recrystallised from acetone to give as yellow  flakey crystals, m.p. 
211-212 °C; R f 0.65 (ethyl acetate); (Found: C, 48.41; H, 2.62; N, 12.42; M +, 222.0912. 
C9H6N 20 j requires C, 48.66; H, 2.72; N, 12.61%; M, 222.0953); v raa*(KBr disc)/cm''
Synthesis and Biological Evaluation o f Anticancer Agents Page 174
3145m and 3059m (=C-H), 2984m/w, 2960w (CH3), 2235m/w (CN), 1715s (C =0), 1622m  
(C=C), 1562m/s (Ar), 1532s (N 0 2), 1473m/s and 1343s (C -0 ^ ra/l), 844m, 812m, 767m/w  
and 741m/w (=C-H); 5 H(200 MHz; DMSO-ds ) 8.27 (1 H, s, 3-H), 7.83 (1 H, d, SJ5.H
3.98 Hz, 6-H), 7.68 (1 H, d, i / 6.H 3.99 Hz, 5-H), 3.93 (3 H, s, CH3); 8C(50 MHz; DMSO-d6)
161.7 (C =0), 153 (7-C; weak signal), 148.8 (4-C), 138.3 (3-CH), 123.8 (6 -CH), 113.9 
(5-CH), (1-CN masked), 103.8 (2-C), 53.7 (CH3); m/z 222 (M+, 25%), 206 (M + -  CH4 , 2), 
191 (M+ -O C H 3, 11), m ^ - N O *  100), 164 (MH+ -  C 0 2CH3, 3), 161 ( M I T - N O j ,-  
0 ,2 2 ) ,  148(M + - N 0 2, - C N ,  17), 117 (M+ - N 0 2, -  C 0 2CH3, 8), 133 (19), 105(21), 88 
(24).
Ethyl 2-cyano-3-[5-(2-nitrofuranyl)]propenoate (146)— U sing Method B, a 
100 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (1.000 g,
7.09 mmol), absolute ethanol (5 ml) and ethyl cyanoacetate (0.802 g, 7.09 mmol) diluted in 
ethanol (5 ml). The reaction was heated with ethanolic piperidine (1:1, 2 drops) and on 
cooling (after 20 min) the crystals were collected (1.292 g, 77 %). A portion was 
recrystallised from ethyl acetate and gave: m.p. 146-147 °C (from EtOAc); RF 0.73 (diethyl 
ether); (Found: C, 50.93; H, 3.54; N, 11.76; M +, 236.0902. C 10H 8N 2O5 requires C, 50.86; 
H, 3.41; N, 11.86%; M. 236.0852); v max(KBr disc)/cm‘' 3160m/w, 3138m/w and 3045m  
(=C-H ), 2984m /w, 2938m/w and 2871 w (CHX), 2232m /w (CN), 1738s (C =0), 1625m  
(C=C), 1561s (Ar), 1526s (N 0 2), 1474m/s and 1348s ( C - O ^ ) ,  823m, 812m, 762m and 
739m/s (=C-H); 8h(200 MHz; acetone-d6) 8.20 (1 H, s, 3-H), 7.72 (1 H, d, J/ S.H4.01 Hz,
6 -H), 7.69 (1 H, d, 3J(M 4.01 Hz, 5-H), 4.37 (2 H, q, 3J  7.12 Hz, CH2), 1.36 (3 H, t, 3J  
7.11 Hz, CH3); 8 C(50 MHz; acetone-d6) 161.9 (C =0), 154 0(7-C (?), 149.9 (4-C), 138.6 
(3-CH), 123.1 (6-CH), 114.7 (1-CN), 114.0 (5-CH), 105.8 (2-C), 63.6 (CH2), 14.2 (CH3); 
m/z 236 (M+, 20%), 220 (M + -  CH4, 1), 208 (MH+ -  CH2CH3, 2), 191 (M + -  OCH2CH3,
17), 190 (M* -  N 0 2, 18), 178 (M* -  NO, -  CN, 7), 162 (M+ -  H C 0 2, -  CH2CH3, 100), 134 
(M+ - H N 0 2, - C 0 2, - C H 2CH3, 49), 106 (14), 89 (26.5).
n-Butyl 2-cyano-3-[5-(2-nitrofuranyl)]propenoate (147)— Using Method C, a 
100 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (1.197 g,
8.48 mmol), n-butanol (5 ml) and n-butyl cyanoacetate (1.198 g, 8.49 mmol) dissolved in 
n-butanol (5 ml). The reaction was heated with 5% piperidine in ethanol (1 drop) and on 
cooling the cream crystalline precipitate was collected over a sinter, washed with ethyl
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acetate and dried with n-pentane/ether washings under suction: (1.753 g, 51 %), m.p. 
125.0-125.3 °C (from rc-butanol); RF 0.82 (diethyl ether); (Found: C, 54.83; H, 4.38; N, 
10.62; M+, 264.0489. C 12H 12N 20 5 requires C, 54.55; H, 4.58; N, 10.60%; M , 264.0427); 
vmax(KBr discVcm ' 1 3157w, 3137m/w and 3060m (=C-H), 2965m, 2933m/w, 2899m/w and 
2875m (CHX), 2236w  (CN), 1720s (C =0), 1621m (C=C), 1562s (Ar), 1530s ( N 0 2), 
1475m/s and 1344s (C-Ofuran), 829m/s, 813m/s and 738m /s (=C -H ); 5H(200 MHz; 
DMSO-d6) 8.28 (1 H, s, 3-H), 7.87 (1 H, d, 3J5.H 3.99 Hz, 6-H), 7.69 (I H, d, 3J(f.H 4.00 Hz,
5-H), 4 .32 (2 H, t, 3J  6.47 Hz, CH 2CH2CH2CH31. 1.72 (2 H, q t, 3J  6 .8  Hz, 3 J  6.45 Hz, 
CH2CH2£ H 2CH3), 1.43 (2 H, tt, J77.23 Hz, 3J 7.0 Hz, CH2£ H 2CH2CH3), 0.97 (3 H, t, 3J  
7.26 Hz, CHjCH2CH2CHi ); 8C(50 MHz; DMSO-d6) 161.2 (C =0), 153.2 (7-C), 148.8 (4-C),
138.2 (3-C H ), 124.3 (6 -CH), 114.2 (1-CN), 114.0 (5-CH ), 103.6 (2-C), 66 .4  
(£H 2CH2CH2CH3), 3 0 .0  (C H 2 £H 2CH2CH3), 18.6 (C H 2 CH2£ H 2CH3), 13 .6
(CH2CH2CH2CH31: m/z 264 (M +, 21%), 234 (M+ - N = 0 , 2), 218 (M+ - N 0 2, 17 ),209 (M + 
-C H 2CH2CH2CH3, 2 1 ), 191 (M H+ -  N 0 2, -  CN, 46), 162 (MH+ - C 0 2 CH2CH2CH2CH3, 
9 1 ), 134 (M H + -  C 0 2CH2CH2CH2CH3, -  CN, 39), 117 (M + -  N 0 2, -  
C 0 2CH2CH2CH2CH3, 17), 105 (16), 89 (38), 77 (13), 62 (24), 56 ((CH3CH=CHCH3]+, 
100).
tert -Butyl 2-cyano-3-[5-(2-nitrofuranyl)]propenoate (148)— Using Method C, a 
50 ml round-bottomed flask was charged with 2-nitrofuran-5-carbaldehyde (0.985 g,
6.98 mmol), isopropanol (5 ml) and ferf-butyl cyanoacetate (1.050 g, 7.44 mmol). The 
reaction was heated with 5 % piperidine in isopropanol (2 drops) and after 1 h the 
precipitate was collected (1.214 g, 66  %), m.p. 157-158 °C (from z-PrOH); RF 0.83 (diethyl 
ether); (Found: C, 54.43; H, 4.71; N, 10.45; M +, 264.0749. C12H 12N 20 5 requires C, 54.55; 
H, 4.58; N, 10.60%; M, 264.0746); v raax(KBr discVcm ' 1 3132m and 3059m (=C-H), 2996m, 
2940w (CH3), 2232m/w (CN), 1718s (C =0), 1622m (C=C), 1561m/s (Ar), 1527s (N 0 2), 
1473m/s and 1344s (C -O y ^ ) , 823m/s, 812m/s, 766m/w and 738m /w (=C-H); 5^ 200  
MHz; DMSO-dg) 8.17 (1 H, s, 3-H), 7.83 (1 H, d, 3JS.H 3.99 Hz, 6 -H), 7.66 (1 H, d, 3J(M 
3.96 Hz, 5-H), 1.59 (3 H, s, Bu'); 5C(50 MHz; DMSO-d6) 160.0 (C =0), 149.0 (7-C), 137.6 
(3-CH), 123.2 (6 -CH), 114.3 (1-CN), 114.0 (5-CH), 105.7 (4-C), 84.2 (2-C), 27.7 ( ‘Bu); m/z 
264 ( M \  25%), 249 (M + -  CH3 , 2), 220 (M+ -  N 0 2 , 1), 208 (M + -  Bu', + H, 6 ), 191 (M + -
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OBu‘, 27), 162 (M+ -  C 0 2Bu‘, -  H, 3), 148 (M+ -  N 0 2, -  CN, 17), 134 (M+ -  C 0 2, -  H Bu\ 
-  HCN, 3), 117 (M + -  N 0 2, -  C 0 2Bu', 7), 105 (3), 89 (10), 57 ([ 'Bu}*, 100)
2-Cyano-3-[5-(2-nitrofuranyl)]propenoic acid  (149)— A 25 ml round-bottomed 
flask was charged with terf-butyl 2-cyano-3-[5-(2-nitrofuranyl)]propenoate (0.763 g, 
2.89 mmol) and dissolved in a minimum amount of 98 % formic acid (ca. 10 ml) by heating 
to reflux for 15 min. After this time the reaction was allowed to cool to room temperature 
(unstirred) and the crystals were filtered, washed in ethyl acetate and ether to give the title 
acid (0.412 g, 68  %), m.p. 242 °C (decomp.) (from H C 0 2H); (Found: C, 46.02; H, 1.89; N, 
13.42; M+, 208.0123. C8H4N 20 5 requires C, 46.17; H, 1.94; N, 13.46%; M , 208.0120); 
v max(KBr discVcm ' 1 3436m/w (broad C 0 2H), 3141m and 3054m (=C-H  deformations), 
2235m/w (CN), 1688s (C =0), 1616s (C=C), 1561m/s (Ar), 1529s (N 0 2), 1474s and 1344s 
(C -O y ^ J , 842m and 809m (=C-H); 8H(200 MHz; DMSO-d6) 8.21 (1 H, s, 3-H), 7.86 (1 H, 
d, 3/ j . h ’3.97 Hz, 6 -H), 7.64 (1 H, d, 3JM  3.99 Hz, 5-H); Sc (50 MHz; DM SO-d6) 162.6 
(C =0), 153.4(7-C), 149.0(4-C), 137.7 (3-CH), 123.6 (6 -CH), 114.8 (1-CN), 114.1 (5-CH),
105.1 (2 -C); m/z 208 (M +, 42%), 192 (M + -  O, 4), 178 (M+ -  N = 0 , 32), 164 (M + -  C 0 2,
31), 162 (M+ - N 0 2, 58), 148 (M + - N 0 2 , - C N , 3.5), 134 (M+ -  C 0 2H, -  HCN, 100), 124 
(M + -  NC-C-C02 ,21), 117 (M+ - N 0 2 , - C 0 2H, 4), 106 (43), 90 (32).
2-Cyano-3-[5-(2-nitrothienyl)]propenonitrile (151)— Using Method C, a 50 ml 
round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (1.045 g, 6.65 
mmol), absolute ethanol (5 ml), malononitrile (0.439 g, 6.65 mmol) and 50 % ethanolic 
piperidine (1 drop). After 30 min the precipitate was filtered: (1.121 g, 82 %), m.p. 
147-149 °C (from EtOH); RF 0.55 (ethyl acetate/petroleum ether 1:1); (Found: C, 46.44; H, 
1.53; N, 20.75; M +, 204.9949. C8H3N 30 2S requires C, 46.83; H, 1.47; N, 20.47%; M, 
204.9971); v max(KBr discVcm ' 1 3050s (=C-H ), 2240s (CN), 1590s and 1545m (C=C), 
1485s (N 0 2), 815w (=C-H); Sh(200 MHz; DMSO-d6) 8.79 (1 H, s, 3-H), 8.23 (1 H, d, 3JS_H
4.4 Hz, 6-H), 7.89 (1 H, d, J7frH 4 -4  Hz, 5-H); 8C(50 MHz; DMSO-d6) 155.9 (7-C), 152.5 
(3-CH), 139.2 (4-C), 137.9 (6-CH), 129.6 (5-CH), ca. 113 (2 x  CN, broad signals), 82.7 
(2-C); m/z 205 (M+, 61%), 175 (M+ -  N = 0 , 14), 159 (M+ -  N 0 2, 31), 147 (M+ -  HCN, -  
HS, 9), 132 (M + -  N 0 2, -  HCN, 21), 115 (M + -  N 0 2, -  C sS , 52), 94 (13), 88 (38), 82 (17).
3-Amino-2,4-dicyano-5-[5-(2-nitrothieny I) ]penta-2,4-dienonitrile (152)— Using 
Method C, a 50 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde
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(2.875 g, 18.29 mmol), THF (10 ml), 1.1.3-tricyano-2-amino-propene (2.415 g, 18.28 
mmol) and 50 % piperidine in ethanol (5 drops). After 6 h the orange precipitate was filtered 
and crystallised from ethyl acetate to give dark red crystals: (1.501 g, 30 %), m.p. 214-215 
°C (from EtOAc); Rp 0.51 (ethyl acetate); (Found: C, 48.51; H, 1.90; N, 25.93; M +, 
271.0134. C n H 5N 50 2S requires C, 48.71; H, 1.86; N, 25.82%; M, 271.0172); vmax(KBr 
discycm ' 1 3330m  (NH2), 3090w (=C -H ), 2250s and 2220s (3 x  CN), 1640s (H 2N- 
C=C(CN)2), 1585w and 1540w (Ar), 1520s (N 0 2), 815ws (=C-H); 5 H(200 MHz; DMSO- 
dg) 9.17 (2 H, br s, NH2), 8.41 (1 H, d, 4JS.H 0.4 Hz, 3-H), 8.23 (1 H, d, 3J5.H 4.4 Hz, 6-H),
7.88 (1 H, dd, 3 J(M 4 .4  Hz, 4 J 3. H 0 .4 Hz, 5-H); S c (50 MHz; D M SO -d6) 163.8 
(H2N-£=C(CN)2), 154.9 (7-C), 145.3 (3-CH), 139.9 (4-C), 136.8 (6 -CH), 129.7 (5-CH), 
115.3 and 114.4 ( 1- CN and H2N-C=C(£N)2), 103.0 (2-C), 50.4 (H2N -C =£(C N )2); m/z 271 
(M+, 34%), 241 (M+ -  N = 0 ,7), 225 (M+ -  N 0 2, 13), 198 (MH+ -  N 0 2, -  CN, 54), 154 (M + 
-  CN, -  H2N-C=C(CN)2, + H, 23), 127 (9), 88 ( 11).
2-Cyano-3-[5-(2-nitrothienyl)]propenamide (153)— Using Method C, a 50 ml 
round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (1.283 g, 
8.16 mmol), absolute ethanol (4 ml), cyanoacetamide (0.686 g, 8.16 mmol) in hot ethanol 
(11 ml) and 50 % piperidine in ethanol (2 drops). After 1 h the precipitate was filtered and 
gave: (1.203 g, 66  %), m.p. 231-233 °C (from EtOH); Rp 0.58 (ethyl acetate); (Found: C, 
43.68; H, 2.17; N, 18.59; M+, 223.0956. C8H5N 3O3S requires C, 43.05; H, 2.26; N, 18.83%; 
M, 223.0998); v max(KBr discycm ' 1 3350m and 3250m (NH2), 3005w (=C-H ), 2200w (CN), 
1690s (C =0), 1599s and 1542m (Ar, C=C), 1500s (N 0 2), 820m (=C-H ); 5 H(200 MHz; 
DMSO-d6) 8.46 (1 H, s, 3-H), 8.24 (1 H, d, 3J5.H 4.4 Hz, 6-H), 8.03 and 7.96 (2 H, 2  x  br s, 
NH2), 7.90 (1 H, d, 3J&h 4.4 Hz, 5-H); Sc (50 MHz; DMSO-d6) 161.4 (C =0), 154.1 (7-C), 
142.6 (3-CH), 141.1 (4-C), 136.2 (6 -CH), 129.7 (5-CH), 115.8 (1-CN), 107.4 (2-C); m/z 223 
(M+, 37%), 193 (M + - N = 0 , 7), 179 (M+ -C O N H 2, 48), 177 (M +- N 0 2 , 100), 127 (9), 107
(6 ), 92 (5).
2-Cyano-3-[5-(2-nitrothienyl)]propenothioamide (154 )— U sing Method C, a 
100 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (2.044 g,
13.01 mmol), absolute ethanol (10 ml) and cyanothioacetamide (1.303 g, 13.01 mmol). 
After the reaction reached ambient temperature the precipitate was filtered and gave: 
(2.503 g, 80 %), m.p. 137-139 °C (from EtOH); Rp 0.46 (ethyl acetate); (Found; C, 39.89;
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H, 2.07; N, 17.22; M +, 238.9940. C 8H5N 30 2S2 requires C, 40.16; H, 2.11; N, 17.56%; M, 
238.9958); v max(KBr discVcm ' 1 3360m and 3150s (NH2), 3060w (=C -H ), 2190w (CN), 
1620s (C=S), 1500s (N 0 2), 1460s (C-N), 820m (=C-H); 5 H(200 MHz; DM SO-d6) 8.46 
(1 H, s, 3-H), 8.22 (1 H, d, J73.H4 .4  Hz, 6-H), 7.98 and 7.95 (2 H, 2  x  br s, NH2), 7.90 (1 H, 
d, 3J(,h  4 .4 Hz, 5-H); m/z 239 (M+, 37%), 206 (M + -  H 2S, 11), 193 ( M * -  N 0 2, 68), 179 
(M+ -C S N H 2 ,3 7 ) ,8 8 (8 ) .
Methyl 2-cyano-3-[5-(2-nitrothienyl)]propenoate (155 )— U sing Method C, a 
50 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (2.417 g, 
15.38 mmol), methanol (10 ml) and methyl cyanoacetate (1.354 g, 13.66 mmol). The 
reaction was heated and on cooling the crystals were collected: (2.948 g, 91 %), m.p. 
172-173 °C (from MeOH); i?F 0.62 (ethyl acetate); (Found: C, 45.10; H, 2.49; N, 11.61; M+, 
238.0052. C9H6N 20 4S requires C, 45.38; H, 2.54; N, 11.76%; M, 238.0080); v ^ tK B r  
discVcm ' 1 3100m  (=C-H), 2950m (C H J, 2220w (CN), 1720s (C =0), 1500s (N 0 2), 1340s 
(C-O), 835m and 815m (=C-H); §h(200 MHz; DMSO-d6) 8.67 (1 H, s, 3-H), 8.22 (1 H, d, 
f / j .H 4.4 Hz, 6-H), 8.02 (1 H, d, 1J(M 4.4 Hz, 5-H), 3.85 (3 H, s, CH3); m/z 238 (M+, 40%), 
207 (M + -O C H 3, 15), 192 (M+ - N 0 2, 100), 179 (M + -  C 0 2CH3, 18), 133 (M+ - N 0 2, -  
C 0 2CH3, 34), 127 (7), 88  (9).
Ethyl 2-cyano-3-[5-(2-nitrothienyl)]propenoate  (1 5 6 )— U sing Method C, a 
100 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (2.001 g,
12.73 mmol), absolute ethanol (20 ml), ethyl cyanoacetate (1.440 g, 12.73 mmol) and 50 % 
piperidine in ethanol (4 drops). The reaction was heated and on cooling (after 20 minutes) 
the crystals were collected: (1.725 g, 54 %), m.p. 126-127 °C (from EtOH); i?F 0.54 (ethyl 
acetate); (Found: C, 47.37; H, 3.14; N, 11.00; M+, 252.0221. C 10H 8N 2O4S requires C, 
47.62; H, 3.20; N, 11.10%; M , 252.0201); v max(KBr discVcm ' 1 3132m, 3102m  and 3026w  
(=C -H ), 2 9 9 lw  and 2942m (CH2CH3), 2225m (CN), 1718s (C = 0 ), 1607s (C=C), 1539s 
(N 0 2), 1259s (C -O ), 879m, 782m, 762m and 736m (=C-H); 5 H(200 MHz; DMSO-dj) 8.64 
(1 H, s, 3-H), 8.22 (1 H, d, J75.H4.3 Hz, 6 -H), 8.03 (1 H, d, 3J(M 4.3 Hz, 5-H), 4.35 (2 H, q, 
3J  7.1 Hz, CH2), 1.33 (3 H, t, 3J 1 . \  Hz, CH3); 8C(50 MHz; DM SO-d6) 161.0 (C =0), 155.1 
(7-C), 146.4 (3-CH), 140.3 (4-C), 138.0 (6-CH), 129.6 (5-CH), 115.2 (1-CN), 103.6 (2-C),
62.8 (CH2), 14.0 (CH3); m/z 252 (M +, 74%), 236 (M+ -  CH4, 3), 224 (M+ -  CH2CH3, + H, 
29), 207 (M * -  OCH2CH3, 69), 179 (M* -  C 0 2CH2CH3, 25), 174 (M+ - N Q 2, -  S, 91), 161
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(M+ -  N 0 2, -  H-CS, 21), 146 (M + -  C 0 2CH2C R 3, -  HS, 100), 133 (M + -  N 0 2, -  
C 0 2CH2CH3, 45), 122 (21), 107 (16), 94 (14), 82 (29).
n-Butyl 2-cyano-3-[5-(2-nitrothienyl)]propenoate (157)— Using Method C, a 
50 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (1.475 g,
9.39 mmol), isopropanol (20 ml) and n-butyl cyanoacetate (1.325 g, 9.39 mmol). The 
reaction was heated and on cooling the crystals were collected over a sinter, washed with 
ijopropanol and dried with /t-pentane washings under suction: (1.753 g, 71 %), m.p. 
112-113 °C (from /-PrOH); Rp 0.73 (ethyl acetate); (Found: C, 51.07; H, 4.21; N, 10.13; 
M+, 280.0489. C 12H 12N 20 4S requires C, 51.42; H, 4.32; N, 9.99%; M, 280.0520); v max(KBr 
discVcm ' 1 3100m (=C-H), 2950m (CHX), 2225w (CN), 1720s (C =0), 1605w (C=C), 1500s 
(N 02), 1340s (C -O ), 840m and 825m (=C-H); 8 ^ 2 0 0  MHz; DMSO-d^) 8.65 (1 H, s, 3-H), 
8.22 (1 H, d, } J5.h 4.5 Hz, 6 -H), 8.03 (1 H, d, 3J&H 4.5 Hz, 5-H), 4.26 (2 H, t, 3J  6.4 Hz, 
CH2CH2CH2CH3), 1-65 (2 H, q t, 3J 7.2 Hz, J/6 .4  Hz, CH2CH2CH2CH3'). 1.33 (2  H, tt, 3J
7.2 Hz, 3J 1 .2  Hz, CH2£ H 2CH2CH3), 0.91 (3 H, t, 3J 1 .2  Hz, CH2 CH2CH2£ H 3); m/z 280 
(M+, 22%), 234  (M+ -  N 0 2 , 7), 224 (M+ -  CH2=CHCH2CH3, 41), 180 (MH+ -  
C 0 2CH2CH2CH2CH3, 18), 133 (M + -  N 0 2 , -  C 0 2 CHjCHjCHjCHj, 17), 56 
({CH 3CH=CHCH3l  100).
tett-Butyl 2-cyano-3-[5-(2-nitrothienyl)]propenoate (158)— Using Method C, a 
50 ml round-bottomed flask was charged with 2-nitrothiophene-5-carbaldehyde (1.245 g,
7.92 mmol), isopropanol (10 ml) and terf-butyl cyanoacetate (1.302 g, 9.22 mmol). The 
reaction was heated and on cooling the crystals were collected (0.948 g, 45 %), m.p. 
170-171 °C (from EtOH); Rp 0.73 (1:1 ethyl acetate/petroleum ether); (Found: C, 51.76; H, 
4.29; N, 9.87; M+, 280.0522. C 12H 12N 20 4S requires C, 51.42; H, 4.32; N , 9.99%; M, 
280.0538); v max(KBr discVcm ' 1 3106m, 3079m and 3032m (=C -H ), 2986m, 2955m and 
2937m (C(CH3)3), 2224m (CN), 1728s (C =0), 1604s (C=C), 1531s ( N 0 2), 1508s (Ar), 
1343s, 1275s and 1163 (C-O), 839m/s and 824m/s (=C -H  deformations); 8 h(200M Hz; 
DMSO-ds ; 333 K) 8.57 (1 H, s, 3-H), 8.24 (1 H, d, 3J5.H 4.31 Hz, 6 -H), 8.04 (1 H, d, 3J&li 
4.33 Hz, 5-H ), 1.58 (9 H, s, Bu‘); Sc (50 MHz; DMSO-d6; 333 K) 159.6 (C 0 2Bu‘), 154.7 
(7-C), 145.4 (3-CH), 140.2 (4-C), 137.1 (6 -CH), 129.4 (5-CH), 115.0 (1-CN), 105.0 (2-C),
52.2 (£(CH3)3), 27.4 (C (£H 3)3); m/z 280 (M +, 2%), 265 (M + -  CH 3, 0.2), 234 (M+ -  N 0 2,
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0.5), 207 (M + -  OBu‘, 12), 178 (M+ -  CO,, -  HBu', 10), 133 (M + -  N 0 2, -  COjBu1, 11), 
107 (4), 88  (4), 82 (11), 69 (10), 57 ([B i/]+, 100).
2-Cyano-3-[5-(2-nitrothienyl)]propenoic acid  (159)— A 25 ml round-bottomed 
flask was charged with terf-butyl 2-cyano-3-[5-(2-nitrothienyl)]propenoate (0.456 g,
1.63 mmol) and dissolved in a minimum amount of 98 % formic acid (ca. 3 ml) by heating 
to reflux for 5 min. After this time the reaction was allowed to cool to room temperature 
(unstirred) and the crystals were filtered, washed in ethyl acetate and ether to give the title 
acid (0.301 g, 82 %), m.p. 192-194 °C (from H C 02H); (Found: C, 42.65; H, 1.87; N, 12.24; 
M +, 223.9903. C 8H4N 20 4S requires C, 42.86; H, 1.78; N, 12.50%; M, 223.9892); v ^ tK B r  
discVcm ' 1 3428m  (broad C 0 2H), 3100m and 3047m (=C-H ), 2243w (CN), 1694s (C =0), 
1599s (C=C), 1527s (N 0 2), 1501s (Ar), 1339s, 1279m/s and 1210m/s (C-O ), 818m/s and 
731m (=C-H); 8 H(200 MHz; DMSO-d6) 8.62 (1 H, s, 3-H), 8.27 (1 H, d, V 5.H 4.26 Hz,
6-H), 8.04 (1 H, d, 3J6,h 4.34 Hz, 5-H); Sc(50 MHz; DMSO-d6) 162.4 (C 0 2H), 154.8 (7-C),
145.5 (3-CH), 140.8 (4-C), 137.3 (6-CH), 129.7 (5-CH), 113.8 (1-CN), 105.5 (2-C); m/z 224 
(M+, 19%), 194 (M+ -  NO, 3), 180 (M + -  C 02, 50), 178 (M+ -  N 0 2, 38), 150 (M+ -  H N 02, 
-H C N , 8 8 ), 134 (M + -  N 0 2, -  C 0 2, 15), 122(78), 107(18), 88(16.5).
2-Cyano-3-[4-(2-nitrothienyl)]propenonitrile (160)— Using Method C, a 25 ml 
round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.540 g, 
3.44 mmol), absolute ethanol (5 ml), malononitrile (0.227 g, 3 .44 mmol) and 50 % 
piperidine in ethanol ( 2 drops). After 5 h the precipitate was filtered and crystallised from 
isopropanol to give: (0.195 g, 28 %), m.p. 106-107 °C (from f-PrOH); Rp 0.60 (ethyl 
acetate); (Found: C, 46.74; H, 1.53; N, 20.55; M +, 204.9941. C8H3N 30 2S requires C, 46.83; 
H, 1.47; N, 20.47%; M, 204.9989); v ^ K B r  discVcm' 1 3103s (=C-H ), 2233s (CN), 1597s, 
1545m and 1530s (Ar), 1508s (N 0 2), 819s (=C-H); 8H(200 MHz; DM SO-ds) 8.75 (1 H, dd, 
^J5.h 1.93  Hz, 4Ji_H0A% Hz, 8-H), 8.48 (1 H, dd, 4J5_H0.95  Hz, V s.h0.48 Hz, 3-H), 8.45 
(1 H, dd, V j.h1.93 Hz, V j.h0.95 Hz, 5-H); 8C(50 MHz; DMSO-ds ) 153.4 (3-CH), 152.8 
(7-C), 143.5 (8 -CH), 132.0 (4-C), 127.5 (5-CH), 113.7 and 113.0 (2 x  CN), 82.1 (2-C); m/z 
205 (M +, 67%), 175 (M+ -  N = 0 ,23), 159 (M+ -  N 0 2, 13), 147 (M+ -  HCN, -  HS, 88), 132 
(M+ -  N 0 2 , -  HCN, 18), 115 (M+ -  N 0 2, -  O S ,  31), 88  (33), 82 ([fA]+, 10), 69 (23), 45 
(100).
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3-Amino-2,4-dicyano-5-[4-(2-nitrothienyl)]penta-2,4-dienonitrile (161)— Using 
Method C, a 50 ml round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde 
(1.036 g, 6.59 mmol), tetrahydrofuran (10 ml), 1.1.3-tricyano-2-amino-propene (0.871 g, 
6.59 mmol) and 50 % piperidine in ethanol (5 drops). After 4.5 h the precipitate was filtered 
and subjected to chromatography through silica using ethyl acetate:petroleum ether ( 1:1) 
elutions. The main fraction obtained (0.74 g, 41 %) was then crystallised from isopropanol 
to give: (0.350 g, 20 %), m.p. 185-186 °C (from i-PrOH); RF 0.52 (ethyl acetate/petroleum 
ether 1:1); (Found: C, 48.99; H, 1.97; N, 26.08; M +, 271.0150. C u H 5N 50 2S requires C, 
48.71; H, 1.86; N, 25.82%; M, 271.0115); v max(KBr discVcm*1 3330m (NH2), 3038w  
(=C-H), 2231s and 2229s (CN), 1636s (C=C(CN)2), 1585s and 1540s (Ar), 1522s (N 0 2), 
870s and 834s (=C-H); 8H(200 MHz; DMSO-d6) 9.10 (2  H, br s, NH2), 8.70 (1 H, d, V 5.H
2.3 Hz, 8 -H), 8.58 (1 H, d, V 8.H 2.3 Hz, 5-H), 8.15 (1 H, s, 3-H); 8 C(50 MHz; DMSO-d6)
164.6 (H2N-C=C(CN)2), 152.9 (7-C), 145.8 (3-CH), 141.6 (8 -CH), 132.4 (4-C), 127.6 
(5-CH), 115.4 (1-C N ), 114.7 and 114.6 (H ,N -C =C (C N )2), 102.6 (2-C), 50.1  
(H2N-C=C(CN)2); m/z 271 (M +, 65%), 241 (M + - N = 0 ,  23), 225 (M + - N 0 2, 100), 198 (M + 
-  N 0 2, -  HCN, 43), 181 (M+ -  N 0 2, -  C=S, 6 8 ), 154 (M+ -  CN, -  H 2N-C=C(CN)2, + H, 
18), 142 (M + -  NC-C(H2N)=C(CN)2, + H, 12), 92 ([H 2N-C=C(CN)2]+, 13).
2-Cyano-3-[4-(2-nitrothienyl)]propenamide (162)— Using Method C, a 50 ml 
round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.517 g,
3.29 mmol), absolute ethanol (5 ml), cyanoacetamide (0.277 g, 3.29 mmol) and 50 % 
piperidine in ethanol (3 drops). After 5 h the precipitate was filtered, subjected to column 
chromatography on silica with ethyl acetate/petroleum ether (bp 30-40 °C) dilutions and 
gave: (0 .229  g, 31 %), m.p. 217-219  °C (from  EtOH); R F 0 .56 (ethyl 
acetate:petroleum /ether,l:l); (Found: C, 43.02; H, 2.22; N, 18.90; M+, 223.0897. 
C8H5N 30 3S requires C, 43.05; H, 2.26; N, 18.83%; M , 223.0973); v max(KBr discVcm*1 
3422m, 3335m and 3289m (NH2), 3125m (=C-H ), 2849w (C -N H 2), 2 2 0 0 w (CN), 1686s 
(C =0), 1597s and 1491s (C=C, Ar), 1526s (N 0 2), 840m (=C-H); 8 H(200 MHz; DMSO-d6)
8.63 (1 H, d, ‘Vj.h 1-7 Hz, 8-H), 8.50 (1 H, d, % H 1.7 Hz, 5-H), 8.13 (1 H, s, 3-H), 7.84 and 
7.80 (2 x 1 H, 2 x  br s, NH2); 8C(50 MHz; CDC13) 162.0 (C =0), 152.4 (7-C), 143.2 (3-CH),
140.8 (8 -CH), 133.1 (4-C), 127.9 (5-CH), 116.3 (1-CN), 106.8 (2-C); m/z 223 (M+, 12%),
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207 (M + -  NH2, 2), 179 (M + -  CONH2, 8), 177 (M+ -  N 0 2, 100), 149 (M + -  H N 02, -  HCN,
18), 133 (M + -  N 0 2, -  CONH2, 12), 122(10), 105(17), 82 ([r/i]+, 8).
2-Cyano-3-[4-(2-nitrothienyl)]propenothioamide (163)— U sing Method C, a 
50 ml round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.536 g,
3.41 mmol), absolute ethanol (5 ml) and cyanothioacetamide (0.342 g, 3.42 mmol). After 
the reaction reached ambient temperature the precipitate was filtered and gave: (0.573 g, 
70 %), m.p. 199-201 °C (from EtOH); RF 0.51 (ethyl acetate/petroleum ether, 1:1); (Found: 
C, 40.12; H, 2.08; N, 17.32; M +, 238.9910. C 8H5N 30 2S2 requires C, 40.16; H, 2.11; N, 
17.56%; M , 238.9956); vmax(KBr discVcm ' 1 3135s (NH2), 3080m (=C-H ), 2215m (CN), 
1480s ( N 0 2), 1470s (S=C -N H 2), 840w (=C-H); 5h(200 MHz; DMSO-ds ) 8.69 and 8.61 
(2 x  1 H, 2 x  br s, N H 2), 8.17 (1 H, d, V 5.H 1.9 Hz, 8-H), 8.10 (1 H, d, 1.9 Hz, 5-H),
8.02 (1 H, s, 3-H); 5 C(50 MHz; DMSO-d6) (C=S not observed), 152.4 (7-C), 140.8 (8-CH),
139.3 (3-CH), 132.9 (4-C), 128.0 (5-CH), 116.1 (1-CN), 112.6 (2-C); m /z 239 (M+, 22%), 
205 (M + -  H2 S, -  H, 2), 193 (M+ -  N 0 2, 100), 166 (M+ -  N 0 2, -  HCN, 21), 161 (M* -  
N 0 2, -  S, 9), 149 (M+ -  N 0 2, -  C = S ,  32), 122 (M +-  N 0 2, -  C sS , -  HCN, 13), 105 (9), 90
( 11), 82 ([th]*, 9), 69 (16.5), 60 ( [CSNH2] \  40).
M ethyl 2-cyano-3-[4-(2-nitrothienyl)]propenoate (164)— Using Method C, a 
50 ml round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.504 g, 
3.21 mmol), methanol (5 ml), methyl cyanoacetate (0.318 g, 3.21 mmol) and 50 % 
piperidine in methanol (1 drop). The reaction was heated and on cooling the crystalline 
precipitate was collected: (0.303 g, 68  %), m.p. 89-90 °C (from MeOH); R F 0.50 (ethyl 
acetate/petroleum ether, 1:1); (Found: C, 45.04; H, 2.41; N, 11.50; M +, 238.0035. 
C9H6N 20 4S requires C, 45.38; H, 2.54; N, 11.76%; M, 238.0051); v ^ N u jo lV c m ' 1 2200w  
(CN), 1720m (C = 0), 1618s (C=C), 1498s (N 0 2), 1265s (C-O); 5 H(200 MHz; DMSO-d6) 
8 .86  (1 H, d, ■05.h 0.5 Hz, 8 -H), 8.62 (1 H, d, 4Jm 0.5 Hz, 5-H), 8.45 (1 H, s, 3-H), 3.85 
(3 H, s, CH3); Sc (50 MHz; DM SO-d6) 162.0 (C =0), 153.0 (7-C), 147.3 (3-CH), 142.9 
(8 -CH), 132.8 (4-C), 128.3 (5-CH), 115.5 (1-CN), 102.8 (2-C), 53.5 (CH3); m/z 238 (M+, 
21%), 207 (M + -O C H 3, 13), 192 (M + - N 0 2, 100), 179 (M +- C 0 2CH3, 7), 177 (M+- N 0 2, 
-  CH3, 19), 161 (M H+ -  N 0 2, -  S, 6.5), 133 (M+ -  N 0 2, -  C 0 2CH3, 20.5), 121 (10), 106 
(7), 82 ([rft]+, 20), 69 (15), 59 ([C 0 2CH3]+, 18).
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Ethyl 2-cyanO’3-[4-(2-nitrothienyl)]propenoate (165 )— U sing Method C, a 
25 ml round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.535 g,
3.40 mmol), absolute ethanol (5 ml), ethyl cyanoacetate (0.385 g, 3.40 mmol) and 50 % 
piperidine in ethanol (2 drops). The reaction was heated and on cooling the precipitate was 
collected and crystallised from isopropanol: (0.351 g, 76 %), m.p. 108-109 °C (from  
/-PrOH); Rp 0.45 (ethyl acetate/petroleum ether, 1:1); (Found: C, 47.49; H, 3.09; N, 10.95; 
M+, 252.0224. C 10H8N 2O4S requires C, 47.62; H, 3.20; N, 11.10%; M, 252.0199); 
v max(KBr d iscycm ' 1 3100m (=C-H ), 2990w (CHX), 2240m  (CN), 1720m (C =0), 1450s 
(N 02), 1300s (C -O ), 825m (=C-H); 5h(200 MHz; DMSO-d6) 8 .86  (1 H, d, *Ji .H 1.96 Hz,
8-H), 8.63 (1 H, d, 47 ^ 1 .9 6  Hz, 5-H), 8.42 (1 H, s, 3-H), 4.30 (2 H, q, 3J 1 . 1 Hz, CH2),
1.29 (3 H, q, 3 J  7.1 Hz, CH3); 8C(50 MHz; DMSO-ds) 161.5 (C =0), 152.5 (7-C), 147.1 
(3-CH), 142.8 (8 -CH), 132.6 (4-C), 128.3 (5-CH), 115.5 (1-CN), 103.0 (2-C), 62.6 (CH2), 
14.0 (CHj); m/z 252 (M +, 19%), 224 (MH+-C H 2CH3, 2 ), 206 (M+ -  HOCH2 CH3, 53), 178 
(M+ -  C 0 2CH2CH3, -  H, 100), 161 (M* -  N 0 2, -  H-CS, 7), 150 (18), 133 (M+ -  N 0 2, -  
C 0 2CH2CH3, 25), 122 (19), 106 (9), 82 ( [* ]+, 26).
n-Butyl 2-cyano-3-[4-(2-nitroth.ienyl)]propenoate (166)— Using Method C, a 
25 ml round-bottomed flask was charged with 2-nitrothiophene-4-carbaldehyde (0.601 g,
3.88 mmol), n-butanol (6  ml) and /i-butyl cyanoacetate (0.540 g, 3.82 mmol). The reaction 
was heated and on cooling the crystals which formed were collected: (0.420 g, 39 %), m.p. 
144-145 °C (from /-PrOH); RF 0.71 (ethyl acetate/petroleum ether, 1:1); (Found: C, 51.37; 
H, 4.08; N, 10.10; M +, 280.0527. C 12H 12N 20 4S requires C, 51.42; H, 4.32; N, 9.99%; M , 
280.0521); v max(KBr discycm ’1 3100m (=C-H), 2940m (CHX), 2 2 0 0w (CN), 1718m (C=0), 
1610m (C=C), 1491s (N 0 2), 1280s (C-O), 817w (=C-H); 5 H(200 MHz; DMSO-d^) 8.86  (1 
H, m, 8 -H ), 8 .64  (1 H, m, 5-H ), 8.42 (1 H, m, 3-H), 4 .26 (2 H, t, 3J  6.5 Hz, 
CH2CH2CH2CH3), 1.63 (2 H, tq, 3J 1 2  Hz, 3J 6 A  Hz, CH2CH2£ H 2CH3), 1.39 (2 H, tt, 3J
6.4 Hz, 3J 6 .5 Hz, CH2f l i 2CH2CH3), 0.90 (3 H, t, 3J 7.2 Hz, CH2 CH2CH2O i 3); m/z 280 
(M+, 21%), 234 (M + -  N 0 2 , 100), 223 (M+ . -  CH 2CH2CH2CH3, 31), 207 (M+ -  
OCH2CH2CH2CH3, 32), 179 (M+ -  C 0 2CH2CH2CH2CH3, 43), 133 (M+ -  N 0 2 , -  
C 0 2CH2CH2CH2CH3, 27), 82 ([di]+, 14), 69 (25), 57 ([CH2CH2CH2CH3]+, 87).
4-Nitro-2-thiophenecarbaldehyde (168)— While stirring at ambient temperatures 
with an overhead mechanical stirrer, a 50 ml beaker was charged with concentrated sulfuric
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concentrated sulfuric acid (98 % (w/v), 21.20 g, 0.22 mol) and thiophene-2-carbaldehyde 
(8.71 g, 0.078 mol). This solution was cooled to ca. -10 °C in an ice/salt water bath while a 
nitrating solution of concentrated sulfuric acid (16.3 g, 0.17 mol) plus fum ing  nitric acid 
(18.9 g, 0.30 mol) was prepared and similarly cooled to ca. -10 °C. The nitrating solution 
was slowly added to the reaction solution (1.5 h) while keeping the temperature between -10 
and -20 °C by the addition of freshly crushed carbon dioxide snow. The reaction mixture 
was allowed to reach room temperature over 1.5 h and was poured onto ice (300 g) in a 1 1 
wide-necked conical flask. The aqueous solution was extracted with diethyl ether (3 x  150 
ml), and the ether extracts were dried over anhydrous sodium sulphate and concentrated in 
vacuo. By 90 MHz 1H NMR spectroscopy an ca. 3:2 mixture of the 4- and 5-nitrothiophene- 
2-carbaldehyde products were obtained. This was subjected to column chromatography on 
silica with petroleum ether (bp 30-40 °C)/ethyl acetate (4:1) and the oily main fraction was 
subjected to a series of crystallisations at ca. O °C and -15 °C in isopropanol with added n- 
pentane or petroleum ether (bp 30-40 °C). This gave 4-nitrothiophene-2-carbaldehyde as 
flakey brown crystals (4.07 g, 33 %), m.p. 47.4 °C (/-PrOH/«-pentane) (lit.,269 35-37 °C); R F 
0.84 (diethylether); (Found: C, 37.70; H, 1.80; N, 9.22; M +, 157.1483. C5H3N 0 3S requires 
C, 38.22; H, 1.92; N, 8.91%; M, 157.1419); vmax(KBr discycm ' 1 3118m and 3088m (= C -  
H), 2835w (CHO), 1683s (C =0), 1540s (C -N 02), 1513s (Ar), 881s, 784s, 738s, 710s and 
662s (=C-H); 8 h(200M Hz; CDC13) 9.93 (1 H, d, 4Jyn  1.38 Hz, 1-HC=0), 8.63 (1 H, dd, 
^ i - h / 5 - h  1 4 3  Hz, 3-H), 8.26 (1 H, d, 4J±H 1.48 Hz, 5-H); 5C(50 MHz; CDC13) 182.0 
(CHO), 148.7 (4-C), 134.4 (3-CH), 131.2 (2-C), 129.4 (5-CH); m/z 157 (M +, 100%), 127 
(M+ -N O , 15), 110 (M+ - N 0 2, -  H, 16), 82 ([r/i]+,M + - N 0 2, -  CHO, 46).
2-Cyano-3-[2-(4-nitrothienyl)]propenonitrile (169)— Using Method C, a 50 ml 
round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.232 g,
1.48 mmol), absolute ethanol (3 ml), malononitrile (0.098 g, 1.48 mmol) and ethanolic 
piperidine (1:1, 1 drop). After 10 min the precipite was filtered and gave: (0.212 g, 70 %), 
m.p. 169-171 °C (from EtOH); RF 0.81 (diethyl ether); (Found: C, 46.44; H, 1.53; N, 20.75; 
M+, 204.9938. C 8H3N 30 2S requires C, 46.83; H, 1.47; N, 20.47%; M, 204.9983); vmax(KBr 
discycm ' 1 3092s, 3073s and 3039s (=C-H), 2232s (CN), 1685w (C=C), 1592s, 1542m and 
1531s (Ar), 1531s (N 0 2), 883m, 782s and 746s (=C-H); 8H(200 MHz; acetone-d6) 9.11 
(1 H, q, SJ7_„ 1.52 Hz, J  0.56 Hz, 5-H), 8.52 (1 H, s, 3-H), 8.46 (1 H, dd, 4J5.H 1.60 Hz, 4J3.H
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0.44 Hz 7-H); 8 C(50 MHz; acetone-d6) 151.9 (3-CH), 149.8 (6 -C), 136.1 (5-CH), 132.2 
(7-CH), 117.3 (4-C), 112.6 and 113.1 (2 x CN), 84.3 (2-C); m/z 205 (M +, 61%), 204 (M+ -  
H, 100), 175 (M+ -  N =0, 14), 159 (M+ -  N 0 2, 31), 147 (M + -  HCN, -  HS, 9), 132 (M+ -  
N 0 2, -  HCN, 21), 115 (M+ -  N 0 2, -  C=S, 52), 94 (13), 88 (38), 82 (17), 69 (22).
3-Amino-2,4-dicyano-5-[2-(4-nitrothienyl)]penta-2,4-dienonitrile (170)— Using 
Method C, a 100 ml round-bottomed flask was charged with 4-nitrothiophene-2- 
carbaldehyde (0.550 g, 3.50 mmol), absolute ethanol (10 ml), 1.1.3-tricyano-2-amino- 
propene (0.461 g, 3.49 mmol) and ethanolic piperidine (1:1, 1 drop). After 1 h the yellow  
precipitate was filtered and gave: (0.526 g, 56 %), m.p. 270-273 °C (from EtOH); R F 0.16 
(diethyl ether); (Found: C, 48.47; H, 1.73; N, 25.88; M +, 271.0169. C u H 5N 50 2S requires C, 
48.71; H, 1.86; N, 25.82%; M , 271.0112); vmax(KBr disc)/cm'! 3373m, 3330m and 3216m  
(NH2), 3094s and 3005m (=C-H), 2227s and 2215s (CN), 1654s (C=C), 1587s and 1540s 
(Ar), 1639s (N 0 2), 780m, 733s and 618s (=C-H); 8 H(200 MHz; DMSO-d6) 9.19 and 9.17 
(2  H, 2  x  br s, N H 2), 9.18 (1 H, s, 5-H), 8.42 (2 H, s, 3- and 5-H); 8 C(50 MHz; DMSO-d6)
164.3 (H2N-D=C(CN)2), 147.9 (6 -C), 145.1 (3-CH), 136.8 (5-CH), 130.8 (7-CH), 130.7 
(4-C), 115.4 (1-CN), 114.6 and 114.6 (2 x CN), 101.2 (2-C), 50.2 (H2N-C=£(CN)2); m/z 
271 (M+, 39%), 254 (M+-N H 3, 3), 241 (M + - N = 0 ,  14), 224 (M + - H , - N 0 2, 13), 193 (M + 
-  N 0 2 , -  HS, 100), 154 (M + -  CN, -  H2N-C=C(CN)2, + H, 10), 139 (7), 92 
([H2N-C=C(CN)2)+, 9.
2-Cyano-3-[2-(4-nitrothienyl)]propenamide (171)— Using Method C, a 50 ml 
round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.397 g,
2.53 mmol), absolute ethanol (4 ml), cyanoacetamide (0.212 g, 2.52 mmol) and ethanolic 
piperidine (1:1, 1 drop). After 3.25 h the precipitate was filtered, subjected to 
chromatography on silica with ethylacetate/petroleum ether (bp 30-40 °C) dilutions and 
gave: (0.103 g, 18 %), m.p. 202-204 °C (from EtOH); RF 0.34 (diethyl ether); (Found: C, 
43.98; H, 2.08; N, 18.59; M+, 223.0896. C8H5N 30 3S requires C, 43.05; H, 2.26; N, 18.83%; 
M, 223.0968); v max(KBr disc)/cm'' 3423m and 3181m (NH2), 3089s and 3048m (=C-H), 
2216s (CN), 1690s (C =0), 1599s and 1542m (Ar), 1541s ( N 0 2), 865m, 781m and 738m  
(=C-H); 8 h(200 MHz; DMSO-d6) 9.16 (1 H, br s, 5-H), 8.62 (1 H, s, 3-H), 8.41 (1 H, br s,
7-H), 7.92 (2 H, v.br s, NH 2); Sc (50 MHz; DMSO-d6) 161.8 (C =0), 147.8 (6 -C), 142.6 
(3-CH), 136.6 (4-C), 134.8 (5-CH), 130.0 (7-CH), 116.2 (1-CN), 105.6 (2-C); m/z 223 (M+,
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13%), 207 (M + -  N H 2, 4), 193 (M+ -  N = 0 ,5), 179 (M+ -  CONH2 , 3), 176 (M+ -  N 0 2, -  H,
8 ), 145 (M + - N 0 2 , - S ,  100), 136(22), 133(12), 107 (6 ) ,9 0 (5 ) ,8 2 (8 ) , 69(11), 63 (14.5).
2-Cyano-3-[2*{4-nitrothienyl)]propenothioamide (172)— U sing Method C, a 
50 ml round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.668 g, 
4.25 mmol), absolute ethanol (5 ml) and cyanothioacetamide (0.426 g, 4.25 mmol). After 
the reaction reached ambient temperature the precipitate was filtered and gave: (0 .535  g, 
53 %), m.p. 212 °C (decomp.) (from EtOH); R¥ 0.62 (diethyl ether); (Found: C, 39.77; H, 
2.09; N, 17.01; M +, 238.9910. C8H5N 30 2S2 requires C, 40.16; H, 2.11; N, 17.56%; AT, 
238.9956); v max(KBr disc)/cm*1 3367m, 3277m and 3170m (NH2), 3098s, 3084s and 3012m  
(=C-H ), 2209m (CN), 1628s (C=S), 1596s and 1541m (Ar), 1540s ( N 0 2), 877s, 865m, 
780m and 732m (=C-H); 5h(200 MHz; DMSO-d*) 10.22 and 9.66 (2 x  1 H, 2 x  br s, NH 2), 
9.15 (1 H, d, 4J7.h 1.17 Hz, 5-H), 8.40 (1 H, d, % H 1.17 Hz, 7-H), 8.36 (1 H, s, 3-H); 8^50  
MHz; DMSO-d6) 191.1 (C=S), 147.9 (6 -C), 148.8 (3-CH), 136.5 (4-C), 135.0 (5-CH), 130.0 
(7-CH), 116.1 (1-CN), 111.3 (2-C); m/z 239 (M +, 17%), 205 (M+ -  H 2S, -  H, 11), 192 (M* 
- N 0 2 , - H ,  8 ), 161 (M+ - N 0 2, - S ,  100), 148 (M+ - N 0 2, - C sS , - H, 8 ), 133 (5), 115(6), 
88  (7.5), 82 (6), 69 (12), 60 (21.5).
M ethyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (173)— Using Method C, a 
50 ml round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.370 g, 
2.35 mmol), methanol (3 ml) and methyl cyanoacetate (0.234 g, 2.36 mmol). The reaction 
was heated and on cooling the crystals were collected: (0.303 g, 54 %), m.p. 173-174 °C 
(from EtOH); RF 0.81 (diethyl ether); (Found: C, 45.15; H, 2.47; N, 11.90; M+, 238.0031. 
C ,H sN 20 4S requires C, 45.38; H, 2.54; N, 11.76%; M , 238.0052); v max(KBr discj/cm ' 1 
3 1 14m, 3 102m and 3025m (=C-H), 2958w and 2854m (CH3), 2225m (CN), 1716s (C =0), 
1604s (C=C), 1533s ( N 0 2), 1266s (C -O ), 875m, 782m , 762m  and 742m  (=C-H ); 
Sh(200 MHz; DMSO-ds) 9.18 (1 H, d, *J7.H 1.37 Hz, 5-H), 8.69 (1 H, s, 3-H), 8.59 (1 H, d, 
*J7.h 1.36 Hz, 7 -H), 3.90 (3 H, s, CH3); 5C(50 MHz; DM SO-d6) 161.9 (C =0), 147.8 (6-C),
146.5 (3-CH), 136.4 (5-CH), 136.0 (4-C), 132.3 (7-CH), 115.3 (1-CN), 101.4 (2-C), 53.6 
(CH3); m/z 238 (M +, 43%), 222 (M + -  CH4 , 2), 207 (M + -O C H 3, 33), 191 (M + -  N 0 2, -  H,
9), 179 (M +- C 0 2CH3, 9), 160 (M+ - N 0 2, - S ,  100), 133 (M+ - N 0 2, - C 0 2CH3, 17), 121
(7), 107 (5.5), 88  (9).
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Ethyl 2-cyano-3-[2-(4-nitrothienyl)]propenoate (1 7 4 )— U sing Method C, a 
50 ml round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.380 g,
2.42 mmol), absolute ethanol (3 ml) and ethyl cyanoacetate (0.274 g, 2.42 mmol). The 
reaction was heated and on cooling the crystals were collected: (0.351 g, 57.5 %), m.p. 
170-171 °C (from EtOH); R? 0.84 (diethyl ether); (Found: C, 47.38; H, 3.20; N, 11.28; M+, 
252.0221. C 10H 8N 2O4S requires C, 47.62; H, 3.20; N , 11.10%; M, 252.0201); v max(KBr 
discycm ' 1 3132m, 3102m and 3026w (=C-H), 2991w and 2942m (CH2CH3), 2225m (CN), 
1718s (C =0), 1607s (C =Q , 1539s (N 0 2), 1259s (C -O ), 879m, 782m , 762m  and 736m  
(=C-H); 5„(200 MHz; DMSO-d6) 9.16 (1 H, d, 4J7.H 0.80 Hz, 5-H), 8.69 (1 H, s, 3-H), 8.61 
(1 H, d, 4J5_u 0.93 Hz, 7-H), 4.39 (2 H, q, J/ 7.11 Hz, CH2), 1.38 (3 H, t, 3J I M  Hz, CH3); 
8C(50 MHz; DM SO-d6) 161.2 (C = 0), 148.0 (6-C), 145.8 (3-CH), 136.1 (4-C), 135.3 
(5-CH), 131.5 (7-CH), 114.8 (1-CN), 102.0 (2-C), 62.4 (CH2), 13.4 (CH3); m/z 252 (M +, 
74%), 236 (M* -  CH4, 3), 224 (M + -  CH2CH3, + H, 29), 207 (M+ -  OCH2CH3, 69), 179 
(M+- C 0 2CH2CH3, 25), 174(M + - N 0 2, - S ,9 1 ) ,  161 (M + - N O ,,- H - C S ,  21), 146 (M + -  
C 0 2CH2CH3, -  HS, 100), 133 (M+ -  N 0 2, -  C 0 2CH2CH3, 45), 122 (21), 107 (16), 94 (14), 
82 (29).
n-Butyl 2-cyano-3’[2-(4-nitrothienyl)]propenoate (175)— Using Method C, a 
50 ml round-bottomed flask was charged with 4-nitrothiophene-2-carbaldehyde (0.389 g,
2.48 mmol), isopropanol (3 ml) and n-butyl cyanoacetate (0.349 g, 2.47 mmol). The 
reaction was heated and on cooling the crystals were collected: (0.283 g, 41 %), m.p. 
150-151 °C (from z-PrOH); R? 0.89 (diethyl ether); (Found: C, 51.36; H, 4.10; N, 10.15; 
M+, 280.0519. C 12H 12N 20 4S requires C, 51.42; H, 4.32; N, 9.99%; A/, 280.0518); v max(KBr 
disc)/cm ' 1 3123m, 3097m and 3024w (=C-H), 2964m , 2937m and 2875w  (CH2 CH3), 
2223w (CN), 1713s (C =0), 1608s (C=C), 1540s (N 0 2), 1278s (C-O), 878m, 782m, 761m  
and 736s (=C-H); 5H(200 MHz; DMSO-c^) 9.20 (1 H, q, J/ 7_H1.66  Hz, J  0.70 Hz, 5-H), 
8.71 (1 H, s, 3-H), 8.63 (1 H, dd, 4Js_li 1.66 Hz, 4J 3.H 0.42 Hz 7-H), 4.31 (2 H, t, 3J 6.44 Hz, 
£H 2CH2CH2CH3), 1.71 (2 H, tt, 3 J  6.42 Hz, J/6 ,8 4  Hz, CH2Q i 2CH2CH3), 1.44 (2 H, q t, J
7.3 Hz, CH2CH2£ H 2CH3), 0.97 (3 H, t, 3J1.21  Hz, CH2CH2CH2O i 3); 5C(50 MHz; DM SO- 
d«) 161.4 (C = 0), 147.9 (6 -C), 146.4 (3-CH), 136.4 (5-CH), 136.1 (4-C), 132.3 (7-CH),
115.4 (1-C N ), 101.7 (2-C), 66.2 (CH-,CH,CH-,CH3). 30.1 (CH2 Q 1 2CH2CH3), 18.6 
(CH2CH2O I 2CH3), 13.7 (CH2 CH2CH2CB3); m /z  280  (M +, 17% ), 224  (M + -
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CH2CH2CH2CH3, + H> 36)> 207  (M+ -  OCH2CH2CH2CH3, 41), 202 (M+ -  N 0 2, -  S, 39), 
180 (M + -  C 0 2 CH2CH2CH2CH3, + H, 13), 146 (M+ -  C 0 2CH2CH2CH2CH3, -  HS, 23), 
133 (M + -  N 0 2, -  C 0 2CH2CH2CH2CH3, 23), 82 (14), 69 (14), 52 ([CH3CH=CHCH3], 
100).
2-N itro-3-(dichlorom ethyl)thiophene  (177)— Using oven dried glassware, a 
two-necked 250 ml round-bottomed flask equipped with a nitrogen bubbler and 
equilibrating dropping funnel was charged with a magnetic stirrer and potassium  
terr-butoxide (11.48 g, 0.102 mol, 3 equivalents). Under a nitrogen atmosphere, dry DMF 
(25 ml) and THF (25 ml) (recently distilled over sodium/benzophenone) were added and the 
dispersion formed was cooled below -70 °C. While maintaining the temperature below -65 
°C, a solution of 2-nitrothiophene (4.326 g, 0.0335 mol) and dry chloroform (4.3 ml, 0.0345 
mol) in DMF (6  ml), was added dropwise. After the addition was complete the dark 
coloured solution was immediately quenched over 10 min with acetic acid/methanol ( 1:1, 12 
ml, 3 equivalents) and then further acidified with another 12 ml. The reaction was allowed 
to reach ambient temperature, transferred to a separating funnel and partitioned between 
distilled water (150 ml) and diethyl ether (3 x 150 ml). The combined ether layers were 
washed with saturated sodium hydrogencarbonate (1 0 0  ml), brine (1 0 0  ml), dried over 
sodium sulphate and concentrated in vacuo to give a dark brown oil. This was subjected to 
column chromatography through a plug of silica using c-hexane and gave the title 
compound as a yellow crystalline paste (3.782 g, 53 %), 5 H(200 MHz; acetone-d6) 8.01 
(1 H, d, 3J4.H 5.69 Hz, 5-H), 7.75 (1 H, s, CHC12), 7.66 (1 H, d, 3J5.H 5.70 Hz, 4-H); 
8C(50 MHz; acetone-d6) 140.9 (2-C), 133.3 (5-CH), 133.1 (3-C), 128.9 (4-CH), 63.9 
(CHCl,).
2-Nitrothiophene-3-carbaldehyde (178)Z7°— Under a nitrogen atmosphere, a 
250 ml round-bottomed flask equipped with a reflux condenser and nitrogen bubbler was 
charged with 2-nitro-3-(dichloromethyl)thiophene (3.529 g, 0.0166 mol), a magnetic stirrer 
and 85 % formic acid (100 ml: prepared from 98-100 % formic acid and distilled water) was 
degassed under vacuum and put through a nitrogen atmosphere. The reaction was heated at 
reflux for 18 h, left to reach room temperature for 2 h, concentrated in vacuo and partitioned 
between water (200 ml) and diethyl ether (3 x 150 ml). The combined ether extracts were 
washed with water (2 x 150 ml), then re-washed with water (150 ml; which was continually
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basified with sodium hydrogencarbonate until pH remained at 8 ), dried over sodium  
sulphate and concentrated in vacuo to give a light brown oil which crystallised on standing 
(1.823 g, 70 %). This was dissolved in isopropanol/petroleum ether (3:5, 30 ml), filtered 
through a pad of Celite and crystallised at ca. -15 °C to give the title compound as yellow  
flakey crystals (1.251 g, 48 %), m.p. 60-61 °C (from /-PrOH/petroleum ether) (lit. ,270 54 °C); 
Rf  0.38 (9:4 n-hexane/diethylether); (Found: C, 38.11; H, 1.87; N, 8.85; M +, 156.9913. 
C5H3N 0 3S requires C, 38.22; H, 1.92; N, 8.91%; M, 156.9925); v max(KBr discycm ’1 
3110m, 3096m  and 3080m (C=C-H), 2910w (0=C -H ), 1680s (ArCHO carbonyl), 1534s 
(C -N 0 2), 1510s (Ar), 1387s, 1332s and 1228s (C -Sr/l), 820s, 743m/s and 774m/s (=C-H); 
8„(200 MHz; DMSO-d6) 10.55 (1 H, s, CHO), 7.76 (1 H, dd, 3J4_H 5.56 Hz, 4i CH0 0.70 Hz,
5-H), 7.51 (1 H, d, j / 5.H 5.57 Hz, 4-H); 8 C(50 MHz; DMSO-d6) 183.7 (CHO), (2-C not 
observed), 137.2 (3-C), 131.1 (5-CH), 126.7 (4-CH); m/z 157 (M+, 1.4%), 140 (M+ -  OH, 
7), 127 (M + -  CHO, -  H, 9), 113 (M + -  C=S, 42), 110 (M + -  H N 02, 48.5), 99 (M+ -  H- 
O C -S H , 11), 82 ([th]*, M+ -C H O , - N 0 2, 48), 71 ([C3H3S]+ e .g [H 2C=CH-CmS]+, 18), 55 
(I[C3H30]+  e.g. [H 2C =C H -C eO]*, 34), 39 (86), 28 (100).
2-Cyano-3-[3-(2-nitrothienyl)]propenonitrile (180)— Using Method C, a 25 ml 
round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde (0.162 g,
1.03 mmol), absolute ethanol (2 ml), malononitrile (0.068 g, 1.03 mmol) and ethanolic 
piperidine (1:1 ,1 drop). After 1 h the precipitate was filtered to give (0.142 g, 67 %), m.p. 
194-195 °C (from EtOH); Rp 0.67 (ethyl acetate/petroleum ether, 1:1); (Found: C, 46.47; H, 
1.51; N, 20.72; M +, 205.0003. C8H3N 30 2S requires C, 46.83; H, 1.47; N, 20.47%; M, 
204.9987); v max(KBr discycm ' 1 3038s (=C-H ), 2230w  (CN), 1636m (C=C), 1580s 
and1545m (Ar), 1522s (C -N 0 2), 870w and 834w (=C-H); 8H(200 MHz; DMSO-d6) 8.72 
(1 H, s, 3-H), 8.22 (1 H, d, J/ 8.H 5.7 Hz, 7-H), 7.76 (1 H, d, 3J1M 5.7 Hz, 8 -H); 8C(50 MHz; 
DMSO-d6) (5-C maybe masked by 3-CH), 152.2 (3-CH), 134.3 (7-CH), 131.6 (4-C), 127.3 
(8-CH), 113.3 and 112.2 (2 x CN), 88.3 (2-C); m/z 205 (M+, 46%), 188 (M+ -  OH, 15), 175 
(M+ - N = 0 ,4.5), 159 (M+ - N O 2, 20), 147 (M+ -  HCN, -  HS, 8 ), 132 (M + - N 0 2, -H C N ,  
17), 115 (M + -  N 0 2, -  C=S, 18), 97 (51), 88 (49), 82 ([th]*, 17), 70 (44).
3-Amino-2,4-dicyano-5-[3-(2-nitrothienyl)]penta-2,4-dienonitrile (181)— Using 
Method C, a 25 ml round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde 
(0.176 g, 1.12 mmol), absolute ethanol (10 ml), 1.1.3 -tricyano-2 -amino-propene (0.149 g,
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1.13 mmol) and ethanolic piperidine ( 1:1, 1 drop). After 1 h the yellow precipitate was 
filtered to give (0.185 g, 61 %), m.p. 210-212 °C (from EtOH); R F 0.58 (ethyl 
acetate/petroleum ether, 1:1); (Found: C, 48.58; H, 1.70; N, 25.71; M +, 271.0027. 
Cn H jN j0 2S requires C, 48.71; H, 1.86; N, 25.82%; M , 271.0112); vmax(KBr disc)/cm4 
3052m (=C-H ), 2726m (C -NH 2), 2223m and 2209m (CN), 1647s (C =Q , 1607s and 1540s 
(Ar), 1489s (C -N 0 2), 820w (=C-H); 5H(200 MHz; DMSO-d^) 9.27 (2 H, br s, NH2), 8.40 
(1 H, s, 3-H), 8.23 (1 H, d, 3Ji . li 5.6 Hz, 7-H), 7.78 (1 H, d, 3J7.H 5.6 Hz, 8-H); 5C(50 MHz; 
DMSO-d6) 164.0 (H2N-C=C(CN)2), 151.2 (5-Q , 143.8 (3-CH), 134.3 (7-CH), 132.2 (4-C),
127.2 (8 -CH), 115.1 (1-CN), 114.4 and 114.0 (H 2N-C=C(£N)2), 108.2 (2-C), 50.7  
(H2N-C=£(CN )2); m/z 271 (M+, 5%), 240 (M+ -  H -N =0, 12), 224 (M + -  H, -  N 0 2, 100), 
197 (M+ - H N 02, -  HCN, 56), 180 (M + -H N-C=C(CN)2, 30), 170 (M+ - H N 0 2 , - 2 x  CN, 
29), 158 (M + - N 0 2,-H C (C N )2, 17), 92 ([H2N-C=C(CN)2]*, 15).
2-Cyano-3-[3-(2-nitrothienyl)]propenamide (182)— Using Method C, a 50 ml 
round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde (0.156 g, 
0.99 mmol), absolute ethanol (2 ml), cyanoacetamide (0.091 g, 1.08 mmol) and ethanolic 
piperidine (1:1, 1 drop). After 3 h the precipitate was filtered to give (0.064 g, 29 %), m.p. 
217-219 °C (from EtOH); R ? 0.57 (ethyl acetate/petroleum ether, 1:1); (Found: C, 43.76; H, 
2.07; N, 18.47; M +, 223.0876. C8H5N 30 3S requires C, 43.05; H, 2.26; N , 18.83%; M, 
223.0959); v raax(KBr disc)/cm'' 3455m and 3380m (NH2), 3077s (=C -H ), 2200m (CN), 
1618s (C =0), 1599m (Ar), 1495m (N 0 2), 824m (=C-H); 8H(200 MHz; DMSO-d6) 8.21 
(1 H, s, 3-H), 8.19 (1 H, d, 3JS.H 5.6 Hz, 7-H), 8.08 (2 H, br s, NH2), 7.79 (1 H, d, J/ 7.H
5.6 Hz, 8 -H); 8C(50 MHz; DM SO-d6) 161.3 (C =0), 150.5 (5-C), 141.9 (3-CH), 133.8 
(7-CH), 133.4 (4-C), 127.7 (8-CH), 115.3 (1-CN), 112.3 (2-C); m/z 223 (M*. 5%), 206 (M + 
- N H 3, 2), 193 (M + -  N = 0, 5), 179 (M + -C O N H 2, 11), 177 (M+ - N 0 2, 100), 163 (13.5), 
153 (M+ -C O N H 2, -C N ,  17), 136 (19), 133 (M+ - N 0 2, - C 0 N H 2, 17), 110(14), 107 (12), 
97 (15), 95 (23.5), 88 (18), 82 ([tf if , 14), 69 (24).
2-Cycmo-3-[3-(2-nitrothienyl)]propenothioamide (183)— Using Method C, in 
the absence o f light and under a nitrogen atmosphere, a 25 ml round-bottomed flask was 
charged with 2-nitrothiophene-3-carbaldehyde (0.152 g, 0.97 mmol), absolute ethanol (2 ml) 
and cyanothioacetamide (0.098 g, 0.98 mmol). After the reaction reached ambient 
temperature no precipitation occurred. The reaction was re-heated to near boiling and
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petroleum ether was added. On cooling the precipitate was filtered o ff to give (0.155 g, 
66 %), m.p. 90-93 °C (from EtOH/Petroleum ether); Rp 0.55 (ethyl acetate/petroleum ether, 
1:1); (Found: C, 39.81; H, 2.06; N, 17.13; M+, 239.0001. C8H5N 30 2S2 requires C, 40.16; H, 
2.11; N, 17.56%; M, 238.9941); v max(KBr discycm '1 3330m (NH2), 3096s (=C-H), 2188m  
(CN), 1625s (C=S), 1598m and 1545m/w (Ar), 1507s (N 0 2), 818w (=C-H); 8^ 200  MHz; 
DMSO-ds) 9.84 and 9.55 (2 x  1 H, 2 x  br s, NH2), 8.05 (1 H, d, i 78_H 5.6 Hz, 7-H), 7.73 
(1 H, s, 3-H), 7.62 (1 H, d, J/ 7.„ 5.6 Hz, 8-H); m/z 239 (M+, 7%), 193 (M + - N 0 2, 100), 160 
CM* -  N 0 2, -  HS, 10), 149 (M + -  N 0 2, -  C=S, 8), 133 (M+ -  N 0 2, -  CSNH2, 17), 95 (23), 
88 (14), 82 ([i/i]+, 16), 69 (12).
M ethyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (184)— U sing Method C, a 
25 ml round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde (0.130 g, 
0.83 mmol), methanol (1.5 ml) and methyl cyanoacetate (0.103 g, 1.04 mmol). The reaction 
was heated with 5% piperidine in methanol (1 drop) and on cooling the crystals were 
collected to give (0.085 g, 43 %), m.p. 120-121 °C (from MeOH); Rp  0.46 (ethyl 
acetate/petroleum ether, 1:1); (Found: C, 45.27; H, 2.48; N , 11.63; M +, 238.0036. 
C9H6N 20 4S requires C, 45.38; H, 2.54; N, 11.76%; M , 238.0057); v ^ K B r  discycm '1 
3125m (=C-H ), 2920w (CH3), 2250w (CN), 1717s (C =0), 1530m/s (C -N 0 2), 1270s (C-O), 
820m (=C-H); 5 H(200 MHz; DMSO-d6) 9.00 (1 H, s, 3-H), 8.28 (1 H, d, J/g .H 5.7 Hz, 7-H),
7.83 (1 H, d, Jy7.H 5.7 Hz, 8-H), 3.86 (3 H, s, CH3); Sc (50 MHz; DM SO-d6) 161.6 (C =0),
151.8 (5-C), 145.4 (3-CH), 133.9 (7-CH), 132.3 (4-C), 127.3 (8-CH), 114.6 (1-CN), 108.1 
(2-C), 53.8 (CH3); m/z 238 (M +, 9%), 207 (M+ -OCH3, 2.5), 192 (M + - N 0 2, 100), 179 (M + 
- C 0 2CH3, 5), 177 (12), 161 ( M H * - N 0 2, - S ,  19), 133 ( M * - N 0 2, -  C 0 2CH3, 18), 121
(12), 111 (16), 107 (11), 97 (16), 88 (18), 59 ([C 0 2Me]+, 33.5).
Ethyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (1 8 5 )— U sing Method C, a 
25 ml round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde (0.127 g, 
0.81 mmol), absolute ethanol (1.5 ml)and ethyl cyanoacetate (0.118 g, 1.04 mmol). The 
reaction was heated with 5% piperidine in ethanol (1 drop) and on cooling the crystals were 
collected: (0.096 g, 47 %), m.p. 90-91 °C (from EtOH); Rp 0.63 (ethyl acetate/petroleum 
ether, 1:1); (Found: C, 47.35; H, 3.23; N, 11.04; M +, 252.0183. C 10H 8N 2O4S requires C, 
47.62; H, 3.20; N, 11.10%; M, 252.0199); v ^ tK B r  discycm '1 3115m (=C -H ), 2993w and 
2942m (CHX), 2240w (CN), 1725s (C =0), 1607s and 1501s (Ar and C = Q , 1532s (C -N 0 2),
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1265s (C -O ), 819m (=C-H); 5 H(200 MHz; DMSO-d6) 8.72 (1 H, s, 3-H), 8.20 (1 H, d, 
j 78.h 5.6 Hz, 7-H), 7.83 (1 H, d, 3J1.H 5.6 Hz, 8-H), 4.36 (2 H, q, J/7 .1  Hz, CH2), 1.36 (3 H, 
t, 3J 1 .\  Hz, CH 3); 5c (50 MHz; DMSO-d6) 161.2 (C =0), 151.8 (5-C), 145.3 (3-CH), 133.9 
(7-CH), 132.4 (4-C), 127.4 (8-CH), 114.6 (1-CN), 108.4 (2-C), 63.0 (CH2), 14.0 (CH3); m/z 
252 (M+, 7%), 222 (M + -  CH2CH3, -  H, 2), 206 (M+ -  HOCH2CH3, 20), 178 (M + -  
C 0 2CH2CH3, -  H, 93), 161 (M + -  N 0 2, -  H-C=S, 25), 150 (M+ -  N 0 2 , -  C=C=S, 36.5), 
147 (M+ -  C 0 2CH2CH3, -  S, 4), 133 (M+ -  N 0 2, -  C 0 2CH2CH3, 19), 122 (14), 107 (9), 97
(22), 82 ([* ]* , 29).
n-Butyl 2-cyano-3-[3-(2-nitrothienyl)]propenoate (186)— Using Method C, a 
25 ml round-bottomed flask was charged with 2-nitrothiophene-3-carbaldehyde (0.090 g, 
0.57 mmol), isopropanol (1 ml) and n-butyl cyanoacetate (0.146 g, 1.03 mmol). The 
reaction was heated with 5% piperidine in ethanol (1 drop) and on cooling the crystals were 
collected. These were washed briefly with wopropanol/Ax-pentane (1:2, 2 x  3 ml) and then 
>i-pentane ( 3 x 5  ml) to give (0.078 g, 49 %), m.p. 69-70 °C (from i-PrOH/rc-pentane); 
R f 0.60 (ethyl acetate/petroleum ether, 1:1); (Found: C, 51.34; H, 4.28; N, 9.72; M+, 
280.0525. C 12H 12N 20 4S requires C, 51.42; H, 4.32; N, 9.99%; M, 280.0517); vmax(KBr 
discycm '1 3120w (=C-H), 2950w (CHX), 2250w (CN), 1725s (C =0), 1608s and 1522s (Ar 
and C=C), 1530s (N 0 2), 1275s (C-O), 822s (=C-H); 8^ 200  MHz; DMSO-d6) 8.82 (1 H, s,
3-H), 8.20 (1 H, d, 3Ji .H 5.6 Hz, 7-H), 7.86 (1 H, d, 3J1.n 5.6 Hz, 8-H), 4.35 (2 H, t, J/6 .4  
Hz, CH2CH2CH2CH3), 1.73 (2 H, tt, J77.8 Hz, 3J 6 A  Hz, CH2f l i 2CH2CH3), 1.41 (2 H, q t, 
3J  7.8 Hz, 3J  7.1 Hz, CH2CH2£ H 2CH3), 0.93 (3 H, t, J/7 .1  Hz, CH2CH2CH2CH3); m/z 280 
(M+> 11%), 234  (M+ -  N 0 2 , 39), 223 (M+ -  C H 2CH2CH2CH3, 16), 207 (M+ -  
OCH2CH2CH2CH3, 21), 179 (M + -  C 0 2 CH2CH2CH2CH3, + H, 81), 147 (M + -  
C 0 2CH2CH2CH2CH3, -  S, 9), 133 (M* -  N 0 2, -  C 0 2CH2CH2CH2CH3, 13), 107 (13), 97
(23), 82 ([ A ]+, 11), 69 (14), 57 ([CH2CH2CH2CH3], 26).
2-C yan o-3 -(2 -q u in o lin y l)p ro p en o n itr ile  ( 1 8 7 ) — U sin g  M ethod  B , 
2-quinolinecarbaldehyde (1.270 g, 8.08 mmol) and malononitrile (0.536 g, 8.11 mmol) were 
reacted in ethanol (10 ml) with piperidine (2 drops). After 1.5 h the orange precipitate was 
collected (1.491 g, 90 %) and crystallised from isopropanol: (0.567 g, 35 %), m.p. 
168-170 °C (from z-PrOH); R F 0.67 (diethyl ether); (Found: C, 76.00; H, 3.47; N, 20.42; 
M+, 205.0636. C l3H 7N 3 requires C, 76.10; H, 3.41; N , 20.49%; M , 205.0632); v ^ tK B r
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disc)/cm'' 3045m (Ar-H), 2230s (CN), 1615w (C=C), 1600m, 1585m and 1500m (Ar), 
825s and 765s (=C-H); 5 H(200 MHz; DMSO-d6) 8.63 (1 H, s, 3-H), 8.52 (1 H, d, J/8 .4 6  
Hz, 7-H), 8.00 (2 H, 2 x  br d (eclipsing), 3J I M  Hz, 3J  8.44 Hz, 12- and 13-H), 7.85 (1 H, 
m, 3J  6.75Hz, 8-H), 7.76 (1 H, d, 10-H), 7.71 (1 H, m, 3J  6.73Hz, 9-H); 8C(50 MHz; 
DMSO-d6) 158.5 (3-CH), 148.8 (4-C), 146.9 (6-C), 137.9 (12-CH), 131.2 (7-CH), 129.4 and
129.2 (8- and 9-CH), 128.9 (11-C), 128.1 (10-CH), 124.1 (13-CH), 114.4 and 112.9 (2 x  
CN), 85.7 (2-C); m /z  205 (M +, 100%), 179 (M+ -  CN, 12), 154 (35), 129 (M + -  
HC=C(CN)2, + H, 25), 102 (M+ -  HC=C(CN)2 , -  H-C^C-H, 22.5), 75 (52), 63 (33), 51 
(49).
3-Amino-2,4-dicyano-5-(2-quinolinyl)penta-2,4-dienonitrile ( 188)  —  U s i n g  
Method B, 2-quinolinecarbaldehyde (1.053 g, 6 .70 mmol) and 1,1,3-tricyano- 
2-am inopropene (0 .887 g, 6.71 mmol) were reacted in THF (10 ml) with 
l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (3 drops) and after 8.5 h the yellow precipitate 
w as collected: (0.844 g, 46 %), m.p. 190 °C (decomp.) (from THF); RF 0.23 (diethyl ether); 
(Found: C, 70.84; H, 3.34; N, 25.82; M+, 271.0854. C 16H 9N 5 requires C, 70.61; H, 3.20; N, 
25.63%; M, 271.0851); vmax(KBr disc)/cm-1 3325s and 3180s (N H 2), 3045w (Ar-H), 2210s 
and 2020s (CN), 1650s and 1620m (C=C), 1605m and 1545s (Ar), 830m and 765m (Ar-H); 
8h(200 MHz; DM SO-d6) 9.39 and 9.31 (2 x  1 H, 2 x  br s, NH2), 8.62 (1 H, d, 3J l3.H
8.43 Hz, 12-H), 8.30 (1 H, s, 3-H), 8.10 (2 H, 2 x  d (overlapping), J  6.3 Hz, 7- and 10-H),
7.92 (2 H, t and d (overlapping), 3J \2-h 8.47 Hz, 9- and 13-H), 7.78 (1 H, dt, J  7.6 Hz, J
1.1 Hz, 8-H); 8C(50 MHz; DMSO-d6) 165.7 (H2N-£=C(CN)2), 150.4 (3-CH), 149.5 (4-C),
147.1 (6-C), 137.8 (12-CH), 131.0 (7-CH), 129.1 (8-CH), 128.8 (10-CH), 128.4 (11-C),
128.1 (9-CH), 123.6 (13-CH), 115.6 (1-CN), 114.5 (H2N-C=C(£N)2), 106.6 (2-C); tn/z 271 
(M+, 89%), 245 (M +-  CN, 88), 217 (M+-  2 x HCN, 17), 206 (M+-  CH(CN)2, 61), 179 (M +-  
H2N-C=C(CN)2, 39), 129 ([Ar]+, M + - H 2N-C=C(CN)2, -  C=C-CN, 100), 101 (38), 77 (38), 
63 (23).
2-Cyano-3-(2-quinolinyl)propenamide (189)— Using Method B and oven dried 
equipment, under a nitrogen atmosphere, 2-quinolinecarbaldehyde (1.038 g, 6.60 mmol) and 
cyanoacetamide (0.555 g, 6.60 mmol) were reacted in freshly distilled THF (10 ml) 
containing 4 A molecular sieves (ca  .1.5.g) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 
3 drops). After 4.5 h the reaction solution was concentrated under vacuum with some silica
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gel in preparation for column chromatography. After eluting with ethyl acetate and 
petroleum ether; bp 30-40 °C (1:1 to 8:5 mixtures) the main fraction (0.485 g, 32 %) was 
triturated in ethylacetate to give the title compound (0.111 g, 7.2 %), m.p. 245 °C (decomp.) 
(from EtOAc); R F 0.10 (diethyl ether); (Found: C, 69.49; H, 3.98; N, 18.67; M+, 223.0733. 
C13H9N 30  requires C, 69.95; H. 4.06; N, 18.82%; M ,  223.0721); v ^ K B r  disc)/cm4  
3200m (NH2), 2210w (CN), 1710s (C =0), 1645w (C=C), 1590s and 1495m (Ar), 1380s, 
1175m and 1130m (C-O), 880m, 855m/s and 680m (=C-H); 8 H(200 MHz; DMSO-d6) 8.57 
(1 H, d, j / i 3.h 8.5, 12-H), 8.31 (1 H, s, 3-H), 8.08 (2 H, t & d (overlapping), 3J  8.4 Hz, 9- 
and 13-H), 7.98 (2 H, 2 x  d (overlapping), 7- andlO-H), 7.73 (1 H, m, 8-H); § c (50 MHz; 
DMSO-d6) 163.0 (C =0), 151.5 (3-CH), 148.0 (6-C), 147.3 (4-C), 136.0 (12-CH), 130.1 
(8 -CH), 130.1 (7-CH), 129.8 (10-CH), 128.7 (11-C), 127.6 (9-CH), 122.7 (13-CH), 115.5 
(CN), 111.8 (2-C); m/z 223 ([M]+, 61%), 206 ( [M f -  NH3, 9), 194 ([M]+ -  HCN, 24), 179 
([M]+ -  N H 3, -  CO, 31), 152 ([M]+ -  HCN, -  CONH2, 36), 128 ([M ]+ -  CONH2, -  
H-C=C-CN, 53), 101 (22), 75 (35).
2-Cyano-3-(2-quinolinyl)propenothioamide ( 1 9 0 ) — U s in g  M eth od  B ,
2-quinolinecarbaldehyde (0.207 g, 1.32 mmol) and cyanothioacetam ide (0.132 g,
1.32 mmol) were reacted in ethanol (4 ml) with piperidine (2 drops) and after 1.5 h the solid 
was collected: (0.104 g, 33 %), m.p. 210 °C (decomp.) (from EtOH); RF 0.23 (diethyl ether); 
(Found: C, 64.87; H, 3.57; N, 17.16; M+, 239.0524. C 13H9N 3S requires C, 65.25; H, 3.79; 
N, 17.56%; M,  239.0518); vmax(KBr disc)/cm4  3335s (CSNH2), 3020s and 3005s (Ar-H), 
2215s (CN), 1660s (C=S), 1600s, 1570s and 1490s (Ar-H), 885s, 785s, 745s and 620s 
(=C-H); Sh(200 MHz; DMSO-d*) 10.1 (2 x  1 H, 2 x  br s, NH 2), 8.65 (1 H, d, 5/ 13.H 8.4 Hz, 
12-H), 8.17 (1 H, s, 3-H), 8.12 (1 H, br d, j / i 3. h 8.6 Hz, 12-H), 8 .10 (2 H, t & d 
(overlapping), f / 12.h 8.4 Hz, 9- and 13-H), 8.02 (2 H, 2 x  d (overlapping) , 3J  7.8 Hz, 7- and
10-H), 7.78 (1 H, dt, J  7.0 Hz, J  1.2 Hz, 8-H); Sc (50 MHz; DM SO-d6) 192.7 (C=S), 152.2 
(3-CH), 147.2 (6-C), 143.3 (4-C), 137.0 (12-CH), 130.2 (7-CH), 130.1 (8-CH), 129.0 
(10-CH), 128.6 (11-C), 127.7 (9-CH), 122.7 (13-CH), 117.8 (2-C), 115.5 (CN); m/z 239 
(M+, 91%), 206 (M+ -  HS, 79), 179 (M+ -  CSNH2, 41), 152 (M + -  CSNH2, -  HCN, 32), 
142 (M+ -  NC-CH-CSNH2, 33), 128 (M+ -  CSNH2, -  H-C^C-CN, 24), 115 (16), 101 (26), 
87 (18), 75 (36).
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Ethyl 2-cyano-3-(2-quinolinyl)propenoate  ( 1 9 1 ) — U sin g  M ethod B ,
2-quinolinecarbaldehyde (0.515 g, 3.28 mmol) and ethyl cyanoacetate (0.371 g, 3.28 mmol) 
were reacted in ethanol (5 ml) with piperidine (4 drops) and after 2.5 h the precipitate was 
collected: (0.490 g, 59 %), m.p. 108-109 °C (from EtOH); RF 0.74 (diethyl ether); (Found: 
C, 71.24; H, 4.68; N, 11.04; M +, 252.0902. C 15H 12N 20 2 requires C, 71.42; H, 4.79; N,
11.10%; M ,  252.0890); v^C K B r disc)/cm‘' 3055m (Ar-H), 2985m  and 2960m (CHX), 
2220m (CN), 1730s (C =0), 1620m (C=C), 1600s (Ar), 1250s, 1230s and 1205s (C-O), 825s 
and 755s (Ar-H deformations); 8H(200 MHz; CDC13) 8.48 (1 H, s, 3-H), 8.29 (1 H, br d, 
■% .H 8.60 Hz, 12-H), 8.21 (1 H, dm, J  8.4 Hz, 10-H), 8.05 (1 H, d, 3JU.H 8-54 Hz, 13-H), 
7.95 (1 H, dd, J/ 8.H 8.12 Hz, 4S9_H 1.2 Hz, 7-H), 7.80 (1 H, ddd, 3J l0mH. 8.48 Hz, J/ 8.H 6.90 
Hz, 4J1.h 1.60 Hz, 9-H), 7.65 (1 H, ddd, 3J7.H 8.08 H z ,3 J9.H 6.88 Hz, *J10.H 1.25 Hz, 8-H),
4.43 (2 H, q, 3J 7.14 Hz, CH2), 1.43 (3 H, t, 3J 7.13 Hz, CH3); 8 C(50 MHz; CDC13) 162.0 
(C =0), 153.8 (3-CH), 149.9 (4-C), 148.2 (6-C), 137.2 (12-CH), 130.6 (7-CH), 130.3 
(8 -CH), 129.0 (10-CH), 128.6 (11-C), 127.6 (9-CH), 121.9 (13-CH), 114.8 (1-CN), 107.8 
(2-C), 63.0 (CH2), 14.2 (CH3); m/z 252 (M+, 3%), 223 (M + -  C2H5, 2), 208 (M + -  OC2H5, +
H, 59), 180 (M + -  C O oQ H j, + H, 100), 153 (M+ -  CO jCjH j, -  CN, 6), 128 ([C9H5N, Ar]+, 
- C 0 2C2H5, -  H-CsC-CN, 43), 101 {[CSHS]+, [Ar/+-C N , 16), 77 (10).
tert-Butyl 2-cyano-3-(2-quinolinyl)propenoate (1 9 2 )— U sin g  M ethod B ,
2-quinolylcarbaldehyde (0.515 g, 3.28 mmol) and rm -butyl cyanoacetate (0.371 g, 
3.28 mmol) were reacted in absolute ethanol (5 ml) with the addition o f piperidine (4 drops) 
and after 2.5 h the precipitate was collected (0.490 g, 59 %), m.p. 73-74 °C (from i-PrOH); 
Rf  0.82 (diethyl ether); (Found: C, 72.86; H, 5.81; N, 10.01; M+, 280.1213. C 17H 16N 20 2 
requires C, 72.84; H, 5.75; N, 9.99%; M,  280.1211); v max(KBr disc)/cm4  3074w and 3010w  
(Ar-H), 2976m and 2930w (CH3), 2224w (CN), 1720s (C =0), 1626m (C=C), 1592m/w and 
1504m/w (Ar), 1284s, 1256m/s, 1248m and 1156s (C -O ), 834m /s and 752m/s (Ar-H 
deformations); 5 H(200 MHz; CDC13) 8.39 (1 H, s, 3-H), 8.29 (1 H, br d, f / 13.H8.52 Hz,
12-H), 8.21 (1 H, dm, J  8.3 Hz, 10-H), 8.07 (1 H, d, J/ 12.H 8.55 Hz, 13-H), 7.87 (1 H, br d, 
J/ 3.H 8.10 Hz, 4J9.h (unresolved), 7-H), 7.80 (1 h ' ddd, J/ 10.H 8.46 Hz, 6.96 Hz, 4Jr l i
I.54 Hz, 9-H), 7.64 (1 H, ddd, 3Jn.H 8.07 Hz, SJ9.H 6.85 Hz, 4Jl0_H 1.22 Hz, 8-H), 1.62 (9 H, 
s, lBu); 8C(50 MHz; CDC13) 160.7 (C =0), 153.0 (3-CH), 150.2 (6-C), 137.1 (12-CH), 130.5 
(7-CH), 130.2 (8-CH), 128.8 (10-CH), 128.4 (11-C), 127.5 (9-CH), 121.9 (13-CH), 115.0
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(1-CN), 109.5 (4-C), 84.2 (2-C), 27.9 (Bu‘); m/z 280 (M+, 17%), 224 (M+ -  ‘Bu, + H, 5), 207 
(M+ -  O'Bu, 27), 180 (M+ -  C 0 2'Bu, + H, 75), 152 (M + -  C 0 2‘Bu, -  HCN, 5), 128 
([C9H5N, Ar]+, -  C 0 2cBu, -  H-C=C-CN, 39), 101 ([Cs tf j ]+, [Ar]+ -  CN, 19), 77 (13), 57 
(j[‘Bu]+, 100).
2-C yano-3-(3 -qu ino liny l)propenon itr ile  ( 1 9 3 ) — U sin g  M ethod  B ,
3-quinolinecarbaldehyde (0.147 g, 0.935 mmol) and malononitrile (0.063 g, 0.960 mmol) 
were reacted in ethanol (2.5 ml) with piperidine (1 drop) and after 2.5 h the precipitate was 
collected: (0.122 g, 64 %), m.p. 171-172 °C (from EtOH); RF 0.68 (diethyl ether); (Found: 
C, 76.03; H, 3.19; N, 20.43; M +, 205.0639. C]3H 7N 3 requires C, 76.09; H, 3.44; N, 20.48%; 
M, 205.0640); v max(KBr disc)/cm'' 3040m (Ar-H), 2230s (CN), 1615m (C=C), 1595s, 
1565m and 1490m (Ar), 790s and 765m (=C-H); SH(200 MHz; DM SO-d6) 9.25 (1 H, s,
3-H), 8.86 (1 H, s, 5-H), 8.72 (1 H, s, 13-H), 8.09 (2 H, 2 x  d (coinciding), J  7.0 Hz, 8- and
11-H), 7 .94(1 H, AA1 (= t), Jy I0.H 7.68 Hz, 9-H), 7.71 (1 H, A A '(= t), 3 Jw  7.41 Hz, 10-H); 
Sc (50 MHz; DMSO-d6) 158.8 (3-CH), 150.0 (5-CH), 148.8 (7-C), 138.8 (13-CH), 133.1 
(9-CH), 129.8 (8-CH), 128.9 and 128.2 (10- and 11-CH), 126.3 (12-C), 124.8 (4-C), 113.9 
andl 13.1 (2 x CN), 83.4 (2-C); m/z  205 (M+, 100%), 178 (M+ -  HCN, 35), 154 (M+ -  
H O C -C N , 46), 151 (M + -  2 x  HCN, 28), 140 (M+ -  CH(CN)2 , 1.5), 129 (M+ -  
HC=C(CN)2 , + H, 23), 124(11), 100 (14), 75 (23), 63 (18).
2-Amino-2,4-dicyano-3-(3-quinolinyl)penta-2,4-dienonitrile ( 1 9 4 )  —  U s i n g  
Method B, 3-quinolinecarbaldehyde (0.108 g, 0 .687 mmol) and 1,1,3-tricyano-
2-aminopropene (0.093 g, 0.706 mmol) were reacted in methanol (2.5 ml) with piperidine 
(2 drops). After 1.5 h the reaction was heated for 0.5 h and methanol was evaporated off. 
Crystallisation from ethyl acetate/ethanol gave (16 mg, 0.84 %), m.p. 200 °C (decomp.) 
(from EtOH/EtOAc); RF 0.09 (diethyl ether); (Found: C, 70.71; H, 3.18; N, 25.62; M+, 
271.0847. C 16H9N 5 requires C, 70.84; H, 3.34; N, 25.82%; M , 271.0858); v max(KBr 
discycm '1 3415m, 3325m and 3230s (NH2), 2215s and 2205m (CN), 1645s and 1620w 
(C=C), 1600m, 1581m and 1525m (Ar), 790w and 760w (Ar-H); 5H(200M Hz; DMSO-d6)
9.31 (1 H, d, 4Jn .H 2.2 Hz, 5-H), 9.31 and 9.26 (2 x 1 H, 2 x  br s, N H 2), 8.99 (1 H, d, 4Js_vl
2.0 Hz, 13-H), 8.40 (1 H, s, 3-H), 8.18 (2 H, 2 x  d (overlapping), 8- and 11-H), 7.99 (1 H, 
ddd, '378/io.h 6.9 Hz, 4JU.H 1.34 Hz, 9-H), 7.78 (1 H, ddd, 3J9IU.H 7.5 Hz, 4Jm  1.03 Hz,
10-H); Sc (50 MHz; DMSO-ds) 165.0 (H2N-£=C(CN)2), 150.8 (3-CH), 150.2 (5-CH), 148.6
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(7-C), 137.8 (13-CH), 132.6 (8-CH), 129.6 (9-CH), 129.4 (11-CH), 128.2 (10-CH), 126.7 
(12-C), 115.5 (1-CN), 114.8 and 114.7 (H2N-C=C(£N)2), 104.3 (2-C); m/z 111 (M+, 79%), 
245 (M +-  CN, 45), 217 (M +-  2 x  HCN, 17), 206 (M +-  CH(CN)2 , 72), 179 (M+-  
H2N-C=C(CN)2, 11), 142 ([C10H 8N, ArCH2]+, M + -  NC-CH-C(NH2)=C(CN)2, 96), 101 
(11), 76 (16).
2-C yan o-3 -(3 -qu in o lin y l)p ropen am ide  ( 1 9 5 ) — U s in g  M eth od  B ,
3-quinolinecarbaldehyde (0.110 g, 0.700 mmol) and cyanoacetamide (0.060 g, 0.714 mmol) 
were reacted in ethanol (2.5 ml) with piperidine (2 drops) and after 2 h the precipitate was 
collected (0.119 g, 76 %), m.p. 240 °C (decomp.) (from EtOH); R F 0 .10 (diethyl ether); 
(Found: C, 69.87; H, 3.91; N, 18.77; M+, 223.0732. C 13H 9N 30  requires C, 69.95; H, 4.06; 
N, 18.82%; M, 223.0719); v max(KBr disc)/cm'‘ 3230m and 3100m  (NH2), 2200w (CN), 
1710s (C = 0), 1645w (C=C), 1590s and 1495m (Ar), 1380s, 1175m and 1130m (C -X ), 
880m, 8S5m/s and 680m (Ar-H); 8H(200 MHz; DMSO-d6) 9.26 (1 H, d, 4/ 13.H 2 .2 7 ,5-H), 
8.88 (1 H, d, 47j_h 2.21, 13-H), 8.39 (1 H, s, 3-H), 8.06 (3 H, d, 8-H /l 1-H and */2 NH2), 7.88 
(2 H, ddd, 4J  1.4, 3J l0.H 6.79, 9-H and h 2 NH2), 7.68 (1 H, ddd, 4J  1.3, 3J9.li 6.82, 10-H); 
5C(50 MHz; DM SO-d6) 162.3 (C =0), 150.5 (3-CH), 148.3 (7-C), 147.8 (5-CH), 137.5 
(13-CH), 132.0 (9-CH), 129.3 (3-CH). 128.9 (11-CH), 127.8 (10-CH), 126.7 (12-C), 125.5 
(4-C), 116.3 (CN), 108.6 (2-C); m/z 223 ([M]+, 75%), 206 ([M]+ -  N H 3, 53), 194 ([M]+ -  
HCN, 17), 179 ([M ]+ -  NH3, -  CO, 30), 152 ([M ]+ -  HCN, -  CONH2, 46), 128 ([M ]+ -  
CONH2,-H -C sC -C N , 13), 125 (24), 101 (22), 75 (35).
2-Cyano-3-(3-quinolinyl)propenothioamide ( 1 9 6 ) — U s in g  M eth od  B ,
3-quinolinecarbaldehyde (0.102 g, 0.649 mmol) and cyanothioacetam ide (0.069 g, 
0.692 mmol) were reacted in ethanol (3 ml) with piperidine (1 drop) and after 2.75 h the 
precipitate was collected: (0.113 g, 73 %), m.p. 235 °C (decomp.) (from EtOH); RF 0.27 
(diethyl ether); (Found: C, 65.07; H, 3.51; N, 17.36; M +, 239.0512. C 13H 9N 3S requires C, 
65.25; H, 3.79; N, 17.56%; M ,  239.0517); vmax(KBr discycm '1 3365s (CSNH2), 3020s and 
3005s (Ar-H), 2210s (CN), 1655s (C=S), 1600s, 1570s and 1490s (A r-H ), 885s, 785s, 745s 
and 620s (=C-H); 8 H(200 MHz; DMSO-d*) 10.27 and 9.77 (2 x  1 H, 2 x  br s, NH2), 9.24 
(1 H, d, 4J l3_h 2.3 Hz, 5-H), 8.93 (1 H, d, 4J5_H 2.2 Hz, 13-H), 8.28 (1 H, s, 3-H), 8.10 and
8.08 (2 H, 2 x  dd (overlapping), 3J  7.89 Hz, 3J  7.91 Hz, 8- and 11-H), 7.90 (1 H, td, 
^s-mo-H 6-91 Hz, 4J [ i_H 1.5 H z,9-H ),7.70 (1 H, td, 3J%mUH 6.88 Hz, 4Jm  1.3 Hz, 10-H);
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5C(50 MHz; DM SO-d6) 191.8 (C=S), 150.7 (3-CH), 148.2 (7-C), 143.7 (5-CH), 137.5 (13- 
CH), 132.1 (9-CH), 129.3 (8-CH), 128.9 (11-CH), 127.9 10-CH, 126.8 (12-C), 125.5 (4-C),
116.2 (CN), 114.4 (2-C); m/z 239 (M+, 95%), 206 (M + -  HS, 78), 179 (M + -  CSNH2, 38), 
152 (M+ -  CSNH2, -  HCN, 38), 142 (M+ -  NC-CH-CSNH2, 31), 128 (M + -  CSNH2, -  
H-C^C-CN, 17), 115 (16), 101 (26), 87 (15), 75 (46), 60 (47).
Ethyl 2-cyano-3-(3-quinolinyl)propenoate ( 1 9 7 ) — U sin g  M ethod B ,
3-quinolinecarbaldehyde (0.105 g, 0.668 mmol) and ethyl cyanoacetate (0.078 g, 
0.687 mmol) were reacted in ethanol (2 ml) with piperidine (2 drops) and after 0.5 h the 
precipitate was collected:(0.129 g, 77 %), m.p. 174-175 °C (from EtOH); RF 0.55 (diethyl 
ether); (Found: C, 71.33; H, 6.64; N, 11.00; M +, 252.0888. C 15H 12N 20 2 requires C, 71.42; 
H, 4.79; N, 11.10%; M, 252.0899); vmax(KBr discVcm'1 3030w (Ar-H), 2985m and 2940w  
(CH2CH3), 2210w (CN), 1720s (C =0), 1605s, 1590s and 1485m (C=C, 1280s and 1250s 
(C-O), 760s (=C-H); 8 H(200 MHz; DMSO-d6) 9.36 (1 H, d, 4/ 13.H 2.25 Hz, 5-H), 8.90 
(1 H, d, ‘'y5.H 2.21 Hz, 13-H), 8.58 (1 H, s, 3-H), 8.08 (2 H, br d, 3J 8.4 Hz, 8- and 11-H), 
7.92(1 H, td, 9-H), 7.72(1 H, td, 10-H ),4.36 (2 H, q, 3J  7.10H z, CH2), 1.33 (3 H, t, ^  7.09 
Hz, CH3); Sc (50 MHz; DMSO-d6) 161.3 (C =0), 152.0 (3-CH), 150.4 (5-CH), 148.5 (7-C),
138.6 (13-CH), 132.3 (9-CH), 129.2 (8-CH), 128.7 (11-CH), 127.8 (10-CH), 126.4 (12-C),
124.8 (4-C), 115.3 (CN), 104.5 (2-C), 62.4 (CH2), 13.8 (CH3); m/z 252 (M +, 65%), 223 (M+ 
- C 2H5, 30), 208 (M + -  OC2H5, + H, 100), 179 (M + - C 0 2C2H5, 37), 152 (M + - C 0 2C2H5, 
-  HCN, 49), 128 ([C9H5N, A r f ,  -  C 0 2C2H5, -  H-C=C-CN, 13), 101 ([C8H5]+, [Ar]+ -  CN, 
22), 77(10).
2-C yano-3 -(4 -qu ino liny l)propenon itr ile  ( 1 9 8 ) — U sin g  M eth od  B ,
4-quinolinecarbaldehyde (0.508 g, 3.23 mmol) and malononitrile (0.214 g, 3.24 mmol) were 
reacted in ethanol (5 ml) with piperidine (3 drops) and after 1 h the precipitate was collected 
(0.330 g, 50 %) and crystallised from isopropanol to give the title compound as yellow  
needles (0.165 g, 25 %), m.p. 170-173 °C (from i-PrOH) (lit.,332 146-147 °C); R F 0.62  
(diethyl ether); (Found: C, 75.83; H, 3.46; N, 20.42; M+, 205.0630. C 13H 7N 3 requires C, 
76.10; H, 3.41; N, 20.49%; M, 205.0589); v max(KBr disc)/cm '‘ 3065w, 3045w and 3030 
(Ar-H), 2220m/s (CN), 1615w (C=C), 1595s, 1565m and 1505m (Ar), 1245m and 1145m 
(C-X), 920m/s, 785s and 765m (=C-H); 8 H(200 MHz; DMSO-d6) 9.40 (1 H, s, 3-H), 9.11 
(1 H, d, 4.5 Hz, 6-H), 8.22 (1 H, d, 3JU.H 8.4 Hz, 12-H), 8.14 (1 H, d, Ji , 0.H8.2 Hz,
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9-H ), 7.93 (1 H, d, 3J6.H 4.7 Hz, 5-H), 7.89 (1 H, dt, 11-H), 7.75 (1 H, dt, 10-H); Sc(50 
MHz; DM SO-d6) 158.9 (3-CH), 150.4 (6-CH), 147.9 (8-C), 136.3 (4-C), 131.2 (9-CH),
130.6 (5-CH), 129.7 (10-CH), 129.2 (11-CH), 124.4 (12-CH), 124.2 (13-C), 120.2 (9-CH),
113.2 and 112.2 (2 x  CN), 89.8 (2-C); m/z 205 (M+, 92%), 178 (M + -  HCN, 100), 151 (M+ 
- 2 x  HCN, 32), 127(M +- H 2C=C(CN)2, 14), 100 (M + - H 2C=C(CN)2, - H 2C=CH, 21), 75 
(34), 63 (21).
2-Amino-2,4-dicyano-3-(4-quinolinyl)penta-2,4-dienonitrile ( 1 9 9 )  —  U s i n g  
Method B, 4-quinolinecarbaldehyde (0.102 g, 0 .649 mmol) and 1,1,3-tricyano-
2-aminopropene (0.087 g, 0.658 mmol) were reacted in methanol (3 ml) with DBU  
(1 drop). After 2 h the reaction was left at ca . 0 °C overnight (17 h), the solvent was 
removed under vacuum and crystallisation of the gum formed was attempted from 
isopropanol at 40 °C. However only a solid formed (0.127 g, 72 %), m.p. 190 °C (decomp.) 
(from i-PrOH); RF 0.07 (diethyl ether); (Found: C, 70.84; H, 3.34; N, 25.82; M +, 271.0856. 
C16H9N 5 requires C, 70.51; H, 3.17; N, 25.73%; A/, 271.0854); v max(KBr discycm'1 3445s, 
3335s and 3175s (NH2), 3030m (Ar-H), 2230s and 2220s (CN), 1685m and 1660s (C=C), 
1605w, 1545s and 1535s (Ar), 800w and 780w (Ar-H); SH(200 MHz; DMSO-d6) 9.47 and
9.36 (2 x  1 H, 2 x  br s, NH 2), 9.16 (1 H, d, Jy5.H 4.46 Hz, 6-H), 8.95 (1 H, s, 3-H), 8.29 
(1 H, d, -Vh.h 8.10 Hz, 12-H), 8.20 (1 H, d, J/ 10.H 8.25 Hz, 9-H), 7.93 (1 H, t, ^ .h /u -h  7.3 
Hz, 10-H), 7.83 (2 H, d & t (overlapping), 5- and 11-H); S c (50 MHz; DMSO-d6) 164.2 
(H2N-C=C(CN)2), 150.9 and 150.6 (3-CH and 6-CH), 147.9 (8-C), 137.6 (4-C), 130.7 
(9-CH), 129.8 (10-CH), 128.0 (12-CH), 124.9 (13-C), 124.7 (11-CH), 120.2 (5-CH), 115.8 
(1-CN), 113.9 and 113.7 (H2N-C=C(CN)2), 109.9 (2-C), 50.7 (H2N-C=C(CN)2); m/z 271 
(M+, 100%), 245 (M +-  CN, 85), 217 (M+-  2 x  HCN, 23), 206 (M +-  CH(CN)2, 53), 179 
(M+- H 2N-C=C(CN)2, 23), 152 (M + -  H2N-C=C(CN)2, -  CN, 23), 101 (19), 75(34).
2-C yan o-3 -(4 -qu in o lin y l)p ropen am ide  ( 2 0 0 ) — U sin g  M eth od  B ,
4-quinolinecarbaldehyde (0.241 g, 1.53 mmol) and cyanoacetamide (0.129 g, 1.53 mmol) 
were reacted in ethanol (3 ml) with piperidine (2 drops). After 2 h the precipitate (0.286 g, 
80 %) was dissolved (reluctantly) in methanol (50 ml), plus DMSO (ca , 5 ml) and 
crystallisation at ca. 0 °C gave (0.095 g, 27%), m.p. 200 °C (decomp.) (from  
MeOH/DMSO) (lit.,332 253 °C); RF 0.02 (diethyl ether); (Found: C, 69.87; H, 3.96; N, 18.90; 
M +, 223.0739. C 13H9N 30  requires C, 69.95; H, 4.06; N, 18.82%; M , 223.0732); v max(KBr
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disc)/cm"’ 3440s and 3430sh (NH2), 2200w (CN), 1700s (C =0), 1608m, 1585m and 1505m 
(C=C, 1395s, 1385s andl240m  (C -X ), 795w, 760w  and 750w  (Ar-H); 8H(200 MHz; 
DMSO-d6) 9.05 (1 H, d, 3JM{ 4.47 Hz, 6-H), 8.83 (1 H, s, 3-H), 8.34 and 8.01 (2 x 1 H, 2 x  
br s, N H 2), 8.15 (2 H, 2 x  d (overlapping= t), 3J  9 Hz, 9- and 12—H), 7.87 (2 H, m (= 
overlapping t & d), 10- and 5 -H ), 7.72 (1 H, ddd, 479.H 1.38 Hz, 3J \ i -h 8.30 Hz, 3JX0.H 6.92 
Hz, 11-H); 8 C(50 MHz; DMSO-d6) 162.0 (CONH2), 150.4 (3-CH), 147.8 (8-C), 146.7 (6 - 
CH), 138.0 (4-C), 130.3 (9-CH), 129.8 (5-CH), 127.8 (12-CH), 125.0 (13-C), 124.4 (10- 
CH), 120.3 (11 -CH), 115.2 (1-CN), 114.8 (2-C); m/z 223 ( [M ]\ 99.9%), 206 ([M]+ -  NH3,
22.5), 194 ([M] + -  HCN, 15), 179 ([M]+ -  NH3, -  CO, 100), 152 ([M ]+ -  HCN, -  CONH2, 
50), 128 ([M] + -C O N H 2,-H -C sC -C N , 13), 125 (21), 101 (25), 75 (49).
2-Cyano-3-(4-quinolinyl)propenothioamide (201)— U sin g  M ethod B, 4- 
quinolinecarbaldehyde (0.132 g, 0.840 mmol) and cyanothioacetam ide (0.085 g, 
0.849 mmol) were reacted in ethanol (3 ml) with DBU (2 drops) and after 3.3 h the product 
was precipitated with diethyl ether: (0.139 g, 69 %), m.p. 180 °C (decomp.) (from EtOH); 
R ¥ 0.25 (diethyl ether); (Found: C, 65.07; H, 3.51; N, 17.36; M +, 239.0523. C 13H9N 3S 
requires C, 64.81; H, 3.39; N, 17.28%; M, 239.0519); v max(KBr disc)/cm_1 3365s (CSNH2), 
3015s (Ar-H), 2210s (CN), 1650s (C=S), 1600s, 1570s and 1490s (Ar-H), 780m and 760m  
(=C-H); 8 h(200 MHz; DMSO-d6) 8.9 (1 H, d, 3J5.H 4.5 Hz, 6-H), 8.5 (1 H, s, 3-H), 8.3 
(2 H, 2 x d, J 8.2 Hz, 12-H and 9-H), 7.8 (3 H, m, 5-H and 10-H/l 1-H); m/z 239 (M +, 84%), 
206 (M + -  HS, 67), 179 (M+ -  CSNH2, 27), 152 (M+ -  CSNH2, -  HCN, 29), 142 (M+ -  
NC-CH-CSNH2, 20), 128 (M+ -C S N H 2,-H -C = C -C N , 7), 115 (18), 101 (27), 87 (13), 75 
(43).
Ethyl 2-cyano-3-(4-quinolinyl)propenoate  (2 0 2 ) — U sin g  M ethod B , 
4-quinolinecarbaldehyde (0.349 g, 2.22 mmol) and ethyl cyanoacetate (0.251 g, 2.22 mmol) 
were reacted in ethanol (3 ml) with piperidine (3 drops) and after 2.5 h the solvent was 
removed under vacuum. The crude product was dissolved in ethyl acetate and put through a 
plug of silca gel using petroleum ether; bp 30-40 °C/ethyl acetate mixtures. The main 
fraction was then crystallised from ethyl acetate (0.120 g, 21 %), m.p. 98-99 °C (from 
EtOAc) (lit.,332 98-99 °C); RF 0.62 (diethyl ether); (Found: C, 71.54; H, 4.78; N, 11.14; M +, 
252.0903. C 15H 12N 20 2 requires C, 71.42; H, 4.79; N, 11.10%; M, 252.0891); v max(KBr 
discycm'1 3020w (Ar-H), 2995w (CHX), 2230w (CN), 1725s (C=Q), 1610m (C=C), 1280s,
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1270s and 1235s (C-O), 850m, 775m, 755m/s and 745m (Ar-H deformations); 8 H(200 
MHz; CDC13) 9.07 (1 H, d, SJ5_H 4.52 Hz, 6-H), 9.00 (1 H, s, 3-H), 8.22 (1 H, d, 8.47 
Hz, 12-H), 8.14 (2 H, 2 x  d, overlapping, 9-H  and 5-H ), 7.83 (1 H, ddd, 4J9_H 1.47 Hz, 3J12. 
H 8.40 Hz, j 710.h 6.93 Hz, 11-H), 7.83 (1 H, ddd, 3J9.H 8.29 Hz, • % .„  6.94 Hz, 4J n .H 1.35 
Hz, 10-H), 4.47 (2 H, q, i /7 .1 4  Hz, CH2), 1.45 (3 H, t, }J1.\5  Hz, CH3); m/z 252 (M +, 
52%), 224 (M+ -  C 2H6, 6), 207 (M + -  OC2H5, 17), 179 (M+ -  C 0 2C2H5, 100), 153 (M + -  
C 0 2C ,H 5, -  CN, 37), 125 (15), 101 ([C8H5]+, [Ar] + -  CN, 11), 75 (17).
N-tert-Bu.tyl-3,4-dimethoxy-6-nitrobenzaldimine ( 2 0 3 ) — A so lu tio n  o f
3.4-dim ethoxy-6-nitrobenzaldehyde (6-nitroveratraldehyde; 5.43 g, 0 .0257 m ol), 
tert-butylamine (1.95 g, 0.0267 mol) and p-toluenesulphonic acid (15 mg) in toluene 
(200 ml) was azeotropically heated at reflux (Dean-Stark apparatus) for 4 h. The solvent was 
removed in vacuo and the solid washed and dried with diethyl ether under suction to give 
the title compound (6.21 g, 91 %), m.p. 110-111 °C; R F 0.72 (diethyl ether); (Found: C, 
58.72; H, 6 .86 ; N, 10.61; M+, 266.1276. C 13H 18N 204  requires C, 58.64; H, 6.81; N, 
10.52%; M, 266.1267); v max(KBr discycm'1 3096w and 300 lw  (=C-H of aromatic), 2936m  
and 2850m/w (CH3), 1638m/s (C=N), 1596m/s and 1514s (=C-H of aromatic), 1285s and 
1117s (C-O), 789m (=C-H deformation); 8H(200 MHz; acetone-d6) 8.52 (1 H, s, 1-H), 7.34 
(2 H, br s, 3- and 6-H), 3.83 and 3.82 (6 H, s, 4- and 5-OMe), 1.15 (6 H, s, C(CH3)3); 
5C(50 MHz; acetone-d6) 154.0 (4-C), 152.2 (1-CH), 151.0 (5-C), 143.1 (7-C), 127.2 (2-C),
110.0 (6-CH), 107.6 (3-CH), 57.2 (C(CH3)3), 56.4 and 56.2 (4- and 5-OCH3), 29.4  
(C(CH3)3); m/z  266 (M+, 3%), 251 (M+ -  CH3, 11), 236 (M + -  N = 0 , 2), 210 (M+ -  
H2C=C(CH3)2, 9), 193 (M+ -  OC(CH3)3, 12), 180 (M+ -  H 2C=C(CH3)2, -  N = 0 , 9), 163 
(M+ -  C(CH3)3, -  N 0 2 , 23), 150 (M+ -  C(CH3)3, -  CO, -  N = 0 , 9), 136 (M + 
-C=N-C(CH3)3, -  N 0 2, [dimethoxybenzyne]+, 36), 121 ([dimethoxybenzyne]+ -  CH3, 13), 
104 ([ tropylium-0]+, 16), 93 {[phenoxy]+, 29), 77 ([phenyl]+, 24), 63 (18), 57 ( [C(CH3)3]+, 
92), 41 (100).
N-4-Chlorophenyl-3,4-dimethoxy-6-nitrobenzaldimine (2 0 4 )— A solution o f
3.4-dim ethoxy-6-nitrobenzaldehyde (6-nitroveratraldehyde; 5.03 g, 0 .0238 m ol),
4-chloroaniline (3.12 g, 0.0244 mol) and p-toluenesulphonic acid (15 mg) in toluene 
(150 ml) was azeotropically heated at reflux (Dean-Stark apparatus) for 4 h. The solvent was 
removed in vacuo and the solid was washed and dried with diethyl ether under suction and
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crystallised from ethyl acetate to give the title compound (5.08 g, 65 %), m.p. 130-131 °C; 
i?F 0.81 (diethyl ether); (Found: C, 56.32; H, 4.11; N, 8 .88; M+, 320.0550. C 13H 18N 20 4 35C1 
requires C, 56.17; H, 4.09; N, 8.73%; M, 320.0564); v max(KBr discycm '1 3098w (=C-H of 
aromatic), 2928m and 2850m/w (CH3), 1608m/w (C=N-Ar), 1566m/s and 1516s (=C-H of 
aromatic), 1224s and 1064m/s (C-O ), 882m/w, 830m/w, 798m and 754m/w (=C -H  
deformations); 8H(200 MHz; CDC13) 8.95 (1 H, s, 1-H), 7.70 (1 H, s, 6-H), 7.60 (1 H, s,
3-H), 7.33 (2 H, dm, 3Jy. 8.71 Hz, 2'- and 6'-H), 7.17 (2 H, dm, s Jx.lve.n 8 71 Hz, 3’- 
and 5’-H), 4.04 (3 H, s, 4- or 5-OMe), 3.97 (3 H, s, 5- or 4-OMe); 5C(50 MHz; CDC13)
156.4 (1-CH), 153.1 (4'-C), 150.7 (7-C), 149.6 (4-C), 142.6 (5-C), 132.2 ( l ’-C), 129.3 (2 -  
and 6'-CH), 125.4 (2-C), 122.5 (3 - and 5'-CH), 109.7 (6-CH), 107.3 (3-CH), 56.6 (4- or
5-OMe), 56.5 (5- or 4-OMe); m/z 322 ((37C1)M+, 8%), 320 ((35C1)M+, 23%), 305 ((37C1)M+ 
-  OH, 33), 303 ((35C1)M+ -  OH, 100), 290 ((35C1)M+ -  N = 0, 11), 275 ((35C1)M+ -  N = 0 , -  
CH3, 9); 260 ((35C!)M+ -  N = 0 , -  2 x  CH3, 9), 244 ((35C1)M+ -  N 0 2, -  2 x  CH3, 20), 225 
(26), 197 (24), 164 (M+ -  PhCl, -  N 0 2, 36), 150 (M+ -  NPhCl, -  N 0 2, 9), 136 (M+ -  
C=N-PhCl, -  N 0 2, [dimethoxybenzyne]*, 23), 113 {[ch loro(37)phenyl] +, 12), 111 
([chloro(35)phenyl]+, 36), 93 ([phenoxy]+, 14), 75 (26).
Hydrazone o f  3,4-dimethoxy-6-nitrobenzaldehyde (209)— A fresh sample of 
nickel boride was prepared by adding an aqueous solution of 1.0 M sodium borohydride in 
0.1 M sodium hydroxide (6.0 ml, 6.0 mmol) to a stirred aqueous solution of 0.1 M nickel(II) 
acetate (60 ml, 6.0 mmol). After the liberation o f hydrogen gas subsided the black 
voluminous precipitate was allowed to settle, the supernatant was decanted, the solid was 
washed with absolute ethanol (4 x  30 ml) and then immersed in ethanol (40 ml). To this was 
added A/-terf-butyl-3,4-dimethoxy-6-nitrobenzaldimine (1.31 g, 4.92 mmol) and at reflux 
temperature a solution of hydrazine monohydrate (0.53 g, 10.58 mmol) in absolute ethanol 
(20 ml) was added drop wise over 20 min. After refluxing for 2 h the reaction was filtered 
through a pad of celite, the solvent was removed in vacuo and the residue was subjected to 
silica column chromatography using hexane/ethyl acetate elutions to give predominantly the 
undesired hydrazone (209) of 3,4-dimethoxy-6-nitrobenzaldehyde (0.81 g, 73 %), m.p. 
176.0-177.5 °C; R F 0.54 (diethyl ether); (Found: C, 48.11; H, 4.95; N, 18.71; M+, 225.0744. 
C9H u N 30 4 requires C, 48.00; H, 4.92; N, 18.66%; M ,  225.0750); v max(KBr discycm'1 
3424m and 3275w (NH2), (=C-H of aromatic obscured), 2932m/w and 2830w (CH3),
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1623m/s (C=N-NH2), 1554m/s and 1509s (=C-H of aromatic), 1276m/s, 1239s and 1142s 
(C-X), (=C-H  deformations weak); 8H(200 MHz; acetone-d6) 8.52 (1 H, s, 1-H), 7.34 (2 H, 
br s, 3- and 6-H), 3.83 and 3.82 (6 H, s, 4- and 5-OMe), 1.15 (6 H, s, C(CH3)3); 8C(50 MHz; 
acetone-d6) 153.1 (4-C), 158.7 (5-C), 139.8 (7-C), 138.2 (1-CH), 125.5 (2-C), 108.2 (6-CH),
107.2 (3-CH), 56.4 and 56.3 (4- and 5-OCH3); m/z 225 (M +, 5%), 196 (M + -  N 2, -  H, 19), 
180 (M +- H N 20 ,  9), 168 (M+ -  HC=N-N=0, 100), 164 (M+ -C H 3, - N H 2, - N = 0 ,  12), 152 
(M+ -  N 0 2, -  HCN, 9), 136 (M+ -  HC=N-NH2, -  N 0 2, [dimethoxybenzyne]*, 74), 121 
([dimethoxybenzyne]+ -  CH3, 24), 108 ([phenyl-N=OH]+, 56), 104 ([tropylium-0]+, 18), 94 
([p h en oxy-H t , 52), 77 ([phenyl]+, 49), 63 (18).
3,4-Dimethoxy-6-aminobenzaldazine (210)— A fresh sample o f nickel boride 
was prepared by adding an aqueous solution of 1.0 M sodium borohydride in 0.1 M sodium 
hydroxide (35.0 ml, 0.035 mol) to a stirred aqueous solution of 0.1 M nickel(II) acetate 
(350 ml, 0.035 mol). After the liberation of hydrogen gas subsided the black voluminous 
precipitate was allowed to settle, the supernatant was decanted, the solid was washed with 
absolute ethanol (4 x  50 ml) and then immersed in ethanol (150 ml). To this was added
3.4-dimethoxy-6-nitrobenzaldehyde (7.02 g, 0.0332 mol) and at reflux temperature a 
solution o f hydrazine monohydrate (5.12 g, 0.102 mol) in absolute ethanol (50 ml) was 
added dropwise over 30 min. After heating at reflux for 4.5 h the reaction was filtered 
through a pad of celite, the solvent was removed in vacuo and the residue was subjected to 
column chromatography using hexane/ethyl acetate elutions to give the hydrazone o f
3.4-dimethoxy-6-nitrobenzaldehyde (1.28 g, 17 %) and the undesired title compound 
(8.74 g, 73 %) which was crystallised from ethyl acetate (3.210 g, 27 %), m.p. 246-248 °C; 
RF 0.24 (diethyl ether); (Found: C, 60.11; H, 6.24; N, 15.82; M+, 358.1647. C 18H 22N 40 4 
requires C, 60.32; H, 6.19; N, 15.63%; M ,  358.1641); v max(KBr discj/cm'1 3440m (with 
shoulders - N H 2), 2933m/w and 2830w (CH3), 236 lw  and 2343w (cummulative double 
bonds), 1628s and 1606m/s (C=N-N=C), 1560m/s and 1509s (=C-H of aromatic), 1274m/s, 
1240s and 1144s (C -X ), 812 m (=C-H deformation); SH(200 MHz; DM SO-d6/acetone-d6)
8.69 (1 H, s, 1-H), 6.94 (1 H, s, 3- H), 6.87 (2 H, br s, 7-NH2), 6.48 (1 H, s, 6- H), 3.83 (3 H, 
s, 4- or 5-OM e), 3.76 (3 H, s, 5- or 4-OMe); 8 C(50 MHz; DM SO-d6/acetone-d6) 161.7 
(1-CH), 152.9 (7-C), 145.4 (5-C), 140.1 (4-C), 116.6 (3-CH), 106.8 (2-C), 98.5 (6-CH), 56.0 
(4- or 5-OCH3), 54.7 (5- or 4-OCH3); m/z 358 (M+, 100%), 342 (M+ -  N H 2, 45), 327 (M+ -
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OCH3, 31), 311 (M + -  OCH3, -  N H 2, 9), 296 (M + -  2 x  OCH3, 38), 179 
([(CH30 ) 2(NH2)Ph-CH=N] + , 4 6 ), 165 ([(  C H 30 ) 2(NH2)Ph-CH]+ , 6 5 ), 150
{[(CH30 ) 2PhCH]+, 53), 135 ([dimethoxybenzyne -  H ]+, 29), 120 ([dimethoxybenzyne]+ -  
CH4, 19), 105 ([tropylium-OH]+, 11), 94 ([phenoxy-H]+, 35).
Experimental Procedures— Chapter 8
N-Phenylcyanoethanamide (213)2306— A stirred mixture o f methyl cyanoacetate 
(15 ml) and aniline (4.56 g, 0.049 mol) was heated at 90-100 °C for 16 h. After cooling the 
crystals were collected, washed with ethyl acetate and dried under suction using diethyl 
ether to give the title compound as off-white crystalline flakes (4.78 g, 61 %), m.p.
194.5-195.5 °C (lit.,2300 192 °C); R F 0.32 (diethyl ether); (Found: C, 67.53; H, 5.04; N, 
17.55; M +, 160.0641. C9H8N 20  requires C, 67.49; H, 5.03; N, 17.49%; M , 160.0637); 
v max(KBr discycm '1 3271m and 3209m (CONHPh), 3146m, 3105m, 3054m/w and 3031w  
(Ph), 2955w and 2916w (CH2), 2261 w (CN), 1670s (CONHPh), 1622m/s and 1611m/s 
(double bond character), 1601 m/s, 1561 m/s and 1447m/s (Ph), 1350m/s and 1300m/s (C -  
O), 948m, 754s and 698m (=C-H deformations); 5 H(200 MHz; DMSO-d6) 10.34 (1 H, br s,
4-NH), 7.60 (2 H, dm, 3J 8.1 Hz, 6- and 10-H), 7.38 (2 H, tm, 3J 7.85 Hz, 7- and 9-H), 7.13 
(1 H, tm, i 77.H/9-H 7 -34 Hz> 8‘H)> 3-93 (2 H, s, 2-CH2); 5 C(50 MHz; DMSO-d6) 161.1 (3- 
C =0), 138.5 (5-C), 129.0 (7- and 9-CH), 124.0 (8-CH), 119.4 (6- and 10-CH), 116.1 (1- 
CN), 26.9 (2-CH2); m/z 160 (M +, 72), 120 (M + -  CH2CN, 32), 93 (MH+ -  C = 0, -  CH2CN, 
[PhNH2]+, 100), 77 ([PhNH2]+ -  NH 2, [Ph]+, 31), 65 {{PhNH2f  -  C=NH2, [C5H5]+, 30), 51 
([Ph]+~ H-C^C-H, [C4H3]+, 13), 39 ([C3H3] \  22).
N -P h e n y l -2 -c y a n o -3 - (3 ,4 -d ih y d r o x y p h e n y l )p r o p e n a m id e  (59)— Using 
Method B, 3,4-dihydroxybenzaldehyde (1.034 g, 7.49 mol) and A/-phenylcyanoethanamide 
(1.254 g, 7.83 mol) were reacted in absolute ethanol (15 ml) with 10 % ethanolic piperidine 
(5 drops). After 5 h the precipitate was crystallised from ethyl acetate to give the title 
compound as fine yellow crystalline needles (0.845 g, 40 %), m.p. 249.5-250.5 °C (lit.,2300 
258 °C); RF 0.38 (diethyl ether); (Found: C, 68.64; H, 4.33; N, 10.16; M+, 280.0851. 
C 16H 12N 20 3 requires C, 68.57; H, 4.32; N, 9.99%; M ,  280.0848); v max(KBr disc)/cm'‘ 
3410m/s (broad OH stretches and CONHPh), (C-H  stretches obscured), 2 3 6 lw  and 2342w  
(cummulative double-bonds), 2210w (CN), 1664s (CONHPh), 1603m/s (C=C), 1577s, 
1498s andl445s (Ph), 1249m/s, 1195m/s and 1175m/s (C-O), 948m, (=C-H  deformations
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weak); 5H(200 MHz; DMSO-d6/acetone-d6) 10.02 (1 H, br s, 4-NH), (OH broad signal 
observed along baseline from 10.5 to 8.5), 8.12 (1 H, s, 3-H), 7.79 (2 H, dm, ^ S .O  Hz, 3'- 
and 5'-H), 7.73 (1 H, d, 4J9.H 2.18 Hz, 5-H), 7.43 (ca. 1 H, dd, 3/ 9_H 8.18 Hz, 4J5.H 2.15 
Hz, 9-H), 7.39 (ca. 2 H, tm, 3J  7.82 Hz, 2'- and 6'-H, overlaps with 9-H), 7.15 (1 H, tt, 3Jy. 
h/5'-h 7.36 Hz, 1-H Hz> 4 '-H), 7.00 (1 H, d, J/ 9.H 8.29 Hz, 8-H); 8 C(50 MHz;
DMSO-d6/acetone-d6) 161.0 (CONHPh), 151.0 (7-C), 150.9 (3-CH), 145.9 (6-C), 138.7 (1'- 
C), 128.4 (3 - and 5-CH), 125.1 (9-CH), 123.8 (4'-CH), 123.5 (4-C), 120.4 (2’- and 6'-CH),
116.8 (1-CN), 116.3 (5'-CH), 115.8 (8'-CH), 101.8 (2-C); m/z 280 (M +, 39), 188 (M + -  
PhNH, 30), 170 (M + -  PhNH2, -  HO, 30), 160 (M + -  PhNHCO, 8), 142 (M+ -  PhNHCO, -  
CO, 8), 114 (M + -  PhNHCO, -  2 x  CO, 17), 93 ([PhNH2]+, 100), 77 ([PhNH2]+ -  NH2, 
[Ph]+, 10), 65 ([PhNH2]+ -  C=NH2, [ C5H5)+, 7), 51 ( [Ph]+ -  H-C=C-H, [C4H3]+, 6), 39 
([C3H3]+, 6).
4-Hydroxy-3-methoxy-5-(N,N-dimethylamino)methylbenzaldehyde (215)295— To 
a stirred solution of aqueous formaldehyde (ca. 37 % w/v; 30.1 g, 0.37 mol) and aqueous 
dimethylamine (ca. 40 % w/v; 45.2 g, 0.40 mol) in absolute ethanol (250 ml) was added 
vanillin (3-methoxy-4-hydroxybenzaldehyde; 38.0 g, 0.25 mmol). The mixture was refluxed 
for 3 h and then stirred at room temperature for 19 h. The solid obtained was collected by 
filtration, washed with acetone (30 ml at ca. 0 °C) and dried under suction (28.24 g, 54 %). 
The liquors were concentrated to ca. two-thirds volume and crystallised at ca. O °C to give 
the title compound as large yellow crystals (13.16 g, 25 %), m.p. 135.0-136.5 °C (from 
EtOH/H20 )  (lit.,295 139-141 °C); RF 0.10 (ethanol); (Found: C, 62.98; H, 7.21; N, 6.92; M+, 
209.1057. C n H 15N 0 3 requires C, 63.15; H, 7.23; N, 6.70%; M , 209.1052); vmax(KBr 
discycm '1 3426w (OH), 3002w (=C-H of aromatic), 2952w, 2920w and 2834m/w (CHX), 
2807m/w and 2751w (CHO), 1649s (H-C=0), 1594s, 1469s, 1448m/s and 1435s (=C-H of 
aromatic), 1269s and 1148s (C-O), 710m (=C-H deformation); 8H(200 MHz; DMSO-d6) 
9.74 (1 H, s, 1-CHO), 8.30 (1 H, v.br s, 5-OH), 7.34 (2 H, br s, 3- and 7-H), 3.85 (3 H, s,
4-OMe), 3.76 (2 H, s, 6-CH2), 2.36 (6 H, s, N(CH3)2); Sc (50 MHz; DMSO-d6) 190.6 
(1-CHO), 155.2 (4-C), 148.3 (5-C), 126.4 (2-C), 126.0 (7-CH), 122.1 (6-C), 109.6 (3-CH),
59.8 (CH2N(CH3)2), 55.5 (OCH3), 43.7 (CH2N(CH3)2); m/z 209 (M +, 81%), 192 (M+ -  OH, 
5), 178 (M + -  OMe, 4), 166 (M + -  Me, -  CO, 12), 165 (M + -  N M e2, 21), 164 (M + -  
HNMe2, 31), 163 (M + -H N M e 2, -  H, 34), 150 (M + -  H2C=NMe2, 11), 134 (M + -H N M e2,
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-  H, -  CHO, 18), 121 ([MeO-phenylCH2], 8), 107 ([.MeO-phenyl]+, 13), 93 ([phenoxy]+, 7), 
77 ( [phenylf , 12), 65 (18), 58 ([H 2C=NMe2]+, 80), 44 ([AMe2]+, 100).
5-Chloromethyl-4-hydroxy-3-methoxybenzaldehyde ( 2 1 7 ) 295— A solution o f
4-hydroxy-3-methoxy-5-(Af,,/V-dimethylamino)methylbenzaldehyde (15.5 g, 0.074 mol) in 
acetic anhydride (60 ml) was refluxed for 25 h and then subjected to fractional distillation. 
To the main fraction (bp 40-65 °C, at ca. 0.1 mbar/140 °C) was added 37 % hydrochloric 
acid (50 ml) and the mixture was stirred at room temperature for 3 h. The precipitate was 
filtered, washed with copius amounts of water and air dried to give the title compound as a 
discoloured white powder (7.5 g, 50 %), m.p. 103.5-105.0 °C; R F 0.22 (diethyl ether); 
(Found: C, 53.54; H, 4.39; M +, 200.0247 (for35Cl). C9H90 3C1 requires C, 53.88; H, 4.52%; 
M, 200.0240 (for 35C1)); v max(KBr discycm '1 3327m (OH), 2964w, 2936w and 2866m/w  
(CHX), 1666s (H -C =0), 1594s, 1501s, 1468m/s and 1431s (=C -H  of aromatic), 1295s, 
1267s and 1145s (C-O), 697m (=C-H deformation); 8 h(200M H z; CDC13) 9.81 (1 H, s,
1-CHO), 7.51 (1 H ,d / y 3.H 1.70 Hz, 7-H), 7 .38(1 H, d, 477.H 1.72 Hz, 3-H), 6.65 (1 H ,brs,
5-OH), 4.70 (2 H, s, 6-C H ,), 3.95 (3 H, s, 4-OMe); 8C(50 MHz; CDC13) 190.7 (1-CHO),
149.6 (4-C), 147.1 (5-C), 129.2 (2-C), 128.1 (7-CH), 123.4 (6-C), 108.6 (3-CH), 56.4 
(OCH3), 40.0 (CH,C1); m/z 202 ((37C1)M+, 12%), 202 ((35C1)M+, 35%), 182 ((35C1)M+ -  
H20 ,4 ) ,  165.(M + -  Cl, + H, 21), 164 (M+ -  HC1, 31), 163 (M+ -H C 1 ,-H , 34), 150 (M+ -  
[H ,C -C 1]+, 8), 134 (M + -  HC1, -  H, -  CHO, 38), 121 ([MeO-phenylCH2], 27), 107 
([MeO-phenyl]+, 34), 93 ([phenoxyl]*, 25), 77 ([phenyl]*, 34), 65 (100).
4-Hydroxy-3-methoxy-5-(2-benzothiazolylthiomethyl)benzaldehyde (21  8 ) 2308—  
To a stirred solution of 5-chloromethyl-4-hydroxy-3-methoxybenzaldehyde (3.07 g, 0.0153 
mol) in dichloromethane (10 ml) was added dropwise a solution of 2-mercaptobenzothiazole 
(2.52 g, 0.0151 mol) and triethylamine (1.67 g, 0.0165 mol) in dichloromethane (10 ml) 
over 10 min. After stirring for 8 h at room temperature the solvent was removed in vacuo 
and the residue subjected to silica column chromatography using ethyl acetate/hexane 
elutions to give the title compound as a white amorphous solid (1.64 g, 34 %), m.p. 
108.6-109.3 °C (lit.,2308 1 16 °C); RF 0.57 (diethyl ether); (Found: C, 58.17; H, 3.98; N, 4.51; 
M+, 331.0339. C 16H 15N 0 3S2 requires C, 57.99; H, 3.95; N, 4.23%; M, 331.0337); vmax(KBr 
discVcm*1 3406m and 3171m (OH), 2964m/w, 2934w and 2848m/w (CHX), 1665s (H- 
C =0), 1593s, 1499s, 1464s and 1428s (=C-H of aromatic), 1308s, 1288s, 1263s and 1146s
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(C -X ), 752m, 746m and 718m (=C-H deformations); SH(200 MHz; CDC13) (5-OH not 
observed), 9.65 (1 H, s, 1-CHO), 7.80 (1 H, dm, 3J j .H 8.03 Hz, 8'-H), 7.57 (1 H, dm ,5/ ^
7.33 Hz, 5'-H), 7.36 (1 H, d / / 3.H 1.65 Hz, 7-H), 7.28 (1 H, dt/^ '-H  8 02 Hz, 3/ j..h 1.30 Hz,
7-H ), 7.18 (1 H, d, 4J1M 1.56 Hz, 3-H), 7.15 (1 H, dt, 3JT_H 7.32 Hz, 5/ 5..H 1.25 Hz, 6’-H, 
overlaps with 3-H and residual CHC13), 4.49 (2 H, s, 6-CH2), 3.74 (3 H, s, 4-OMe); 5C(50 
MHz; CDC13) 190.8 (1-CHO), 168.3 (2'-C), 151.9 (4-C), 150.8 (9-C ), 148.9 (5-C), 134.9 
(4’-C), 129.0 (2-C), 128.3 (7-CH), 126.4 (8'-CH), 124.7 (5’-CH), 123.9 (6-C), 121.1 and
121.0 (6’- and 7’-CH), 108.8 (3-CH), 56.1 (OCH3), 32.3 (CH2SAr); m/z 331 (M+, 22%), 
298 (M + -  MeOH, -  H, 5), 167 {[2-mercaptobenzothiazole] + , 100), 165 (M+ -  
[2-dehydromercaptobenzothiazole]+, 16), 150 (M+ -  [2-methylenemercaptobenzothiazole]+,
2.5), 135 (M + -  [2-mercaptobenzothiazole] +, -  CHO, or [benzothiazole]+, 18), 123 
([2-mercaptobenzothiazole]+ -  C=S, 8), 121 { [Me O - p  h e n y l  C H 2], 5 ), 109
([2-mercaptobenzothiazole] + -  S-C=N, 11), 107 ([MeO-phenyl]+, 4), 93 ([phenoxy]+, 3), 91 
([2-mercaptobenzothiazole] + -  CS 2, 9), 77 ([phenyl]*, 6), 65 (14).
2 - Cyano-3-[4 -hydroxy-3-methoxy-5-(2-benzothiazolylthiomethyl )phenylJ 
propenamide (61)2308— To a stirred solution of 4-hydroxy-3-methoxy-5-(2-benzothiazolyl 
thiomethyl)benzaldehyde (0.590 g, 1.78 mmol) and cyanoacetamide (0.179 g, 2.12 mmol) in 
absolute ethanol (5 ml) was added piperidine (3 drops). After stirring for 6 h at room 
temperature the precipitate was collected and crystallised from ethyl acetate to give the title 
compound as a fine yellow mesh (0.121 g, 17 %). The combined liquors were concentrated 
in vacuo and the residue subjected to silica column chromatography using ethyl 
acetate/hexane elutions (0.314 g, 44 %), m.p. 254-256 °C (from EtOAc) (lit.,230g 268 °C); 
Rf 0.29 (diethyl ether); (Found: C, 57.57; H, 3.82; N, 10.51; M +, 397.0559. C 19H 15N 30 3S2 
requires C, 57.41; H, 3.80; N, 10.57%; M, 397.0555); vmax(KBr disc)/cm '’ 3302m, 3215m  
and 3152m (OH and CONH2), 2962m/w, 2936w and 2851m/w (CHX), 1695s (CONH2), 
1592s (C=C), 1502s, 1463s and 1427s (=C-H of aromatic), 1308s, 1285s, 1260s and 1149s 
(C-X), 758m, 745m and 716m (=C-H deformations); 8H(200 MHz; DMSO-d6) 8.07 (1 H, s,
3-H), 8.03 (1 H, dm, 7.83 Hz, 8'-H), 7.96 (1 H, dm, 7.85 Hz, 5'-H), 7.80 (1 H, d, 
4JiAi 1.92 Hz, 9-H), 7.68 (1 H, d, 4J9M 1.99 Hz, 5-H), (CONH2 singlets coincide with 5- 
and 9-H doublets), 7.52 (1 H, dt, % .H 7.7 Hz, 1.35 Hz, 7'-H), 7.40 (1 H, dt, J7r .H 7.6 
Hz, 3JS.H 1.30 Hz, 6 '-H), 4.66 (2 H, s, 8-CH2), 3.91 (3 H, s, 6-OMe); 8C(50 MHz;
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DMSO-d6) 166.5 (2'-C), 163.3 (CONH2), 152.7 (6-C), 150.5 (3-CH), 149.5 (9'-C), 147.7 
(7-C), 134.8 (4'-C), 126.6 (9-CH), 126.5 (8'-CH), 124.6 (5’-CH), 123.8 (8-C), 122.7 (4-C),
121.9 and 121.3 (6'- and 7'-CH), 117.4 (1-CN), 112.7 (5-CH), 102.2 (2-C), 56.1 (OCH3),
31.8 (CH2SAr); m/z 397 (M +, 26%), 380 (M + - N H 3, 4), 327 (M + -  CN, -  CONH2, 13), 230 
(M+ -  \2-dehydromercaptobenzothiazole]+, 17), 167 ([2-mercaptobenzothiazole]+, 100), 150 
(M+ -  [2-methylenemercaptobenzothiazole]+, 3), 135 (M + -  [2-mercaptobenzothiazole] +, -  
CHO, or [benzothiazole]+, 15), 123 ([2 -m ercap toben zo th iazo le ]+ -  C =S, 9), 121 
([MeO-phenylCH 2], 7 ), 109 ( [2-mercaptobenzothiazole]+ -  S -C sN , 10), 107 
([MeO-phenyl]*, 5), 93 ([phenoxy]+, 4), 91 ([2-mercaptobenzothiazole]+ -  CS2, 7), 77 
([phenyl]+, 6), 65 (18).
Ethyl 2-cyano-2,3-epoxy-3-(4-nitrophenyl)propanonitrile (220)— To a stirred 
solution of ethyl 2-cyano-3-(4-nitrophenyl)propenonitrile (4.948 g, 20.10 mmol) in dry 
dichloromethane (250 ml) was added ca. 80 % meta-chloroperoxybenzoic acid (5.015 g,
44.11 mmol) over 15 min. After 4 h, TLC indicated that the reaction was incomplete. Thus 
ca. 80 % meta-chloroperbenzoic acid (5.015 g, 44.11 mmol) was added and the reaction was 
stirred at room temperature for a further 27 h. After this time saturated sodium carbonate 
(150 ml) was added, the dichloromethane layer was separated and the aqueous layer was 
extracted with ethyl acetate (2 x  100 ml). The organic layers were dried over sodium  
sulphate (anhydrous), combined, concentrated in vacuo and the solid obtained (6.437 g) was 
crystallised from dichloromethane to give the title epoxide (4.142 g, 79 %), m.p. 116-117 °C 
(from EtOAc); R F 0.72 (diethyl ether); (Found: C, 54.63; H, 3.82; N, 10.45; M+, 274.0951. 
C 14H 14N 20 4 requires C, 54.96; H, 3.84; N, 10.68%; M , 274.0954); v max(KBr discycm '1 
3125w and 3093w (=C-H), 2992w and 2948w (CH3), 2361 w (CN), 1760s (C 02Et), 161 lm  
(A r), 1519s (C -N 0 2), 1348s, 1300s, 1290s and 1011m (C-O), 860m, 828m, 730m/s and 
696m (=C-H deformations); 5H(200 MHz; CDC13) 8.28 (2 H, d, J75_H/9_H 8.80 Hz, 6- and 
8-H), 7.62 (2 H, d, j 76.H/8-h 8-72 Hz, 5- and 9-H), 4.64 (1 H, s, 3-H), 4.39 (2 H, dq, J/7 .1 4  
Hz, J  1.55 Hz, CH2CH3), 1.37 (3 H, t, 3J  7.14 Hz, C H jO Is); Sc (50 MHz; CDC13) 161.9 
(C 0 2CH2CH3), 149.0 (7-C), 136.8 (4-C), 127.9 (6- and 8-CH), 123.9 (5- and 9-CH), 112.3 
(1-CN), 64.5 (CH2CH3). 62.9 (3-CH), 53.1 (2-C), 13.9 (CHjCTIj); m/z 262 (M+, 4%), 246 
(M+ -  O, 5), 234 (M+ -  HCN, -  H, 18), 218 (MH2+ -  N 0 2, 8), 218 (MH+ -  Et, 8), 218 (M+ 
-O H ,-H C N , 8), 188 (M + - N 0 2, -  CN, 3), 188 (MH+ -  N=Q, -  Et, 3), 180 (MH+ -O E t, -
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CCN, 12), 172 (M+ -  C 0 2Et, -  H, 3), 152 (M H+ -  N C -C -C 02Et, 100), 135 (M+ -  
NC-C-C02Et, -O H , 5), 122 (6), 115 (6), 105 (7), 89 (23), 83 (24), 77 (13).
Attempted, formation o f  the trans-form  o f  Ethyl 2-cyano-3-(4-nitrophenyl) 
propenonitrile  (116): Ethyl 2-oxo-3-(4-nitrophenyl)propanoate (221) isolated.— Using 
oven-dried glassware, a 50 ml three-necked round-bottomed flask (equipped with an 
equilibrating dropping funnel capped with a rubber septum, digital temperature probe and 
nitrogen bubbler) was charged with ethyl 2-cyano-2,3-epoxy-(4-nitrophenyl)propenonitrile 
(220) (0 .868 g, 3.31 mmol), l,3-dim ethyl-3,4,5,6-tetrahydro-2(l//)-pyrim idinone  
(iV,A/’-dimethyl-^V,iV,-propylene urea or DMPU; 4 ml) and a magnetic stirrer bar. The 
reaction system was thoroughly evacuated and then purged with dry nitrogen. To the 
dropping funnel (closed) was added, via septum, a solution of hexamethyldisilane (0.776 g,
5.32 mmol) in DMPU (4 ml) followed by the slow administration o f ca. 1.4 M 
methyllithium (in diethyl ether) over 20 min. The reaction mixture was then cooled to ca. 
-10 °C on an ice/salt water bath and the preformed solution of trimethylsilyllithium was 
added drop wise over 20 min. After 30 min at -10 °C and 2.5 h at room temperature the 
reaction was quenched with saturated ammonium chloride solution (10 ml) and partioned 
with toluene (3 x 30 ml). The combined organic layers were washed with brine (2 x  20 ml), 
dried (anhydrous Na2S 0 4) and concentrated in vacuo. The brown oil was subjected to 
column chromatography (silica) using ethyl acetate/petroleum ether (bp 40-60 °C) elutions 
(20 % to 100 %). The required t r a n s - isomer o f ethyl 2-cyano-3-(4-nitrophenyl)- 
propenonitrile was not formed but from the complex mixture the title (3-keto ester was 
identified (0.120 g, 15 %), m.p. 161-163 °C (from EtOAc); RF 0.11 (ethyl acetate); (Found: 
C, 55.34; H, 4.39; N, 6.12; M+, 237.0644. C n H n N 0 5 requires C, 55.70; H, 4.67; N, 5.90%; 
M, 237.0637); v max(KBr disc)/cm'1 3103w, 3078w and 3034w (=C-H ), 2982w and 2940w  
(CHX), 1740s (C 0 2Et), 1686m/s, 1597m and 1625m/s (Ar and C=C-OH), 1522s (C -N 0 2), 
1345s, 1300s, 1291s and 1156s (C-O), 853m/s (=C-H deformation); 5 H(90 MHz; CDC13)
8.2 (2 H, d, j / 3.h/7-h 8-7 Hz. 4 ‘ and 6"H)> 8.1 (2 H, d, ■j/ 4.h/6-h 8-8 Hz, 3- and 7-H), 6.5 (1 H, 
s, 3-H ),4.45 (major rotamer) and4.2 (minor rotamer) (2 H, 2 x  q, 3 J 1 A  Hz, CH2CH A  1.55 
(major rotamer) and 1.35 (minor rotamer) (3 H, 2 x  t, 3 J 7.1 Hz, CH2C H A  m/z 237 (M +, 
24%), 207 (M+ -  N = 0 , 0.7), 192 (MH+ -  N 0 2, 0.9), 163 (M + - C 0 2Et, -  H, 100), 147 (M+ 
-  C 0 2Et, -  O, 9), 136 (M + -  C 0 2Et, -  CO, 87), 133 (M + -  C 0 2Et, -  NO, 45), 117 (M+ -
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C 0 2Et, -  N 0 2, 11), 106 (M + -  C 0 2Et, -  CO, -  NO, 25), 89 (M + -  C 0 2Et, -  CO, -  H N 0 2, 
81), 78 (44).
4-Nitrophenylethanamide (2 2 2 )—  After performing chromatography as 
described for the a-keto ester ( 221) the title acetamide (222) was also isolated (0.113 g, 
19 %), m.p. 182-184 °C (from EtOAc); RF 0.19 (ethyl acetate); (Found: C, 53.01; H, 4.42; 
N, 15.10; M+, 180.0545. C 8H8N 20 3 requires C, 53.33; H, 4.48; N, 15.55%; M ,  180.0535); 
v max(KBr disc)/cm '‘ 3414m/s and 3335m (NH2), 1655s (CONH2), 1686m, 1624m and 
1613m (Ar and C=C), 1539s (C -N 0 2), 1395m/s andl352s (C-O), 771m/s and 706m (=C-H  
deformations); 8H(200 MHz; DMSO-d6) 8.22 (2 H, d, ^T^h/s-h 8.78 Hz, 5- and 7-H), 7.61 
and 7.07 (2 x 1 H, 2 x  br s, CONH2), 7.58 (2 H, d, J/ 5. H,7.H 8.75 Hz, 4- and 8-H), 3.60 (2 H, 
s, 2-CH2); 8c (50 MHz; DMSO-d6) 171.1 (CONH2), 146.3 (6-C), 144.7 (3-C), 130.6 (5- and
7-CH), 123.4 (4- and 8-CH), 41.9 (2-CH2); m/z 180 (M+, 4%), 162 (M+ -  H20 ,  1), 150 (M+
f
-  N =0, 0.6), 137 (MH+ -  CONH2, 100), 120 (M+ -  CONH2, -  O, 14), 107 (MH+ -  CONH2,
-  N =0, 50), 90 (M + -C O N H 2, - N 0 2, 62), 89 (M + - C 0 N H 2,- H N 0 2, 54), 78 (21).
(Z)-2-(3-Pyridyl)-3-(3,4-dimethoxyphenyl)propenonitrile ( 66 )— An oven dried 
two-necked round bottom flask (50 ml), equipped with a rubber septum and nitrogen inlet, 
was charged with 3-pyridylacetonitrile (1.507 g, 0.0127 mol) and dry tetrahydrofuran 
(20 ml). The solution was cooled on an ice/salt water bath and 95% NaH (0.324 g, 
0.0135 mol) was cautiously added. This was stirred at room temperature for 2 h and 
carefully added to a solution of 3,4-dimethoxybenzaldehyde (1.997 g, 0.120 mol) in 
tetrahydrofuran (10 ml). The reaction mixture was stirred for a further 2 h, quenched with 
ethyl acetate (50 ml) and the tetrahydrofuran removed under reduced pressure. The residue 
was partitioned between water (50 ml) and ethyl acetate (3 x  50 ml) and the ethyl acetate 
extracts dried (Na2S 0 4) filtered and concentrated to give 3.0 g of crude product which was 
crystallised from isopropanol to yield the title compound (1.73 g, 54 %).
Alternatively, using Method D, piperidine (10 drops) was added to a hot stirred solution of
3,4-dimethoxybenzaldehyde (2.08 g, 0.0125 mol) in absolute ethanol (5 ml). After 5 min,
3-pyridylacetonitrile (1.46 g, 0.0124 mol) was added followed by cautious addition of a 
catalytic amount of potassium terr-butoxide (ca. 10 mg) and the yellow crystals obtained 
were filtered, washed (diethyl ether) and dried to afford the title compound (3.13 g, 94 %). 
Recrystallisation from ethyl acetate gave yellow  flakes (2.83 g, 85 %) and, for
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crystallographic purposes, ca. 0.5 g of this was further recrystallised from diisopropyl ether 
at 0 °C to give pale yellow  rhombic crystals, m.p. 117.7 °C; R F 0.42 (1:2 ethyl 
acetate/petroleum ether, bp 30-40°C); (Found: C, 72.18; H, 5.35; N, 10.69; M+, 266.1051. 
C16H 14N 20 2 requires C, 72.17; H, 5.30; N, 10.51%; M, 266.1055); v max(KBr discycm '1 
3050w and 3015w (=C-H), 2969w and 2938w (CH3), 2843w (CH3OAr), 2361w and 2344w  
(cumulative double-bonds), 2207m (CN), 1593s (C=C), 1578m, 1570m and 1516s (Ar), 
1447m and 1424m (CH3 deformations), 1275s, 1147s and 1020s (C-O), 808m and 708m  
(=C-H deformations); 8H(200 MHz; acetone-d6) 8.94 (dd, 1 H, 4./15_H 2.52 Hz, 4J lA_H 0.87 
Hz, 11-H), 8.60 (dd, 1 H, J/ 14.H 4.71 Hz, Ji 15.H 1.56 Hz, 13-H), 8.08 (ddd, 1 H, 3JX± H
8.11 Hz, 4 J\ [,H 2.54 Hz, 4J n .H 1.57 Hz, 15-H), 7.92 (1 H, br s, 3-H), 7.77 (d, 1 H, 4J9.H 
2.16 Hz, 5-H), 7.58 (ddd, 1 H, ■?78_H 8.45 Hz, 4Ji.H 2.17 Hz, 4JW  0.60 Hz, 9-H), 7.48 (ddd,
1 H, J7I5_H 8.08 Hz, 4J U.H 4.75 Hz, ^ iu .H 0.86 Hz, 14-H), 7.11 (d, 1 H, JJ9.H 8.46 Hz, 8-H), 
3.91 (s, 3 H, 7-OM e), 3.89 (s, 3 H, 6-OMe); 5H(200 MHz; CDC13) 8.90 (dd, 1 H, 4J X5.H
2.50 Hz, 4J l4. H 0.84 Hz, 11-H), 8.59 (dd, 1 H, 3J xi_H 4.78 Hz, *y15.H 1.56 Hz, 13-H), 7.93 
(ddd, 1 H, 3J l4_h 8.05 Hz, 4y |l41 2.50 Hz, 4Jn .n 1.57 Hz, 15-H), 7.72 (d, 1 H, 4J9.H 2.14 Hz,
5-H), 7.49 (1 H, br s, 3-H), 7.38 (ddd, 1 H, 3JSrii 8.3 Hz, 4JS_H 2.2 Hz, 4J3.H 0.6 Hz, 9-H),
7.36 (ddd, 1 H, Jy ,5.H 8.1 Hz, 4J n .H 4.85 Hz, J/ n .H 0.85 Hz, 14-H, overlaps with 9-H), 6.93 
(d, 1 H, 3J9.h 8.46 Hz, 8-H), 3.97 (s, 3 H, 6-OMe), 3.95 (s, 3 H, 7-OMe); SH(200 MHz; 
THF-d8 at 3.584 and 1.731 ppm) 8.92 (dd, 1 H, V,3.H 2.50 Hz, 4J l4_H 0.76 Hz, 11-H), 8.53 
(dd, 1 H, 3J l4.h 4.73 Hz, *y15.H 1.55 Hz, 13-H), 8.01 (ddd, 1 H, 3J XA. H 8.08 Hz, 4yu.„ 
2.53 Hz, 4/ i3_h 1.57 Hz, 15-H), 7.78 (d, 1 H, 4J%H 2.18 Hz, 5-H), 7.77 (1 H, s, 3-H, overlaps 
with 5-H), 7.48 (dd, 1 H, 3JSrH 8.41 Hz, V 5.H 2.0 Hz, 9-H), 7.38 (ddd, 1 H, Jy,5.H 8.07 Hz, 
4J [3_h 4.75 Hz, 4J\ i_H 0.85 Hz, 14-H), 7.03 (d, 1 H, 3J%H 8.44 Hz, 8-H), 3.87 (br s, 6 H, 7- 
and 6-OMe); 5 C(50 MHz; acetone-d6) 152.9 (7-C), 150.4 (11-CH), 150.1 (6-C), 147.7 
(13-CH), 144.7 (3-CH), 133.5 (15-CH), 131.7 (10-C), 127.3 (4-C), 125.3 (9-CH), 124.5 
(14-CH), 118.7 (1-CN), 112.5 (5-CH), 112.3 (8-CH), 105.3 (2-C), 56.1 (6-OCH3), 56.0  
(7-OCH3); 8c (50 MHz; CDC13) 151.6 (7-C), 149.5 (U -C H ), 149.0 (6-C), 146.8 (13-CH),
143.5 (3-CH), 133.0 (15-CH), 130.8 (10-C), 126.1 (4-C), 124.9 (9-CH), 123.4 (14-C), 117.8 
(1-C), 110.9 (5-CH), 110.5 (8-CH), 104.9 (2-C), 55.9 (6- and 7-OCH3); m/z 266 (M +, 
100%), 251 (M + - C H 3, 18), 223 (M + -  CH3, -  CO, 22), 220 (M+ -  CH3, -  CH30 ,  6), 208 
(M+ -  2 x C H 3, -  CO, 21), 195 (M+ -  CH3, -  H -C =0, -  HCN, 22), 192 (M + -  CH3, -  
CH30 ,  -  CO, 32), 191 (M+ -  CH3, -  CH3OH, -  CO, 34), 180 (M + -  2 x  CH3, -  2 x  CO, 32),
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179 (M + -  2 x  CH3, -  2 x  CO, -  H, 66), 154 ([H-C=C-CH=C(CN)-Py]+, M+ -  
H2C=C(OCH3)-C(OCH3)=CH2, 20), 167 (12), 164 (15), 138 {[(CH 30 ) 2Ph]+, 6), 114 (7), 
100 (12), 87 (10), 77 ([Py]+ -  H, 10), 63 (21), 51 (21).
2-(3-Pyridyl)-3-(3,5-dichlorophenyl)propenonitrile ( 6 7 ) — An oven dried 
two-necked round bottom flask (50 ml), equipped with a rubber septum and nitrogen inlet, 
was charged with 3-pyridylacetonitrile (1.03 g, 8.68 mmol) and dry tetrahydrofuran (20 ml). 
The solution was cooled on an ice/salt water bath and 95% NaH (0.26 g, 0.011 mol) was 
cautiously added. This was stirred at room temperature for 2 h and carefully added to a 
solution of 3,5-dichlorobenzaldehyde (1.50 g, 8.57 mmol) in tetrahydrofuran (10 ml). The 
reaction mixture was stirred for a further 2.5 h. After quenching with ethyl acetate (50 ml) 
and removing tetrahydrofuran under reduced pressure, the residue was partitioned between 
water (50 ml) and ethyl acetate (3 x  50 ml). The ethyl acetate extracts were dried, filtered 
and concentrated to give 1.0 g of an orange crude viscous oil which was crystallised from 
ethyl acetate to yield the title compound (0.56 g, 24 %).
Alternatively, using Method D, piperidine (8 drops) was added to a hot stirred solution of
3,5-dichlorobenzaldehyde (1.78 g, 0.0102 mol) in absolute ethanol (5 ml). After 5 min,
3-pyridylacetonitrile (1.18 g, 0.0100 mol) was added followed by cautious addition of a 
catalytic amount of potassium terr-butoxide {ca. 10 mg) and the yellow crystalline mesh 
obtained was filtered, washed (diethyl ether) and dried to afford the title compound (2.19 g, 
80 %). Recrystallisation from ethyl acetate gave light-yellow fine needles (1.34 g, 49 %) 
m.p. 148.1-148.5 °C (EtOAc); RF 0.42 (diethyl ether); (Found: C, 61.02; H, 3.07; N, 10.16; 
M+, 274.0061 (for 35C1). C 14H 8N 2C12 requires C, 61.12; H, 2.93; N, 10.18%; M, 274.0065 
(for 35C1)); v max(KBr discycm'1 3098m, 3020m and 3018m (=C-H), 2217m (CN), 1579m/s, 
1560s, 1478m/s, 1412m/s and 1354m/s (C=C and Ar), 1256m/s, 1213m and 1008s (C-N), 
855s, 807s, 704s and 670s (=C-H deformations); 5 H(200 MHz; CDC13) 8.92 (dd, 1 H, 4/ 15.H
2.50 Hz, 5/ 14.h 0.81 Hz, 11-H), 8.67 (dd, 1 H, 4/ I4.H 4.80 Hz, 5/ 15.H 1.56 Hz, 13-H), 7.96 
(ddd, 1 H, 37 14.h 8.07 Hz, 2.50 Hz, 4713.H 1.60 Hz, 15-H), 7.75 (dd, 2 H, V7.H 1.8 Hz, 
5/ 3.h 0.6 Hz, 5- and 9-H), 7.46 (br s, 1 H, 3-H), 7.43 (ddd, 1 H, 3/ 15.H 8.05 Hz, 3/ 13.H 4.82 
Hz, 5y n .H 0.85 Hz, 14-H), 7.42 (t, 1 H, 4/ 7.H 1.9 Hz, 7-H); 8 C(200 MHz; CDC13) 150.7 
(11-CH), 147.1 (13-CH), 140.1 (3-CH), 135.7(5) and 135.7(0) (6- and 8-C), 133.5 (15-CH),
130.6 (14-CH), 129.6 (4-C), 127.3 (5 - and 9-CH), 123.7 (7-CH), 116.2 (1-CN), 111.5 (2-C);
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m/z 278 ((37C1)M+, 10%), 276 ((35C1/37C1)M+, 60), 274 ((35C1)M+, 100), 247 ((35C1)M+ -  
HCN, 6,5), 241 ((37C1)M+ -  37C1, 16), 239 ((35C1)M+ -  35C1 and (35C1/37C1)M+ -  37C1, 51), 
213 ((35C1)M+ -  35C1 or (35C1/37C1)M+ -  37C1, -  CN, 11.5), 211 ((35C1)M+ -  H35C1 or 
(35C1/37C1)M+ -  H37C1, -  HCN, 10), 203 (M + -  2 x  Cl, -  H, 34), 177 (M+ -  2 x  Cl, -  HCN, 
29), 150(14), 101 (13), 88(11), 75(12).
2-(3-Pyridyl)-3-phenylpropenonitrile (226)— Using Method D, benzaldehyde 
(2.46 g, 0.027 mol) and 3-pyridylacetonitrile (3.22 g, 0.027 mol) were reacted in absolute 
ethanol {ca. 5 ml) with the addition of piperidine (10 drops) and potassium terr-butoxide 
{ca. 15 mg) to give the title compound as light-brown crystals (2.67 g, 48 %), m.p. 96.0-96.5 
°C; RF 0.44 (diethyl ether); (Found: C, 81.35; H, 4.85; N, 13.44; M+, 206.0849. C 14H 10N 2 
requires C, 81.53; H, 4.89; N, 13.58%; M, 206.0844); v max(KBr discycm '1 3092m, 3038m  
and 3018m (=C-H), 2213m (CN), 1604m, 1598m, 1572m, 1566m, 1496m, 1483m, 1449m, 
1427m/s and 1362m/s (C=C and Ar), 1024m/s and 990m/s (C-N), 807s, 701s and 686s 
(=C-H deformations); 5H(200 MHz; CDC13) 8.87 (dd, 1 H, 4/ i 5_h 2.44 Hz, 5/ 14_h 0-69 Hz,
1 l-H), 8.57 (dd, 1 H, 4i | 4.H 4.81 Hz, 5/ 15.H 1.52 Hz, 13-H), 7.92 (ddd, 1 H, 3i 14.H 8.07 Hz, 
4/ u .h 2.47 Hz, V,3.H 1.57 Hz, 15-H), 7.8-7.9 (m, 2 H, 5- and 9-H), 7.53 (br s, 1 H, 3-H),
7.43 (m, 3 H, 6- and 7- and 8-H), 7.33 (ddd, 1 H, 3/ 15.H 8.10 Hz, 3/ 13.H 4.81 Hz, 5/ n .H 0.80 
Hz, 14-H); 5C(200 MHz; CDCI3) 149.9 (3-CH), 146.9 (11-CH), 143.8 (13-CH), 133.4 
(15-CH), 133.1 (10-C), 131.1 (14-CH), 130.5 (4-C), 129.4 (5- and 9-CH), 129.0 (6- and
8-CH), 123.6 (7-CH), 117.1 (1-CN), 108.3 (2-C); m/z 206 (M +, 44%), 205 (M+ -  H, 100), 
179 (M+ -H C N , 5), 177 (9), 151 (15), 126 (6), 102 (6), 84 (6), 76(12).
2-(2-Pyridyl)-3-(3,4-dimethoxyphenyl)propenonitrile (227)— Using Method D,
3,4-dimethoxybenzaldehyde (1.93 g, 11.61 mmol) and 2-pyridylacetonitrile (1.44 g, 
12.19 mmol) were reacted in absolute ethanol (8 ml) with the addition of piperidine 
(8 drops) and potassium terf-butoxide (15 mg). The crystals formed (2.87 g, 93 %) were 
recrystallised from ethyl acetate to give the title compound as a light yellow microcrystalline 
powder (2.28 g, 74 %), m.p. 108.5-109.0 °C; RF 0.65 (diethyl ether); (Found: C, 72.01; H, 
5.32; N, 10.46; M+, 266.1057. C 16H 14N 20 2 requires C, 72.17; H, 5.30; N, 10.51%; M, 
266.1055); v max(KBr d isc e r n '1 3001w (=C-H ), 2963w and 2936w (CH3), 2211m (CN), 
1595m/s (C=C), 1585s and 1516s (Ar), 1470m (CH3 deformation), 1280s, 1269s, 1148m 
and 1024m (C-O), 793m and 775m (=C-H deformations); 8H(200 MHz; CDC13) 8.59 (ddd,
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1 H, ^ 13-H 4.73 Hz, 1.70 Hz, 15-H 0*70 Hz, 12-H), 7.36 (1 H, br s, 3-H), 7.79-7.66 
(3 H, m, 5- and 14- and 15-H), 7.47 (dd, 1 H ,3J^H 8.55 Hz, 4JS_H 2.17 Hz, 9-H), 7.48 (ddd,
1 H, 3J\i.w 6.65 H z ,3J\2-h 4.72 Hz, 1.95 Hz, 13-H, overlaps with CHC13 signal), 6.91 
(d, 1 H, 3 8.44 Hz, 8-H), 3.94 (s, 3 H, 7-OMe), 3.92 (s, 3 H, 6-OMe); 5C(50 MHz; 
CDCI3) 151.6 and 151.4 (7- and 6-C), 149.5 (12-CH), 148.9 (10-C), 144.9 (3-CH), 137.3 
(14-CH), 126.3 (4-C), 125.5 (9-CH), 123.0 (15-CH), 120.9 (13-CH), 118.5 (1-CN), 111.2 
(5-CH), 110.9 (8-CH), 106.9 (2-C), 55.9 (6- and 7-OCH3); m/z 266 (M+, 56%), 265 (M + -  
H, 100), 251 (M+ -C H 3, 18), 223 (M + -C H 3, -  CO, 19), 220 (M+ -  CH3, -  CH3O, 9), 208 
(M+ -  2 x C H j, -  CO, 34), 192 (M + -  CH3, -  CH3O, -  CO, 46), 179 (M+ -  2 x CH3, -
2 x CO, -  H, 95), 154 ([H-C=C-CH=C(CN)-Py]+, M + -  H2C=C(OCH3)-C(OCH3)=CH2, 
36), 166 (11), 139 ([(CH 30 ) 2PhH]+, 7), 127 ([H-C^C-CsC-Py]*,  M+ -  H2C=C(OCH3)- 
C(OCH3)=CH2,-H C N , 18), 114(7), 100(12), 87 (11), 78 ([Py]+, 38).
i
2-(2-Thienyl)-3-(3,4-dimethoxyphenyl)propenonitrile (228)— Using Method D,
3,4-dimethoxybenzaldehyde (2.38 g, 14.32 mmol) and 2-thienylacetonitrile (previously 
purified over activated charcoal; 1.81 g, 14.69 mmol) were reacted in absolute ethanol 
(4 ml) with the addition of piperidine (5 drops) and potassium terJ-butoxide (13 mg). The 
crystals formed (3.68 g, 95 %) were recrystallised from ethyl acetate to give the title 
compound (3.15 g, 81 %), m.p. 80-81 °C; R? 0.79 (diethyl ether); (Found: C, 66.41; H, 4.87; 
N, 5.14; M +, 271.0649. C 15H I3N 0 2S requires C, 66.42; H, 4.74; N, 5.16%; M, 271.0667); 
v max(KBr disc)/cm_1 3102w and 3097w (=C-H of thienyl), 3043w (=C-H of phenyl), 2969w  
and 2938w (CH3), 2843w (CH3OPh), 2363w and 2347w (cumulative double-bonds), 2212m  
(CN), 1602m/w and 1595m/w (C=C), 1574m/w, 1540m and 1512m/s (Ar), 1275s, 1147m 
and 1020s (C -O ), 738m (=C-H deformation); 8H(200 MHz; CDC13) 7.60 (d, 1 H, 4J9M
2.03 Hz, 5-H), 7.31-7.22 (m, 4 H, 3- and 9- and 12- and 14-H), 7.02 (dd, 1 H, J/ 14.H
5.11 Hz, 3J u .n 3.67 Hz, 13-H), 6.87 (d, 1 H, 3J%H 8.40 Hz, 8-H), 3.93 and 3.90 (2 x  s, 6 H,
6- and 7-OMe); 8 C(50 MHz; CDC13) 151.1 (7-C), 149.0 (6-C), 139.6 (3-CH), 139.5 (10-C),
128.0 (12-CH), 126.4 (14-CH), 126.3 (4-C), 125.6 (13-CH), 124.2 (9-CH), 117.4 (1-CN),
110.9 (5-CH), 110.4 (8-CH), 103.2 (2-C), 55.9 (6- and 7-OCH3); m/z 271 (M +, 67%), 256 
(M+ -  CH3, 19), 228 (M+ -  CH3, -  CO, 27), 224 (M + -  CH3, -  CH3OH, 11), 212 (M+ -  
2 x CH3, -  CO, -  H, 12), 200 (M + -  CH3, -  H -C =0, -  HCN, 22), 196 (M + -  CH3, -  
CH3O H ,-C O , 100), 185 (M+ - 2  x CH3, - 2  x CO, 45), 1 8 4 (M+ - 2  x CH 3, - 2  x C O ,-H ,
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32), 171 (M+ - C H 3,- C H 30 , - C 0 , - C N ,  100), 159 ([.H-C=C-CH=C(CN)-thieny[]+, M+ -  
H2C=C(OCH3)-C(OCH3)=CH2, 20), 143 ( [ (C H 30) 2Ph]+, 6), 127 (17), 114 (23), 82 
([thienyl]+ — H, 8).
(Z)-2-(3-Thienyl)-3-(3,4-dimethoxyphenyl)propenonitrile (229)— Using Method 
D, 3,4-dimethoxybenzaldehyde (2.78 g, 16.73 mmol) and 3-thienylacetonitrile (previously 
purified over activated charcoal; 2.06 g, 16.72 mmol) were reacted in absolute ethanol 
(5 ml) with the addition of piperidine (5 drops) and potassium rm -butoxide (15 mg). The 
crystals formed (3.97 g, 88 %) were recrystallised from ethyl acetate and then diethyl ether 
to give the title compound as yellow rhombic crystals suitable for X-ray crystallography 
(3.28 g, 72 %), m.p. 95-96 °C (from EtOAc); RF 0.74 (diethyl ether); (Found: C, 66.37; H, 
4.72; N, 5.16; M+, 271.0667. C 15H 13N 0 2S requires C, 66.42; H, 4.74; N, 5.16%; M , 
271.0667); v max(KBr discVcm'1 31 lOw, 3098w and 3084w (=C-H o f thienyl), 3026w and
i
301 lw  (=C-H  of phenyl), 295 lw  and 2932w (CH3), 2840w and 2830w (CH3OPh), 2205w 
(CN), 1593m (C=C), 1574m/w, 1522m and 1506m/s (Ar), 1269s, 1145m and 1020m (C-O), 
795m and 629m (=C-H deformations); 5 H(200 MHz; CDC13) 7.63 (d, 1 H, V 9.H 2.07 Hz,
5-H), 7.51 (dd, 1 H, 47 I4.H 2.84 Hz, * / 13.H 1.45 Hz, 11-H), 7.38-7.27 (m, 4 H, 9- and 13- and 
14-H), 7.34 (s, 3-H, overlaps with multiplet signals), 6.89 (d, 1 H, 3Jg.H 8.41 Hz, 8-H), 3.94 
and 3.91 (2 x s, 6 H, 6- and 7-OMe); 5C(50 MHz; CDC13) 150.9 (7-C), 149.0 (6-C), 140.3 
(3-CH), 136.7 (10-C), 127.2 (11-CH), 126.5 (4-C), 124.0 (14- and 13-CH), 122.8 (9-CH),
118.5 (1-CN), 110.9 (5-CH), 110.5 (8-CH), 103.9 (2-C), 55.9 (6- and 7-OCH3); m/z 111 
(M+, 83%), 256 (M + -  CH3, 11), 228 (M+ -  CH3, -  CO, 31), 225 (M+ -  CH3, -  CH30 ,  17), 
213 (M+ - 2  x CH3, -  CO, 16), 200 (M + - CH3, -  H -C=0, -  HCN, 12), 196 (M + - C H 3>-  
CH3O H ,-C O , 100), 185 (M+ -  2 x CH3, -  2 x C O ,45), 1 8 4 (M+ - 2  x CH3, - 2  x C O ,- H,
33), 171 (M+ - C H 3,- C H 30 , - C 0 , - C N ,  100), 159 ([H-C=C-CH=C(CN)-thienyl\+, M+ -  
H2C=C(OCH3)-C(OCH3)=CH2, 25), 127 (15), 114 (22), 82 ([thienyl]* -  H, 7).
2-(2-Pyridyl)-3-(2-quinolinyl)propenonitrile  (230)— U sin g  M ethod D,
2-quinolylcarbaldehyde (0.524 g, 3.33 mmol) and 2-pyridylacetonitrile (0.394 g,
3.34 mmol) were reacted in absolute ethanol (ca. 2 ml) with the addition of piperidine 
(5 drops) and potassium te/t-butoxide (ca. 10 mg) to give the title compound as yellow  
crystals (0.612 g, 71 %), m.p. 124.5-125.1 °C (EtOH); R F 0.59 (diethyl ether); (Found: C, 
79.12; H, 4.14; N, 16.19; M+, 257.0939. C 17H n N 3 requires C, 79.36; H, 4.31; N, 16.33%;
Synthesis and Biological Evaluation o f Anticancer Agents Page 216
M, 257.0952); v max(KBr discVcm"1 3062w, 3046w and 2998w (=C-H), 2218m (CN), 1590s, 
1582s, 1566m/s, 1498s, 1468s, 1434s and 1422s (aromatic stretches), 822s, 782s, 772s and 
760s (=C-H deformations); 8H(200 MHz; CDC13) 8.64 (ddd, 1 H, J/ 17_H 4.71 Hz,
1.77 Hz, 571 9 . h  0.99 Hz, 16-H), 8.62 (1 H, s, 3-H), 8.62 (2 H, d, SJ U_H 8.50 Hz, 12-H, 
multiplet from 19-H coincides), 7.92-7.66 (5 H, multiplet signals), 7.92 (1 H, d, 3 J\2-h
8.50 Hz, 13-H), 7.87 (dt, 1 H, 76.73 Hz, J/ 16_H 1.18 Hz, 7-H), 7.80 (m, 1 H, 4J l6.H 1.80 Hz, 
18-H), 7.73 (2 H, 2 x  m (overlapping), 7 6.89 Hz, 7 1.57 Hz, 8- and 10-H), 7.55 (ddd, 1 H, 
j 710. h  8.10 Hz, 578_h  6.89 Hz, *77_H 1.21 Hz, 9-H), 7.28 (ddd, 1 H, 57 18_H 7.31 Hz, J716.H 
4.73 Hz, 47 1 9 _h  1.34 Hz, 17-H); 5C(50 MHz; CDC13) 151.6 (4-C), 150.8 (14-C), 149.7 
(16-CH), 143.6 (3-CH), 137.4 (12-CH), 136.8 (18-CH), 130.2 (7-CH), 129.9 (8-CH), 128.0 
(11-C), 127.9 (9-CH), 127.5 (10-CH), 124.1 (19-CH), 122.0 (17-CH), 121.8 (13-CH), 117.2 
(1-CN), 114.7 (2-C); m/z 257 (M+, 95%), 256 (M +- H ,  100), 229 (M +- H ,- H C N , 15), 203 
(M+ -  2 x  HCN, 4), 179 (M + -  [C4H4N]+ i.e. [pyridyl]+, 13), 152 (M+ -  [C4H4N]+ i.e. 
[pyridyl]+, -  CN, 5), 128 ( [C9H6N]+ i.e. [quinolinyl]*, M+ -  [pyridyl]+, -  C=C-CN, 30), 115 
([quinolinyl-H] + -  N, 38), 101 ([quinolinyl-H] + -  CN, 38), 78 (16), 63 (7), 51 (21).
2-(3-Pyridyl)-3-(2-quinolinyl)propenonitrile  ( 2 3 1 ) — U sin g  M ethod D,
2-quinolylcarbaldehyde (0.352 g, 2.24 mmol) and 3-pyridylacetonitrile (0.265 g, 
2.24 mmol) were reacted in absolute ethanol (ca. 1.5 ml) with the addition of piperidine 
(3 drops) and potassium ferf-butoxide (ca. 1 mg) to give the title compound as yellow  
crystals (0.402 g, 70 %), m.p. 134.9-135.2 °C (EtOH); R F 0.15 (diethyl ether); (Found: C, 
78.94; H, 4.07; N, 16.27; M+, 257.0941. C 17H n N 3 requires C, 79.36; H, 4.31; N, 16.33%; 
M, 257.0953); v max(KBr disc)/cm'' 3070w, 3034w and 3000w (=C -H ), 2214m/w (CN), 
1592s, 1502s, 1478m/s and 1426m/s (aromatic stretches), 912m/s, 842m/s, 830m/s, 748s 
and 698s (=C-H deformations); 8 H(200 MHz; CDC13) 9.00 (dd, 1 H, 4J X9.H 2.50 Hz, J718.H 
0.85 Hz, 15-H), 8.63 (dd, 1 H, J718.H 4.81 Hz, 4JX9.H 1.57 Hz, 17-H), 8.21 (dd, 2 H, J713_H 
8.59 Hz, 47io_h 0.65 Hz, 12-H), 8.17 (dm, unresolved, 10-H, coincides with 12-H), 8.03 
(ddd, 1 H, f / lg_H 8.08 Hz, 4J XS.H 2.50 Hz, 4J X1. H 1.58 Hz, 19-H), 8.62 (1 H, d, 3JX2_H 
8.57 Hz, 13-H), 8.62 (2 H, s, 3-H), 7.80 (dm, 8.5 Hz, 4J9.H 1.2 Hz, 7-H, coincides with
3-H), 7.72 (ddd, 1 H, 3J1.H 8.49 Hz, SJ9_H 6.91 Hz, 4J l0_H 1.58 Hz, 8-H), 7.56 (ddd, 1 H, 
J/ | 0.H 8.13 Hz, 3Jm  6.90 Hz, 4J1M 1.23 Hz, 9-H), 7.37 (ddd, 1 H, J7 19.H 8.13 Hz, 3JX1.H 
4.82 Hz, Ji l5.H 0.89 Hz, 18-H); 8 C(50 MHz; CDC13) 151.3 (4-C), 150.6 (15-CH), 148.0
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(6 -C), 147.4 (17-CH), 142.5 (19-CH), 137.0 (3-CH), 133.8 (12-CH), 130.4 (7-CH), 130.1 
(11-C), 129.7 (8-CH), 128.0(5) (10-CH), 127.9(6) (14-C), 123.7 (18-CH), 121.0 (13-CH),
116.6 (1-CN), 112.8 (2-C); m/z 257 (M +, 100%), 229 (M + -  H, -  HCN, 22), 203 (M + -  
2 x HCN, 14), 179 (M + -  [C4H4N]+ i.e. [pyridyl]+, 3), 128 ([C9H 6N]+ i.e. [quinolyl}+, M+ -  
[p y r id y l t , -  C=C-CN, 19), 114 ([quinolyl]* -  N, 38), 101 ([quinolyl-H]+ -  CN, 25), 88 (7), 
75 (18), 63 (10), 51 (18).
2-(3-Thienyl)-3~(2-quinolinyl)propenonitrile ( 2 3 2 ) — U sing  M ethod D,
2-quinolylcarbaldehyde (0.336 g, 2.14 mmol) and 3-thienylacetonitrile (previously purified 
with activated carbon; 0.263 g, 2.14 mmol) were reacted in absolute ethanol (ca. 2 ml) with 
the addition of piperidine (5 drops) and potassium ferf-butoxide (ca. 1.0 mg) to give the title 
compound as yellow crystals (0.312 g, 56 %), m.p. 135.3-135.6 °C (EtOH); RF 0.75 (diethyl 
ether); (Found: C, 72.84; H, 3.62; N, 10.38; M +, 262.0546. C16H 10N 2S requires C, 73.26; H, 
3.84; N ’ 10.68%; M, 262.0531); v max(KBr disc)/crn' 3098w, 3074w and 3056w (=C-H ), 
2226w (CN), 1594s, 1550m/s, 1566m/s and 1500s (aromatic stretches), 922m/s, 838s, 784s 
and 760s (=C-H deformations); 5 H(200 MHz; CDC13) 8.1 (2 H, br s), 7.9 (1 H, br d, J  9.3 
Hz), 7.6(5) (4 H, br d, J 18.2 Hz, includes 3-H), 7.6 (0.5 H, br d, 77.1 Hz), 7.4 (2.5 H, br s); 
5C(50 MHz; CDC13) 152.0 (4-C), 148.0 (6-C), 139.1 (15-CH), 136.8 (3-CH), 136.3 (11-C),
130.2 (12-CH), 129.6 (7-CH), 127.6 (8- and 9- and 10-CH), 125.5 (17-CH), 124.2 (18-CH),
120.7 (13-CH), 117.3 (1-CN), 110.8 (2-C); m/z 262 (M+, 75%), 261 (M +- H ,  100), 236 (M + 
-  CN, 21), 229 (M + -  HS, 50), 216 (M + -  H-C=S, -  H, 15), 203 (M+ -  H-C=C-H, -  HS, 6), 
190 (M+ -  H-C=S, -  HCN, 8), 128 ([C9H6N]* i.e. [quinolyl]*, M+-  [thienyl]*, -  C=C-CN, 
12), \ \ 4([quinolyl ]+ - N , 4 ) ,  101 ([quinolyl-Hf -  CN, 15), 77(10), 63 (13), 51 (15).
(E)-2-(3-Pyridyl)-3-(3,4-dimethoxyphenyl)propenonitrile (233)— Using a reflux 
condenser and cold-finger to prevent solvent loss, a solution o f (Z)-2-(3-pyridyl)-3- 
(3,4-dimethoxyphenyl)propenonitrile (1.175 g) in acetonitrile (180 ml) was stirred under 
irradiation from a 500 W halogen lamp for 26 h. The temperature did not exceed 60 °C 
throughout the experiment. After additional stirring at room temperature for 2 h, some silica 
was added and the solvent was removed in preparation for column chromatography. The 
two isomers were separated (ca. 60:40 (E) to (Z)-forms by 90 MHz *H NMR spectroscopy) 
through silica using cyclohexane/diethyl ether combinations followed by pure diethyl ether 
and ethyl acetate elutions. This gave the (Z)-isomer (0.48 g, 41 %) and the desired
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(£)-isomer (0.51 g, 43 %) which was crystallised from diethyl ether at 0 °C to afford white 
needles (0.311 g, 26.5 %). For crystallographic purposes, ca. 0.1 g o f this was further 
crystallised from diethyl ether at ca. -10°C to give white rod-like crystals, m.p. 86.8 °C; RF 
0.34 (1:2 ethyl acetate/petroleum ether, bp 30-40°C); (Found: C, 72.10; H, 5.36; N, 10.51; 
M+, 266.1062. C16H 14N 20 2 requires C, 72.17; H, 5.30; N, 10.51%; M, 266.1055); vmax(KBr 
discycm'1 3056w and 3004w (=C-H), 2967w, 2938w and 2917w (CH3), 2842w (CH3OAr), 
2203m (CN), 1597s (C=C), 1576w, 1566w andl512s (Ar), 1426m and 1412m (CH3 
deformations), 1273s, 1246m and 1019s (C -O ), 814m, 770m  and 718m  (=C -H  
deformations); 8H(200 MHz; acetone-d6) 8.64 (br dd, 2 H, 3J X4.H 4.85 Hz, 4J\$.n 1.64 Hz,
13-H with 11-H overlapping), 7.88 (ddd, 1 H, 3J\^.y[ 7.92 Hz, 47n-H 2-28 Hz, 4/ i 3.h
1.70 Hz, 15-H), 7.57 (1 H, br s, 3-H), 7.51 (ddd, 1 H, 7.93 Hz, 4713.H 4.81 Hz, ‘,711.H 
0.91 Hz, 14-H), 6.91 (d, 2 H, 4JgM 1.15 Hz, 8- and 9-H coincide), 6.68 (br t, 1 H, 
unresolved, 5-H), 3.82 (s, 3 H, 6-OMe), 3.48 (s, 3 H, 7-OMe); SH(200 MHz; CDC13) 8.67 
(dd, 1 H, 4J X5.H 2.33 Hz, 57 ,4. H 0.88 Hz, 11-H), 8.62 (dd, 1 H, 3/ 14. H 4.86 Hz, 4/ 15.H 
1.67 Hz, 13-H), 7.77 (ddd, 1 H, V !4.H 7.91 Hz, V n .H 2.22 Hz, V l3.H 1.76 Hz, 15-H), 7.10  
(1 H, br s, 3-H), 7.51 (ddd, 1 H, J/ | 5.H 7.93 Hz, 4/ 13.H 4.85 Hz, 0.89 Hz, 14-H), 6.83 
(ddd, 1 H, 3JS_H 8.37 Hz, 4/ 5.H 1.94 Hz, 4J3.H 0.32 Hz, 9-H), 6.77 (d, 1 H, JJ9.H 8.39 Hz,
8-H), 6.68 (br d, 1 H, 4J9_H 1.93 Hz, 5-H), 3.87 (s, 3 H, 6-OMe), 3.54 (s, 3 H, 7-O M e); 
8h(200 MHz; THF-d8 at 3.584 and 1.731 ppm) 8.60 (dd, 1 H, 4J l5.H 2.3 Hz, J/ 14_H 0.8 Hz,
11-H), 8.56 (dd, 1 H, 4.81 Hz, 4/ 15.H 1.66 Hz, 13-H), 7.78 (ddd, 1 H, JJ I4.H 7.92 Hz, 
4J n .H 2.25 Hz, 4i , 3.H 1.76 Hz, 15-H), 7.49 (1 H, s, 3-H), 7.39 (ddd, 1 H, J/ I5.H 7.88 Hz, 
V 13.H 4.81 Hz, 4J X , .H 0.87 Hz, 14-H), 6.83 (d, 2 H, J  1.04 Hz, 8- and 9-H), 6.64 (br t, 1 H, 
unresolved, 5-H), 3.77 (s, 3 H, 6-OMe), 3.46 (s, 3 H, 7-OMe); 8C(50 MHz; acetone-d6)
152.3 (7-C), 150.9 (11-CH), 150.6 (13-CH), 149.8 (6-C), 146.9 (3-CH), 137.3 (15-CH),
130.9 (10-C), 126.7 (4-C), 125.5 (9-CH), 124.9 (14-CH), 120.6 (1-CN), 113.2 (5-CH),
112.3 (8-CH), 108.4 (2-C), 56.0 (6-OCH3), 55.5 (7-OCH3); Sc (50 MHz; CDC13) 151.1 
(7-C), 150.0 (2) and 149.9 (8) (11- and 13-CH), 148.7 (6-C), 146.0 (3-CH), 136.5 (15-CH),
129.6 (10-C), 125.6 (4-C), 124.6 (9-CH), 123.8 (14-CH), 119.8 (1-CN), 111.7 (5-CH),
110.9 (8-CH), 107.9 (2-C), 55.9 (6-OCH3), 55.4 (7-OCH3); m/z 266 (M +, 100%), 251 (M+ -  
CH3, 16), 223 (M+ -  CH3, -  CO, 28), 220 (M+ -  CH3, -  CH30 ,  8), 208 (M + -  2 x C H 3, -  
CO, 29), 195 (M + -  CH3, -  H -C=0, -  HCN, 30), 192 (M + -  CH3, -  CH30 ,  -  CO, 46), 191 
(M+ -C H 3,- C H 3O H ,-C O , 46), 180(M+ - 2  x CH3, -  2 x CO, 49), 179 (M + - 2 x  CH3, -
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2 x CO, -  H, 96), 154 ([H-C=C-CH=C(CN)-Py]+, M + -  H2C=C(OCH3)-C(OCH3)=CH2,
33), 167 (17), 164 (22), 139 ([(CH30 ) 2PhH]+ , 13), 127 ([H-C^C-C=C-Py]+, M+ -  
H2C=C(OCH3)-C(OCH3)=CH2, -  HCN, 33), 114(11), 100(21), 87(18), 77 ([Py]+ - H ,  17), 
63 (39), 51 (42).
(Z)-2,3-Epoxy-2-(3-pyridyl)-3-(3,4-dimethoxyphenyl)propenonitrile (2 3 4 ) —  
A fter perform ing  chrom atography as d escrib ed  for (£>2-(3-pyridyl)-3- 
(3,4-dimethoxyphenyl)propenonitrile (233) the (Z)-epoxide (0.105 g, 8.4 %) was isolated, 
extracted into diethyl ether, to remove insoluble material, and crystallised from acetone, 
m.p. 108 °C; R F 0.12 (1:2 ethyl acetate/petroleum ether, bp 30-40 °C); (Found: C, 72.18; H, 
5.35; N, 10.69; M+, 282.1011. C 16H 14N 20 3 requires C, 72.17; H, 5.30; N, 10.51%; M, 
282.1004); v max(KBr disc)/cm'' 3047w and 301 lw  (=C-H ), 2968w and 2940w (CH3), 
2844w (CHjOAr), 2243w  (CN), 1596s and 1518s (Ar), 1447m and 1424m (CH3 
deformations), 1276s, 1149s and 1019s (C-O), 808m and 712m (=C -H  deformations); 
5H(200 MHz; acetone-d6) 8.64 (dd, 1 H, 4J ls.H 2.65 Hz, 4JU.H 0.86 Hz, 11-H), 8.63 (dd,
1 H, Jy |4.H 4.77 Hz, “' /u .h  1-53 Hz, 13-H), 7.89 (ddd, 1 H, 3J iA.H 8.15 Hz, " % .H 2.65 Hz, 
4J n .H 1.55 Hz, 15-H), 7.41 (ddd, 1 H, Ji 15.H 8.11 Hz, 4J n .n 4.77 Hz, 47U.H 0.83 Hz, 14-H), 
7.23 (dd, 1 H, Jy8.H 8.36 Hz, 4J5_H 2.23 Hz, 9-H), 6.98 (d, 1 H, % H 2.21 Hz, 5-H), 6.92 (d,
1 H, 3J9.h 8.37 Hz, 8-H), 5.77 (1 H, s, 3-H), 3.80 (s, 3 H, 7-OMe), 3.60 (s, 3 H, 6-OMe); 
8C(50 MHz; acetone-d6) 150.9 (7-C), 150.4 (11-CH), 150.3 (13-CH), 149.8 (6-C), 136.5 
(15-CH), 132.2 (10-C), 125.9 (4-C), 124.3 (9-CH), 124.2 (14-C), 121.9 (1-CN), 114.9 
(5-CH), 112.1 (8-CH), 56.0 (6-OCH3), 55.5 (7-OCH3), 54.4 (3-CH), 48.0 (2-C); m/z 282 
(M+, 15%), 267 (M + -  CH3, 14), 266 (M +-  0 , 6), 256 (M + -  CN, 4), 239 (M + -  CH3, -  CO, 
26), 236 (M + -  CH3, -  CH30 ,  8), 224 (M +-  2 x  CH3, -  CO, 23), 211 (M + -  CH3, -  H-C=0, 
-  HCN, 27), 208 (M + -  CH3, -  CH30 ,  -  CO, 34), 2071 (M+ -  CH3, -  CH3OH, -  CO, 35), 
196 (M + -  2 x C H 3, -  2 x  CO, 34), 195 (M + -  2 xC H 3, -  2 x  CO, -  H, 54), 148 
([H-C=C=CH-C(0)-Py]+, M+ -  H2C=C(OCH3)-C(OCH3)=CH2, -  CN, 10), 167 (15), 164 
(17), 138 U(CH30 ) 2Ph]+, l ) ,  100 (12), 87 (13), 77 ([Py]+ -  H, 12).
2-Cyano-3-(3,4-dimethoxyphenyl)propenonitrile ( 2 3 6 )— U sin g  M ethod C,
3,4-dimethoxybenzaldehyde (6.996 g, 0.0421 mol) and malononitrile (2.781 g, 0.0421 mol) 
were reacted in absolute ethanol (15 ml) with the addition of piperidine (5 drops) and after
2 h the crystals were collected (7.683 g, 85 %), m.p. 144.3-145.4 °C (from EtOH) (lit.,333
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144 °C); R f  0.93 (diethyl ether); (Found: C, 67.12; H, 4.52; N, 13.01; M+, 214.0745. 
C12H 1oN20 2 requires C, 67.29; H, 4.67; N, 13.08%; M, 214.0742); v max(KBr discycm '1 
3105w, 3026w  and 3009w (=C -H ), 2965w and 2936w  (CH3), 2849w  and 2834w  
(CH3OPh), 2224m /s (CN), 1601m/w (C=C), 1581m, 1568m and 1508s (Ar), 1273s, 
1144m/s and 1016m (C-O), 850m/w, 822m/w and 629m/w (=C-H  deformations); 8 H(200 
MHz; CDC13) 7.68 (d, 1 H, 4Jg_H 2.2 Hz, 5-H), 7.67 (s, 1 H, 3-H, overlaps with 5-H), 7.51 
(dd, 1 H, 3J%H 8.46 Hz, 4J5_H 2.12 Hz, 9-H), 6.98 (d, 1 H, JJ9_H 8.48 Hz, 8-H), 4.00 and 3.94 
(2 x  s, 6 H, 6- and 7-OMe); 8 C(50 MHz; CDC13) 159.5 (3-CH), 154.6 (7-C), 149.4 (6-C),
128.2 (9-CH), 124.2 (4-C), 114.4and 113.6 (2 x C N ), 111.1 (5-CH), 110.7 (8-C H ),78.2 (2- 
C), 56.3 and 56.0 (6- and 7-OCH3); m/z 214 (M +, 45%), 199 (M+ -  CH3, 26), 171 (M+ -  
CH3, -  CO, 87), 168 (M+ - C H 3, - C H 30 ,  3), 156 (M+ - 2  x  CH3,-C O , 3), 143(M + - C H 3, 
-  H-C=0, -  HCN, 83), 128 (M+ -  2 x  CH3, -  2 x  CO, 49), 116 (M + -  CH3, -  CH30 ,  -  2 x  
CN, 100), 114 (M + -  CH3, -  CH30 ,  -  CO, -  CN, 44), 101 ([H2C=C-CH=C(CN)2]+, M + -  
HC=C(OCH3)-C(OCH3)=CH2, 87), 89 (39), 75 (46), 63 (37), 50 (52), 39 (28).
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EXPERIMENTAL—BIOLOGY
M a t e r ia l s  a n d  I n s t r u m e n t a t io n
Glutamine, RPMI 1640, Dubeco’s Modified Eagle’s Medium (DMEM), foetal calf serum 
(FCS), and donor calf serum (DCS) were all obtained from Gibco BRL (Paisley, UK). 
[3H]Thymidine and [y-32P]ATP were obtained from Amersham Ltd (Amersham, UK). 
Ecoscint A was obtained from National Diagnostics.
MCF-7 breast adenocarcinoma cells were obtained from the American Type Culture 
Collection (Rockville, MD) and were maintained in RPMI 1640 supplemented with 2 m M  
glutamine and 10 % (v/v) FCS. Fibroblasts transfected with the human EGF receptor 
(HER 14)334 were a kind gift from Dr J. Schlessinger (New York University School of 
Medicine) and were maintained in DMEM supplemented with 2 mM  glutamine and 10 % 
DCS. The HN5 cell line derived from a human squamous cell carcinoma of the tongue,335 
was a kind gift from Dr B. Ozanne (Beatson Institute, Glasgow). The cell lines A 431336, 
CaSki337 and SiHa338 were all obtained from the ATCC and maintained in Ham’s 
F10:DMEM (50:50) supplemented with 2 m M  glutamine and 10 % (v/v) FCS.
Cell harvesting was performed on an LKB Cell Harvester and radioactivity was determined 
with a Packard Liquid Scintillation Analyser.
Experimental Procedures
All of the biochemical methods were performed at the Cancer Research Campaign (CRC) 
Department of Medical Oncology, CRC Beatson Laboratories, University of Glasgow, 
Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK.
MCF-7 Antiproliferative Assay
MCF-7 cells were plated at a concentration of 1 x  10 cells/well in 96 well plates and grown 
in a humidified atmosphere of 5 % (v/v) carbon dioxide:air at 37 °C for 72 h. For each plate, 
a range of inhibitor concentrations in 10 % (v/v) FCS was then added (in triplicate) and 
12 wells were left untreated to act as a control. After 24 h, [3H]thymidine (0.25 (iCi/well) 
was added to each well for a 1 h pulse. Following removal of the medium, the cell sheets 
were washed twice with ice-cold phosphate-buffered saline, subjected to trypsin/EDTA 
(0.25 % /l m M ) for a 20 min period and then harvested onto filter mats. These were washed
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three times with distilled water, allowed to dry, covered with Ecoscint A (10 ml) and their 
radioactivity measured in counts-per-minute (cpm). The amount o f incorporation of 
[3H]thymidine (in cpm) was then expressed as a percentage of the uninhibited growth of the 
control. Log-concentration response curves were generated from which IC50 values were 
determined as the concentration of drug required to inhibit growth of the control by 50 %.
The inhibitor concentrations were prepared by forming fresh  10 m M  solutions of the 
inhibitors in DMSO and then diluting with 10 % (v/v) FCS to the desired concentration. 
Depending on the inhibitor, the concentration range was generally [1.0 10.0, 20.0, 50.0, and
100.0 JIM] or [0.1, 1.0, 10.0, 20.0, and 50.0 p.M] or [0.001, 0.01, 0.1, 1.0, and 20.0 |XM]. For 
most experiments, use of stock  10 m M  solutions stored at -20 °C was avoided due to 
suspected inhibitor instability.
Initially for the MCF-7 antiproliferatve assay a parallel experiment using charcoal stripped 
serum (CSS) was performed. Compared to FCS the results obtained were near identical and 
the use of CSS, which lacks the growth factor oestrogen, was no longer necessary.
HER-14 Antiproliferative Assay
For the HER-14 cell line the procedure was as for MCF-7 except: a 2 % (v/v) carbon 
dioxide:air atmosphere was generally used to confluence; inhibitors were added in 10 % 
(v/v) DCS and 0.1% (v/v) DCS plus 10 ng/ml EGF; a 48 h inhibitor exposure time was 
adopted and [ HJthymidine incorporation was measured over 16 h.
Cytotoxicity Assay
Compounds against an appropriate carcinoma cell line, e.g. MCF-7, HN5, A431, CaSki or 
SiHa, were assayed for their cytotoxicity as given below. This work was carried out by Dr 
Valerie G. Brunton. For a comparative procedure see reference 339.
Carcinoma cells were seeded at the appropriate cell density in 96-well plates and grown for 
72 h in a humidified atmosphere of 2 % (v/v) C 0 2:air at 37 °C before addition of a range of 
inhibitor concentrations in 200 jil of medium. Four replicate wells were used for each drug 
concentration. Cells alone were used as a control and medium alone was used as a blank. 
After 24 h the inhibitors were removed and fresh medium added. The medium was replaced 
every 24 h for a further 3 days allowing the cells to pass through 2 to 3 doublings. This 
allowed the assay to be used as a measure of cell kill. On the third day 3-(4,5-dimethylthiaz-
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2-yl)-2,5-diphenyltetrazolium (MTT) (5 mg/ml) was added to each well. The plates were 
then incubated in the dark at 37 °C for 4 h. Medium and MTT were then removed and the 
formazan crystals (formed following redution o f MTT by live cells) were dissolved in 
DMSO (200 jxl) and Sorensen’s glycine buffer (25 jil) (0.1 M glycine plus 0.1 M NaCl 
adjusted to pH 10.5 with 0.1 M NaOH) then added. The absorbance was read at 570 nm in 
an enzyme-linked immunosorbent assay plate reader (Model 2550; Bio-Rad Laboratories). 
Log-concentration response curves were generated from which IC50 values were determined 
as the dose to inhibit MTT absorbance by 50 %.
Measurement of EGF-R Kinase Activity
EGF receptor tyrosine kinase activity was measured in membrane fractions prepared from 
the HN5 cell line by measuring the EGF-dependent phosphorylation o f a synthetic substrate, 
poly(Glu6, Ala3, Tyrj). This work was performed by Dr Valerie G. Brunton.
The membrane fractions (0.5 jig protein) were incubated with kinase buffer (45 mM HEPES, 
pH 7.4, 100 JIM sodium orthovanadate, 0.05 % Triton X-100, 2 % glycerol), 25 mM MgCl2, 
2 mg/ml poly(Glu6, Ala3 , TyrL) and inhibitors at a range o f concentrations. Parallel 
incubations were carried out in either the presence or absence o f  0.25 |IM  EGF. The 
inhibitors were prepared as stock solutions in dimethylsulphoxide (DMSO) and the final 
concentration of DMSO in the incubations (1 %) had no effect on the reaction rate. The 
reaction was initiated by addition of [y-32P]ATP (0.5 pCi, 20 pM , sp. ac. 3000 Ci/mmol) and 
after 20 min at 30 °C the reaction was terminated by the addition o f 1 mM  ATP on ice. The 
products were spotted onto Whatman 3MM paper and the peptide was precipitated with 10 
% trichloroacetic acid containing 0.01 M sodium pyrophosphate. The filters were then 
washed extensively with the trichloroacetic acid solution, allowed to dry, transferred to 
scintillation vials, Ecoscint A (10 ml) was added and the radioactivity was measured.
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0 APPENDIX 0
Listed below are the numbering systems used for the compounds stated in the experimental. 
An arbitrary system is adopted which emphasises the propenonitrile moiety and the (R) 
label refers to anyone o f the following functional groups: CN, CONH2, CSNH2, C 0 2Me, 
C 0 2Et, C 0 2 nBu, C 0 2 lBu, or C(NH2)=C(CN)2. Each group is clearly assigned in the 
experimental data for a given compound.
Chapter 6
Y
(56)-(58) and (69)-(80) 
(X, Y= H and/or OH)
X
(85)-(90) 
(X= Cl orF)
(91) (92)-(95) (96)-(100)
4
16
(101X105) (106)-(110) (111)
(113X 116) 
(X= H or N 0 2)
n o 2
(117)-(118)
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5 3 f
6 CO 2 Bu (or H)
(121X 133)
(X= H, F, Q , N 0 2 ,0H , OMe, and/or 0C H 20)
HN NH
MeO  ^ 6
MeO 7
(136) K + salt (no double-bond)
(137) includes double bond
y - N  NC
• S 4 3
(134X 135)
Bu (or H)
CN CN 
5 N 0 2 1
(138)
0 2N 6 ^  8
(140)
Chapter 2
CN
(141X 149)
CN
CN
2 CHO
(168)
CN
(169X 175)
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(180)-( 186)
n
(198)-(202)(187)-( 192) (193)-( 197)
MeOVs4x ^ 5^ 2^x^^/'B u
MeO 5 7 NOo
6 z
(203)
M eO ^ 4  2
Y  T  N" 1
MeO NO,
6
(204)
3 1
MeO>. ^ NH2N r  n  z
, 4 ^ s n «
6
(209)
MeO 5 v  7 NO9 
 z
( Me°s|A ^ NV
\  MeO 5 ^ 7  NH2 /  
(210)
Chapter 8
O  6'
1 CN
1 CN
HO 7
(213) (59)
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MeO
HO 5
CHO
NMe*
(215)
MeO
HO 5
(218)
MeO CHO
HO 5
(217)
NC . 2  . c o n h 2
MeO
HO 7
3 . 0
O o N  7
COoEt
0 2N 5 ^  7
COoEt
0 2N 6 ^  8
1
CONH-
(220) (221) (222)
MeO
MeO 7
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io N  12
(226)
MeO
MeO 7 ^ 9  
8
(227)
MeO
CN
MeO 7
(228)
13
12 MeO
CN
MeO 7
(229)
M eO 7
MeO
MeO 7 ^  9 
8
(236)
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